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ABSTRACT 
Phosphoinositide 3-kinases (PI3Ks) are a family of enzymes that regulate a diverse array of 
biological functions in every cell type by generating lipid second messengers. The PI3K 
family is comprised of multiple isoforms that are divided into three main classes; class I, II 
and III.  All class I PI3Ks are heterodimers consisting of a ~110 kDa catalytic subunit 
associated with a regulatory subunit.  Class I PI3Ks are further subdivided into class IA and 
class  IB,  which  are  activated  downstream  of  tyrosine  kinases  or  G  protein-coupled 
receptors, respectively.  The mammalian catalytic subunits of class IA PI3Ks are p110ʱ, 
p110β and p110δ.  PI3Ks are involved in multiple cellular processes, and deregulation of 
PI3K  signalling  pathways  have  been  linked  to  a  number  of  diseases  such  as  cancer, 
inflammation and immunity and diabetes. Targeting PI3K itself or downstream effectors of 
PI3K is an approach that has the potential to be of huge therapeutic benefit, however, PI3K 
signalling  is  also  important  in  normal  cell  homeostasis  and  inhibition  of  all  the  PI3K 
isoforms with non-selective PI3K inhibitors is toxic to the cell.  To enable individual PI3K 
isoforms  to  be  targeted  therapeutically,  it  is  first  important  to  understand  the  specific 
signalling mediated by each individual PI3K isoforms.   
 
This work focuses on addressing the isoform-specific role of p110δ. Unlike p110ʱ and 
p110β, p110δ has a more restricted tissue distribution and is most abundantly expressed in 
leukocytes. However, there are instances where cells of non-haematopoietic origin have 
high levels of p110δ expression, such as breast cells, melanocytes and microglia.   
 
Using cell-based models to explore p110δ signalling, our work has revealed that coupling 
of  the  tyrosine  kinase  receptor,  c-kit,  to  p110δ  appears  to  remain  largely  unaltered  in 
primary leukocytes that stably express the transforming polyoma middle T antigen.  Stable 
overexpression of p110δ in a non-leukocyte cell line, NIH 3T3, has revealed that p110δ 
overexpression results in the downregulation of p110ʱ and p110β expression and has a 
striking impact on cell morphology.  Finally, we have identified a potential p110δ gene 
promoter region that mediates leukocyte-specific p110δ gene expression. 
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1. INTRODUCTION 
1.1 PHOSPHOINOSITIDE 3-KINASE AND THEIR LIPID PRODUCTS 
Phosphoinositide 3-kinases (PI3Ks) are a family of enzymes that regulate a diverse array 
of biological functions in every cell type by generating lipid second messengers.  They 
catalyse  the  phosphorylation  of  the  3-OH  position  of  the  inositol  head  groups  of 
phosphatidylinositol  (PtdIns)  and  phosphoinositide  (PI)  lipids  producing  3‟PI  lipid 
derivatives (Sotsios & Ward, 2000; Vanhaesebroeck & Waterfield, 1999).  In mammalian 
cells these lipid derivatives are PtdIns(3)P, PtdIns(3,4)P2, and PtdIns(3,4,5)P3 (the latter 
also referred to as PIP3) (Figure1.1).  
 
Figure 1.1: Simplified chemical structures of phosphatidylinositol (PtdIns) and the 
lipid products generated by PI3K.  PtdIns consists of a cytoplasmic inositol headgroup 
and a hydrophobic tail consisting of two fatty acid chains that are incorporated into the 
inner leaflet  of the membrane lipid  bilayer.  PI3Ks transfer a phosphate from  ATP  to 
phosphorylate the 3-position on the inositol ring  generating PtdIns(3)P, PtdIns(3,4)P2, and 
PtdIns(3,4,5)P3.  
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PI3K can also indirectly generate the lipid product PtdIns(3,5)P2 through the action of the 
Fab1 5-kinase on the PI3K lipid product PtdIns(3)P (Cabezas, et al., 2006; Gary, et al., 
1998; Sbrissa, et al., 1999).  The basal levels of PtdIns(3)P, PtdIns(3,5)P2, and PIP3 are 
very low but can rise sharply upon cellular stimulation, allowing tight control of signalling 
pathways downstream of these lipid products (Maffucci, et al., 2003; Vanhaesebroeck & 
Waterfield, 1999). 
 
The 3‟PI lipid derivatives generated by PI3Ks can activate sets of proteins with specific 
lipid binding domains.  PIP3 interacts with a subset of proteins that contain PH (pleckstrin 
homology)  domains  (Lemmon  &  Ferguson,  2000).      The  PH  domain  is  the  most 
widespread  binding  module  in  higher  eukaryotes  (Lindmo  &  Stenmark,  2006),  but 
although most PH domains bind PIs, only some do with high affinity (Vanhaesebroeck & 
Waterfield, 1999). The first PtdIns(3)P-specific binding domain to be identified was the 
FYVE (for conserved in Fab1, YOTB, Vac1, and EEA1) zinc finger domain.  This domain 
is  evolutionary  more  conserved  than  the  PH  domain,  but  is  less  abundant  and  has  a 
narrower substrate preference (Lindmo & Stenmark, 2006).  The other known PtdIns(3)P-
binding domain is the conserved Phox-homology (PX) domain, which is slightly more 
abundant than the FYVE domain.  A few PX domains can also bind other PtdIns such as 
PtdIns(3,4)P2  (Lindmo  &  Stenmark,  2006).    PIP3  activation  of  PH  domain-containing 
proteins is discussed further in section 1.2.  
 
The level of PI3K lipid products is also regulated by three main phosphatases; PTEN and 
SHIP2,  which  are  broadly  expressed,  and  SHIP1,  which  is  expressed  primarily  in 
haematopoietic cells (Muraille, et al., 1999; Stephens, et al., 2005).  PTEN (phosphatase 
and tensin homolog deleted on chromosome ten) is a well-known tumour suppressor gene 
and is frequently inactivated by mutation, gene deletion, or epigenetic silencing (Cully, et 
al., 2006; Harris, et al., 2008).  PTEN has 3-phosphatase activity and regulates PI3K-
dependent signalling events through dephosphorylation of PIP3 to PtdIns(4,5)P2, thereby 
preventing  membrane-localization  of  PH  domain-containing  effectors.    SHIP1  (SH2 
domain-containing  inositol  5-phosphatase)  and  SHIP2  are  both  5‟phosphatases  which 
dephosphorylate PIP3 to PtdIns(3,4)P2 (Freeburn, et al., 2002; Rohrschneider, et al., 2000).  
As  mentioned  above,  PH-domain  containing  proteins  can  interact  with  PIP3,  however 
certain PH domains exhibit dual specificity for PIP3 and PtdIns(3,4)P2, such as DAPP1 
(dual adaptor of phosphotyrosine and 3-phosphoinositides 1), whereas as others exhibit 
selectivity toward PtdIns(3,4)P2, such as TAPP (tandem PH domain-containing protein). Chapter 1 
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The phosphatase activity of SHIP can therefore regulate PI3K-dependent signalling events 
by redirecting the signalling pathway through another set of 3‟PI lipid-binding effectors 
(Harris, et al., 2008).  In comparison to PTEN, SHIP genes are not widely thought of as 
tumour suppressors although there have been a few reported instances of SHIP mutations 
in a proportion of acute, myeloid and lymphoblastic leukaemias (Luo, et al., 2004b; Zhang, 
et al., 2006). 
 
1.2 CLASSIFICATION OF PHOSPHOINOSITIDE 3-KINASES 
The PI3K family is comprised of multiple isoforms that are divided into three main classes; 
class I, II and III.  All three classes share a homologous region in their catalytic subunit 
consisting of a catalytic core domain linked to a helical or PIK (PI kinase homology) 
domain (Figure 1.2) (Vanhaesebroeck & Waterfield, 1999). The classification of the PI3K 
isoforms is based on their in vitro lipid substrate specificity, structure and possible mode of 
regulation.  A group of PI3K-related kinases sometimes called class IV, also exist, which 
have a kinase domain that has significant homology to the kinase core domain of PI3Ks 
but which do not phosphorylate lipids (Vanhaesebroeck & Waterfield, 1999). 
 
1.2.1 Class I PI3K 
All class I PI3Ks are heterodimers consisting of a ~110 kDa catalytic subunit associated 
with a regulatory subunit.  The in vitro substrates for class I PI3Ks are PtdIns, PtdIns(4)P 
or PtdIns(4,5)P2, however their preferred in vivo substrate appears to be Ptd(4,5)P2, which 
results in PIP3 production.  Class I PI3Ks have been further categorized into class IA and 
class IB, on the basis of whether they are activated downstream of tyrosine kinases or G-
protein coupled receptors (GPCRs), respectively.  However, recent evidence (discussed 
below) presents good reasoning for this classification to be reconsidered. 
 
Class IA PI3Ks: The mammalian catalytic subunits of class IA PI3Ks are p110ʱ, p110β 
and p110δ, as shown in Figure 1.2, which are encoded by three separate genes.  There are 
at least five different class IA regulatory subunits: p85ʱ, p55ʱ and p50ʱ, encoded by the 
PIK3R1 gene, and p85β and p55γ, encoded by PIK3R2 and PIK3R3, respectively.  The 
regulatory subunits contain two Src homology 2 (SH2) domains and the region between 
these two domain, the inter-SH2 domain, mediates the interaction of the regulatory subunit 
with the p110 catalytic subunit (Vanhaesebroeck & Waterfield, 1999). All of the p110 
catalytic subunits are able to bind all the regulatory subunits, with no known specificity for 
a particular p110 to bind a particular p85, at least in cell culture-based experiments.   Chapter 1 
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Figure 1.2: Modular structures of the PI3K catalytic and regulatory subunits.  (a) 
PI3K catalytic subunits are divided into three main groups: Class I, II and III.  They all 
share  a  PIK  domain  and  a  kinase  core  domain,  which  contains  both  the  ATP  and  PI 
binding sites.  Class IA catalytic subunits include p110ʱ, p110β and p110δ, which all have 
a p85 adaptor binding domain. The sole class IB catalytic subunit, p110γ does not contain Chapter 1 
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the p85 adaptor binding domain.  All class I and II catalytic subunits contain a Ras binding 
domain.    Class  II  catalytic  subunits  further  have  a  C-terminal  C2  domain  that  binds 
phospholipids in vitro in a Ca
2+-independent manner. The single class III PI3K catalytic 
subunit is the homologue of the yeast Vps34 protein. (b) At least five class IA regulatory 
subunits exist.  p85ʱ, p55ʱ and p50ʱ, are encoded by the PIK3R1 gene, and p85β and 
p55γ, encoded by PIK3R2 and PIK3R3, respectively.  All class IA regulatory subunits have 
two SH2 domains and an inter SH2 domain that is essential for binding the p110 catalytic 
subunits.  p85ʱ and p85β also have an additional Bcr homology (BH) domain. There are 
two class IB regulatory subunits, p101 and p84. The domains illustrated for p101 and p84 
are not yet well defined.  A region at the N-terminus of p101 has been identified to be 
essential for binding to p110γ and a separate C-terminal region mediates p101 binding to 
GPCRs (Voigt, et al., 2005).  One class III regulator subunit has been identified, p150, 
which has high homology to yeast Vps15p protein kinase.  The domains labelled 1-4 on 
p150 are as follows: 1) represents an N-terminal myristoylation consensus site; (2) Ser/Thr 
protein  kinase  domain;  (3)  region  with  homology  to  the  65-kDa  regulatory  subunit  of 
protein phosphatase 2A; (4) region containing WD repeat motifs (Panaretou, et al., 1997).  
 
The association of the regulatory subunit with p110 stabilises the catalytic subunit but 
inhibits  its  catalytic  activity  (Yu,  et  al.,  1998b).    The  interaction  of  p85  with  p110  is 
extremely  strong,  withstanding  high  concentrations  of  salt,  urea  or  detergent,  which 
indicates that under physiological conditions, it is unlikely that there is dissociation of the 
p110-p85 heterodimer (Fry, et al., 1992; Geering, et al., 2007a; Geering, et al., 2007b) . 
 
Upon activation of protein tyrosine kinases, p110 catalytic inhibition is relieved through 
engagement of the regulatory subunit SH2 domains with phosphotyrosine residues in a 
specific  Y(P)xxM  motif, where x is  any  amino acid  (Yu,  et  al., 1998b).  The protein 
tyrosine kinases involved can be integral to the receptor itself, as is the case for many 
growth factor receptors or can be activated by direct or indirect association to the receptor, 
such as Src family of protein tyrosine kinases  associated with receptors for antigen or 
antibodies (Figure 1.3) (Hawkins, et al., 2006).  Likewise, the critical tyrosine residues that 
are phosphorylated to mediate p50/p55/p85 binding, may be located on the receptor itself, 
such  as  PDGF  receptor,  or  on  receptor-associated  proteins  (or  adaptors),  such  as  IRS 
(insulin receptor substrate) (Hawkins, et al., 2006).  Through binding Y(P)xxM motifs, the 
regulatory subunit serves to transport the p110 subunit to the cell membrane where it is 
brought into close proximity with its lipid substrate Ptd(4,5)P2 to generate PIP3.  
 
Class  IA  p110  isoforms  are  differentially  distributed  within  tissue;  p110ʱ  and  p110β 
isoforms  are  widely  distributed  in  mammalian  tissue,  whereas  p110δ  shows  a  more 
restricted  distribution,  and  is  mainly  found  in  leukocytes  (Chantry,  et  al.,  1997; 
Vanhaesebroeck, et al., 1997). Chapter 1 
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Figure 1.3: Activation of class I PI3K. (a) Activation of Class IA PI3Ks by receptors 
activating protein tyrosine kinases.  The schematic represents the activation of Class IA 
heterodimers by a growth factor receptor with intrinsic protein tyrosine kinase activity. 
Ligand-induced dimerisation of the receptor results  in phosphorylation of multiple key 
tyrosine residues in the cytoplasmic tails, some of which are within YxxM motifs that act 
as docking sites for the SH2 domains of the class IA regulatory subunits.  This leads to 
recruitment  of  the  p110  catalytic  subunit  to  the  plasma  membrane  where  it  can 
phosphorylate PtdIns(4,5)P2 to PIP3. GTP-bound Ras is also known to bind the catalytic 
subunits of class I PI3Ks. (b) Activation of class IB PI3Ks is downstream of heterotrimeric 
G-protein activation. The schematic represents the activation of p110γ-p101/p84 dimer by 
a Gi-coupled receptor. Ligand binding of these receptors induces a conformational change 
which results in an exchange of GDP for GTP on the ʱ subunit, inducing dissociation from 
both the receptor and Gβγ subunits.  The free Gβγ subunit binds directly to the p101/p84 
subunit of p110γ, thus bringing p110γ to the plasma membrane. Chapter 1 
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Class IB PI3K:  This  class  of PI3K only has  one catalytic subunit  and two regulatory 
subunits.  The  catalytic  subunit  p110γ  binds  both  p101  and  the  relatively  recently 
characterised  p84  regulatory  subunit  (Stephens,  et  al.,  1997;  Suire,  et  al.,  2005).  
p110γ/p101/p84 heterodimers are activated by the Gβγ subunits of heterotrimeric GPCRs 
(Figure 1.3).  The role of p101/p84 in recruitment of p110γ to the cell membrane is less 
clear, with evidence that a substantial portion of p110γ is constitutively present at the cell 
membrane (Krugmann, et al., 2002).  p110γ, like p110δ, is predominantly, although not 
exclusively expressed in cells of the immune system and is involved in both innate and 
adaptive  immune  responses  (Hirsch,  et  al.,  2006;  Laffargue,  et  al.,  2002;  Lemmon  & 
Ferguson, 2000; Rommel, et al., 2007; Sasaki, et al., 2000). 
 
Although originally classified as a class IA PI3K, p110β is also activated downstream of 
GPCRs. Over ten years ago, p110β (and not p110ʱ or p110δ) was found to be activated by 
Gβγ subunits in vitro (Kurosu, et al., 1997; Maier, et al., 1999).  In addition, dominant-
negative p110β but not p110γ, has been found to inhibit mitogen-activated protein kinase 
(MAPK) in response to lysophosphatidic acid (LPA), a GPCR ligand (Yart, et al., 2002).  
However, it is only recently that p110β has been found to be activated predominantly 
downstream  of  GPCRs,  rather  than  tyrosine  kinase  receptors,  in  cell-based  studies 
(Guillermet-Guibert, et al., 2008).  The classification of p110β as a class IA PI3K therefore 
perhaps needs to be redefined. 
 
1.2.2 Class II PI3K 
Class II PI3Ks are larger than class I PI3Ks (170 – 210 kDa).  There are three class II PI3K 
catalytic subunits; PI3K-C2ʱ, PI3K-C2β and PI3K-C2γ with no adaptor protein identified 
to  date.    Class  II  PI3K  catalytic  subunits  share  45-50%  similarity  with  class  I  PI3K, 
containing both a PIK and kinase core domain and also a Ras binding domain (Figure1.2).  
They differ at the C-terminus, containing a C2 domain that binds phospholipids in vitro in 
a Ca
2+-independent manner.  Class II catalytic subunits also differ in a large N-terminal 
region, which shows no homology to any known protein.   
 
A  number  of  ligands  can  activate  class  II  PI3K,  such  as  insulin,  EGF,  integrins, 
chemokine, MCP-1 and more recently LPA (Maffucci, et al., 2005; Vanhaesebroeck & 
Waterfield, 1999). However, in respect to class I PI3K, relatively few studies have been 
made to elucidate the isoform-specific roles of class II PI3Ks and their mechanism of Chapter 1 
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activation, partly due to the lack of class II PI3K-specific inhibitors and mutant (class II 
PI3K gene knock-out) mice.  Nevertheless, employing other strategies such as RNAi to 
knock-down specific class II PI3K isoform expression, progress is being made to shed 
some light on the involvement of class II PI3K in various cellular processes. 
 
In  vitro,  class  II  PI3Ks  have  a  preference  for  the  lipid  substrate  PtdIns,  but  can  also 
phosphorylate PtdIns(4)P and PtdIns(4,5)P2.   Phosphorylation of PtdIns by class II PI3K 
generates PtdIns(3)P, which has now been recognized as dynamic intracellular messenger 
alongside PIP3.  PtdIns(3)P is generated upon insulin stimulation and plays a critical role in 
the insulin signalling pathway (Chaussade, et al., 2003; Maffucci, et al., 2003).  LPA also 
induces  PtdIns(3)P  production  (and  not  PtdIns(3,4,5)P3)  at  the  plasma  membrane  in  a 
number of cell lines (Maffucci, et al., 2005).  LPA was found to induce cell migration 
through activation of PIK3C2β, and not PIK3C2ʱ, identifying class II PI3K and PtdIns(3)P 
production as important players in cell migration (Maffucci, et al., 2005).  Recently, PI3K-
C2ʱ, but not PI3KC2β has been found to be important in controlling cell survival (Elis, et 
al., 2008).  In the latter study, lowering the levels of PI3KC2ʱ protein in a number of 
cancer  cell  lines  led  to  reduction  in  proliferation  and  cell  viability,  arguing  that  PI3K 
inhibitors targeting not only the class I PI3K isoforms but also class II PI3K isoforms, in 
this case PIK3C2ʱ, may contribute to an effective anticancer strategy. 
 
Class  II  PI3Ks  are  predominantly  associated  with  the  membrane  fraction  of  cells,  as 
opposed to class I PI3Ks, which are mainly cytosolic.  PI3KC2ʱ and PI3KC2β are fairly 
ubiquitously expressed in mammalian tissue, whereas PI3KC2γ is mainly found in the liver 
(Vanhaesebroeck & Waterfield, 1999).  
 
1.2.3 Class III PI3K 
Class III PI3Ks are homologues of the Saccharomyces cerivisiae vascular protein-sorting 
protein, Vps34p. Vps34p can only phosphorylate PtdIns to generate PtdIns(3)P.  In all 
eukaryotes investigated, a single Vps34 homologue has been identified, which has both the 
PIK and kinase core domain (Figure 1.2). In both  yeast and mammals, class III PI3K 
catalytic subunits exist in complex with a Ser/Thr protein kinase, named Vps15p in yeast 
and  p150  in  mammals  (Vanhaesebroeck  &  Waterfield,  1999).  Originally  isolated  as  a 
mutant of vesicle-mediated vacuolar protein sorting in yeast, class III PI3Ks are implicated 
in  endosome  fusion  during  intracellular  trafficking  events  and  are  located  mainly  on 
intracellular membranes (Foster, et al., 2003). Chapter 1 
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A number of studies in 2001-2002 have further implicated the involvement of class III 
PI3K in diverse intracellular trafficking events, such as autophagy in yeast (Kihara, et al., 
2001),  the  fusion  of  formed  phagosomes  with  late  endosomes/lysosomes  in  a  mouse 
macrophage  cell  line  (Vieira,  et  al.,  2001),  internal  vesicular  formation  within 
multivescicular endosomes in a human cancer cell line (Futter, et al., 2001) and efficient 
endosome-to-Golgi retrograde transport in yeast (Burda, et al., 2002).  Recently, it has 
been shown that mammalian hVps34 plays  an important  role in  the ability of cells  to 
respond to changes in nutrient conditions, through the activation of mTOR (mammalian 
target of rapamycin)/S6K1 (S6 kinase 1) pathway, which regulates protein synthesis in 
response to nutrient availability (Backer, 2008).  
 
1.3 SIGNALLING DOWNSTREAM OF CLASS I PI3K 
As mentioned in the introduction, class I PI3K preferentially produce PIP3 at the inner 
leaflet of the plasma membrane.  A wide variety of cell-surface receptors stimulate class I 
PI3Ks,  such  as  growth  factors,  inflammatory  stimuli,  hormones,  neurotransmitters  and 
antigens (Hawkins, et al., 2006).  PIP3 acts as a docking site for a wide variety of proteins 
containing  the  lipid-binding  PH  domain,  including  proteins  include  serine/threonine 
kinases,  tyrosine  kinases,  nucleotide  exchange  factors,  GTPase-activating  factors, 
phospholipases and adaptor proteins, which mediate a diverse array of cellular functions 
(Hawkins,  et  al.,  2006;  Vanhaesebroeck  &  Waterfield,  1999)  (Figure  1.4).    PI3K 
activation, therefore, represents one of the most prevalent and varied signal transduction 
events associated with mammalian cell-surface receptor activation.  
 
The precise mechanism of activation of PI3K effector proteins through engagement of PH 
domains with PIP3 is, in most cases, not clear.  However, in several cases the interaction is 
of  sufficient  affinity  to  target  the  effector  protein  from  the  cytoplasm  to  the  plasma 
membrane (plasma-membrane translocation). This translocation brings the effector protein 
into proximity with substrates or binding partners.  PIP3 binding to PH domains can also 
relieve  PH  domain-mediated  intramolecular  inhibition  in  the  effector  protein,  thereby 
activating the effector downstream pathways (Hawkins, et al., 2006). 
 Chapter 1 
30 
 
 
Figure 1.4: Downstream effectors of class I PI3K.  There are a number of PH domain-
containing proteins that act as downstream effectors of class I PI3K activation.  These 
include Ser/Thr kinases, tyrosine kinases, regulators of small GTPases such as GAPs and 
GEFs and adaptor or scaffold proteins.  These effector proteins regulate diverse cellular 
responses  such  as  cell  growth,  cell  survival,  gene  transcription  and  cytoskeletal 
organization. 
 
 
1.3.1 PI3K activation of serine/threonine protein kinases 
The serine/threonine protein kinase Akt (also known as PKB), is considered the major 
effector of the class I PI3K signalling pathway.  Indeed, activation of class I PI3K is often 
assessed by the activation of Akt (since measuring the changes in PI products is relatively 
technically demanding).  Full activation of Akt requires another PH-domain containing 
protein serine/threonine kinase, PDK1, which will be discussed in the next section. 
 
In addition to translocating Akt to the plasma membrane, the interaction of the PH domain 
of Akt with PIP3 is thought to relieve PH domain-mediated intramolecular inhibition, thus 
provoking  a  conformational  change  in  Akt,  resulting  in  the  exposure  of  two  main 
phosphorylation sites, Thr308 in the T-loop of its kinase domain and Ser473 located in a 
C-terminal  non-catalytic  region.    Phosphorylation  at  both  of  these  sites,  Thr308  and 
Ser473,  is  necessary  for  full  activation  of  Akt.    In  contrast,  PDK1  appears  to  be 
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„constitutively  active‟  and  its  activity  is  independent  of  PIP3/PH  domain  binding.  
However, the ability of PDK1 to phosphorylate Akt on Thr308 in its kinase domain is 
highly dependent on the conformational change of Akt induced by class I PI3Ks, hence its 
name 3‟-phosphoinositide-dependent kinase-1.  PDK1 does not, however, phosphorylate 
Ser473 on Akt which is required for full activation of Akt.  The kinase responsible for Akt 
Ser473  phosphorylation  has  remained  elusive  for  many  years  and  was  initially  termed 
„PDK-2‟.  Recently, a rapamycin-insensitive form of mTOR protein kinase in complex 
with Rictor and GβL, termed the mTORC2 complex, has been proposed to phosphorylate 
Akt Ser473 (Sarbassov, et al., 2005). 
 
Akt plays  a central  role in  multiple signalling  pathways  involved in  cell survival,  cell 
metabolism and proliferation pathways as shown in Figure 1.5.  The involvement of Akt in 
certain aspects of these pathways is briefly discussed below.  
 
Cell  survival:  One  of  the  mechanisms  by  which  Akt  promotes  cell  survival  is  by 
phosphorylating and inhibiting the pro-apoptotic protein BAD (Bcl-2/Bcl-XL antagonist, 
causing cell death).  BAD binds and inhibits the anti-apoptotic proteins Bcl-2 and Bcl-XL, 
therefore Akt inhibition  of BAD allows  Bcl-2  and Bcl-XL  to  exert their anti-apoptotic 
effects.  Another pro-apoptotic protein, Caspase-9, is also phosphorylated and inhibited by 
Akt (Hawkins, et al., 2006; Vanhaesebroeck & Waterfield, 1999). 
 
Akt is also a major regulator of the forkhead box (FOXO) family of transcription factors.  
All mammalian FOXO proteins have highly conserved sites for phosphorylation by Akt, 
which  include  FOXO1  (FKHR),  FOXO3a  (FKHRL1),  FOXO4  (AFX)  and  FOXO6  in 
humans  (Huang  &  Tindall,  2007).  Akt-phosphorylated  FOXO  proteins  bind  to  14-3-3 
chaperone proteins and become sequestered in the cytoplasm, where they are unable to 
regulate gene expression.  Gene expression regulated by FOXO proteins include the pro-
apoptotic  gene,  Fas  Ligand  (FasL),  which  encodes  a  protein  that  activates  the  death 
receptor Fas/CD95/APO-1 and promotes mitochondria-independent apoptosis (Huang & 
Tindall, 2007).  In addition to the death receptor ligands, FOXO proteins have also been 
shown to be involved in the transactivation of BIM, a gene that encodes a member of the 
pro-apoptotic  BH3-only  subgroup  of  BCL-2  family  proteins,  which  functions  in  a 
mitochondrial-dependent apoptotic pathway.  Akt-induced sequestering of FOXO proteins 
in the cytoplasm therefore results in increased cell survival.    Chapter 1 
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Figure 1.5: Signalling downstream of Akt activation. Cell metabolism: Akt activation 
regulates cell metabolism through phosphorylation and inhibition of GSK3 resulting in 
increased activation of glycogen synthase and the transcription factor eIF2B.  PFK2 and 
GLUT4  are  also  activated  downstream  of  Akt,  which  promote  glycolysis  and  glucose 
uptake,  respectively.    Cell  cycle  progression:  Akt  activation  promotes  cell  cycle 
progression through inhibiting p27 and p21, which would otherwise inhibit CDKs.  Mdm2 
is a phosphorylated and activated by Akt, which inhibits the tumour-suppressor activity of 
p53.    Akt-induced  inactivation  of  the  tumour-suppressor  retinoblastoma  (Rb)  and 
activation of c-Myc also promotes cell cycle progression.  Cell survival:  Akt promotes 
cell survival through inhibition of the FOXO family of transcription factors, which if active 
would induce transcription of pro-apoptotic proteins FasL and BIM.  The pro-apoptotic 
proteins  Caspase-9  and  BAD  are  also  inhibited  by  Akt.    Akt  activates  NFκB-induced 
transcription by activating IKK which in turn phosphorylates and causes the degradation of 
inhibitor of NFκB, IκB.  Akt phosphorylates and suppresses the TSC1/2 complex, resulting 
in  increased  activation  of  the  Rheb  GTPase  and  enhanced  mTOR  activity.    The  main 
downstream targets of mTOR are 4E-BP and S6K.  It should be noted that there is overlap 
between the pathways involved in cell metabolism, cell cycle progression and cell survival. 
 
NFκB is another factor involved in cell survival that has been identified as a functional 
target of Akt (Ozes, et al., 1999).  The NFκB family of transcription factors induce the 
expression of a wide variety of genes involved in cell survival, including the Bcl-2 family 
member Bfl-1, and the caspase inhibitors c-IAP1 and c-IAP2.  Binding of NFκB to IκB 
sequesters it to the cytoplasm.  Akt-induced phosphorylation of IκB kinase (IKK), result in Chapter 1 
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IκB  degradation  allowing  NFκB  to  enter  the  nucleus  and  induce  gene  transcription 
(Khwaja, 1999).  Akt-induced phosphorylation of IKK appears to be indirect and the exact 
mechanism of NFκB activation by Akt requires further investigation. 
  
Cell metabolism:  The first function that was attributed to Akt was glycogen metabolism. 
Upon stimulation of cells by insulin, Akt has been shown to phosphorylate a number of 
important components of the insulin signal transduction pathway: 1) Akt phosphorylates 
and inhibits  glycogen synthase kinase 3 (GSK3) whose downstream  targets  include of 
glycogen  synthase  and  translation  initiation  factor  eIF2B;  2)  Akt  phosphorylates  and 
activates 6-phosphofructo-2-kinase (PFK2), one of the enzymes that is involved in the 
glycolysis  pathway;  3)  Akt  activates  phospshodiesterase-3B  (PDE-3B),  an  enzyme 
important in the regulation of the cellular concentration of the second messenger, cAMP; 
4) activation of Akt by insulin may enhance glucose uptake by increasing the expression 
levels  of  the  glucose  transporters,  GLUT1  and  GLUT3  (Barthel,  et  al.,  1999);  and  5) 
Insulin stimulates Akt activation of mTOR, an enzyme that regulates protein translation 
(Patel,  et  al.,  2002).    mTOR  is  activated  by  the  GTPase  Rheb,  which  is  negatively 
regulated by the TSC1/2GTPase-activating complex.  Activation of Akt phosphorylates 
TSC1/2  suppressing  the  GTPase-activating  effects  of  TSC1/2  on  Rheb  and  enhances 
mTOR activity. The mTOR complex with Raptor mediates the phosphorylation of 4E-BP1 
and S6K1, which stimulate translational initiation and contribute to cell growth.  Akt can 
also  activate  mTOR  through  phosphorylation  and  relieving  the  inhibitory  effect  of 
PRAS40 (proline-rich Akt substrate of 40 kDa, which represses mTOR activity), a protein 
in complex with mTOR and Raptor (Wullschleger, et al., 2006).  
 
Cell  cycle  progression/proliferation:  As  described  above,  Akt  activation  of  mTOR  is 
involved in cell metabolism and also increased cell growth and proliferation.  Numerous 
regulators  of  cell  cycle  progression  are  also  activated  Akt.    Akt  activity  increases  the 
transcription of c-Myc, which when overexpressed or hyperactivated is a strong promoter 
of cell cycle progression.  Akt can also phosphorylate and deactivate the tumour suppressor 
retinoblastoma (Rb), which leads to activation of E2F, a transcription factor that drives cell 
cycle progression (Brennan, et al., 1997).  Furthermore, Akt activation leads to enhanced 
cyclin D1 expression, a protein that is involved in cell progression through the G0 and G1 
stage of the cell cycle (see section 1.4.1.2 for a more detailed description of the cell cycle).   
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Akt activation is also associated with the regulation of the CDK (cyclin-dependent kinase) 
inhibitors p27 and p21.  Both p27 and p21 function to block the activation of CDK-cyclin 
dimers, which inhibits cell cycle progression.  Akt activation diminishes p27 expression 
levels and sequesters p21 to the cytosol, consequently promoting cells to advance through 
the cell cycle (Chakravarthy, et al., 2000; Graff, et al., 2000; Zhou, et al., 2001) 
 
Finally, the oncogene Mdm2 is a direct target of Akt in cell cycle regulation (Mayo & 
Donner, 2001).  Mdm2 is a regulator of p53, a tumour suppressor that halts the cell-cycle 
in the G1 phase or triggers apoptosis in response to DNA damage or other cellular stresses.  
Mdm2  binds  to  and  inhibits  the  tumour  suppressor  function  of  p53  by  promoting  its 
ubiquitin-dependent degradation.  Akt phosphorylates and activates Mdm2, resulting in 
decreased p53 activity and therefore promoting cell cycle progression and cell survival 
(Mayo & Donner, 2001).  
 
1.3.2 PI3K activation of protein tyrosine kinases 
Tec/Btk tyrosine kinases are members of a subgroup of the Src tyrosine kinase family, 
which all share a homologous SH3/SH2/kinase core structure.  Unlike Src family kinases 
Tec kinases do not contain an N-terminal membrane-targeting motif, they do however have 
an N-terminal PH domain.  Similarly to membrane-targeting motif, the PH domain serves 
to target Tec family tyrosine kinases to the plasma membrane, where further activating 
phosphorylations occur.  
 
Tec  family  members  include  Btk  (Bruton‟s  tyrosine  kinase)  and  Itk  (inducible  T-cell 
kinase).  The PH domain of Btk binds PIP3 with high affinity.  Btk is critical for B cell 
development and function and several germline mutations that map to the PH domain have 
been shown to cause immunodeficiency (Vanhaesebroeck & Waterfield, 1999). 
 
1.3.3 PI3K activation of regulators of small GTPases 
Small GTPases cycle between an active GTP-bound conformation and an inactive GDP-
bound  conformation.    This  cycle  is  regulated  by  guanine  nucleotide  exchange  factors 
(GEFs)  and  GTPase  activating  proteins  (GAPs).    The  regulation  of  small  GTPases  is 
discussed in more depth in section 1.4, but briefly, GEFs catalyse the exchange of GDP on 
small GTPases for GTP, activating the small GTPase.  GAPs on the other hand stimulate 
the intrinsic GTPase activity of the small GTPases, resulting in hydrolysis of GTP to GDP 
and subsequent inactivation. 
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All GEFs for the Rho family of small GTPases (Rho, Rac and Cdc42) contain PH domains, 
along with GEFs for ARF family small GTPases.  The binding of GEFs to PIP3 is thought 
to relieve PH domain-mediated inhibition of the GEF Dbl catalytic domain, and also bring 
the GEF into proximity with its lipid-tethered GTPase (Hawkins, et al., 2006; Welch, et al., 
2003). A number of GAPs are also able to bind PIP3, including the centaurins, GAP1
m, and 
GAP
IP4BP  proteins.    The  centaurins  have  homology  to  yeast  GAPs  for  ARF-GTPases, 
whereas GAP1
m, and GAP
IP4BP are Ras GAPs.  Since the key regulators of small GTPases, 
namely GEFs and GAPs, are activated by PIP3 production, it is not surprising that PI3K 
activation  regulates  the  downstream  cellular  response  of  small  GTPases.    The  Rho 
GTPases are involved in organisation of the cell cytoskeleton, which has implications in 
cell migration, cell cycle progression and cell adhesion (see section 1.4), whereas ARF 
GTPases  play  a  role  in  vesicular  membrane  trafficking  in  several  intracellular 
compartments (Vanhaesebroeck & Waterfield, 1999). 
 
1.4 CONVERGING SIGNALLING PATHWAYS OF PI3K AND RHO GTPASES  
1.4.1 Introduction to Rho GTPases  
Rho GTPases are members of the Ras superfamily of monomeric 20 - 30 kDa GTP-binding 
proteins.    Since  the  discovery  of  the  Ras  proto-oncogene  more  than  20  years  ago 
(Barbacid, 1987) and the recognition that oncogenic mutations in the Ras genes occur 
frequently in human carcinomas, there has been a widespread effort in identifying other 
Ras-like small GTPases.  Over 100 Ras-like GTPases are known to date.  These can be 
classified into five main groups: Ras, Rab, Arf, Ran and Rho GTPases (Aspenstrom, et al., 
2004).  The latter will be discussed in more detail here. 
 
To  date,  twenty-two  mammalian  genes  encoding  different  mammalian  Rho  GTPases 
family  members  have  been  described.    These  Rho  GTPases  can  be  divided  into  nine 
groups, most of which include multiple isoforms: Rho (A, B and C); Rac (1, 2 and 3); 
Cdc42, (Cdc42, TCL10, TCL, Chp, Wrch-1); RhoD (RhoD and Rif); Rnd (Rnd1, Rnd2, 
RhoE/Rnd3); RhoH/TTF; RhoBTB (RhoBTB1 and RhoBTB 2); RhoG; and Miro (Miro-1 
and Miro-2) (Aspenstrom, et al., 2004; Hall, 2005).  From these, RhoA, Rac1 and Cdc42 
have been the most extensively studied and have been found to regulate specific aspects of 
actin-dependent cellular processes (Etienne-Manneville & Hall, 2002; Takai, et al., 2001). 
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1.4.2 Regulation of Rho GTPases  
Similar to other GTPases, Rho GTPases act as molecular switches, cycling between an 
active GTP-bound conformation and an inactive GDP-bound conformation (Figure 1.6).   
 
 
Figure 1.6: The Rho GTPase cycle. Rho GTPases cycle between an active GTP-bound 
conformation and an inactive GDP-bound conformation.  GEFs replace GDP with GTP 
thereby  activating  Rho  GTPase  signalling  pathways.    GTP  hydrolysis  and  therefore 
inactivation of Rho GTPases is facilitated by GAPs.  GDIs also participate in inhibiting 
Rho GTPase signalling through binding GDP-bound Rho GTPases and preventing GDP-
GTP exchange.  
 
 
GEFs catalyse the exchange of GDP for GTP thereby activating the molecular switch.  
Conversely, GAPs increase the intrinsic enzymatic activity of the Rho GTPase resulting in 
the hydrolysis of GTP to GDP, thereby inactivating the switch (Takai, et al., 2001).  Rho 
GTPases are further regulated by another class of regulators guanine dissociation inhibitors 
(GDIs)  (Fukumoto,  et  al.,  1990;  Hiraoka,  et  al.,  1992).    GDIs  appear  to  inhibit  Rho 
GTPase  activity  by  forming  a  soluble  complex  with  GDP-bound  Rho  GTPase  thus 
sequestering the  complex in  the cytoplasm  and inhibiting their spontaneous  GDP-GTP 
exchange activity.  It is thought that in a resting cell, Rho GTPases reside in this inactive 
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GDI  complex,  which  dissociates  upon  cell  stimulation  thereby  allowing  GDP-GTP 
exchange. 
 
Over thirty GEFs have been identified although they still remain largely uncharacterised 
(Kjoller & Hall, 1999; Van Aelst & D'Souza-Schorey, 1997).  All Rho-GEFs contain a 
Dbl-homology  (DH)  domain  which  encodes  the  catalytic  activity  and  an  adjacent  PH 
domain (Bishop & Hall, 2000; Cherfils & Chardin, 1999).   About twenty Rho-GAPs have 
been  identified  to  date  (Lamarche  &  Hall,  1994),  eight  of  which  are  encoded  on 
chromosome 22 (Dunham, et al., 1999).  Table 1.1 lists the main regulators of the best 
characterised Rho GTPases Rho, Rac and Cdc42. 
 
Regulator  Substrate 
GEFs   
Dbl  Rho, Rac, Cdc42 
Vav1  Rho, Rac, Cdc42 
Dbs  Rho, Cdc42 
Lbc  Rho 
Lfc  Rho 
Vav2    Rho 
p115   Rho 
PDZ-Rho-GEF  Rho 
Tiam-1  Rac 
Sos  Rac, (Ras) 
p-Rex1  Rac 
SWAP-70  Rac 
FGD1  Cdc42 
Frabin  Cdc42 
GAPs   
p50 RhoGAP  Rho, Rac, Cdc42 
p190 RhoGAP  Rho, Rac, Cdc42 
Graf  Rho 
myr5  Rho, Cdc42 
Bcr  Rac, Cdc42 
n-Chimaerin  Rac, Cdc42 
3BP-1   Rac 
Abr  Rac 
GDIs   
Rho GDI  Rho 
D4/Ly-GDI  Rho 
Rho GDI-3  RhoB (not RhoA or C) 
 
Table 1.1: Regulators of the Rho GTPase proteins Rho, Rac and Cdc42.  The GEFs, 
GAPs and GDIs listed have various degrees of specificity for each Rho GTPase.  Adapted 
from Takai et al, 2001. 
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1.4.3 Effector proteins of Rho GTPases 
The nucleotide-dependent alteration of protein conformation of Rho GTPases enables the 
enzyme to relay intracellular signals (Aspenstrom, et al., 2004).   In the active GTP-bound 
conformation, Rho GTPases bind a specific set of downstream effector proteins.  To date, 
around thirty potential effectors for Rho GTPases have been identified, which are listed in 
Table 1.2 (Bishop & Hall, 2000).  The most common mechanism of effector activation by 
Rho  GTPases  appears  to  be  the  disruption  of  autoinhibitory  interactions,  to  expose 
functional domains within the effector protein (Bishop & Hall, 2000). 
 
Effector Protein  Type of protein  Functions  Rho GTPase 
selectivity 
ROCKʱ, ROCKβ  Ser/Thr kinase  Actin/myosin  Rho 
PKN/PRK1, PRK2  Ser/Thr kinase  Unknown  Rho 
Citron kinase  Ser/Thr kinase  Cytokinesis  Rho 
p70 S6 kinase  Ser/Thr kinase  Translation  Rac, Cdc42 
Mlk2, 3  Ser/Thr kinase  JNK  Rac, Cdc42 
MEKK1, 4  Ser/Thr kinase  JNK  Rac, Cdc42 
PAK1, 2, 3  Ser/Thr kinase  JNK/actin  Rac, Cdc42 
PAK 4  Ser/Thr kinase  Actin  Cdc42 
MRCKʱ, MRCKβ  Ser/Thr kinase  Actin  Cdc42 
Ack1,2  Tyr Kinase  Unknown  Cdc42 
MBS  Phosphatase subunit  MLC inactivation  Rho 
PI-4-P5K  Lipid kinase  PIP2 levels/actin  Rho, Rac  
PI3K  Lipid kinase  PIP3  Rac, Cdc42 
DAG kinase  Lipid kinase  PA levels  Rho, Rac 
PLD  Lipid kinase  PA levels  Rho, Rac, Cdc42 
PLC-β2  Lipid kinase  DAG/IP3 levels  Rac, Cdc42 
Rhophilin  Scaffold  Unknown  Rho 
Rhotekin  Scaffold  Unknown  Rho 
Kinectin  Scaffold  Kinesin binding  Rho 
Dia1, Dia2  Scaffold  Actin organisation  Rho 
WASP, N-WASP  Scaffold  Actin organisation  Cdc42 
WAVE/Scar  Scaffold  Actin organisation  Rac 
POSH  Scaffold  Unknown  Rac 
POR-1  Scaffold  Actin organisation  Rac 
p140Sra-1  Scaffold  Actin organisation  Rac 
p67
phox  Scaffold  NAPDH oxidase  Rac 
MSE55, BORGs  Scaffold  Unknown  Cdc42 
IQGAP1, 2  Scaffold  Actin/cell-cell 
contacts 
Rac, Cdc42 
CIP-4  Scaffold  Unknown  Cdc42 
 
Table 1.2: Potential effector proteins for Rho, Rac and Cdc42.  Where a function for 
the Rho GTPase effector protein has been reported it is noted, but in many cells this is far 
from clear.  Table adapted from Bishop et al, 2000. 
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1.4.4 PI3K:  A downstream effector or upstream regulator of Rho GTPases? 
The p85 regulatory subunit of PI3K contains a region of homology to the Rac GAP domain 
in Bcr (BH domain) (Fry, 1992).  Although highly homologous, the BH domain in p85 
differs from the Bcr Rac GAP domain at residues critical for GAP activity, suggesting p85 
BH domain does not activate the intrinsic GTPase activity of Rho GTPases but retains the 
ability to bind small GTP binding proteins (Beeton, et al., 1999).  However, relatively 
recently, GAP activity of the p85ʱ BH domain has been reported towards Rab5, Rab4, 
Cdc42,  Rac1  and  to  a  lesser  extent  Rab6,  with  little  GAP  activity  toward  Rab11 
(Chamberlain, et al., 2004).  In a follow up study, disruption of the Rab GAP function of 
p85ʱ,  due  to  a  single  point  mutation,  was  found  to  be  sufficient  to  cause  cellular 
transformation,  although PI3K signalling appeared unaltered (Chamberlain, et al., 2008). 
  
In addition to the presence of a p85 BH domain, Rho GTPases and PI3Ks have several 
overlapping  cellular  functions.    These  observations  have  lead  to  a  number  of  studies 
investigating the potential partnership between PI3K and Rho GTPases in regulating their 
converging signalling pathways.   
 
Both Rac1 and Cdc42 have been found to bind PI3K in vitro (Zheng, et al., 1994).  Using 
an immobilised glutathione S-transferase (GST)-Rho GTPase fusion protein in either a 
GDP or GTP-bound state, GTP-bound Cdc42 and Rac-1 (but not RhoA) were found to 
bind the regulatory subunit of PI3K, p85.  GTP-bound Cdc42 was further found to activate 
PI3K activity, albeit weakly (Zheng, et al., 1994).  In another later study, PI3K activity has 
also been found to be associated with GTP-bound Cdc42 and also GTP-bound Rac1 in 
vitro (Tolias, et al., 1995).  Consistent with the earlier study by Zheng et al, PI3K activity 
was  not  associated  with  RhoA  and  the  GTP-bound  forms  of  Cdc42  and  Rac1  were 
associated with increased PI3K activity compared to their GDP-bound forms.  To further 
corroborate  these  findings,  highly  purified  bovine  brain  p85  was  found  to 
immunoprecipitate  with  Rac1  and  Rac2  (but  not  with  RhoA)  and  p85  binding  was 
increased when Rac was in a GTP-bound active conformation (Bokoch, et al., 1996).  The 
Bcr homology domain of p85 was indicated to be involved in the interaction between p85 
and Rac1 as the isolated p85 Bcr domain showed similar levels of Rac-1 binding when 
compared  to  full-length  p85  (Bokoch,  et  al.,  1996).    To  corroborate  these  findings,  a 
mutation in the BH domain and not SH3 domain of p85ʱ has been found to inhibit GTP-
loaded Rac-induced lipid kinase activity in p85ʱ/p110 heterodimers (Beeton, et al., 1999). Chapter 1 
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Various  cell  lines  have  been  used  to  investigate  the  potential  in  vivo  capacity  of  Rho 
GTPases to interact with PI3K.  Cdc42 has been found to be constitutively associated with 
high PI3K activity in Cdc42 immunoprecipitates from COS7 cells, whereas only a small 
amount  of  PI3K  activity  was  detected  in  Cdc42  immunoprecipitates  from  PDGF-
stimulated Swiss 3T3 cells (Tolias, et al., 1995).  On the contrary to Cdc42, the in vivo 
association of Rac1 with PI3K has been found to be clearly regulated by PDGF stimulation 
in Swiss 3T3 cells (Tolias, et al., 1995).  These results highlight the cell type and stimulus-
dependency of Rho GTPase regulation. 
 
Collectively,  these  investigations  suggest  that  the  interaction  of  PI3K  with  Rac  is 
dependent on Rac/Cdc42 activation, thus placing PI3K downstream of Rac.  However, 
there is a growing body of evidence that suggests the contrary, that PI3K may be upstream 
of Rac activation.  Dominant-negative PI3K constructs or the PI3K inhibitor wortmannin 
inhibit the Rac-dependent pathways of PDGF and insulin-stimulated membrane ruffling 
(Hawkins, et al., 1995; Kotani, et al., 1995).  More conclusively proof lies in that in Rac-
overexpressing  endothelial  cells,  PDGF-stimulated  Rac  GTP-loading  is  sensitive  to 
wortmannin (Hawkins, et al., 1995). 
It has been suggested that PI3K regulates Rac activation via inhibition of Rac GTPase 
activity and secondly, by activating a PIP3-sensitive Rac-GEF and increasing nucleotide 
exchange (Hawkins, et al., 1995).  Among the Rac-GEFs identified, members of the Vav, 
Sos, Tiam, PIX, SWAP-70 and P-Rex families have been suggested to be regulated by 
PI3K in vivo.  PIP3 directly binds and strongly activates the Rac-GEF activities of P-Rex1 
and SWAP-70 in vitro (Shinohara, et al., 2002; Welch, et al., 2002), and weakly activates 
those of Vav1, Sos1 and possibly Tiam1 (Han, et al., 1998; Innocenti, et al., 2003).  The 
ability of PI3K/PIP3 to activate the other Rac-GEFs has not yet been studied (Welch, et al., 
2003). Indeed, PIP3 can also directly bind Rac in vitro and at high concentrations PIP3 
facilitates  the  dissociation  of  GDP  from  Rac.    However  PIP3  preferentially  binds  the 
nucleotide-free form of Rac and does not promote GTP loading, therefore the significance 
of this interaction in vivo is unclear (Missy, et al., 1998).   
Recently, PI3K, specifically p110δ, has been shown to negatively regulate RhoA activity 
in  macrophages  (Papakonstanti,  et  al.,  2007).    Under  basal  and  CSF-1  stimulated 
conditions,  macrophages  homozygous  for  p110δ  inactivation  (p110δ
D910A/D910A)  display 
increased levels of RhoA-GTP compared to wild-type macrophages.  In contrast, upon 
CSF-1  stimulation,  Rac-GTP  levels  are  reduced  in  p110δ
D910A/D910A  macrophages.    In Chapter 1 
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p110δ
D910A/D910A  macrophages,  p190RhoGAP  activity  is  also  decreased,  which  is 
accompanied  by  an  increase  in  the  phosphatase  activity  of  PTEN.    Furthermore, 
p110δ
D910A/D910A macrophages were found to have decreased cytosolic p27 upon CSF-1 
stimulation.  Cytosolic p27 has been reported to bind and inhibit RhoA, and in accordance 
with this in wild-type macrophages a greater proportion of RhoA was found to bind p27 
than  in  p110δ
D910A/D910A  macrophages.    A  signalling  pathway  was  proposed  to  explain 
these findings, in which p110δ activation negatively regulates RhoA activity by increasing 
the activity of p190RhoGAP and increasing the cytoplasmic proportion of p27.  If p110δ 
activity is  inhibited, either  genetically or pharmacologically, the negative regulators  of 
RhoA are suppressed resulting in activation of RhoA and its downstream effector ROCK, 
which  in  turn  activates  PTEN  and  its  phosphatase  activity  for  PIP3.    This  proposed 
pathway introduces an interesting concept of p110δ, and possibly other p110 isoforms, 
regulating its own activity via a feedback loop involving RhoA and PTEN (Papakonstanti, 
et al., 2007). 
Cumulatively, these findings paint a somewhat confusing picture of the regulation of Rho 
GTPases by PI3K.  On the one hand, PI3K interaction with Rac appears to be downstream 
of Rac activation and on the other hand the activation of Rac appears to be a target of 
PI3K, placing PI3K upstream of Rac.  A positive feedback loop has been suggested, in 
which Rac once activated by PI3K, can in turn further activate PI3K.  This feedback loop 
may play an essential role is establishing cell polarity in neutrophils (Weiner, et al., 2002).  
In  the  case  of  RhoA,  PI3K,  specifically  p110δ,  appears  to  be  an  upstream  negative 
regulator of RhoA activity (Papakonstanti, et al., 2007). 
It is apparent however, that PI3K is not solely activated by Rac (Welch, et al., 2003).  
Inversely and just as clear, is that Rac activation is not exclusively PI3K-dependent, an 
example being PI3K-dependent but Rac-independent insulin-stimulated glucose transport 
(Marcusohn, et al., 1995; Welch, et al., 2003).  The relative importance of PI3K-dependent 
versus PI3K-independent pathways of Rac activation for a given downstream response is 
still unclear in most circumstances and requires further investigation (Welch, et al., 2003).   
 
1.4.5 Biological functions of Rho GTPases 
The first described biological function of Rho GTPases was regulating the assembly and 
organisation of the actin cytoskeleton.  A plethora of cellular processes are regulated by 
changes in the actin cytoskeleton such as cell migration, cell cycle progression, cell-cell Chapter 1 
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interactions, cell adhesion, phagocytosis, pinocytosis, axon guidance and morphogenesis 
thereby indicating Rho GTPases as multifaceted cellular regulators.  Furthermore, it is now 
known  that  Rho  GTPases  are  involved  in  several  other  cellular  processes  such  as 
transcriptional activation and cell growth.  An outline of the role Rho GTPases play in 
these biological functions is discussed below. 
 
1.4.5.1 Regulation of the actin cytoskeleton: The actin cytoskeleton of mammalian cells is 
composed of actin filaments and actin-binding proteins.  Filamentous actin is generally 
organised into three discrete structures: 1) Filopodia - thin, dynamic finger-like protrusions 
comprising tight bundles of long actin filaments in the direction of the protrusion. They 
can change their length rapidly, span many cell diameters, and interact with other cells; 2) 
Lamellipodia – flat protrusive actin sheets that form at the leading edge of fibroblasts and 
many motile cells.  Membrane ruffles observed at the leading edge of cells results from 
lamellipodia  that  lift  up  off  the  substrate  and  fold  backward;  3)  Actin  stress  fibres  – 
bundles of actin filaments that traverse the cell and are linked to the extra cellular matrix 
(ECM) through focal adhesions (Van Aelst & D'Souza-Schorey, 1997).   
 
Rho, Rac and Cdc42 have each been linked to each of the distinct types of actin assembly.  
Studies  carried  out  using  quiescent  Swiss  3T3  fibroblasts,  a  cell  line  that  has  a  low 
background of organised F-actin structures under serum-starvation conditions, have lead to 
the  designation  of  Rho  as  a  regulator  of  actin-myosin  stress  fibre  assembly,  Rac  as  a 
regulator of lamellipodia assembly, and Cdc42 as a regulator of filopodia assembly (Figure 
1.7) (Kozma, et al., 1995; Ridley & Hall, 1992; Ridley, et al., 1992).  In a brief summary 
of the findings leading to these conclusions; LPA induces stress fibres and associated focal 
adhesions, which is blocked by C3 transferase, a Rho inhibitor (Ridley & Hall, 1992).  
Growth factors, such as PDGF, insulin or EGF induce the formation of lamellipodia and 
membrane  ruffles  associated  with  focal  contacts,  a  response  that  is  blocked  by  the 
dominant-negative  [Asn
17]Rac  (Ridley,  et  al.,  1992).    Finally,  bradykinin  induces  the 
formation of peripheral filopodia, which are also associated with focal contacts, and this is 
inhibited by dominant-negative [Asn
17]Cdc42 (Kozma, et al., 1995).  It should be noted 
however, that although these findings define specific roles for Rho GTPases in Swiss 3T3 
cells, the specific roles for Rho, Rac and Cdc42 in regulating the actin cytoskeleton are 
variable and cell type-dependent. Chapter 1 
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Figure 1.7: Schematic to show the types of actin filament organisation specifically 
induced by Rho, Rac or Cdc42 activation in Swiss 3T3 cells.  
 
Actin filaments are polar, with a fast-growing barbed end (+ end) and a slow-growing 
pointed end (- end).  Actin filament polymerisation occurs mostly at the barbed end and 
depolymerisation at the pointed end and is tightly controlled by regulatory proteins.  Two 
major polymerisation factors are Arp2/3 and Formin.  Rac and Cdc42 activate Arp2/3 via 
WAVE  [a  WASP  (Wiskott-Aldrich  syndrome  protein)  family  protein]  and  WASP, 
respectively to initiate a branched filament network (Jaffe & Hall, 2005).  Rho stimulates 
actin polymerisation in mammalian cells through diaphanous-related formin, mDia1.  Rho 
directly activates mDia to expose a FH2 domain that binds to the barbed end of actin 
filaments.  mDia1 also has a FH1 domain which mediates the delivery of a profilin/actin 
complex to the filament end (Jaffe & Hall, 2005). 
 
1.4.5.2 Cell cycle progression: The eukaryotic cell cycle consists of four main phases, a 
DNA replication or synthesis phase (S) and a nuclear/cell division or mitotic phase (M) 
separated by two gap phases (G1 and G2) (Figure 1.8).  Rho GTPases are required for 
progression through the G1 and M phase.  Inhibition of Rho, Rac or Cdc42 blocks G1 
progression  in  a  variety  of  cell  types  but  the  precise  mechanism  of  Rho  GTPase 
involvement  is  unclear  and  appears  to  be  cell-type  dependent  (Olson,  et  al.,  1995; 
Yamamoto, et al., 1993).    
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Figure 1.8: The cell cycle. The cell cycle is divided into the first growth phase (G1), the 
DNA replication or synthesis phase (S), the second growth phase (G2) and the mitotic 
phase  (M).    The  M  phase  is  further  subdivided  into  6  phases:  1)  Prophase  –  each 
chromosome  has  duplicated  and  now  consists  of  two  sister  chromatids.  At  the  end  of 
prophase, the nuclear envelope breaks down; 2) Prometaphase – mitotic spindles (formed 
from  bundles  of  microtubules)  from  centrosomes  attach  to  the  kinetochore  of 
chromosomes;  3)  Metaphase  –  chromosomes  line  up  along  the  metaphase  plate;  4) 
Anaphase  –  sister  chromatids  are  cleaved  and  pulled  apart  by  shortening  kinetochore 
microtubules  towards  their  respective  centrosome  at  opposite  ends  of  the  cells;  5) 
Telophase  –  microtubules  that  are  not  attached  to  kinetochores  continue  to  length  to 
elongate  the  cell.    New  nuclear  envelopes  form  around  the  set  of  separated  sister 
chromatids; 6) Cytokinesis – this is not technically a part of mitosis but is an essential 
process to complete cell division. A cleavage furrow and associated contractile ring forms 
where the metaphase plate used to be and pinches the cell into two daughter cells. 
 
G1 progression is controlled by two types of cyclin-dependent kinases, CDK4/CDK6 and 
CDK2,  which  are  activated  by  binding  to  cyclin  D  and  cyclin  E,  respectively.  Rho 
GTPases are involved in the temporal control of cyclin D expression, although the specific 
role of Rho, Rac and Cdc42 and how they work together in this temporal control remains 
ambiguous (Joyce, et al., 1999; Welsh, et al., 2001).  Rho GTPases also regulate the levels 
of the CDK2 inhibitors, p21
Cip1 and p27
Kip1 (Weber, et al., 1997).  The critical role of Rho 
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GTPases  for  G1  progression  is  also  thought  to  reflect  the  dependency  on  the  cell  for 
anchorage and adhesion signals for proliferation.  
 
The  M  phase  of  the  cell  cycle  is  when  nuclear  division  and  cytokinesis  (cyoplasmic 
division) occurs.  The M phase is divided into the prophase, prometaphase, metaphase, 
anaphase and telophase. Microtubules make up the spindle fibres, which emanate from the 
two centrosomes, and play a major role during cell cycle progression through the M phase, 
driving the alignment and separation of chromosomes during prophase and metaphase.    
Microtubules are polarised polymers of ʱ- and β-tubulin dimers and are a key component 
of the cytoskeleton.  The minus end is usually anchored at the centrosome and the dynamic 
plus end usually at the cell periphery.  It has been shown that ROCK, the main downstream 
effector of Rho, controls the actin-myosin  filaments at the cell cortex required for the 
positioning of the centrosomes (Rosenblatt, et al., 2004).  
 
At the end of mitosis, two identical daughter cells form through cytokinesis.  Cytokinesis 
results  through  the  assembly  of  a  cleavage  furrow  and  an  associated  contractile  ring 
consisting of actin and myosin filaments.  When the fibre ring around the centre of the cell 
contracts, it pinches the cell into two daughter cells.  Rho plays a crucial role in contractile 
ring  function  and  localizes  to  the  cleavage  furrow  along  with  at  least  three  known 
effectors, ROCK, Citron kinase and mDia (Glotzer, 2001; Jaffe & Hall, 2005). 
 
1.4.5.3 Cell migration: Apart from leukocytes, most cells in the human body are immotile, 
aside  from  during  development  and  wound  healing.    Cell  migration  in  the  latter  two 
processes is considerably slower than leukocyte chemotaxis and non-leukocytes do not 
move as single cells, but attached to one another (Barber & Welch, 2006).  During cancer 
progression, subsets of tumour cells change from an immotile to motile state, which may 
lead to metastasis. 
 
For directed leukocyte cell migration, cells first establish a polarised morphology.  This 
involves  cells  responding  to  extracellular  cues,  such  as  chemokine  gradients,  growth 
factors or ECM molecules, resulting in relocation of signalling molecules.  Subsequent 
actin polymerisation and filament  elongation at the front  of the cell, coupled to  actin-
myosin filament contraction in the rear of the cell results in the transformation of the cell 
from a spherical shape to an asymmetric polarised state with a leading edge and a trailing 
uropod (Figure 1.9) (Barber & Welch, 2006; Ridley, et al., 2003). Chapter 1 
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Figure 1.9: PI3K and Rho GTPases in cell polarisation and migration. In the presence 
of a chemoattractant gradient PIP3 is produced at the leading edge of the cell through 
activation of PI3K.  The polar distribution of PIP3 in the cell is enhanced through localized 
phosphatase activity of PTEN at the rear and sides of the cell, which dephosphorylates 
PIP3 to PIP2.  Cdc42 is essential for cell polarisation and is localized at the leading edge 
along  with  Rac.    Activation  of  Cdc42  and  Rac  results  in  activation  of  WASP/WAVE 
proteins that regulate the formation of actin branches and cell protrusions and the cells 
leading edge.  Protrusions are stabilised by the formation of adhesions, requiring integrin 
activation  and  clustering.    Rho  is  located  at  the  rear  of  the  cell  and  is  involved  in 
disassembling cell adhesions and rear cell contraction to drive the cell forward.  Figure 
adapted from Ridley et al, 2003. 
 
PI3K  and  Rho  GTPases  are  key  signalling  molecules  regulating  cell  polarisation  and 
migration.  PIP3 is localized at the leading edge of the cell and seems to be maintained 
through  spatially  and  temporally  positive  feedback  and  negative  regulation.    PIP3 
stimulates PI3K to synthesis more PIP3, a positive feedback loop which is likely to involve 
localized Rac and Cdc42 activity. In addition, Cdc42 has been found to be essential for 
maintaining cell polarity (Allen, et al., 1998; Nobes & Hall, 1999).  The phosphoinositide 
phosphatase, PTEN, is localized in the rear of the cell and catalyses the conversion of PIP3 
to PIP2 thereby maintaining an accumulation of PIP3 at the leading edge (Funamoto, et al., 
2002; Iijima & Devreotes, 2002).  RhoA, localized in the rear of the cell, activates PTEN 
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indirectly through its downstream effector ROCK (Li, et al., 2005).  PIP3 at the leading 
edge binds a large group of proteins that contain PH domains, which are subsequently 
translocated  and/or  activated  in  the  process  and  mediate  the  PI3K  signal.    Indeed,  as 
mentioned in section 1.4.4, a number of Rac-GEFs are activated by PIP3, which accounts 
for localized Rac activity at the cells leading edge.  
 
Actin polymerisation at the leading edge of the cell result in broad lamellipodia or spike-
like filopodia protrusions, mediated by Rac and Cdc42 activity, respectively.  Protrusions 
are stabilised by adhesions to the ECM mediated by integrin receptor activation, which 
serve as traction sites for migration as the cell moves forward over them.  Adhesions are 
disassembled at the cell rear to allow cell detachment, a process promoted by Rho (Ridley, 
et al., 2003).   
 
The force directing cell migration is generated from the interaction of myosin II with actin 
filaments  attached  to  sites  of  adhesion.    Myosin  II  activity  is  positively  regulated  by 
myosin  light-chain  (MLC)  phosphorylation  by  MLC  kinase  (MLCK)  or  ROCK  and 
negatively regulated by MLC dephosphorylation by MLC phosphatase.  MLC phosphatase 
is itself phosphorylated and inhibited by ROCK.  Active Rho, being directly upstream of 
ROCK, therefore plays a major role in cell contractility and transmission of tension to sites 
of adhesion (Ridley, et al., 2003; Riento & Ridley, 2003).   
 
As for most cellular processes, the model of cell migration described above does not apply 
in  all  cell  types.    Recent  migration  studies  have  revealed  striking  differences  between 
tumour cell migration on two-dimensional tissue culture plates  and migration in three-
dimensional matrices.  In a three dimensional matrix, neither Rho nor ROCK activity was 
required in some tumour cells (Sahai & Marshall, 2003).  It is likely that more in vivo 
studies  will  further  our  understanding  the  roles  of  Rho  GTPases  and  PI3K  in  cell 
migration. 
 
1.4.5.4  Cell-cell  interactions:  The  morphogenesis  of  many  cell  types  is  driven  by  the 
assembly of distinct cell-cell adhesion complexes (Jaffe & Hall, 2005).  For example, in 
epithelial cells, Rho GTPases regulate the formation of specialised junctional adhesion 
complexes, namely tight junctions and adherens junctions (AJs), which are required for the 
barrier function of epithelial layers and to establish apical-basolateral polarity (Malliri & 
Collard, 2003).  In fibroblasts, AJs are the major junctional apparatus.   Chapter 1 
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AJs  enhance  cell-cell  contacts  through  linking  transmembrane  cadherin  receptors,  and 
recently identified nectin molecules, in neighbouring cells to the cytoskeleton.  Cadherins 
are  calcium-dependent  cell-cell  adhesion  molecules,  which  have  a  single  extracellular 
cytoplasmic  domain,  a  transmembrane  region,  and  a  cytoplasmic  domain.    The 
extracellular domain mediates homophilic recognition and interaction with cadherin dimers 
on  neighbouring  cells  (Figure  1.10).    The  cytoplasmic  region  is  linked  to  the  actin 
cytoskeleton  through  many  peripheral  proteins,  including  p120-catenin,  β-catenin,  ʱ-
catenin, ʱ-actinin, and vinculin (Fukuyama, et al., 2006). Rho, Rac, and Cdc42 have been 
implicated  in  AJ  assembly,  stability  and  dissolution,  through  regulation  of  cadherin 
function, which is dependent on cell-type.   
 
Figure  1.10:  Cell-cell  interactions  mediated  by  cadherins.  Cadherin  receptors  form 
dimers  at  the  cell  membrane  that  can  interact  with  the  same  molecular  dimers  on 
neighbouring cells (homophilic binding) through its extracellular domain.  This results in 
lateral clustering of cadherin complexes at sites of cell-cell contact.  Calcium ions are 
required for stabilisation of the homophilic interaction and for association of the receptors 
to the actin cytoskeleton, mediated through Rho GTPases.  The intracellular domain of 
cadherin receptors are constitutively associated with cytoplasmic catenin proteins such as 
ʱ-catenin and β-catenin. 
 
E-cadherin, expressed mainly on epithelial cells, activates Rac which stabilises AJs though 
inhibition of E-cadherin endocytosis mediated by IQGAP (Kuroda, et al., 1998).  It has 
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also  been  suggested  that  AJs  stabilisation/formation  is  through  localized  induction  of 
filopodia and/or lamellipodia (through Cdc42 and Rac activation, respectively) which drive 
intimate contacts between adjacent cells.  Activation of Rac by E-cadherin has been found 
to be dependent on PI3K in L-cells stably expressing E-cadherin (Fukuyama, et al., 2006).  
As Rac is seemingly involved in two opposing processes, namely cell migration and AJ 
formation, it is fitting that Rac function is largely cell-type and environment-dependent.    
 
Signalling through Rho has been found to both regulate the formation and dissolution of 
cell junctions.  Constitutively active RhoA can induce an increase in the tightness of TJs in 
MDCK cells, which is mediated by Rho-associated kinase and a yet-to-be identified Rho 
effector (Fujita, et al., 2000).  Similarly, Rho signalling through the downstream effector 
Dia1 is crucial for localization of AJ components to the cell periphery mediated by changes 
in  the  actin  network  (Sahai  &  Marshall,  2002).    On  the  other  hand,  activation  of  the 
effector kinase ROCK and acto-myosin contraction disrupts AJs downstream of Rho in 
epithelial cells (Sahai & Marshall, 2002).  In direct contrast to this finding, ROCK has 
been suggested to regulate the recruitment of myosin II to cadherin contacts, to mediate the 
regional  distribution  of  cadherins  at  the  cell  surface,  positively  regulating  cell-cell 
adhesions (Shewan, et al., 2005). 
 
1.4.1.5 Gene transcription: Rho GTPase regulation of the cytoskeleton also has an impact 
on gene transcription.  The serum response element  is found in many promoters, including 
those  of  genes  encoding  components  of  the  cytoskeleton  (Cramer,  et  al.).    Two 
transcription factors act at the SRE: 1) the ternary complex factor (TCF) regulated by 
Ras/MAP kinase pathway and 2) the serum response factor (SRF) regulated by Rho (Jaffe 
& Hall, 2005). Rho mediates change in the actin cytoskeleton to promote translocation of 
the SRF co-activator, MAL, to the nucleus (Miralles, et al., 2003).   It has been proposed 
that under serum-starvation conditions, MAL is bound to nuclear actin, which promotes 
nuclear export of MAL, resulting in mainly cytoplasmic MAL.  Nuclear actin bound to 
MAL, under serum-starvation, prevents the proportion of MAL localized in the nucleus 
from activating SRF, possibly through recruitment of transcription repressors or inhibition 
of  transcriptional  coactivator  recruitment.  Upon  serum-stimulation,  the  cellular  G-actin 
pool  is  depleted  through  actin  polymerisation,  which  is  suggested  to  result  in  an 
accumulation of nuclear-actin-free MAL in the nucleus and subsequent SRF activation 
(Vartiainen, et al., 2007).  However, the precise mechanism by which Rho induces MAL Chapter 1 
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translocation remains obscure, as although Rac and Cdc42 are also strong inducers of actin 
polymerisation, they are poor activators of SRF in comparison to Rho.   
Rho GTPases also regulate gene transcription through actin-independent pathways.  Rho, 
Rac and Cdc42 are all capable of activating the JNK and p38 MAP kinase pathways in a 
cell-context dependent manner (Minden, et al., 1995; Puls, et al., 1999).  MLK2, MLK3, 
and  MEKK4  interact  with  Rac/Cdc42,  whereas  MEKK1  interacts  with  all  three  Rho 
GTPases, Rho, Rac and Cdc42, although through different sites (Burbelo, et al., 1995). 
Rho, Rac and Cdc42 have also been reported to activate NFκB in response to inflammatory 
stimuli  (Perona,  et  al.,  1997).    Since  Rac  and  Cdc42  also  stimulate  the  production  of 
reactive  oxygen  species  (ROS)  and  inflammatory  cytokines,  which  are  both  potent 
activators  of NFκB, it is  difficult  to  elucidate the mechanism of GTPase activation of 
NFκB (Jaffe & Hall, 2005). 
 
1.5 THERAPEUTIC POTENTIAL OF TARGETING PI3K 
PI3Ks  are  involved  in  multiple  cellular  processes,  therefore  it  is  not  surprising  that 
deregulation  of PI3K  signalling  has  been linked to  a number of disease contexts.   To 
highlight the therapeutic potential of targeting PI3Ks, the involvement of PI3Ks in cancer, 
inflammation, immunity and diabetes is described below. 
 
1.5.1 PI3K and cancer  
Tumour formation and progression is as a result of a shift in the balance between cell 
proliferation and cell death.  Proteins and signalling pathways regulating cell growth, cell 
survival and differentiation are widely implicated in oncogenesis.  The PI3K pathway is no 
exception to this and deregulation of the PI3K pathway has been implicated in several 
human  cancers  (Berrie,  2001;  Stephens,  et  al.,  2005).    To  give  an  outline  of  PI3K 
signalling in cancer, the involvement of PI3K with oncogenes, in the context of genetic 
alterations, and in tumour metastasis is discussed below. 
 
Oncogenes:  Oncogenes have been found to use PI3Ks as intracellular relay or effector 
molecules.    Such  oncogenes  include  growth  factor  receptors  such  as  the  ErbB/EGFR 
family.    This  family  consists  of  four  distinct,  but  structurally  similar,  transmembrane 
tyrosine kinase receptors: EGFR (ErbB1, HER1), ErbB2 (HER2, neu), ErbB3 (HER3) and 
ErbB4 (HER4) (Bianco, et al., 2006).  Aberrant expression and signalling of the HER 
family of proto-oncogenes and the receptor tyrosine kinases encoded by these genes have Chapter 1 
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been  associated  with  bladder,  brain,  breast,  colon,  head  and  neck,  lung,  ovarian,  and 
pancreatic cancers (Lafky, et al., 2008; Salomon, et al., 1995). Several factors affect the 
activation  status  of  EGFR,  including  receptor  mutations,  receptor  heterodimerization, 
increased  expression  of  ligands,  and  activation  of  alternative  pathways  (Bianco,  et  al., 
2006).    The  two  main  signalling  pathways  activated  downstream  of  EGFRs  are  the 
Ras/Raf/Mek/erk1/2  pathway  together  with  the  PI3K/Akt/mTOR  pathway  (Johnston, 
2006). In fact, in some instances increased activation of the PI3K pathway induced by 
growth factors is associated with resistance to EGFR-targeted therapies, which highlights 
the therapeutic potential of additionally targeting PI3Ks (Jones, et al., 2004; Lu, et al., 
2001; Pao & Miller, 2005). 
 
Ras oncogenes are thought to play a role at multiple stages of tumorigenesis.  Mutations in 
codon 12, 13, or 61 of one of the three ras genes, H-ras, K-ras, and N-ras convert these 
genes into active oncogenes.   Ras gene mutations are found in a variety of human tumours 
including adenocarcinoma of the pancreas, colon and the lung; in thyroid tumours and in 
myeloid  leukaemia  (Bos,  1989).    Although  the  role  and  mechanisms  by  which  Ras 
oncogenes maintain the transformed state of human cancer cells are not clearly understood, 
it has been found that Ras-dependent PI3K activation is essential for several cell processes 
necessary for cell transformation (Gupta, et al., 2007; Warne, et al., 1993).   
 
Genetic alterations and PI3K: One of the main discoveries that indicated a role for PI3K 
in cancer was the discovery that the tumour suppressor PTEN is a PIP3 3-phosphatase. The 
mutation and/or loss of PTEN occurs in a variety of human cancers (Simpson & Parsons, 
2001),  subsequently  leading  to  increased  PIP3  levels  and  a  constitutively  active  PI3K 
pathway.   
 
PIK3CA, the gene encoding the p110 catalytic subunit, has been found to have somatic 
(tumor-specific) mutations occurring in 32% of colorectal cancer  and has also been found 
in glioblastomas, gastric cancers, breast cancers and lung cancers (Broderick, et al., 2004; 
Ikenoue, et al., 2005; Karakas, et al., 2006; Samuels, et al., 2005; Samuels & Velculescu, 
2004; Samuels, et al., 2004).  Greater than 75% of PIK3CA mutations occur in the helical 
and kinase domain of PIK3CA and are thought to confer increased kinase activity (Miled, 
et al., 2007; Samuels, et al., 2005; Samuels & Velculescu, 2004; Samuels, et al., 2004; 
Zhao & Vogt, 2008).  Chapter 1 
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Furthermore, increased PIK3CA DNA copy numbers have frequently been found in human 
ovarian cancer cell lines and in several other human cancers, which was associated with 
increased PIK3CA transcription and p110ʱ protein expression (Shayesteh, et al., 1999). 
The overexpression of PIK3CA in ovarian cancer has been found to positively correlate 
with  VEGF  at  both  the  mRNA  and  protein  level  implicating  p110ʱ  in  the  process  of 
angiogenesis, a key mark of cancer progression (Zhang, et al., 2003)  To date there have 
been no somatic mutations reported for p110β or p110δ (Cornillet-Lefebvre, et al., 2006; 
Knobbe & Reifenberger, 2003; Phillips, et al., 2006).  However, p110δ has been found to 
be expressed at high levels in nonhaematopoietic cell types of breast or melanocytic origin, 
which is discussed further in section 1.8 (Sawyer, et al., 2003). 
 
There are now also several examples of somatic and oncogenic mutations in the gene for 
p85 that usually focus into small „hot spot‟ regions resulting in mutant proteins that retain 
their  ability  to  bind  p110,  but  lose  their  c-terminal  SH2  domains,  resulting  in  a 
constitutively active heterodimer (Jimenez, et al., 1998; Philp, et al., 2001). 
 
Tumor Metastasis:  Tumor invasion and metastasis are multifaceted processes involving 
adhesion,  proteolytic  degradation  of  tissue  barriers  and  cell  migration,  which  leads  to 
secondary  tumor  formation.    Cell  migration  can  occur  in  response  to  an  extracellular 
chemoattractant  gradient.    This  requires  cell  polarization,  involving  cytoskeletal 
reorganisation and asymmetrical distribution of multiple proteins and lipids resulting in 
distinct cell edges; the „front‟ or leading edge protruding at the anterior of the cell and the 
„back-end‟  or  rear  edge  (Ward,  2004).    Evidence  has  emerged  implicating  PI3K 
phosphoinositide lipids in determining cell polarity. As discussed in section 1.4.5.2, studies 
have  revealed  that  PIP3  accumulation  occurs  at  the  leading  edge  of  chemoattractant-
stimulated  cells  with  relocation  of  PTEN  from  the  leading  edge  to  the  rear  edge 
(Funamoto, et al., 2002).  Overexpression or deficiency of PTEN has been shown to reduce 
or enhance leukocyte motility, respectively, and similarly, mice deficient in SHIP suffer 
from  lethal  infiltration of the lungs  by macrophages  and neutrophils  (Funamoto et  al., 
2002;  Helgason  et  al.,  1998).    The  production  and  degradation  of  3‟-phosphoinositide 
lipids is crucial in maintaining a chemotactic gradient and for the selective recruitment of 
PH domain-containing proteins to the leading edge of chemotaxing cells.  PI3K regulation 
of  Rho  family  GTPases,  including  Cdc42,  Rac1  and  RhoA,  further  implicates  PI3K 
signalling in cell migration and a possibly tumor metastasis. Chapter 1 
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1.5.2 PI3K and diabetes 
As discussed in section 1.3, PI3K is activated by insulin stimulation and the subsequent 
phosphorylation and activation of Akt, the main downstream target of PI3K, results in the 
phosphorylation of a number of components of the insulin signalling pathway.   A number 
of studies have investigated the involvement of PI3K in insulin signalling, largely focusing 
on  insulin-stimulation  of  glucose  transport  and  GLUT4  translocation.    Expression  of 
dominant negative forms of p85 greatly reduces the effect of insulin both in vitro (Katagiri, 
et  al.,  1997;  Quon,  et  al.,  1995))  and  in  vivo  (Miyake,  et  al.,  2002))  and  reversely, 
overexpression of constitutively active class IA PI3K is also sufficient to, at least in part, 
mimic the effects of insulin (Katagiri, et al., 1996; Tanti, et al., 1996).  
 
Using both a pharmacological and a genetic approach p110ʱ has been identified as the key 
PI3K  isoform  in  insulin  signalling  (Foukas,  et  al.,  2006;  Knight,  et  al.,  2006).  Using 
pharmacological tools, p110ʱ has been found to be the primary insulin-responsive PI3K in 
cultured cells, whereas p110β is dispensable for IRS signalling (Knight, et al., 2006).  In 
corroboration with this, mice heterozygous for a p110ʱ-inactivating mutation, have severe 
impairments in signalling via insulin-receptor substrate (IRS) proteins, insulin-like growth 
factor-1 and leptin action leading to hyperinsulinaemia, glucose intolerance, hyperphagia 
and  increased  adiposity  (Foukas,  et  al.,  2006).    However,  these  mice  do  not  become 
diabetic, even at old age (Foukas, et al., 2006). 
 
Recent evidence also indicates that PI3K-C2ʱ may also play a role in insulin signalling 
(Falasca, et al., 2007; Falasca & Maffucci, 2007; Shepherd, 2005).  Insulin stimulation 
causes a very rapid activation of PI3KC2ʱ and it has been suggested that PIK3C2ʱ may 
play a role in insulin-mediated increases in PI(3)P and in stimulation of glucose transport 
(Shepherd, 2005).   
  
1.5.3 PI3K and autoimmune and inflammatory disease 
PI3Ks,  specifically  p110δ  and  p110γ,  represent  attractive  targets  in  autoimmune  and 
inflammatory  conditions.    As  will  be  discussed  in  section  1.6,  through  gene-targeting 
strategies both p110δ and p110γ have been found to play critical roles in immune function.  
Inhibiting p110δ and/or p110γ activity is likely to influence immune function at multiple 
levels,  which  strengthens  the  therapeutic  value  of  PI3K  inhibition.  Furthermore,  the 
inflammatory response is associated with multiple diseases, implicating PI3K inhibition as 
a common point in a therapeutic strategy.  To underscore the potential of targeting PI3K in Chapter 1 
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autoimmune  and  inflammatory  disease,  the  involvement  of  PI3K  in  the  widespread 
inflammatory  diseases,  respiratory  lung  disease  and  rheumatoid  arthritis  is  discussed 
briefly.  
 
Lung disease: Chronic respiratory diseases are defined by inflammatory cell recruitment, 
inflammatory mediator expression, tissue remodelling, and altered airway smooth muscle 
contraction (Medina-Tato, et al., 2007).  Within chronic respiratory diseases, asthma and 
chronic  obstructive  pulmonary  disease  (COPD)  are  the  most  common  clinical  entities.  
PI3K, specifically p110δ and p110γ, have been shown to play a role in the pathology of 
these diseases, along with other respiratory diseases such as acute lung injury (ALI) and 
adult  respiratory  distress  syndrome  (ARDS).    Indeed,  the  p110δ-selective  inhibitor, 
IC87114, has been shown to have a therapeutic effect in a murine model of asthma (Lee, et 
al.,  2006).    In  general,  PI3Ks  have  been  implicated  in  pulmonary  infiltration  of 
lymphocytes  and  eosinophils,  antigen-induced  airway  inflammation  and 
hyperresponsiveness  and  Th2  cytokine  production  (IL-5  and  IL-4)  in  bronchoalveolar 
lavage fluid (Medina-Tato, et al., 2007).   
 
Rheumatoid  arthritis:  Rheumatoid  arthritis  (RA)  is  a  chronic  inflammatory  disease, 
generally  considered  to  be  an  immune-mediated  disease.    Rheumatoid  joints  are 
characterised  by  inflammatory  infiltrates  in  the  synovium  and  synovial  fluid,  pannus 
formation, and eventually by joint erosion.  There are multiple steps in the pathogenesis of 
the  disease  with  interplay  between  the  adaptive  and  innate  immune  response.    The 
activities  of  T  cells,  B  cells  (including  the  production  of  auto-antibodies  and  immune 
complexes  and  cytokine  secretion),  dendritic  cells,  mast  cells,  macrophages  and 
neutrophils have all been shown to have important roles and to affect at least one or several 
aspects of the disease (Rommel, et al., 2007).   p110δ and p110γ are both targets in the 
treatment  of  rheumatoid  arthritis  due  to  their  signalling  roles  in  cells  of  the  immune 
system.  
 
There  is  increasing  interest  in  the  pharmaceutical  industry  to  generate  PI3K  isoform-
specific inhibitors.  Indeed, companies such as  ICOS, PIramed, Novartis, Bayer, Pfizer, 
Serono, Targegen and Calbiochem are involved in the development of inhibitors that target 
p110δ and/or p110γ (Medina-Tato, et al., 2007).  The therapeutic potential of p110δ in 
allergy  has  recently  been  publicly  recognised,  featuring  in  a  BBC  news  article 
(http://news.bbc.co.uk/1/hi/health/7247600.stm, 2008).   
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1.6 ELUCIDATING THE ISOFORM-SPECIFIC ROLE OF PI3K 
Targeting PI3K itself or downstream effectors of PI3K is an approach that has the potential 
to be of huge therapeutic benefit, since deregulation of the PI3K signalling pathway occurs 
in a number of disease settings, as described above.  However, PI3K signalling is also 
important in normal cell homeostasis and inhibition of all the PI3K isoforms with non-
selective PI3K inhibitors may be toxic upon chronic administration.  To enable individual 
PI3K isoforms to be targeted therapeutically, it is first important to understand the specific 
signalling mediated by each PI3K isoform.  This has been carried out using PI3K isoform-
specific inhibitors, PI3K gene-targeted mice and cell-based overexpression studies, which 
are described below. 
 
1.6.1 PI3K gene-targeted mice  
There have been two main genetic approaches of targeting the catalytic PI3K genes.  The 
first is a knockout approach, where targeting of the p110 gene results in failure of gene 
product expression.  The second approach is a more subtle, and is where a mutation is 
introduced  in  the  ATP  binding  site  of  the  catalytic  domain,  which  results  in  protein 
expression but with a resulting amino acid substitution (for example by replacing aspartic 
acid 910 by alanine – D910A for p110δ) in the ATP-binding region, rendering the p110 
catalytically inactive.  The second approach has been termed „knock-in‟, and is considered 
to be more sophisticated than a straight forward knockout, as it is more likely to mimic 
pharmacological inhibition of PI3K.  Furthermore, it has been observed that when a gene is 
completely  knocked-out,  there  is  room  for  compensation  in  the  cell  by  other  related 
proteins, whereas, expression of a protein, albeit a catalytically inactive one, leaves little 
room for compensation by other proteins.  
 
Mouse gene targeting of PI3K class I catalytic isoforms:  All class I catalytic isoforms 
have been inactivated by gene targeting in the mouse.  Mice homozygous for knockout or 
D933A knockin alleles of the widely expressed p110ʱ isoform die at embryonic stage 10.5 
(Bi, et al., 1999; Foukas, et al., 2006), displaying severe defects in angiogenic sprouting 
and vascular remodelling (Graupera, et al., 2008). 
 
Mice  with  a  heterozygous  knockout  of  p110ʱ  are  viable  and  were  reported  to  lack 
metabolic or growth phenotypes (Brachmann, et al., 2005).  In contrast, mice heterozygous 
for the D910A knockin mutation (p110ʱ
D933A/WT) are viable and fertile, but display a strong 
metabolic  phenotype  (Foukas,  et  al.,  2006).  p110ʱ
D933A/WT  mice  display Chapter 1 
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hyperinsulinaemia,  impaired  glucose  and  insulin  tolerance,  increased  food  intake, 
increased adiposity and hyperleptinaemia compared to WT mice (Foukas, et al., 2006).  As 
already mentioned earlier, this has identified p110ʱ as a key intermediate in IGF-1, insulin 
and leptin signalling at the organismal level.   
 
The difference between the phenotypes observed in heterozygous p110ʱ knockout mice 
versus heterozygous p110ʱ knockin mice has been assigned to the stoichiometry of p85-
p110ʱ  complexes.    In  heterozygous  p110ʱ  knockout  mice,  the  capacity  of  any  given 
receptor to signal through p110ʱ will only be reduced if p110ʱ-p85 expression is reduced 
to a level where it is limiting relative to the receptor.  In contrast, in heterozygous p110ʱ 
knockin mice, the capacity of any given receptor to signal through p110ʱ is not dependent 
on the stoichiometry of p110ʱ-p85 heterodimers.  It can be assumed that 50% of receptor 
p110ʱ  complexes  will  be  lacking  p110ʱ  catalytic  activity,  which  results  in  clear 
phenotypes (Foukas, et al., 2006; Graupera, et al., 2008). 
 
Endothelial-specific  homozygous  genetic  inactivation  of  p110  also  caused  embryonic 
lethality due to impaired angiogenesis.  To study the role p110ʱ is playing in vascular 
development,  investigations  have  been  carried  out  on  the  viable  p110ʱ
D933A/WT  mice.   
p110ʱ
D933A/WT mice also display delayed angiogenesis during development and impaired 
angiogenic responses to VEGF-A (Graupera, et al., 2008).  This study has revealed that 
p110ʱ  is  the  key  PI3K  isoform  in  endothelial  cells,  promoting  angiogenesis  through 
regulating endothelial cell migration through the small GTPase RhoA (Graupera, et al., 
2008). 
 
Homozygous  knockout  of  p110β  is  also  embryonic  lethal  at  the  blastocyst  stage  of 
embryonic development (E 3.5) (Bi, et al., 2002).   Such early embryonic lethality has 
made it extremely difficult to study the homozygous loss of p110β, even at the cellular 
level as it also turned out to be impossible to culture cells from the embryo at this stage.  
The early embryonic lethality in  p110β  KO mice suggests an essential role for p110β 
during development. However, mice heterozygous for p110β knockout alleles are viable, 
and do not display any obvious phenotype.  Moreover, mice heterozygous for both p110ʱ 
and p110β deletions also show no obvious phenotype (Brachmann, et al., 2005).  This 
result may not be a true reflection of importance of p110ʱ and p110β, since as mentioned 
before, the heterozygous knockout approach relies on p110-p85 expression levels being 
limiting relative to the receptor.   Chapter 1 
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Germ-line inactivation of p110β has also been carried out through deletion of exons 21 and 
22 (p110β
Δ21+22).  Preliminary results reveal that unlike the homozygous p110β knockout, 
homozygous  p110β  inactivation  is  only  partially  lethal  (Guillermet-Guibert  & 
Vanhaesebroeck, unpublished results).  It is unclear at present, what causes their partial 
lethality and this is currently being investigated.  However, this finding demonstrates that 
by using a protein inactivation approach as opposed to a complete knockout approach, it is 
feasible to investigate the homozygous loss of p110β gene-function. 
 
Mice  have  recently  been  generated  in  which  p110β  activity  has  been  conditionally 
abolished in endothelial cells, to investigate the possible role that p110β may be playing in 
angiogenesis.  In this conditional inactivation of p110β, exons 21 and 22, which lie in the 
catalytic  region  of  p110β  and  contain  the  ATP  binding  site,  are  deleted  resulting  the 
expression of a truncated, inactive p110β protein.  Mice lacking catalytically active p110β 
in  endothelial  cells  are  viable  and  do  not  display  any  developmental  angiogenic 
phenotypes,  indicating  that  p110ʱ  is  the major  p110  isoform  involved  in  angiogenesis 
(Graupera, et al., 2008). 
Mice with a homozygous deletion of the p110δ or p110γ gene (p110δ knockout or p110γ 
knockout) are viable (Clayton, et al., 2002; Jou, et al., 2002; Sasaki, et al., 2000).  The 
viability  of  these  mice,  compared  to  the  lethality  of  p110ʱ  or  p110β  homozygous 
knockout, can be attributed to the restricted tissue distribution of p110δ and p110γ in cells 
of the immune system, compared to the ubiquitous expression of p110ʱ and p110β.  From 
these knockout studies, it has been found that p110δ is critical to the adaptive immune 
response with p110δ
-/- mice displaying impaired B cell development, B cell activation and 
antibody  response  (Clayton,  et  al.,  2002;  Jou,  et  al.,  2002;  Puri,  et  al.,  2004).    Mice 
expressing  a  kinase-dead  p110δ  are  also  viable  and  display  similar  phenotypes  to  the 
p110δ knockout mice, with impaired B-cell development.  In addition, studies on p110δ 
knockin mice have revealed a role for p110δ downstream of the T cell antigen receptor and 
in mediating the allergic response (Ali, et al., 2004; Okkenhaug, et al., 2002).  These 
p110δ knockin studies have indicated that p110δ is the main provider of PI3K activity 
downstream of the TcR (T cell receptor) and BcR (B cell receptor) and in addition p110δ is 
also the main PI3K isoform involved in mast cell signalling in an inflammatory context, a 
component of the allergic response (Ali, et al., 2004; Okkenhaug, et al., 2002).   Chapter 1 
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p110γ is activated downstream of GPCRs, and like p110δ, p110γ expression is mainly 
restricted  to  leukocytes.    In  accordance  to  the  distribution  of  p110γ,  neutrophils, 
macrophages  and  certain  populations  of  mast  cells  from  p110γ  homozygous  knockout 
mice, exhibit defects in migration in response to GPCR agonists and chemotactic agents 
(Hirsch, et al., 2000a; Li, et al., 2000; Sasaki, et al., 2000).  In addition, p110γ has been 
shown to control thymocyte survival and activation of mature T cells but, unlike p110δ, 
does not have a role in the development and function of B cells (Sasaki, et al., 2000) 
 
Studies with mice homozygous for p110γ deletion, have suggested a role for p110γ in the 
IgE/Ag-triggered allergic response.  However, groups differ in their findings of the relative 
importance of p110γ and p110δ in allergic responses in vivo (Ali, et al., 2008; Laffargue, et 
al., 2002).  The reason for this discrepancy between groups is unclear at the moment. 
 
Mouse gene targeting of class IA PI3K regulatory subunits:  The regulatory subunits 
p85ʱ, p55ʱ and p50ʱ are expressed from the same gene (PIK3R1) through the use of 
alternative promoters, p85β is the only gene product of the p85β gene (PIK3R2). Four 
mouse lines have been created targeting the different class IA regulatory subunits.  The 
„pan-p85ʱ  knockout‟  line  targets  all  PIK3R1  gene  products  (p85ʱ,  p55ʱ  and  p50ʱ) 
(Fruman, et al., 1999), „p85ʱ-only knockout‟ has gene deletion of p85ʱ but retains p55ʱ 
and p50ʱ expression (Suzuki, et al., 1999), the „p55ʱ/p50ʱ knockout‟ has gene deletion of 
p55ʱ and p50ʱ but retains p85ʱ expression (Chen, et al., 2004), and finally the fourth line 
„p85β knockout‟ has p85β gene (PIK3R2) deletion (Ueki, et al., 2002b). 
 
Gene disruption targeting all p85ʱ isoforms results in perinatal lethality, whereas mice 
with gene disruption of p85ʱ only are viable.  In both cases however, mice display defects 
in B-cell development and function, with no defects in T-cell function reported.  In other 
tissues,  PI3K  signalling  downstream  of  insulin  was  enhanced  in  p85ʱ  knockout  mice 
compared to cells from wild-type mice (Fruman, et al., 2000; Terauchi, et al., 1999).  Mice 
homozygous for gene deletion of p85β are viable, although they tend to be smaller than 
their wild-type littermates.  Similar to p85ʱ knockout mice, p85β knockout mice display 
hypoinsulinaemia,  hypoglycaemia,  and  improved  insulin  sensitivity.    These  results 
indicating PI3K as a negative regulator of insulin signalling, appear to be in direct contrast 
to the study by Foukas et al., 2006, where p110ʱ was found to positively regulate insulin 
signalling.    However,  further  analysis  of  p85ʱ  knockout  cells  reveals  increased  p85β 
expression (and 55ʱ and p50ʱ in the„p85ʱ-only knockout‟) and reduced expression of each Chapter 1 
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of the class IA catalytic isoforms.  The disruption of PI3K isoform expression in the p85 
knockouts  makes  interpretation  of  the  phenotypes  observed  extremely  difficult,  as  the 
phenotype may be as a result of the disruption of PI3K isoform expression rather than loss 
of the targeted p85. 
 
1.6.2 Cell-based approaches 
A  number  of  different  cell-based  approaches  have  been  used  to  investigate  isoform-
specific PI3K signalling at the cellular level.  These include the overexpression of p110 
isoforms in different cell lines, the derivation of cell lines from p110 knockout/knockin 
mice, the use of RNAi to knock-down p110 expression, and the use of p110 isoform-
specific inhibitors, which are all further discussed below. 
 
Overexpression of p110 isoforms in different cell lines:  Transient overexpression of the 
p110 isoforms has given some insight into PI3K signalling.  Transient expression of a 
constitutively active mutant p110 (called p110*), in which the inter-SH2 domain of p85 is 
covalently linked to the N-terminal-binding site of p110 binding site, has been found to be 
sufficient to activate pathways involved in the regulation of cell proliferation, independent 
of growth factor stimulation (Hu, et al., 1995).   
 
The  effect  of  membrane  localization  of  p110  has  been  investigated  through  transient 
expression of N-terminal myristylated (using the myristylation sequence of pp60
c-Src)
 or C-
terminal farnesylated (using farnesylation signal from H-Ras) p110 and p110* in COS-7 
cells  (Klippel,  et  al.,  1996).    Membrane  targeting  of  p110  subunits  also  results  in  a 
constitutively activate p110.  The use of activated forms of PI3Ks enables the direct study 
of  cellular  processes  regulated  by  PI3K  without  prior  activation  by  growth  factor.  
Furthermore, the use of activated PI3K molecules allows determination of whether PI3K 
activation alone is sufficient for the induction of a signalling event (Klippel, et al., 1996).   
 
It was found that when p110 was directed to the membrane, even low amounts of PI3K 
activity were sufficient to trigger the induction of a subset of intracellular kinases, which 
include p70 S6 kinase, Akt and Jnk.  The activation of these kinases as a result of p110 
membrane-targeting was more effective than their activation as a result of the highly active 
but cytoplasmic p110*.  The combination of high PI3K activity of p110* with membrane-
targeting signals resulted in maximal activation of downstream responses (Klippel, et al., 
1996).  A constitutive active form of the small G protein Ras (RasV12), but not Rac or Chapter 1 
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Cdc42,  was  found  to  increase  activation  of  Akt  and  this  activation  was  wortmannin-
sensitive,  suggesting  Ras  lies  upstream  of  PI3K  activation  (Klippel,  et  al.,  1996).  
However, expression of the dominant negative forms of Ras, Rac or Cdc42 with active 
p110 did not interfere with PI3K-dependent activation of Akt, indicating that Ras mediates 
activation of Akt by an independent pathway.  A proposed mechanism for the observation 
that  RasV12-induced  Akt  activation  is  wortmannin-sensitive,  involves  Ras-induced 
production of autocrine factors that subsequently activate growth factor receptors, which in 
turn  lead  to  the  induction  of  signalling  pathways,  including  the  activation  of  PI3K.    
Indeed, RasV12 was found to secrete autocrine factors in cell culture media which resulted 
in MAPK activation. Unfortunately, due to the lack of a suitable anti-Akt antibody at the 
time of publication, the authors were unable to test whether these autocrine factors could 
also stimulate Akt (Klippel, et al., 1996).   
 
Further investigation into the effect of constitutive active PI3K has been carried out by 
generating inducible PI3K molecules, in  which p110 or p110* have been fused to the 
hormone binding domain (HBD) of a mutated mouse estrogen receptor (mER) (Klippel, et 
al., 1998).  Proteins fused to this mutant ER domain are inactive until the addition of 4-
hydroxytamoxifen (4-OHT).  It was found that activation of PI3K induced immediate early 
responses such as activation of Akt and p70 S6 kinase and a late response of Jnk activation 
and entry into the S-phase of cell cycle although not complete progression through the cell 
cycle (Klippel, et al., 1998).  These studies have strengthened the idea that recruitment of 
p110 subunits to the plasma membrane by the regulatory subunit is a key activator of 
PI3K.  They have also given us some indication of the time frame in which individual 
components downstream of the PI3K signalling pathway are activated. 
 
The C-terminal farnesylation signal from H-Ras is often referred to as CAAX motif as it 
consists of a Cysteine residue, an Aliphatic amino acid, a second Aliphatic amino acid 
followed by any amino acid (X).  The introduction of p110ʱ-CAAX into bone marrow-
derived mast cells has been found to increase the binding affinity of  β1 integrin very late 
Ag-5 (VLA-5) for fibronectin, indicating PI3K as an important modulator of β1 integrin 
affinity (Kinashi, et al., 1999). Employing this plasma membrane-targeting approach to 
investigate constitutively activate p110, p110δ-CAAX has also been transfected in mast 
cells.  p110δ was found to be a critical effector molecule of Ras in activating integrins in 
mast cells (Kinashi et al, 2000). 
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Relatively recently, the oncogenic transformation potential of each p110 catalytic subunit 
has  been  investigated  through  overexpression  of  each  isoform  in  chicken  embryo 
fibroblasts (Kang, et al., 2006).  p110δ, β and γ were found to induce the formation of 
transformed cell foci within 10 days, with p110δ and p110γ inducing more distinct foci 
compared to p110β.  The fusion of a myristylation signal to the N-terminus of the p110 
isoforms (Myr-p110) enhances oncogenic transforming ability, although this enhancement 
is less pronounced with the δ and γ isoforms, which are potent transformers even without 
the added myristylation signal.  In contrast, p110ʱ only had transforming ability when 
myristylated  or  possessing  an  oncogenic  point  mutation,  wild-type  p110ʱ  lacked  any 
transforming potential.  It should be considered however, that overexpression of wild-type 
p110ʱ is  toxic to  the  cell and that only  a low level  of p110ʱ expression  is  achieved, 
consequently not resulting in cell transformation. 
 
The transforming ability of all the p110 isoforms is dependent on the lipid kinase activity 
of the p110 subunit.  Interestingly, only p110δ and the oncogenic p110ʱ mutant induce 
constitutive  activation  of  Akt  under  serum-starvation  conditions,  whereas  in  p110β  or 
p110γ-overexpressing  chicken embryo fibroblasts no increase in  phosphorylated Akt is 
detected compared to control transfected cells (Kang, et al., 2006).   
 
Mutation of the Ras binding domain in each of the p110 subunits has revealed that myr-
p110ʱ or oncogenic p110ʱ and p110δ are not dependent on Ras binding to induce cell 
transformation.  In contrast, in p110β and p110γ-overexpressing cells, abolishing p110-Ras 
binding  significantly  compromises  the  transforming  potential  of  these  p110  isoforms 
(Denley,  et  al.,  2008;  Kang,  et  al.,  2006).    The  upstream  requirements  for  cell 
transformation by p110β and p110γ therefore, appear to be distinct from the upstream 
requirements for cell transformation by p110ʱ and p110δ, which corresponds to the finding 
that p110β and p110γ are activated downstream of GPCRs, whereas p110ʱ and p110δ are 
activated downstream of tyrosine kinases (Guillermet-Guibert, et al., 2008; Kang, et al., 
2006). p110β, p110δ, p110γ and oncogenic p110ʱ are all however dependent on mTOR to 
mediate their oncogenic signal (Kang, et al., 2006). 
 
One interesting observation from the overexpression study by Kang et al, 2006, is that 
overexpression of myr-p110ʱ, p110β and p110δ was possible without cotransfection of a 
regulatory subunit.  Since p110 expression is thought to depend on the availability of p85, 
which may stabilise the catalytic subunit, this study suggests that exogenously expressed Chapter 1 
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p110  subunits  bind  endogenous  p85.    In  addition,  expression  of  one  particular  p110 
isoform was found to affect the expression levels of other isoforms that share the same 
regulatory subunit (Kang, et al., 2006).  For example, the endogenous levels of p110ʱ are 
downregulated in cells overexpressing the β or δ isoform and overexpression of p110δ also 
leads to reduced endogenous levels of p110β.   It has been proposed that overexpression of 
a particular p110 isoform may titrate the corresponding regulatory subunit, limiting the 
availability to other isoforms and thus cause downregulation (Kang, et al., 2006). 
 
Since the Ras  binding domain does  not  appear to  be necessary to  target  p110δ to  the 
plasma membrane, a similar study in chicken embryo fibroblasts has looked at requirement 
of three basic residues within the C2 domain that have been shown to be involved in lipid–
protein interactions (Denley, et al., 2008).  Mutation of all three basic residues to alanine 
was  found  to  almost  completely  inhibit  foci  formation  in  chicken  embryo  fibroblasts 
induced by p110δ overexpression. 
 
Although  these  studies  have  provided  valuable  insights  into  PI3K  signalling,  transient 
overexpression does not allow for full functional analysis of the changes in cell signalling 
as a consequence of the overexpression.  In addition, this work only focused on a single 
p110  isoform  (mostly  p110ʱ);  and  no  comparison  was  made  between  different  p110 
isoforms.  A potentially better way to achieve this is by stable overexpression of p110 
isoforms.  This has proved to be more difficult and there are only a relatively small number 
of studies which document the effect of stable PI3K overexpression.   
 
Stable NIH 3T3 cell lines have been created which express a myr-p110ʱ (Auger, et al., 
2000).  As was previously suggested by Kang et al, 2006, the exogenously expressed myr-
p110ʱ was formally found, by pull-down experiments, to associate with endogenous p85 
regulatory subunits (Auger, et al., 2000).  Myr-p110ʱ-expressing cells were found to have 
altered cell morphology, displaying a more elongated morphology at confluence, and did 
not display strict contact inhibition of growth.   Consistent with their altered morphology, 
myr-p110ʱ-expressing  cells  possessed  disorganized  actin  stress  fibres  compared  to  the 
organised bundles of actin  fibres  in  control  transfected  cells  (Auger, et  al.,  2000).  In 
contrast  to  data  obtained  from  transient  assays,  Akt  and  p70  S6  kinase  were  not 
constitutively  active  in  cells  stably  expressing  myr-p110ʱ  (Auger,  et  al.,  2000).   
Consistent with this finding, in a separate study, NIH 3T3 cells stably expressing Myc-Chapter 1 
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p110ʱ do not show increased basal Akt phosphorylation or p70 S6 kinase phosphorylation 
compared to cells transfected with control (empty) vectors (Ikenoue, et al., 2005). 
 
Myristylated p110ʱ, p110β, p110γ, and p110δ isoforms have all been stably co-expressed 
with the c-Myc oncogene in Rat1 fibroblasts (Link, et al., 2005).  All four p110 isoforms 
protect  c-Myc  overexpressing  cells  from  apoptosis  caused  by  serum  deprivation.  
Expression of each p110 isoform reduces caspase-3 like activity in this apoptosis model, 
which  correlated  with  increased  Akt  phosphorylation.    Interestingly,  clones  expressing 
myristylated p110δ were found to trigger Akt phosphorylation much more efficiently than 
myristylated p110ʱ, p110β, or p110γ (Link, et al., 2005), which corroborates the findings 
from transient expression of myr-p110s previously discussed (Kang, et al., 2006). 
 
Stable expression of GFP-tagged p85ʱ in CHO-K1 cells has shown that in response to 
insulin-like growth factor (IGF), GFP-p85ʱ translocates to distinct, foci-like complexes 
that  contain  p85  bound  to  tyrosine-phosphorylated  insulin  receptor  substrate-1  (IRS-1)  
(Luo, et al., 2005).  These complexes were found to contain primarily monomeric p85 and 
suggests  a  novel  mechanism  to  explain  how  monomeric  p85  inhibits  PI3K  signalling 
downstream  of  IRS-1  (Luo,  et  al.,  2005).    It  is  important  to  mention  that  the  p85-
overexpressing clone in this study may not be representative.  Indeed, one had to screen 
over 1000 colonies to be able to find a clone that could withstand stable overexpression of 
p85 (L. Cantley, personal communication to Bart Vanhaesebroeck).  
 
All previous attempts in the Cell Signalling in Cancer laboratory (The Ludwig Institute for 
Cancer Research and Queen Mary‟s Institute for Cancer Research) to stably overexpress 
p110  isoforms  in  mammalian  cell  lines  using  cDNA  expression  vectors  have  failed. 
However it should be noted that 3‟-Myc tagged p110 cDNAs have often been used in these 
transfections, which have since been shown to produce a kinase-dead p110 that can no 
longer phosphorylate its in vivo substrate PIP2.  Furthermore, the p110 cDNAs used in the 
transfections did not contain a membrane-targeting signal, which have since proved to be 
favourable  in  allowing  stable  p110  expression.  Last  but  not  least,  it  has  now  become 
apparent that p110 cDNAs used for transfection were not full length and did not contain 
5‟UTR regions found in the mRNA of the wild-type p110 genes; this issue is discussed 
further in section 1.9.   
 
Creation of cell lines from p110 knockout mice:  As mentioned above, p110ʱ knockout 
mice die between days 9.5 and 10.5 of embryonic development (Bi, et al., 1999).  This Chapter 1 
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lethality has prevented investigation of the effect of the homozygous loss p110ʱ in the 
adult mouse, however haematopoietic cells extracted from the p110ʱ
D933A/D933A embryo are 
currently  being  used  to  investigate  homozygous  loss  p110ʱ  in  cell-based  signalling 
(Foukas & Vanhaesebroeck, unpublished results).  p110δ knockout mice are viable and 
cell lines have also been established from these mice (Foukas et al., 2006). The p110β 
knockout is embryonic lethal, mice die around the time of embryo implantation, and it has 
not been possible to establish stable cell lines from these mice (Bi, et al., 2002).  However, 
it has been possible to establish mouse embryonic fibroblasts from mice homozygous for 
the p110β
Δ21+22 alleles.  These cells have proved to be a valuable tool in delineating a role 
for p110β downstream of GPCRs (Guillermet-Guibert, et al., 2008). 
 
Knock-down p110 expression using RNAi:  It is possible to knock-down p110 expression 
using  small  interfering  RNAs  (Czauderna,  et  al.,  2003a;  Czauderna,  et  al.,  2003b) 
(Brachmann, et al., 2005).  Stable and transient siRNA-mediated knockdown of p110β was 
found  to  inhibit  invasive  cell  growth  in  vitro  as  well  as  in  a  tumour  model  system 
(Czauderna, et al., 2003a).  Downregulation of p110ʱ in cell lines using RNAi has been 
found to reduce p85 expression, which is consistent with the finding that  double p110ʱ / 
p110β heterozygous knockout mice show approximately 50% decrease in p85 expression 
(Brachmann, et al., 2005).   
 
Use  of  isoform-specific  inhibitors:    Isoform-specific  inhibitors  are  currently  in 
development by a number of pharmaceutical companies and have been a valuable tool in 
investigating the isoform-specific roles of PI3K.  The main problem that accompanies the 
use  of  these  inhibitors  in  investigative  studies  is  the  question  of  their  selectivity.  The 
p110δ-selective inhibitor developed by ICOS corporation (IC87114) has been employed in 
a number of studies at a concentration where there is confidence that it is targeting p110δ 
alone (Sadhu, et  al., 2003).  Kinacia (Australia) and Serono (Geneva) have developed 
p110β  and  p110γ  inhibitors  which  have  high  selectivity  toward  their  targeted  isoform 
(Jackson,  et  al.,  2005;  Condliffe,  et  al.,  2005).    Progress  has  been  made  towards 
developing p110ʱ-selective inhibitors, although several of these compounds are not highly 
selective for p110ʱ and target numerous other kinases (Fan, et al., 2006).  Although the use 
of p110 isoform-specific inhibitors are a useful tool in investigating the isoform-specific 
roles  of  PI3Ks,  complementary  experiments  should  be  performed  to  ascertain  that  the 
effect observed is due to specific PI3K inhibition rather other unintended proteins being 
targeted.  Chapter 1 
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1.7 P110δ SIGNALLING IN MAST CELLS 
1.7.1 Introduction to the mast cell 
Mast cells are derived from multipotential haematopoietic stem cells of the bone marrow, 
expressing the cell surface markers CD13,
 CD34 and CD117/c-kit (Metcalfe, et al., 1997).  
They migrate from the bone marrow to the circulation into the peripheral tissues where 
they terminally differentiate under the influence of environmental factors (Figure 1.11).  
 
Figure 1.11: Simplified model of mouse mast cell development.  Mast cells arise from 
multipotential  haematopoietic  progenitor  cells  but  complete  major  parts  of  their 
differentiation  in  peripheral  tissue.    Fully  mature  mast  cells  express  the  cell  surface 
receptors FcεRI, IL-3 receptor and c-kit receptor. 
 
Mast cells are highly granulated mononuclear cells with a diameter of 4-20 µm.  They are 
widely  distributed  throughout  the  body  in  connective  tissues  and  on  mucosal  surfaces 
(Puxeddu, et al., 2003). They participate in the regulation of adaptive immune responses 
and have a central role in allergic inflammatory responses (Metcalfe, et al., 1997).  Antigen 
cross-linking of IgE bound to its high affinity receptor, FcεRI, at the mast cell surface, 
induces mast cell degranulation and the release of pro-inflammatory mediators (Metcalfe, 
et al., 1997; Puxeddu, et al., 2003). 
 
In addition to FcεRI, mast cells also express the c-kit receptor, which is activated by its 
cytokine ligand SCF (stem cell factor, also known as c-kit ligand).  The c-kit receptor and 
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SCF are encoded at the murine white spotting (W) and steel (Sl) loci, respectively (Chabot, 
et al., 1988; Serve, et al., 1995).  Mice expressing a mutated c-kit receptor (W/W
v) or mice 
lacking  functional  membrane  SCF  (Sl/Sl
d)  express  a  virtual  absence  of  mast  cells, 
demonstrating that SCF is an essential factor for mast cell development (Kitamura, et al., 
1978).  The cytokine, interleukin-3 (IL-3) has also been shown to have an important role in 
mast development.  The presence of IL-3 in cell culture media is critical for the generation 
of populations of immature mast cells from mouse haematopoietic cells in vitro (Tertian, et 
al.,  1981).    In  addition,  IL-3  induces  mouse  mast  cell  growth  and  enhances  their 
development in response to SCF in vitro (Puxeddu, et al., 2003). 
 
1.7.2 PI3K signalling via the c-kit receptor 
Mast cells are commonly used to study signalling downstream of the c-kit receptor, which 
is a single-chain receptor that has inherent protein tyrosine kinase activity.  Binding of SCF 
to  c-kit  results  in  receptor  dimerization  followed  by  activation  of  its  intrinsic  tyrosine 
kinase  activity  (Blume-Jensen,  et  al.,  1991).    Once  activated,  the  receptor  becomes 
autophosphorylated  on  multiple  tyrosine  residues  in  the  cytoplasmic  tail,  which  act  as 
docking  sites  for  SH2  domain-containing  proteins  or  phosphotyrosine  binding  (PTB) 
domains  (Ronnstrand,  2004).    Such  proteins  include  SHC  (Src  homology  2-domain-
containing  transforming  protein  C),  GRB2  (growth  factor  receptor-bound  protein),  Src 
family kinases, phospholipase Cγ and PI3K (Figure 1.12).  
 
Although SCF stimulation alone cannot induce mast cell degranulation, a combination of 
SCF and antigen leads to a synergistic PLCγ activation, leading to an increase in calcium 
mobilisation and degranulation (Hundley, et al., 2004). 
 
A number of studies have implicated PI3K activation in transformation through mutated c-
kit.    PI3K-dependent  activation  of  Akt  and  phosphorylation  of  BAD  (a  pro-apoptotic 
molecule)  by  c-kit  promotes  cell  survival.    For  human  c-kit,  Y721  has  been  found  to 
directly interact with PI3K (Serve, et al., 1995), which corresponds to Y719 in mice.   
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Figure 1.12: The (human) c-kit receptor.  The adaptor APS, Src family kinases, and 
SHP2 tyrosyl phosphatase bind to phosphotyrosine 568.  SHP1 tyrosyl phosphatase binds 
to phosphotyrosine 570 and the adaptor protein SHC can bind to both phosphotyrosine 568 
and phosphotyrosine 570.  These tyrosine residues are in the juxtamembrane domain of c-
kit.  Phosphorylated tyrosine resides in the kinase insert domain attract the adaptor protein 
Grb2 (Y-703), PI3K (Y-721) and phospholipase C-γ (Y-730).  PI3K can also bind Y-900 
in the distal kinase domain, which in turn binds the adaptor CRK.  Phosphotyrosine 936 
binds the adaptor proteins APS, Grb2 and Grb7 (Roskoski, 2005). 
 
1.7.3 p110δ and c-kit: Implications in cancer  
Gain-of-function mutations in c-kit are associated with a number of human cancers.  A 
mutation at codon 816 of the catalytic domain of the human gene (codon 814 of the murine 
gene) is found in patients with mastocytosis and mast cell leukaemia, as well as some 
patients with acute myelogenous leukaemia and germ cell tumours (Longley, et al., 1999; 
Nagata,  et  al.,  1995;  Shivakrupa,  et  al.,  2003).    These  findings  indicate  that 
pharmacological inhibition of signalling components activated by this mutation could be of 
therapeutic benefit.   
 
It  has  been  shown,  in  a  murine  mast  cell  line,  that  mutant  Kit
D814Y  is  constitutively 
phosphorylated on tyrosine 719 and that this is likely to result in constitutive association 
with activated PI3K (Shivakrupa, et al., 2003).  STI-571 (Gleevec, imatinib) is a clinically 
used protein-tyrosine kinase inhibitor, which targets Abl, Bcr-Abl, c-kit and the PDGF 
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receptor.  Its clinical efficacy was first established in the treatment of chronic myelogenous 
leukaemia,  in  which  it  targets  the  Bcr-Abl  oncoprotein.    However,  cancers  that  result 
chiefly from mutation of c-kit at residue 816 are resistant to STI-571, which leaves PI3K 
inhibition as a potentially attractive targeted therapy for these disorders (Roskoski, 2005). 
 
Mast cells, like other leukocytes, express high levels of p110δ.    An investigation into the 
role of p110δ in mast cells has revealed that genetic or pharmacological inactivation of 
p110δ  in  murine  bone  marrow  derived  mast  cells  (BMMCs)  leads  to  defective  SCF-
mediated  in  vitro  proliferation,  adhesion  and  migration,  and  to  impaired  allergen-IgE-
induced  degranulation  and  cytokine  release  (Ali,  et  al.,  2004).    In  p110δ
D910A/D910A 
BMMCs, the total in vitro class IA PI3K lipid kinase activity was found to be reduced by 
90% compared to WT BMMCs, indicating that p110δ is the major isoform contributing to 
overall  class  IA  PI3K  activity  in  mast  cells  (Ali,  et  al.,  2004).  Furthermore, 
p110δ
D910A/D910A BMMCs fail to produce PIP3 upon SCF stimulation in an in vitro lipid 
kinase assay.  Concurring with this result was the almost complete abrogation of SCF-
induced Akt phosphorylation in p110δ
D910A/D910A BMMCs and in WT BMMCs treated with 
the p110δ inhibitor,  IC87114.  These results  indicate that p110δ is  the principal p110 
isoform involved downstream of the c-kit receptor in WT BMMCs. 
 
The  dependence  of  c-kit  to  signal  through  p110δ  demonstrates  p110δ  inhibition  as  a 
potential targeted therapy in cancers with gain-of-function mutations in c-kit such as in 
mastocytomas. This has prompted investigation into the effect of p110δ inhibition on Akt 
phosphorylation  in  the  human  mastocytoma  cell  line  (HMC-1).    HMC-1  is  a  human 
leukaemic mast cell line, which has two point mutations in c-kit resulting in constitutive 
activation of the receptor  and, as a consequence, constitutive Akt activation (Furitsu, et 
al., 1993).  Treatment of HMC-1 cells with the p110δ inhibitor IC87114 results in a partial 
abrogation of Akt phosphorylation although not complete abrogation as was observed upon 
IC87114  treatment  of  SCF-stimulated  WT  BMMCs  (Billottet  &  Vanhaesebroeck, 
unpublished results).  It is important to note, however, that although c-kit is constitutively 
active  in  HMC-1  cells,  phosphorylation  of  Akt  can  be  further  increased  upon  SCF 
stimulation  (Billottet,  C.  unpublished  results).    It  has  yet  to  be  determined  whether 
treatment  of HMC-1 cells  with  IC87114 prior to SCF stimulation would  abrogate this 
increase in Akt phosphorylation. 
 
Collectively,  these  results  indicate  that  p110δ  is  the  critical  PI3K  isoform  signalling 
downstream of the c-kit receptor in WT untransformed BMMCs.  However the constitutive Chapter 1 
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Akt phosphorylation in the transformed mast cell line HMC-1 is less dependent on p110δ, 
which raises the question of whether c-kit signalling remains dependent on p110δ in other 
transformed cells. 
 
 
1.8 P110δ AND NON-HAEMATOPOEITIC CANCER 
In  addition  to  the  high  level  of  p110δ  expression  in  leukocytes,  low  levels  of  p110δ 
expression have been detected in all human and mouse non-leukocyte cell types (Verrall & 
Vanhaesebroeck, unpublished results).  There have been no somatic mutations reported in 
the p110δ gene, PIK3CD (Cornillet-Lefebvre, et al., 2006; Knobbe & Reifenberger, 2003; 
Phillips, et al., 2006), although there are several cases of PIK3CD gene amplification in 
cancer (Knobbe & Reifenberger, 2003; Mizoguchi, et al., 2004; Sawyer, et al., 2003).   
Some of these cancers are of non-haematopoietic origin and it is feasible to think that 
overexpression of p110δ in cells that under normal conditions express very low levels, may 
be sufficient to induce elements of cell transformation.  Some examples of PIK3CD gene 
amplification and/or high p110δ expression in non-haematopoietic cancers are described 
below. 
 
1.8.1 Breast cancer and melanoma 
The study by Sawyer et al, is the only investigation of p110δ isoform expression in cells of 
breast  and  melanocyte  origin,  however  it  brought  to  light  some  interesting  results 
implicating a role for p110δ beyond the immune system and warrants further discussion.  
Through compiling information from the GenBank database on the tissue distribution of 
ESTs (expressed sequence tags) for p110 isoforms, it has been found that the two tissues 
expressing  the  most  abundant  p110δ  ESTs,  outside  the  haematopoietic  system,  are 
melanocyte/melanoma and breast tissue (Sawyer, et al., 2003).  This finding led to analysis 
of p110δ protein expression in cells of melanocyte and breast origin.  In both primary 
normal human breast cells and in primary breast tumour cells, p110δ protein expression is 
high.  In addition, in the primary tumour samples, there appears to be a down-regulation of 
p110ʱ expression and in some cases of p110β (Sawyer, et al., 2003).  This could suggest 
that in primary breast tumour cells, p110δ has in some cases become the principle class IA 
PI3K isoform, however, given that the sample size of the analysis was quite small (two 
primary normal breast samples and four primary tumour samples), further investigation is 
required to corroborate and validate this hypothesis. 
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In established breast tumour cell lines, including MDA-MB-361, BT20, MDA-MB-435, 
GI101 and MDA-MB-231, relatively high p110δ levels have been found in all cell lines 
with exception to MDA-MB-361 in which no p110δ expression was detected.  In most 
cases the relative expression of p110ʱ and p110β also remains high.  Interestingly, the cell 
line MDA-MB-231, which has the highest level of p110δ expression (comparable to levels 
in a leukocyte cell line) has reduced levels of p110ʱ and p110β expression compared to the 
other breast tumour cell lines.  All p110 isoform expression is increased in melanoma cell 
lines compared to melanocytes. 
 
Sawyer et al, has investigated the functional role of p110δ expression in the MDA-MB-
231  breast  cancer  cell  line  in  cell  migration.    Isoform-specific  neutralisation  of  PI3K 
isoforms,  by  PI3K  antibody  microinjection  or  by  using  a  p110δ-selective  inhibitor, 
demonstrates that p110δ is the principle p110 isoform required for regulation of EGF-
driven  motility  in  vitro.    p110δ  was  found  to  control  directionality  and  speed  of  cell 
migration,  whereas  p110β  was  found  to  only  control  direction  and  not  speed  of  cell 
migration.  Remarkably, inhibition of p110ʱ had no impact on cell migration in the MDA-
MB-231 breast cancer cell line.  A further indication that p110δ plays an important role in 
breast cancer cell migration is the finding that the breast cancer cell line MDA-MB-361, 
which has no detectable p110δ protein expression, does not migrate or chemotax when 
exposed to an EGF gradient. 
 
As the authors point out, breast tissue and melanocytes share functional characteristics 
with regard to migration.  Breast tissue is a highly dynamic tissue and migration is critical 
function of melanocytes during development.  Furthermore, breast cancer and melanoma 
metastasis share a similar pattern of metastatic sites.  The expression of p110δ in these 
cells might therefore be causally related to their shared migratory activities under normal 
and transformed conditions (Sawyer, et al., 2003).   
 
1.8.2 Glioma 
In addition to detecting p110δ protein expression in breast tissue and melanocytes, Sawyer 
et  al,  also  detected  high  levels  of  p110δ  expression  in  five  other  cells/tissue  of  non-
haematopoietic origin; three mouse microglia cell lines, ovarian carcinoma cell line and 
primary synoviocytes.  The precise origin and cell lineage of microglia, which are thought 
of as the „macrophages‟ of the nervous system, is still a matter of some debate.  Unlike 
macroglia  (astrocytes  and  oligodendrocytes)  and  neurons,  which  derive  from Chapter 1 
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neuroectoderm, microglia are thought to derive prenatally from mesodermal progenitors, 
that are distinct from monocytes (Chan, et al., 2007).  Microglia-like cells can be derived 
in  vitro  from  embryonic  stem  cells  and  it  is  most  likely  that  microglia  are  in  fact  of 
haematopoietic origin (Chan, et al., 2007).  This would indeed help to explain the high 
p110δ protein expression in these cells.   
 
Malignant gliomas range from low grade glioma, astrocytoma, oligodendroglioma to high 
grade glioblastoma.  The origin of cells found in malignant gliomas remains enigmatic, 
although it is possible that they are derived from neural progenitor cells.   The invasion of 
tumour  cells  into  brain  tissue  is  a  pathologic  hallmark  of  high  grade  gliomas  and 
contributes  significantly  to  the  failure  of  current  therapeutic  treatments  (Louis,  2006). 
Activated microglial cells are abundant in brain tumours and have actually been shown to 
stimulate the motility of glioma cells (Markovic, et al., 2005).  It would be extremely 
interesting to investigate the role of PI3K, specifically p110δ in microglia cells and in 
glioma progression.  In fact, genetic alterations of the gene encoding p110δ, PIK3CD, have 
been  found,  albeit  at  a  low  frequency  of  6%,  in  cases  of  glioblastoma  (Knobbe  & 
Reifenberger,  2003;  Mizoguchi,  et  al.,  2004).    Both  PIK3CD  mRNA  and  gene  copy 
number has been found to be increased in glioblastoma tumours.  
 
Although p110δ is the predominant PI3K isoform in cells of the immune system, it is 
becoming apparent that the role it plays in other cell types should not be overlooked.  
 
 
1.9 REGULATION OF PI3K GENE EXPRESSION 
The  restricted  tissue  distribution  of  p110δ  and  p110γ,  compared  to  the  more  broadly 
expressed  p110ʱ  and  p110β  catalytic  subunits,  has  led  to  studies  investigating  the 
mechanisms by which PI3K gene expression is regulated.  It has been demonstrated that 
for  all  class  I  PI3K  isoforms,  mRNA  and  protein  levels  show  a  reasonable  level  of 
correlation  (Geering,  et  al.,  2007b;  Verrall  &  Vanhaesebroeck,  unpublished  results), 
indicating that significant regulation of PI3K expression occurs at the transcriptional level.   
1.9.1 Transcription 
Transcription is the enzymatic process of synthesising a complementary RNA strand, in 
the form of messenger RNAs (mRNAs), transfer RNAs or ribosomal RNAs, from DNA.  
RNA polymerase II is involved in the synthesis of mRNAs and is one of the first steps 
leading to gene expression.   Chapter 1 
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In eukaryotes, DNA is found wrapped around a set of eight histone molecules making up 
the nucleosome, which is the fundamental repeating unit of chromatin.  The nucleosome 
serves  as  general  repressor  of  gene  transcription,  however  remodelling  of  chromatin 
structure  transiently  exposes  promoter  DNA  sequences  allowing  interaction  of  the 
promoter  regions  with  transcription  machinery  (the  transcription  core  promoter  is 
discussed in more detail in section 1.9.3)  (Boeger, et al., 2003).  Chromatin modifying and 
remodelling complexes target the nucleosome either through acetylation/deacetylation of 
histones or through disruption of histone-DNA interactions and in this way can affect gene 
expression (Vignali, et al., 2000). 
 
The  promoter  region  contains  specific  DNA  sequences  that  are  recognised  by  DNA-
binding proteins, or transcription factors (TFs), which are involved in the recruitment and 
binding of RNA polymerase II.  The RNA polymerase II machinery comprises 6 proteins: 
RNA polymerase II, and five general TFs, known as TFIIB, -D, -E, F, and –H (Conaway & 
Conaway, 1997).   Although RNA polymerase  II  alone is  capable of unwinding DNA, 
synthesising  RNA,  and  rewinding  DNA,  it  requires  the  general  TFs  to  recognise  a 
promoter.  Another protein complex, termed Mediator, which consists of more than 20 
subunits, with a total mass in excess of a million Daltons, is also required for transcription 
regulation (Kim, et al., 1994).  The completed assembly of TFs and RNA polymerase II 
bound to the DNA promoter is called the transcription initiation complex (Figure 1.13). 
 
The promoter surrounds the first base pair that is transcribed into RNA.  From this point, 
RNA polymerase  II moves  along the template  DNA strand, synthesising RNA until  it 
reaches a terminator sequence.  This forms a transcription unit, which may include more 
than one gene.   
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Figure  1.13:  Initiation  of  transcription.  The  first  step  in  initiating  eukaryotic 
transcription is assembly of the preinitiation complex, which comprises of TBP (TATA 
Binding Protein) and an attached complex of TAFs (TBP Associated Factors), collectively 
known as  TFIID  (Transcription  Factor for polymerase  II D).   TFIIB and  TFIIA binds 
TFIID and DNA, stabilizing the first complex, which allows for subsequent recruitment of 
TFIIF associated with  RNA polymerase II, followed by TFIIE and TFIIH recruitment.  
TFIIH  is  a  protein  complex  that  contains  a  DNA  helicase,  which  separates  the  DNA 
strands  at  the  transcription  start  site  (Lennartsson,  et  al.),  and  protein  kinase  that 
phosphorylates  the  C-terminal  domain  (CTD)  of  RNA  polymerase  II.    CTD 
phosphorylation of RNA polymerase II induces it to release from the DNA promoter and 
initiation of RNA synthesis.  Multisubunit cofactors, such as Mediator, can interact with 
enhancers  such  as  SP1,  which  may  be  located  several  kilo-bases  away  from  the  core 
promoter, and the transcriptional machinery to enhance gene transcription.  It is should be 
noted that some promoters do not contain a TATA box. 
 
1.9.2  Transcript processing  
Before an RNA gene transcript is transported out of the nucleus it undergoes 3 processing 
events: 1) addition of a 5‟cap, 2) addition of a 3‟ poly(A) tail (polyadenylation) and 3) 
removal of introns (splicing), events  depicted in Figure 1.14. 
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Figure  1.14:  Schematic  of  transcript  processing.    An  ensemble  of  transcriptional 
complexes in the nucleus transcribes a complementary RNA strand from a DNA template 
strand.  The RNA transcript is subject to modification in the nucleus, which involves the 
addition  of  a  5‟cap  and  3‟  polyadenylation.    Prior  to  RNA  nuclear  export,  intronic 
sequences  are  removed  from  the  RNA  transcript,  in  a  process  termed  RNA  splicing, 
resulting  in  mature  mRNA.    Intron  splicing  most  commonly  occurs  at  GU-AG  intron 
sequences.  Mature cytoplasmic mRNA is subsequently translated.  
 
5’ Capping: Transcription starts with a nucleoside triphosphate, usually either purine A or 
G.    The  first  nucleotide  retains  its  5‟  triphosphate  group  and  makes  the  usual 
phosphodiester bond from its 3‟ position to the 5‟ position of the next nucleotide, which 
can  be  represented  as  5‟  pppA/GpNpNpNp  and  so  on.    However,  immediately  after 
transcription initiation, all transcripts made by RNA polymerase II undergo a 5‟ capping 
process in which a guanine nucleotide is added onto the 5‟ terminal by the nuclear enzyme 
guanylyl transferase.  The additional guanine nucleotide is added in reverse orientation via 
an unusual 5' to 5' triphosphate linkage (Bentley, 2002).  The guanine residue is substrate 
for several methylation events, the first of which involves the addition of a methyl group to 
the  7‟  position  of  the  terminal  guanine  resulting  in  a  cap  structure  resembling 
m
7G(5‟)ppp(5‟)A/GpNpNp. The cap is thought to influence splicing of the first intron, Chapter 1 
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mRNA stability and mRNA transport to the cytoplasm, where it binds translation initiation 
factors.  Any mRNA lacking a cap structure is rapidly degraded by exonucleases.   
3’ Polyadenylation: Many transcripts contain a 3‟ terminal stretch of adenosine residues, 
often referred to as a poly(A) tail.  The poly(A) sequence is added to RNA in the nucleus 
after  transcription  and  is  a  process  requiring  many  nuclear  proteins.  Cleavage  and 
polyadenylation specificity factor (CPSF) recognises and binds RNA at the 3‟ hexamer site 
„AAUAAA‟,  while  cleavage  and  stimulatory  factor  interacts  with  U-rich  or  GU-rich 
regions  enhancing  CPSF  affinity  for  the  hexamer  (Cramer,  et  al.,  2001).    Poly(A) 
polymerase associated with these two factors initiates the polyadenylation reaction, which 
occurs in two stages.  Poly(A) can increase mRNA stability and is important for mRNA 
nuclear export and translation (Wickens, et al., 1997). 
Splicing: The primary transcript, referred to as pre-mRNA, has the same organisation the 
DNA from which it was transcribed.  The removal of introns from pre-mRNA, in a process 
called RNA splicing, results in mRNA which contains only exons.  Splice sites, which 
occur at exon-intron boundaries have well-conserved, although short, consensus sequences.  
The  most  frequently  observed  splice  site  consensus  sequence,  GT-AG  is  found 
immediately  within  the  intron,  shown  here  in  blue  and  underlined, 
AGGTAAGT...YYYAGN, with exon residues shown in red (in RNA the sequence is, of 
course, GU-AG).  Introns can be removed by the spliceosome, a complex of specialized 
RNA and protein subunits, within 30 seconds of transcription of the 3′ splice site, however, 
post-transcriptional splicing also occurs (Bentley, 2002). 
 
1.9.3 The transcription core promoter 
The core promoter is the minimal stretch of immediate DNA sequence that is sufficient to 
direct accurate initiation of transcription by the RNA polymerase II machinery (Butler & 
Kadonaga, 2002).  The core promoter typically encompasses the site of the transcription 
initiation and extends approximately 35 nucleotides upstream or downstream.  There are 
several motifs that are frequently found in some but not all core promoters (Figure 1.15), 
which will be discussed further below.  
 
The  initiator:    The  Inr  element  contains  the  TSS  and  has  been  found  in  a  variety  of 
eukaryotes in both TATA-containing and TATA-less core promoters (Butler & Kadonaga, 
2002). The
 consensus for the Inr in mammalian cells is Py-Py(C)-A+1-N-T/A-Py-Py, where 
the A+1
 represents the common nucleotide at which transcription is initiated (Javahery, et Chapter 1 
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al., 1994).  However,
 more generally,
 transcription initiates at a single site or in a cluster of 
multiple
 sites in the vicinity of the Inr and not necessarily at the A+1
 position (Butler & 
Kadonaga, 2002).  A number of factors have been found to interact with Inr motifs and 
may participate in Inr-dependent transcription at a subset of promoters (Liston, et al., 2001; 
Malecova, et al., 2007). 
 
 
Figure 1.15: Core promoter elements. Common promoter motifs that can participate in 
transcription  by  RNA  polymerase  II  are  depicted,  however,  a  specific  promoter  may 
contain some, all or none of these elements. The BRE (TFIIB recognition element) is an 
upstream extension of a subset of TATA boxes. The DPE (downstream core promoter 
element) requires an Inr (Initiator), and is located precisely at +28 to +32 relative to the 
A+1  nucleotide  in  the  Inr.  The  DPE  consensus  was  determined  with  Drosophila 
transcription factors and core promoters. Adapted from Butler & Kadonaga, 2002. 
 
The downstream core promoter element (DPE):  The DPE was identified in Drosophila 
and acts as cooperative binding site for TFIID in addition to the Inr, although it is also 
present in humans (Burke & Kadonaga, 1996; Zhou & Chiang, 2001).  Mutation of either 
Inr or DPE results in loss of TFIID binding.  DPE motifs most commonly occur with 
TATA-less promoters located precisely at +28 to +32 relative to the A+1 position in the Inr.  
Alteration of the spacing between these two elements by a single nucleotide results in a 
several fold-reduction of transcription activity (Burke & Kadonaga, 1996).   
The TFIIB recognition element (BRE):  The BRE is a TFIIB binding site that is located 
immediately upstream of some TATA boxes (Lagrange, et al., 1998). The BRE consensus 
is G/C-G/C-G/A-C-G-C-C
, where the 3' C of the BRE is followed by the 5' T of the TATA
 
box (Butler & Kadonaga, 2002).  In vitro studies have revealed BRE motifs to have both a 
positive and negative effects on transcription (Evans, et al., 2001; Lagrange, et al., 1998). 
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CpG Islands: CpG sites are regions of DNA in which a cytosine nucleotide is situated next 
to a guanine nucleotide, linked by a phosphate group.  CpG dinucleotides are the substrates 
of DNA methyltransferase, which catalyses the covalent addition of a methyl group (-CH3) 
to the 5‟ position of the cytosine ring.  Spontaneous deamination of the 5-methylcytosine 
to  give
  a  TpG  dinucleotide,  which  is  not  repaired  by  the  DNA  repair  machinery,  has 
subsequently led to loss of CpG sits in the human genome.  Regions of DNA that have a 
higher concentration of CpG sites are known as CpG islands.   
CpG islands are often but not always found in promoter regions with around 40% of genes 
containing  CpG  islands  that  are  situated  at  the  5‟  region  incorporating  the  promoter, 
untranslated regions  and exon 1 (Jones & Baylin, 2002). The rest of the genome, such as 
the intergenic and the intronic regions, is considered to be CpG poor (Miranda & Jones, 
2007).  CpG  islands  typically
  lack  TATA  or  DPE  core  promoter  elements,  but  contain 
multiple
 GC box motifs that are bound by SP1 and related transcription
 factors (Butler & 
Kadonaga, 2002). 
DNA methylation of CpG islands at a promoter region usually prevents gene expression. 
Genome-wide demethylation of normally methylated and silenced chromosomal regions, 
and hypermethylation and silencing of genes including tumour suppressors are common 
features of cancer cells (Barton, et al., 2008; Stirzaker, et al., 2004).  It has been suggested 
that DNA methylation can directly impede the binding of transcriptional factors to their 
target sites, thus prohibiting transcription. Other proposed mechanisms are based on the 
idea that methylation of CpG sequences can alter chromatin structure by affecting histone 
modifications  and  nucleosome  occupancy  within  the  promoter  regions  of  genes.    In 
addition,  DNA  methylation  has  been  found  to  recruit  methyl-binding  proteins  that 
specifically bind to methylated CpG dinucleotides, which  have been shown to play a role 
in methylation-dependent silencing of transcription (Nan, et al., 1998a; Nan, et al., 1998b). 
All of the “housekeeping” genes that are constitutively expressed have CpG islands, which 
accounts for approximately half of the islands altogether.  The rest of the CpG islands 
occur at promoters of tissue-regulated genes, although less than 40% of these genes have 
CpG islands (Jones & Gonzalgo, 1997; Sulewska, et al., 2007).  CpG islands located in 
promoter  regions  are  usually  unmethylated  in  all  normal  tissues,  regardless  of  the 
transcriptional activity of the gene.  Therefore, the presence of unmethylated CpG islands 
indicates genes that can be potentially active, rather than their certain transcription. 
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1.9.4 Spatial and temporal control of gene expression  
Transcription initiation is a key regulatory step in controlling gene expression.  Formation 
of the preinitiation complex must occur at the correct time at a specific promoter to induce 
appropriate mRNA synthesis, for example in tissue-specific gene expression. Metazoan 
organisms  have  evolved  specialized  transcription  initiation  complexes  and  promoter-
selectivity modules that direct coordinated regulation of functionally related gene networks 
(Hochheimer  &  Tjian,  2003).    As  previously  mentioned,  transcription  activation  is 
governed by an ensemble of multisubunit transcription factor complexes at specific DNA 
sequences.  Regulation of transcription may occur at the level of chromatin remodelling 
and nucleosome mobilisation, to expose promoter elements, or at the level of regulation of 
the transcription machinery itself. 
Certain genes display tissue-restricted expression, an example of such a gene is Vav.  Vav 
is a Rho family GTPase GTP/GDP exchange factor, which is expressed in virtually all 
cells of haematopoietic lineage and only expressed in embryonic stem cells outside the 
haematopoietic system (Katzav, et al., 1989; Keller, et al., 1993).  The restricted tissue 
distribution  of  Vav  is  suggested  to  be  due  to  the  presence  of  five  major  DNase  I 
hypersensitive  sites  found  upstream  of  the  TSS  in  the  murine  Vav  gene  in  cells  of 
haematopoietic lineage but not in fibroblasts (Ogilvy, et al., 1998).  DNase I hypersensitive 
sites are destroyed by extremely low concentrations of DNase, indicating that they are 
readily accessible to outside molecules.  This accessibility appears to arise from the almost 
complete  absence  of  nucleosomes  in  this  region  of  DNA,  and  as  a  result  DNase  I 
hypersensitive sites are associated with regions of chromatin containing active promoters 
or  enhancers,  where  DNA-binding  proteins  are  found.    In  addition,  the  murine  Vav 
promoter  sequence  contains  potential  binding  sites  for  tissue-restricted  TFs,  such  as 
GATA, Myb, Oct and Ets proteins, in addition to ubiquitous TF binding sites.   
Temporal  control  of  gene  expression  is  exemplified  by  studies  of  neuronal  gene 
expression.  Neural activity-dependent gene transcription occurs over various time periods, 
from  minutes  to  days.    A  group  of  genes  called  „immediate  early  genes‟  are  rapidly 
upregulated  after neuronal  enhancement, such  as  Arc  transcription  which occurs  in  rat 
brain after 5 min after the animal is moved to a novel environment (Vazdarjanova, et al., 
2002).  Rapid activation of gene transcription occurs is directly regulated by presence of 
specific TFs, in addition to epigenetic processes such as DNA methylation and histone 
modification.  An  intensively  studied  TF  involved  in  neuronal  activity-dependent  gene Chapter 1 
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regulation  is  the  CREB  (cAMP  response  element-binding)  family  of  TFs  (Mayr  & 
Montminy, 2001). CREB promotes cell survival of neurons during development and in 
adult neurons and is involved in the formation of long-term memory (Abe, 2008).  The TF 
CREB  and  family  members  CREM  and  ATF1  are  activated  by  multiple  pathways  in 
neurons and regulate the transcription of a number of neuronal-associated genes.   
Differential gene expression may be regulated by multiple promoters. For example, the 
lymphocyte-specific  proto-oncogene  lck  is  transcribed  from  two  developmentally 
regulated, independently functioning promoters.  It has been found that the lck proximal 
promoter is used in thymocytes, but not in peripheral T lymphocytes, whereas the distal 
promoter operates in all stages of T cell development, but predominates in more mature 
cells (Wildin, et al., 1995).   Another example of gene transcription arising from multiple 
promoters is expression of the active hormonal form of vitamin D, which has a central role 
in  calcium  and  phosphate  homeostasis  and  the  maintenance  of  bone.    Upstream 
untranslated  exons  of  the  human  vitamin  D  receptor  gene  (a  member  of  the  nuclear 
receptor family) are incorporated into numerous variant transcripts, which suggested the 
presence of multiple promoters (Crofts, et al., 1998).  Indeed, transcripts containing one 
particular upstream untranslated exon (exon 1f) were only found in kidney tissue and one 
particular  intestinal  cell  line.    This  tissue-specific  expression  of  so-called  exon  1f-
containing  transcripts  was  found  to  be  mediated  by  a  distal  promoter  more  than  9  kb 
upstream of the other untranslated exons identified (Crofts, et al., 1998). 
 
Heterogeneity in the 5‟ region is a common feature of other nuclear receptor genes. Tissue-
specific alternative-promoter usage generates multiple transcripts of the human estrogen 
receptor  a  (ERʱ),  the  human  and  rat  mineralocorticoid  receptors,  and  the  mouse 
glucocorticoid  receptor,  which  differ  in  their  5‟  UTRs  but  code  for  identical  proteins 
(Keaveney, et al., 1991; Strahle, et al., 1992; Zennaro, et al., 1995).  Other members of the 
nuclear  receptor  superfamily  have  multiple,  functionally  distinct  isoforms  arising  from 
differential promoter usage and/or alternative splicing (Lazar, 1993; Zhu, et al., 1995). 
 
1.9.5 Transcriptional regulation of PI3K expression 
Both p110δ and p110γ are highly expressed in cells of haematopoietic origin compared to 
other cell types, p110ʱ and p110βs in contrast are more broadly expressed, suggesting 
specific PI3K isoform expression can be regulated by alternative mechanisms.  It is likely 
that  p110δ  and  p110γ  gene  expression  is  under  the  control  of  haematopoietic-specific Chapter 1 
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transcriptional regulators, whereas p110ʱ and p110β gene expression is under the control 
of widely expressed regulators of transcription. 
 
1.9.5.1 p110γ gene analysis  
There  has  been  little  investigation  into  the  transcription  control  of  p110γ,  however,  a 
promoter region for murine p110γ has been identified (Hirsch, et al., 2000b).  Murine 
p110γ cDNA is 86% homologous to its pig and human orthologues at the nucleotide level.  
Multiple transcriptional start sites exist for p110γ, which results in transcripts with varying 
5‟UTRs, the longest being 874 bp upstream of the translational start site.  Analysis of 
1.2 Kb of 5′ flanking genomic DNA revealed that the putative promoter region does not 
contain a TATA box and is not GC-rich.   However, consensus sites for housekeeping 
transcription factors such as AP1 and SP1, were identified along with consensus sequences 
included binding sites for transactivators involved in haematopoietic differentiation such as 
C/EBP β, GATA-1 and Ets-2 (Hirsch, et al., 2000b).  Functional analysis of the p110γ 
putative  promoter  region  revealed  it  has  enhanced  promoter  activity  in  the 
myelomonocytic  cell  line  U937,  which  expresses  high  level  of  endogenous  p110γ, 
compared to the human epithelial cell line HeLa, which express undetectable levels of 
p110γ protein expression (Hirsch, et al., 2000b).  These data suggest that the presence of 
haematopoietic-specific  TF-binding  sites  contributes  to  the  tissue-restricted  gene 
expression of p110γ.   
  
1.9.5.2 Transcriptional regulation of PIK3CA oncogene 
PIK3CA upregulation, amplification and mutations have been identified in solid tumours in 
a number of studies (Bachman, et al., 2004; Broderick, et al., 2004; Campbell, et al., 2004; 
Karakas, et al., 2006; Samuels & Velculescu, 2004; Samuels, et al., 2004).  Recently, the 
5‟ upstream regulatory region of human PIK3CA has been located 50 Kb upstream of the 
translational  start  codon  and  was  found  to  be  around  60%  homologous  to  the  murine 
PIK3CA 5‟ upstream regulatory region (Yang, et al., 2008).  Predicted TF-binding sites in 
the human PIK3CA 5‟ upstream regulatory region include NFκB, hypoxia-inducible factor 
(HIF), heat-shock protein (HSP) and activator  protein 1 (AP1).  Consistent  with  these 
findings,  strong  HIF  and  NFκB  staining  is  associated  with  areas  of  high  PIK3CA 
expression in solid tumours.  Furthermore, the human PIK3CA promoter NFκB binding 
site  can  be  activated  by  NFκB,  illustrating  it  is  indeed  functional,  and  results  in 
upregulation of PIK3CA mRNA in ovarian cancer cell lines in vitro (Yang, et al., 2008).  
Based on these findings, stress signalling pathways, namely HIF and NFκB, are implicated Chapter 1 
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in PIK3CA regulation in cancer.  NFκB plays a critical role in inflammation-driven tumour 
formation,  growth  and  progression,  promoting  transcription  of  diverse  genes  encoding 
inflammatory  cytokines,  growth  factors  and  cell  adhesion  molecules  (Lenardo  & 
Baltimore, 1989; Luo, et al., 2004a; Pikarsky, et al., 2004).  This recent data provides 
evidence that NFκB activation directly upregulates PIK3CA transcription.  However, given 
that  NFκB  expression  is  highly  inducible  in  response  to  inflammatory  stimuli  (Tak  & 
Firestein, 2001; Xiao & Ghosh, 2005) whereas p110ʱ expression appears to be unaltered, it 
is clear that the regulation of PIK3CA gene expression by NFκB is more complex than 
what is initially perceived from the study by Yang, et al. 
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1.10 AIMS OF THE STUDY 
PI3Ks are attractive therapeutic targets in inflammation and cancer.  Broad-spectrum PI3K 
inhibitors have proved to be toxic to the organism and therapeutic interference with PI3K 
signalling will most likely have to be targeted at single PI3K isoforms or selected groups 
of PI3K isoforms.  It is therefore critical to elucidate the isoform-specific roles of PI3K so 
that individual isoforms may be targeted.  Various genetic and cell-based approaches have 
revealed  non-redundant  roles  for  PI3K  isoforms  and  have  greatly  enhanced  our 
understanding of specific isoform-mediated functions. 
 
This study is focused on investigating the role of p110δ.  p110δ has a more restricted tissue 
distribution  than  p110ʱ  and  p110β  and  is  predominantly  expressed  at  high  levels  in 
leukocytes and cells of the immune system.  To illustrate an important role of p110δ in 
cells of the immune system, in mast cells, p110δ is the principle isoform mediating PI3K-
dependent signalling downstream of the tyrosine kinase receptor, c-kit.  The mechanism of 
regulation  of  p110δ  gene  (PIK3CD)  expression  leading  to  predominantly  leukocyte-
restricted  p110δ  expression  is  unknown.    In  addition  to  high  expression  of  p110δ  in 
leukocytes,  an  abundant  expression  of  p110δ  has  also  been  found  in  breast  cells  and 
melanocytes and has  been found to  play  an important  role in  the EGF-driven in vitro 
migration of breast cancer cell lines.   
 
The aim of this study was to further investigate the isoform-specific signalling of p110δ 
using cell-based models, aimed at addressing three main questions: 
 
1)  Using p110δ coupling to c-kit in mast cells as model, does coupling of class IA 
PI3Ks to tyrosine kinase receptors remain the same under normal and transformed 
cellular states? 
2)  Using in silico promoter analysis and luciferase reporter assays, is the leukocyte-
restricted  p110δ  gene  expression  mediated  by  a  leukocyte-specific  PIK3CD 
promoter? 
3)  Through stable overexpression of p110δ in the fibroblast cell line NIH 3T3, what is 
the  impact  of  p110δ  overexpression  in  non-leukocyte  mammalian  cells? Chapter 2 
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2. MATERIALS AND METHODS 
Company names and catalogue numbers are provide between brackets. 
 
2.1 BUFFERS, SOLUTIONS AND REAGENTS 
2.1.1 General buffers 
PBS: 137 mM NaCl, 2.7 mM KCl, 9.5 mM Na2PO4H, 1.4 mM K2PO4H2 (Severn Biotech 
LTD). 
TAE buffer: 50 mM Tris-Acetate, 1 mM EDTA, pH8 
PBS-T: 0.1% (v/v) TWEEN
®20 (Sigma, #P1379) in PBS 
TBS: 20 mM Tris-HCl pH7.5, 137 mM NaCl in ddH2O 
TBS-T: 0.1% (v/v) TWEEN
®20 in TBS 
TE: 10 mM Tris-HCl pH 7.5, 1 mM EDTA 
 
2.1.2 General reagents 
Bio-Rad Protein Assay Dye Reagent (BioRad, #500-0006) 
Trypsin-EDTA (GIBCO, #25300) 
Gelatin (Sigma, G1393) 
Fibronectin (Sigma, #F-2006) 
Collagen R (Serva, #47254) 
DMSO (Sigma) 
Giemsa stain (Sigma, 48900) 
May-Grunwald solution (Thermo Scientific 89027) 
 
Inhibitors: (For PI3K inhibitors see section 2.1.5) 
Rac inhibitor: NSC23766 (Calbiochem) 
ROCK inhibitor: Y-27632 (Calbiochem, #688000) 
 
Cytokines: 
Recombinant murine PDGF-BB (Peprotech, #315, 18) 
Recombinant murine IL-3 (Peprotech, #210-31) 
Recombinant murine SCF (Peprotech, #250-03) 
 
Transfection reagents: 
SuperFect Transfection Reagent (Qiagen, 301305). 
FuGENE® 6 Transfection Reagent (Roche, 11 814 443 001). 
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Antibiotics: 
Geneticin® (Invitrogen, 10131-019) 
Ampicillin (Invitrogen, 11593-027) 
 
Dual luciferase reagents: 
Dual-Luciferase
® Reporter Assay System (Promega, E1910).  Each system includes: 
Passive Lysis Buffer, Luciferase Assay Reagent II and Stop & Glo
® Reagent. 
 
Matrigel preparations: 
Collagen type I (Marathon, #354249) 
Powdered ʱ MEM (GIBCO, #11900-073) 
Matrigel (Marathon) 
 
Bacteria: 
LB media: 12.5g LB broth (BD, #244620) in 500 ml dd H20. 
LA plates: 12.5g LB broth (BD, #244620) + 7.5 g Agar (Sigma, #L2897) in 500 ml ddH20. 
Antibiotics: 100 μl ampicillin (100 mg/ml) / ml  LB media and LA plates. 
S.O.C. media: (Invitrogen, 15544-034) 
 
2.1.3 Lysis buffer reagents 
 
Standard lysis buffer :  Final concentration of inhibitors added before use : 
50 mM Tris-HCl pH 7.4  50 mM NaF [phosphatase inhibitor (BDH, #102464T)] 
100 mM NaCl   1  mM  Na3VO4  [tyrosine phosphatase inhibitor (Sigma, 
#S6508)] 
50 mM NaF    10  μM  leupeptin  [serine  and  cysteine  protease  inhibitor 
(SIGMA, #L2884] 
5 mM EDTA    0.7  mM  pepstatin  A  [acid  protease  inhibitor  (Sigma, 
#P4265)] 
2 mM EGTA    27 μM TLCK [serine protease inhibitor (Sigma, #T7254)] 
40 mM β-glycerophosphate    1  mM  PMSF  [serine  protease  inhibitor,  dissolved  in 
isopropanol (Sigma, #F1428)] 
10 mM sodium pyrophosphate  1  μM  okadaic  acid  [phosphatase  inhibitor  (Calbiochem, 
#495604)] 
1% Triton X-100  1 μg/ml aprotinin [trypsin inhibitor (Sigma, #A6103)] 
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Lysis buffer for Rho-pull downs:  Final concentration of inhibitors added before use : 
50 mM Tris-HCl pH 7.5  0.5% β-mercaptoethanol (Sigma M7522) 
1 mM EDTA  1 mM PMSF 
500 mM NaCl  1 mM DTT 
10 mM MgCl2  0.2 mM Na3VO4 
1% Triton X-100  1 μg/ml aprotinin  
0.5% Na Deoxycholate  1 μg/ml leupeptin  
0.1% SDS  1 μg/ml pepstatin A  
10% Glycerol   
 
2.1.4 Buffers and reagents for SDS-PAGE and protein detection 
Preparation of acrylamide separating and stacking gels: 
 
  1 x large gel system (Hoefner)  2 x small gel system (BioRad) 
  8% Separating 
gel 
Stacking gel  8% Separating 
gel 
Stacking 
gel 
1.5 M Tris-HCl 
pH 8.8 
7.5 ml  -  3.75 ml  - 
1 M Tris-HCl pH 
6.8 
-  1.25 ml  -  0.625 ml 
H20  13.9 ml  6.8 ml  6.95 ml  3.4 ml 
30% Acrylamide 
solution 
8.0ml  1.7 ml  4.0 ml  0.85 ml 
10% SDS  0.3 ml  0.1 ml  0.15 ml  0.05 ml 
10% APS  0.3 ml  0.1 ml  0.15 ml  0.05 ml 
TEMED  0.018 ml  0.01 ml  0.01 ml  0.005 ml 
(TEMED = Tetramethylethylenediamine; APS = ammonium persulfate) 
 
The separating gel was made first and left to set before making up the stacking gel to layer 
over the top of the separating gel. 
 
Running buffer: 0.25 M Tris, 0.192 M glycine, 0.1% w/v SDS, pH 8.3 
Transfer buffer: 48 mM Tris-HCl pH 8.5, 0.39 M glycine, .1% SDS, 20% methanol 
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5x SDS sample buffer:  
156.25 mM Tris-HCl pH 6.8 
5% w/v SDS 
25% v/v glycerol 
0.0025% w/v bromophenol blue 
250 mM DTT (add just before use) 
 
Home-made ECL: 
Solution A: 20 mM Tris-HCL pH 8.5, 0.02% H2O2 
Solution B: 20 mM Tris-HCL pH8.6, 13.2 mg coumaric acid (Sigma, #C9008), 0.868 mg 
luminal (Sigma, #A8511). 
Equal volumes of solution A and solution B were mixed before use. 
 
Stripping buffer: 
191.06g  guanidine  hydrochloride  (Sigma,  #G4505)  dissolved  in  250  ml  ddH20.    Once 
dissolved, concentrated HCl was added drop wise to reach pH 3. 
 
2.1.5 PI3K inhibitors 
LY294002: Pan PI3K inhibitor (Calbiochem) 
TGX-115: p110β-selective (Merck-Serono, Geneva) 
IC87114: p110δ-selective (Merck-Serono, Geneva) 
AS604850: p110γ-selective (Merck-Serono, Geneva) 
 
  IC50s (μM) of PI3K inhibitors on class I PI3K p110 isoforms 
Inhibitor  p110ʱ  p110β  p110δ  p110γ 
LY294002  9.3  2.9  6.0  >20 
TGX-115   >20  0.03  0.34  >20 
IC87114   >200  16  0.13  61 
AS604850  3.44  >20  >20  0.19 
Table 2.1: IC50 values of PI3K isoform-selective inhibitors. (Knight, et al., 2004; Knight, 
et al., 2006). 
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2.1.6 Antibodies 
Primary antibodies 
Name  Specificity  Source and  cat. #  Secondary  Concentration/ 
dilution 
Akt  Akt  Cell Signalling, 9272  Rabbit,  pAb  1:1000 (WB) 
pS473  P-Akt (S473)  Cell Signalling, 9271  Rabbit, pAb  1:1000 (WB) 
pT308  P-Akt (T308)  Cell Signalling, 4056  Rabbit, mAb  1:1000 (WB) 
β-actin  β-actin  Sigma, ac-15  Mouse, mAb  1:1000 (WB) 
9E10  c-Myc  Abcam, ab32  Mouse, mAb  1:1000 (WB) 
9B11  Myc-tag  Cell Signalling, 2276  Mouse, mAb  1:1000 (WB) 
1:1000 (IP) 
p110ʱ-15  p110ʱ  In house  Rabbit, pAb  1:500 (WB) 
1:500 (IP) 
p110ʱ  p110ʱ  Transduction Labs 
P94520150 
Mouse, mAb  0.25 mg / ml 
1:1000 (WB) 
PI 3-kinase 
p110β (S-19) 
p110β  Santa Cruz, sc-602  Rabbit, pAb  0.2 mg /ml, 
1:1000 (WB) 
p110δ  p110δ-CT  In house  Rabbit, pAb  1 mg / ml 
1:5000 (WB), 
1:1000 (IP) 
PI 3-kinase 
p110δ 
p110δ-CT  Abcam, 1678  Rabbit, pAb  1 mg / ml 
1:1000 (WB), 
1:1000 (IP) 
p110γ  p110γ  In house  Mouse, mAb  1:100 (WB) 
PI3-Kinase, 
p85 
Pan-p85  Upstate, 06-195  Rabbit, pAb  1:5000 (WB) 
4G10  Phospho-Tyr  Upstate, 05-1050   Mouse, mAb  1:5000 (WB) 
PMT  PMT  Provided by Dr. S. 
Dilworth (Imperial 
College, London) 
Mouse, mAb  1:1000 (WB) 
HOX11 (1D7)  HOX11  Santa Cruz, sc-12760  Mouse, mAb  1:1000 (WB) 
Kit (C-14)  c-Kit receptor  Santa Cruz, sc-1493  Goat, pAb  1:500 (WB) 
1:500 (IP) 
FcεRI (G-14)  FcεRI  Santa Cruz, sc-33484  Goat, pAb   FACS Chapter 2 
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RhoA (26C4)  RhoA  Santa Cruz, sc-418  Mouse, mAb  1:100 (WB) 
Rac1           
(C-23A8) 
Rac1  Upstate, 05-389  Mouse, mAb  1:500 (WB 
Cdc42  Cdc42  Abcam, M152  Mouse, mAb  1:500 (WB 
p190RhoGAP 
(CD2D6) 
P190RhoGAP  Upstate, 05-378  Mouse, mAb  1:1000 (WB) 
PTEN  PTEN  Cell Signalling , 9552  Rabbit, pAb  1:1000 (WB) 
Cyclin D1 (C-
20) 
Cyclin D1  Santa Cruz, sc-717  Rabbit, pAb  1:1000 (WB) 
           
Immunofluorescence         
P-FAK (Y397)  p-FAK  Biosource, 44-624G  Rabbit, pAb  1:100 (IF) 
P-paxillin  p-paxillin  Biosource, 44-722G  Rabbit, pAb  1:100 (IF) 
N-cadherin 
(D-4) 
N-cadherin  Santa Cruz, sc-8424  Mouse, mAb  1:100 (IF) 
Phalloidin-
fluorescein 
F-actin  Sigma, P5382    1:400 (IF) 
DAPI  DNA  Santa Cruz, sc-3598    1:100 (IF) 
 
Secondary antibodies 
Secondary  Source  Source and cat. #  Dilution 
HRP-anti-rabbit IgG  Donkey  Amersham, NA934-1ML  1:5000 (WB) 
HRP-anti-mouse IgG  Sheep  Amersham, NXA931  1:5000 (WB) 
Anti-mouse IgG-FITC  Donkey  Jackson Immuno Research, 715-095-150  1:400 (IF) 
Anti-rabbit IgG-FITC  Donkey  Jackson Immuno Research, 711-095-152  1:400 (IF) 
Anti-rabbit IgG-Cy5  Donkey  Jackson Immuno Research, 711-175-152  1:400 (IF) 
Anti-mouse IgG-Cy5  Donkey  Jackson Immuno Research, 715-175-151  1:400 (IF) 
Anti-rabbit IgG-Cy3  Donkey  Jackson Immuno Research, 711-165-152  1:400 (IF) 
Anti-mouse IgG-Cy53  Donkey  Jackson Immuno Research, 715-165-151  1:400 (IF) 
Anti-mouse IgE-FITC  Rat  BD PharMingen, 553415   1:400 (FACS) 
Anti-mouse c-kit-PE  Rat  BD PharMingen, 553355  1:400 (FACS) 
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2.1.7 Reagents for pull downs and immunoprecipitations 
Beads  Used to pull down:  Source and cat. # 
GST-tagged Rhotekin-RBD 
on agarose beads 
RhoA-GTP  Cytoskeleton, RT02 
GST-tagged  PAK-RBD  on 
agarose beads 
Rac1-GTP/Cdc42-GTP  Cytoskeleton, PAK02 
Protein A sepharose  Anti-rabbit polyclonal or 
monoclonal antibodies 
Amersham, 17-5280-01 
Protein G sepharose  Anti-mouse polyclonal or 
monoclonal antibodies 
Amersham, 17-0618-01 
Glutathione sepharose  GST-tagged proteins  Amersham, 17-5132-01 
 
2.2 MICE 
p110δ
D910A/D910A mice have been described previously (Okkenhaug, et al., 2002) and were 
back-crossed on a Balb/c background. Age-matched, 6-10 week old littermate mice were 
used for all experiments. 
 
2.3 CELL CULTURE 
 
2.3.1 Cell lines and culture media 
Cell line  Species  Type of cell line 
A20  Mus musculus  Mature B cell line 
CT26  Mus musculus  Colon carcinoma cell line 
HEK293T  Homo sapiens  Embryonic kidney cell line 
NIH 3T3  Mus musculus  Fibroblast cell line 
RAW 264  Mus musculus  Macrophage cell line 
Thp-1  Homo sapiens  Acute monocytic leukaemia cell line 
WEHI-231  Mus musculus  Immature B-cell line 
GP E86  Mus musculus  Fibroblast ecotropic packaging cells 
 
WEHI-231, A20 and Thp-1: 
RPMI  1640  supplemented  with  10%  FBS,  1%  penicillin/streptomycin  and  50  μM  β-
mercaptoethanol (for β-mercaptoethanol, 500 μl of a 50 mM stock solution was added to 
500 ml RPMI). Chapter 2 
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NIH 3T3, CT26, HEK 293T and GP E86: 
DMEM supplemented with 10% FBS and 5 ml penicillin/streptomycin. 
 
RAW 264: 
RPMI 1640 supplemented with 10% certified FBS (GIBCO), 1% penicillin/streptomycin. 
 
2.3.2 Primary cells and culture media 
Primary murine bone marrow-derived mast cells (BMMCs): 
RPMI 1640 supplemented with 10% ultra low IgG FBS, 1% penicillin/streptomycin and 
1% L-glutamine.  Cells were cultured in 20 ng / ml recombinant murine IL-3 and 20 ng / ml 
recombinant murine SCF. 
 
2.3.3 Maintenance of mammalian cell lines 
Cells were grown in the indicated cell culture media at 37
oC in a humidified incubator with 
5% CO2.  In general cells were passaged every 2-3 days.  For suspension cells, cells were 
diluted in pre-warmed media.  For adherent cells, cells were washed with PBS and detached 
using trypsin-EDTA before being diluted in pre-warmed media. 
For  the  adherent  RAW  264  cell  line,  cells  were  grown  in  10  cm
2  dishes.    Cells  were 
detached using a cell scraper.  Cells were thoroughly mixed by pipetting to break up cell 
clumps and diluted 1:10 in pre-warmed media every 3-4 days.  
 
2.3.4 Isolation and maintenance of BMMCs 
Isolation:  Bone  marrow  progenitors  were  isolated  from  the  femurs  of  mice  following 
dissection. Isolated femurs were cleaned with alcohol spray and the end the bones carefully 
cut off.  Bone marrow progenitors were flushed out of each bone with 2 ml of RPMI using 
a 25 gauge needle.  Cells were counted using a haemocytometer to distinguish mast cell 
progenitors from red blood cells, muscle cells, fibroblasts, neutrophils and other cell types.  
Generally isolated cell were diluted 1:10 in RPMI containing IL-3 and SCF. 
 
Maintenance: 24 h after isolation of bone marrow progenitors, non-adherent cells were 
transferred to new culture flask (20 ml media in a 75 cm
2 flask).  Media, containing 20 ng / 
ml IL-3 and 20 ng / ml SCF, was replaced every 3 days for the first 2 weeks and then every 
4 days after this time, maintaining cells at a density of 0.5 X 10
6 cells / ml. 
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2.4 CELL STIMULATION 
Cytokine stimulation of mast cells: Cells were starved overnight of IL-3 and SCF-1 in 
normal cell culture media containing 10% serum.  Cells were stimulated with 20 ng/ml 
SCF-1 for 5-10 min at 37
oC.  Cells were then washed twice in ice-cold PBS and total cell 
lysates prepared. 
 
Serum  stimulation  of  cell  lines:  Cells  were  seeded  in  cell  culture  dishes  in  media 
containing serum and left to adhere for 6 – 8 h.  After this time, media was aspirated and 
replaced with media containing no serum and left on the cells overnight.  The following day 
cells  were  stimulated  by  adding  the  appropriate  volume  of  serum  over  the  whole  cell 
culture dishes drop by drop.  During the serum-stimulation, cells were incubated at 37
oC.  
After the allocated time of stimulation, media was removed and cells washed once with 
PBS prior to cell lysis. 
 
2.5 CELL LYSIS, IMMUNOPRECIPITATION AND PULL DOWN 
Cell lysis: Cells were harvested by centrifugation at 1200 rpm for 5 min and subsequently 
washed twice with ice-cold PBS.  The cell pellet was resuspended in ice-cold lysis buffer (1 
ml lysis buffer/10
7 cells) containing protease and phosphatase inhibitors and incubated for 
20-30 min on ice, vortexing every 10 min.  The lysate was centrifuged at 10,000 x g for 10 
min at 4
oC.  The supernatant was transferred to a fresh tube and the protein concentration 
determined using Bio-Rad protein assay dye reagent.   
 
Immunoprecipitations: Primary antibody was added directly to the lysate and incubated 
for 2 h to overnight at 4
oC.  After this time, 10-100 μl of prewashed protein A/G sepharose 
beads in lysis buffer were added to the lysates and samples incubated for a further 2 h at 
4
oC.  Subsequently, beads were washed three times with lysis buffer.  30-100 μl of SDS 
sample buffer was then added to the washed beads and boiled for 5 min at 100
oC. 
 
GTP-RhoGTPase pull downs:  Cells were seeded in 10 cm
2 cell culture dishes the day 
before  performing  the  pull  down.    On  the  day  of  the  pull  down,  cells  were  60-70% 
confluent. The cell culture dishes were placed on a bed of ice and the  media carefully 
aspirated.  500 μl of pre-cooled lysis buffer was subsequently added onto each dish and 
cells scraped (on ice) with a pre-cooled scraper. Scraped cells and lysate were collected in 
pre-cooled 1.5ml Eppendorf tube.  Samples were centrifuge at 13000 rpm for 5 min at 4ºC 
and the supernatant transferred into a fresh pre-cooled 1.5 ml Eppendorf tube. 60 μl of the Chapter 2 
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lysate was taken to which 15 μl SDS sample buffer was added and the sample boiled for 5 
min at 100
oC, for the quantification of total RhoGTPase.  To the remaining lysate, 15 μl of 
GST-tagged Rhotekin-RBD agarose beads (for pull down of RhoA-GTP) or GST-tagged 
PAK-RBD on agarose beads (for pull down of Rac1-GTP or Cdc42-GTP) was added and 
sample incubated for 45 min at 4
oC, rotating.  After this time, beads were washed three 
times with lysis buffer by centrifuging samples at 10,000 rpm for 2 min at 4
oC.  After final 
wash,  lysis  buffer  was  aspirated  and  20  μl  of  SDS-PAGE  sample  buffer  added  to  the 
samples.  Samples were boiled for 5 min at 100
oC and proteins separated on 12.5% gels by 
SDS-PAGE. 
 
2.6 PROTEIN ANALYSIS AND DETECTION 
The immunoblots presented throughout this thesis are representative examples that have 
been selected to most clearly illustrate the data.  In most cases, unless stated, all or parts of 
each experiment have been repeated to allow confidence in the immunoblot presented.  
 
2.6.1 Determination of protein concentration 
The  protein  concentration  of  lysates  was  measured  using  Bio-Rad  protein  assay  dye 
reagent, which is based on the Bradford method in which a differential colour change of a 
dye occurs in response to varying protein concentrations.  5 μl of lysate was added to 1 ml 
of  Bio-Rad  protein  assay  dye  reagent  and  the  absorbance  measured  at  595  nm  with  a 
spectrophotometer.  The spectrophotometer was first blanked by reading the absorbance of 
5 μl of lysis buffer in Bio-Rad protein assay dye reagent at 595 nm.  The obtained value for 
the cell lysate samples were then multiplied by a constant of 24.75 and the dilution factor 
(200) to give the protein concentration in mg/ml. 
 
2.6.2 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
The separating and stacking acrylamide gels were made as described in section 2.1.4.  For 
separation  of  PI3K  subunits,  an  8%  gel  was  used,  whereas  a  12.5%  gel  was  used  for 
separation of Rho GTPases.  Protein samples that had been boiled in lysis buffer and SDS-
PAGE sample buffer were loaded into the wells of the stacking gel.  For large gels, up to 
100 μl of sample was loaded/well and in small gels, up to 50 μl.  For the large gel systems, 
the gel was run at a constant voltage of 200 V for 5 h at 4
oC or 50 V at room temperature 
overnight.  For the small gel system, the gel was run at a constant voltage 100 V for 2 h at 
room temperature. 
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2.6.3 Electroblotting 
After  SDS-PAGE,  proteins  were  transferred  from  the  acrylamide  gel  onto  a  PVDF 
membrane (Immobilon
TM-P, Millipore) by electroblotting.  The PVDF membrane was cut 
slightly larger than the size of the gel and was briefly soaked in methanol and then rinsed 
with ddH20 for 5 min.  Both the gel and the membrane were pre-equilibrated in transfer 
buffer and then sandwiched between two sheets of Whatman 3MM paper and two sponges, 
which had also been pre-equilibrated in transfer buffer.  The „sandwich‟ was placed into the 
electroblotting apparatus cassette and placed in a blotting tank filled with transfer buffer, 
such that the gel  was  facing the cathode.  For large gels  using the Hoefner apparatus, 
proteins  were  transferred  at  60  V  for  4  h  at  4
oC,  for  small  gels  using  the  BioRad 
electroblotting system, proteins were transferred at 100 V for 1 h at 4
oC. 
 
2.6.4 Antibody incubation and protein detection 
After proteins had been transferred to the PVDF membrane, the membrane was blocked for 
1 h in 5% milk dissolved in PBS-T.  The membrane was then washed two times for 5 min 
with PBS-T, before being incubated with the primary antibody.  Primary antibodies were 
either diluted in 5% milk or 3% BSA in PBS-T.  The membrane was incubated with the 
primary antibody overnight, rocking at 4
oC.  The following day, the membrane was washed 
thoroughly with PBS-T and then incubated with the secondary HRP-conjugated antibody 
diluted in 5% milk in PBS-T for 1 h at room temperature.  The membrane was then was 
thoroughly washed again with PBS-T before being incubated with ECL
TM Western Blotting 
Detection  Reagents  (Amersham  Biosciences)  or  home-made  ECL  for  1-3  min.    The 
membrane was wrapped in cling film and exposed to super RX Fuji medical X-ray films 
(Fuji). 
 
2.6.5 Stripping of blots 
Membranes were washed thoroughly in ddH20.  Guanidine hydrochloride stripping buffer, 
described in section 2.1.4, was poured onto the membrane and the left until the membrane 
had  become  transparent  (after  approximately  30  seconds).    Membranes  were  then 
thoroughly washed again in ddH20 until they were no longer transparent.  Membranes were 
blocked again in 5% milk in PBS-T before primary antibody incubation. 
 
2.7 PREPARING SAMPLES FOR IMMUNOFLUORESCENCE  
2.7.1 Preparation of cells 
Cells were seeded on coverslips in 12-well tissue culture plates. For fixation, cells were 
washed with PBS and then incubated with 1 ml 4% paraformaldehyde (PFA) for 15 min at Chapter 2 
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room temperature. After this time, cells were washed with PBS and permeabilised with 1 
ml 0.5% Triton X-100 in TBS for 10 min at room temperature, followed by three separate 5 
minute  incubations  with    0.1%  Triton  X-100  in  TBS  at  room  temperature.  Cells  were 
washed  in  TBS-T  and  then  incubated  with  2%  BSA  in  TBS-T  for  10  min  at  room 
temperature.  Subsequently, cells were washed with TBS-T and incubated with the primary 
antibody (50 μl / coverslip), diluted in 2% BSA in TBS-T, overnight at 4
oC.  From this 
point onwards cells were protected from the light.  Following three 5 min washes in TBS-T, 
the secondary antibody, diluted in 2% BSA in TBS-T, was added to the cells (50 μl / 
coverslip) and left for 1-2 h at room temperature. Following three 5 min washes in TBS-T, 
phalloidin-fluorescein (if staining for F-actin) diluted in 2% BSA in TBS-T, was added 
onto cells (50 μl / coverslip) and left for 20 min at room temperature.  After this time cells 
were washed three times with TBS-T, including DAPI during the last wash step if staining 
DNA.  Coverslips were mounted on slides using Mowiol (Calbiochem, 475904). 
 
2.7.2 Preparation of coverslips 
Fibronectin and collagen solutions were made up at a concentration of 10 μg/ml in PBS.  
For gelatin, a 0.1% solution in sterile ddH20 was used.  Single autoclaved coverslips were 
placed  in  individual  wells  of  a  12-well  tissue  culture  plate.    1  ml  of  the 
fibronectin/collagen/gelatin  solution  was  added  to  each  well  to  cover  the  coverslips.  
Fibronectin  and  collagen  solutions  were  left  on  coverslips  overnight  at  4
oC,  whereas 
coverslips covered in gelatin solution were left at room temperature for 30  min – 1 h.  
Coverslips were washed once with PBS and incubated with 1 ml 2% BSA solution (in PBS) 
for 1 h at 37
oC.  Subsequently, coverslips were washed once with PBS and left to air dry 
before seeding the cells. 
 
2.7.3 Cell adhesion assay 
NIH  3T3  cells  were  detached  using  trypsin-EDTA  and  seeded  onto 
fibronectin/collagen/gelatin-coated coverslips in 12-well plates at a concentration of 10,000 
cell / well.  Cells were left to adhere to the coverslips for time periods ranging from 30 min 
to  6  h.    After  this  time,  cells  were  fixed  with  4%  PFA  and  prepared  for 
immunofluorescence analysis.    
 
2.7.4 Confocal imaging 
To eliminate the detection of background and non-specific fluorescence from the secondary 
fluorophore-conjugated antibodies, the microscope settings were set so that no fluorescence 
was observed from samples that had been incubated with secondary antibodies alone (i.e. Chapter 2 
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without the primary antibody).  Once microscope settings had been optimized for detection 
of a specific primary antibody, these settings were maintained for all samples from the 
same experimental sample set to allow for a direct comparison of signal intensity. 
 
2.8 QUANTITATIVE REAL TIME PCR  
2.8.1 Reagents 
Primer mixes were supplied by Applied Biosystems (see table below).  The primer mix 
contained  two  unlabeled  gene-specific  PCR  primers  and  a  FAM
TM  dye-labelled  gene-
specific Taqman® probe.  Taqman® Universal PCR Master Mix (Applied Biosystems, 
4304437) and sample cDNA were added to the primer mix, which could then be used for 
real time (RT)-PCR.  Primers specifically for exon -2a and exon -2b upstream of mouse 
p110δ  were  ordered  as  part  of  Applied  Biosystems  Assays-on-demand  scheme.    This 
involved submitting the sequences for exon -2a and exon -2b to Applied Biosystems who 
designed primers and probes specifically for PCR amplification of these sequences. Primers 
for the coding region of mouse p110δ, and for p110ʱ, p110β, p85ʱ, p85β, p55γ and β-actin 
were commercially available from Applied Biosystems.   
 
Quantitative RT PCR primers 
Gene Symbol  ABI assay ID  Gene name 
pik3cd -2a  Assay-on-demand  p110δ with exon -2a (mouse) 
pik3cd -2b  Assay-on-demand  p110δ with exon -2b(mouse) 
pik3cd  Mm00435674_m1  p110δ (mouse) 
pik3ca  Mm00435669_m1  p110ʱ (mouse) 
pik3cb  Mm00659576_m1  p110β (mouse)  
pik3r1  Mm00803163_g1  p85ʱ (mouse) 
pik3r2  Mm00435694_m1  p85β (mouse) 
pik3r3  Mm00725051_m1  p55γ (mouse) 
β-actin  Mm00607939_s  β-actin (mouse) 
β-actin  Hs99999903_m1  β-actin (human) 
 
2.8.2 Methods 
The primer mix supplied by Applied Biosystems contains a forward and reverse primer for 
the gene of interest and a FAM
TM dye-labelled gene-specific Taqman® probe.  FAM is a 
high energy green fluorescent dye which is attached to the 5‟ end of the probe (the reporter 
dye). A low energy quencher molecule attached to the 3‟ end of the probe.  During PCR if Chapter 2 
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the target cDNA of interest is present, the Taqman® probe hybridises to a complementary 
sequence between the forward and reverse primers.  When the probe is intact, the proximity 
of  the  reporter  dye  to  the  quencher  dye  results  in  suppression  of  the  reporter  dye 
fluorescence.  During each PCR extension cycle, the 5‟-3‟ exonuclease activity of Taq 
DNA polymerase (in the Taqman® Universal PCR Master Mix) cleaves the probe between 
the  reporter  dye  and  quencher  molecule  displacing  the  two  probe  fragments,  and 
polymerisation of the strand continues (Figure 2.1).   
 
Figure  2.1:  Quantitative  real  time  PCR.  Two  fluorescent  dyes,  a  reporter  (R)  and  a 
quencher (Q) are attached to 5‟ and 3‟ end of a Taqman probe, which hybridises to  a 
complementary sequence between the forward and reverse primer sites. When both dyes are 
attached,  the  reporter  dye  emission  is  quenched.    Taq  DNA  polymerase  drives  DNA 
synthesis from the primer sites. During each extension cycle, the Taq DNA polymerase 
cleaves reporter dye from the probe by its 5‟-exo-nuclease activity.  Once separated from 
the quencher dye, the reporter dye fluorescence emission is detected. 
 
R Q Forward Primer
Reverse Primer
Probe
5‟
3‟
3‟
3‟
5‟
5‟
5‟
3‟
R Q
5‟
3‟
3‟
3‟
5‟
5‟
5‟
3‟
R Q
3‟
3‟
5‟
5‟
3‟ 5‟
3‟
5‟
1. Polymerisation
2. Strand displacement
R
Q
3‟
3‟
5‟
5‟
3‟ 5‟
3‟
5‟
3. Cleavage
4. Polymerisation completed
Reporter
Quencher Q
RChapter 2 
97 
 
The  separation  of  the  reporter  dye  from  the  quencher  molecule  results  in  fluorescence 
emission from the reporter dye.  The fluorescence is detected by the Applied Biosystems 
7500 Real Time PCR System, and is proportional to the amount of PCR product being 
amplified.    The  PCR  cycle  at  which  the  fluorescence  intensity  is  greater  than  the 
background, when target cDNA amplification is first detected is referred to as the „cycle 
threshold‟ or CT value.  If there is a high quantity of target cDNA in the starting sample, 
this will yield a low CT value.  Samples were normalised to the endogenous control, β-actin. 
 
2.8.3 Quantifying the amount of cDNA 
Relative standard curve: A relative standard curve is  commonly used to  quantify the 
amount of target cDNA in samples.  To construct a relative standard curve, a stock of 
cDNA from a cell line known to contain the gene of interest, is used to create a set of 
standards, such as 1 ng of total cDNA diluted in a series of 10-fold dilutions.  Each of these 
standards is added to the Taqman® – gene-specific primer mix and the gene of interest 
amplified to give a series of CT values.  The Applied Biosystems 7500 Real Time PCR 
System constructs a standard curve by plotting the CT value against the log [ng cDNA 
input].  This standard curve can be used to calculate the quantity of target cDNA in a 
sample by using the CT value obtained from sample cDNA amplification. 
 
Limitations of the relative standard curve approach 
This method can only be used to compare the amount of target cDNA between samples that 
have been amplified by the same primer set i.e. it allows for the comparison of a specific 
gene  between  different  samples  but  it  does  not,  however,  allow  for  the  comparison  of 
different  genes  in  one or more samples.   The reason  for this  is  that the given starting 
concentration of total cDNA isolated from a certain cell line, for example 1 ng, will contain 
varying copy numbers of individual genes.  1 ng total cDNA may contain 10,000 copies of 
gene „A‟ and only 100 copies of gene „B‟, which will result in the detection of gene „A‟ 
amplification earlier than gene „B‟, yet they will both be given the same log [ng cDNA 
input]  when  constructing  the  standard  curve.    The  effect  of  this  is  that  the  calculated 
concentration of gene B from the standard curve will be artificially high.  In addition, this 
approach does not take into consideration different primer efficiencies. 
 
Absolute standard curve: To permit the comparison of the levels of different cDNAs in 
cell types, standard curved were constructed that enabled the absolute quantification of the 
amounts of target cDNA.  Plasmids containing the full length DNA sequences for p110ʱ, 
p110ß, p110δ, p110δ-2a, p110δ-2b, p85ʱ, p85ß, p55γ were used to create a set of standards Chapter 2 
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containing 160 – 1 x 10
8 gene copies / μl (160, 800, 4 x 10
3, 2 x 10
4,
 1 x 10
5,
 1 x 10
6,
 1 x 
10
7and
 1 x 10
8).  This was achieved using the following procedures: 
 
1)  Plasmid DNA concentrations (ng / μl)  were determined using a Nanodrop ND-1000 
spectrophotometer (Nanodrop Technologies)   
2)  The following equation was used to calculate pMol concentration:  
pMol DNA = mass of DNA (pg) ÷ [DNA length (bp) x 650pg/pmol/bp] 
3)  The Molar concentration was determined (pMol concentration x 10
12) 
4)  The number of molecules / μl were calculated: [Molar concentration x Avogadro‟s 
constant (6 x 10
23)] 
 
2.8.4 Plasmids used to construct quantitative RT PCR standard curves 
p110ʱ: Riken Fantom Clones, Accession # AK051885 
p110β: Riken Fantom Clones, Accession # AK090116 
p110δ-2a: Mammalian Gene Collection, Accession # BC035203  
p110δ-2b: Riken Fantom Clones, Accession # AK040867 
p85ʱ: Mammalian Gene Collection # 13952, Image #3979333, Accession # BC026146 
p85β: Mammalian Gene Collection #11459, Image #2581969, Accession # BC0067961 
p55γ: Mammalian Gene Collection # 62506, Image #6405534, Accession # BC053102 
 
2.9 TRANSFECTION 
2.9.1 Transfection with SuperFect Transfection Reagent 
Transfection of NIH 3T3 and HEK 293T cells with full length p110δ constructs (p110δ-
2a/2b)  were  carried  using  SuperFect  transfection  reagent  (Qiagen)  according  to  the 
manufacturer‟s protocol.  Similarly, the pMX(s)-neo retroviral vector containing human 
p110δ cDNA sequences was transfected into the GP E86 packaging cell line also using 
SuperFect transfection reagent. 
 
2.9.2 Transfection with FuGENE® 6 Transfection Reagent  
Transfections  of  RAW  264.7,  Thp1,  CT26  and  NIH  3T3  cells  with  luciferase  reporter 
constructs were carried using FuGENE®  6 Transfection Reagent (Roche), according to 
manufacturer‟s protocol. 
 
2.9.3 Retroviral infection  
Transfection of BMMCs with PMT and HOX11: Transfection of BMMCs was enhanced 
using RetroNectin
®-coated plates.  Chapter 2 
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Preparation of retronectin plates: RetroNectin
® (Takara, #T00A/B) is a ~63 kDa protein 
that enhances retroviral-mediated gene transfer into mammalian cells by co-localization of 
retrovirus  particles  with  target  cells.    This  is  accomplished  through  direct  binding  of 
retroviral particles to the heparin-binding domain II of RetroNectin
® and binding of target 
cells to a central cell-binding domain of RetroNectin
®.  A stock RetroNectin
® solution was 
prepared at a concentration of 1 mg/ml in sterile ddH20.  A working solution at 20 μg/ml 
was prepared by diluting the stock retronectin solution with PBS.  1 ml of the working 
RetroNectin
® solution was added per well of a 6-well tissue culture plate and left to stand at 
room temperature for 2 h.  After this time, the solution was removed and 1 ml of 2% BSA 
in PBS was added per well, and the plate left to stand at room temperature for 30 min.  The 
BSA solution was removed and the well washed once with PBS.  The plates were then 
ready to be used. 
 
Cell culture media from packaging cells stably expressing PMT or HOX11 (i.e. the viral 
supernatant) was collected after 24 h from 80% confluent flasks.  The viral supernatant was 
passed through a 0.45 μM filter and pre-loaded onto the RetroNectin
®-coated wells.  Plates 
were incubated for 4 h at 37
oC.  After this time the viral supernatant was removed and 
fresh, filtered viral supernatant was added into the wells and plates incubated for a further 4 
h at 37
oC.  After this time, viral supernatant was aspirated and 1 x 10
6 BMMCs added per 
well and plates incubated at 37
oC with 5% CO2 overnight. The following day the BMMCs 
were subjected to a second round of retroviral infection in the same manner as described 
above. 
 
Transfection of NIH 3T3 cells with human p110ʴ cDNA: GP E86 packaging cells stably 
expressing  pMX(s)-neo  retroviral  vectors  containing  p110δ  constructs  were  used  for 
retroviral  infection of  NIH 3T3 cells.   Fresh  cell culture media was  added to  GP  E86 
packaging cells at 70% confluency.  After 24 h the GP E86 media (viral supernatant) was 
collected and replaced with fresh media.  The viral supernatant was passed through a 0.45 
μM filter and added onto NIH 3T3 cells at 60% confluency and incubated for 24 h at 37
oC 
with 5% CO2.  After this time, NIH 3T3 cells were subjected to a second round of retroviral 
infection, by aspirating the viral supernatant and collecting the fresh GP E86 media, which 
had been on the GP E86 cells for 24 h and contained fresh viral supernatant.  NIH 3T3 cells 
were incubated for a further 24 h with the filtered fresh viral supernatant at 37
oC with 5% 
CO2. After this  time, the viral  supernatant was  replaced with  fresh  normal  cell culture 
media. 
2.9.4 Selection of cells stably expressing neomycin-resistance genes Chapter 2 
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Cells were selected either as single colonies or as a pool of colonies.  For single colony 
selection and expansion, cells were diluted 1:10 48 h after transfection and seeded in 6 cm
2 
cell culture dishes in media containing 500 μg/ml geneticin.  When individual colonies 
were ready to be picked (once they had expanded to a total diameter of approximately 3-5 
mm) the media was aspirated and the colonies marked on the bottom of the plate using a 
pen.  Cloning rings were stuck down surrounding the marked colonies, using autoclaved 
grease.  50 μl of trypsin-EDTA was added onto the cells within the cloning ring and left 
until the cells had detached.  The detached cells were transferred into individual wells of 
12-well tissue culture plate to expand, grown in media containing 500 μg/ml geneticin for 
at least 15 days.  For selection of pooled colonies, 48 h after transfection, cells were diluted 
1:2 in 10 cm
2 cell culture dishes and grown in media containing 500 μg/ml geneticin for at 
least 15 days, passaging accordingly if cells reached confluency.  
 
2.10 DUAL LUCIFERASE ASSAY 
Cells were seeded in 6-well cell culture dishes.  On the day of transfection cells were 60% 
confluent.  2 μg of luciferase reporter vector + 0.5 μg renilla vector were used for the 
transfections with FuGENE® 6 Transfection Reagent (Roche) and each transfection was 
carried out in triplicate.  48 h following transfection, cells were lysed using Passive Lysis 
Buffer [PLB (Promega, #E194A)].  Cells were washed once with PBS and 500 μl of 1 x 
PLB added per well onto adherent cells.  Plates were left at room temperature, rocking for 
30 min.  For suspension cells, cells were washed once in PBS and centrifuged for 5 min at 
1200  rpm.    Cell  pellets  were  resuspended  in  500  μl  PLB  in  1.5  ml  Eppendorf  tubes.  
Samples were left at room temperature rotating for 30 min.  Following cell lysis, 30 μl of 
the cell lysate was pipetted into each well of a 96-well White Cliniplate (Thermo Fisher 
Scientific, #9502887).  Luciferase Assay Buffer II and Stop & Glo
® Buffer (Promega)
 were 
prepared according to the manufacturer‟s protocol.  Firefly and Renilla luciferase activity 
was  measured  using  a  luminescence  plate  reader  (Perkin  Elmer  VICTOR™  X  Light 
Luminescence Plate Reader, #2030-0010).  
 
The Firefly luciferase activity of each reporter construct was calculated by normalising the 
Firefly  luciferase  activity  against  the  Renilla  luciferase  activity  (Firefly  luciferase 
measurement divided by the Renilla luciferase measurement).  Following normalisation, the 
average  Firefly  luciferase  activity  of  pGL3-Basic,  which  represents  the  background 
luciferase activity, was subtracted from the normalised Firefly luciferase activity of each 
reporter construct.  The average and standard deviation of the Firefly luciferase activity of 
each reporter construct was subsequently calculated. Chapter 2 
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2.11 NUCLEIC ACID MANIPULATION 
2.11.1 Preparation of plasmid DNA 
Small and large scale plasmid preparations were carried using QIAprep Spin Miniprep Kit 
(Qiagen, 27106)  or QIAGEN Plasmid Maxi Kit  (Qiagen, 12163), respectively, according 
to the manufacturer‟s protocol. 
 
2.11.2 Purification of PCR DNA products  
For  purification  of  PCR  DNA  products  for  subsequent  cloning  steps,  QIAquick  PCR 
Purification Kit  (Qiagen, 28104) was used according to the manufacturer‟s protocol. 
 
2.11.3 Preparation of cDNA for quantitative real time PCR 
Purification of total RNA from cells: Total RNA was isolated from cells using RNeasy 
Mini Kit  (Qiagen, 74104) according to the manufacturer‟s protocol. 
Reverse  transcription  of  mRNA  to  cDNA:  Using  Oligo(dT),  mRNA  was  reversed 
transcribed  to  cDNA  using  SuperScript™  II  Reverse  Transcriptase  (Invitrogen,  18064-
022) according to the manufacturer‟s protocol. 
 
2.11.4 Agarose gel electrophoresis of DNA 
Molecular biology grade agarose (Helena Biosciences) was dissolved in TAE buffer to a 
final concentration of 0.8-2.0% depending on the size of DNA fragments separated.  The 
solution was heated in the microwave until the agarose powder had completely dissolved.  
Ethidium bromide was added to the solution to a final concentration of 10 μg/ml and the 
solution poured into the gel apparatus and allowed to set. DNA samples were mixed with 
6x DNA Loading Dye solution (Fermentas, #R0611) and loaded into gel wells, with the 
chamber filled with TAE buffer.  DNA samples were run at a constant voltage of 100 V for 
0.5-1 h.  For determination of fragment size, either MassRuler™ DNA Ladder, Low Range 
(Fermentas, SM0383) or MassRuler™ DNA  Ladder, High Range (Fermentas,  SM0393) 
were used depending on the size of DNA fragments expected.  DNA bands were visualized 
under UV-light. 
 
2.11.5 DNA cloning procedures 
2.11.5.1 Restriction enzyme digest of DNA 
Approximately 1 μg of DNA was diluted in 1 x restriction enzyme buffer (Fermentas or 
NEB) to a final volume of 20 μl.  For NEB buffers, an appropriate volume of BSA was 
added if required.  5-10 units of the desired restriction enzyme(s) were added to reaction 
mix. If more DNA was required for subsequent cloning stages, this reaction was scaled up Chapter 2 
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accordingly.  The reaction mix incubated for 1-2 h at the temperature recommended by the 
manufacturer,  usually  37
oC  or  55
oC.    The  reaction  products  were  analysed  by  gel 
electrophoresis. 
 
2.11.5.2 DNA extraction from agarose gel 
To extract DNA from agarose gel fragments for subsequent cloning steps, QIAquick Gel 
Extraction Kit (Qiagen, 28704) was used according to the manufacturer‟s protocol. 
 
2.11.5.3 Ligation of DNA fragments 
DNA fragments were ligated using Quick Ligation™ Kit (NEB, #M2200S) according to 
the manufacturer‟s protocol. 
 
2.11.5.4 Transformation of competent cells 
XL2-Blue ultracompetent cells (Stratagene, 200150) were transformed with Quick Ligation 
products as follows:  Competent cells were thawed on ice, 2 μl of the ligation mixture was 
added to the competent cells, mixed gently and incubated on ice for 30 min.  Competent 
cells were heat shocked for 2 min at 37
oC and then chilled on ice for 5 min.  500 μl of 
S.O.C. media was added to each sample and incubated shaking for 1 h at 37
oC.  100 μl of 
the transformed competent cells was then spread on selective LA plates, which were left at 
37
oC overnight. 
 
2.11.5.5 Sequencing reactions 
DNA sequencing reactions were carried out by MWG-Biotech, Germany.  1 μg of air-dried 
DNA was supplied, along with necessary primer sequences if required. 
 
2.11.5.6 In vitro translation 
In  vitro  translations  were  carried  out  using  the  TNT
®  Quick  Coupled 
Transcription/Translation  Systems  (Promega,  #L1170)  according  to  the  manufacturer‟s 
protocol using [
35S]methionine. 
 
2.12 DNA VECTORS  
2.12.1 Vectors used for cloning and expression of p110δ-2a, p110δ-2b and p85 cDNA 
in mammalian cell lines 
2.12.1.1: p110ʴ-2a 
p110δ-2a  cDNA  was  obtained  from  The  Mammalian  Gene  Collection  (MGC; 
http://mgc.nci.nih.gov/) in pCMV.Sport6 mammalian expression vector (accession number 
BC035203), inserted between Not I and Sal I. Chapter 2 
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Figure 2.2: pCMV.Sport6 vector. Map taken from Invitrogen Life Technologies. 
 
2.12.1.2: p110ʴ-2b 
p110δ-2b  cDNA  was  obtained  from  Riken  Fantom  Clones 
(http://www.cgb.ki.se/se/cgb/groups/liang/RIKEN+.htm) in pBluescript (accession number 
AK040867), inserted between Sal I and Bam HI. 
 
 
Figure 2.3: p110δ-2b cDNA in pBluescript.  
 
p110δ-2b cDNA was cloned into the mammalian expression vector pcDNA3.1(+)  (Figure 
2.4) from pBluescript, inserted between Not I and Apa I. 
DNA insert (p110δ-2b)
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Figure 2.4: pcDNA3.1(+) vector. Map taken from Invitrogen Life Technologies. 
 
2.12.1.3 Vectors conferring antibiotic-resistance   
pIRES vector (Figure 2.5a) was used in cotransfections with p110δ-2a in pCMV.Sport6 to 
enable selection of neomycin-resitant stable transfectants.  pBabe-Hygro (Figure 2.5b) was 
used in cotransfections  with p85ʱ in pCMV.Sport6 in cells stably expressing p110δ-2a 
cDNA (neomycin-resistant), to enable selection of hygromycin-resitant stable transfectants. 
 
 
Figure 2.5: Vectors conferring antibiotic-resistance. a) pIRES vector (map taken from 
Clontech)  and b) pBabe-Hygro vector.  
2.12.1.4 p85 expression vectors 
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pCMV.Sport6  mammalian  expression  vectors  (Figure  2.2)  were  obtained  from  the 
Mammalian Gene Collection containing cDNA for p85ʱ (accession # BC026146) or p85β 
(accession # BC0067961). 
 
2.12.2 Cloning and expression of human p110δ cDNAs  in pMX-neo retroviral vector 
 
2.12.2.1: 5’Myc-p110ʴ-3’CAAX 
Human 5‟Myc-p110δ-3‟CAAX cDNA in the pMX-neo retroviral expression vector (Figure 
2.6) was obtained from Dr. Tatsuo Kinashi (Kinashi, et al., 1999), inserted between BamH I 
and EcoR I. 
 
Figure 2.6: pMX-neo retroviral vector. 
 
2.12.2.2: p110ʴ-3’CAAX 
cDNA  for  human  p110δ-3‟CAAX  was  available  in  the  pcDNA3.1(+)  mammalian 
expression vector (Figure 2.4).  The pcDNA3.1(+)-p110δ-3‟CAAX vector and the pMX-
neo vector (Figure 2.6) were digested with the restriction enzymes BamHI and XhoI.  The 
resulting  digest  fragments  were  separated  on  a  DNA  agarose  gel  and  the  fragments 
corresponding  to  linearised  pMX-neo  and  p110δ-3‟CAAX  DNA  excised,  purified  and 
ligated as described in section 2.11.     
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cDNA for human 5‟Myc-p110δ-3‟CAAX had previously been obtained for the laboratory 
in the pUAST vector (Figure 2.7). The pUAST-5‟Myc-p110δ vector and pMX-neo (Figure 
2.6) were digested with the restriction enzymes BamHI and XhoI.  The resulting digest 
fragments  were  separated  on  a  DNA  agarose  gel  and  the  fragments  corresponding  to 
linearised pMX-neo and 5‟Myc-p110δ DNA excised, purified and ligated as described in 
section 2.11.      
 
Figure 2.7: pUAST vector. 
 
2.12.2.4: Untagged-p110ʴ 
To obtain the pMX-neo expression vector containing untagged human p110δ cDNA, the 
pMX-neo expression vectors containing 5‟Myc-p110δ and p110δ-3‟CAAX were employed.  
Both vectors were digested with the restriction enzyme EcoRI, which cuts within p110δ 
cDNA to after the 5‟Myc-tag and within the pMX-neo vector after the 3‟CAAX motif, and 
the appropriate DNA fragments ligated together (Figure 2.8).  Ligated DNA products were 
sequenced to check the correct orientation of untagged p110δ cDNA in pMX-neo. 
pUAST
9050
H
i
n
d
I
I
I
P
s
t
I
B
a
m
H
I
H
i
n
d
I
I
P
s
t
I
E
c
o
R
I
B
g
l
I
I
N
o
t
I
E
a
g
I
X
h
o
I
K
p
n
I
X
b
a
I
SV40
AmpRChapter 2 
107 
 
 
Figure 2.8: Cloning strategy used to obtain untagged p110δ cDNA in the pMX-neo 
retroviral vector. pMX-neo retroviral vector containing DNA inserts for either 5‟Myc-
p110δ or p110δ-3‟CAAX were digested with the restriction enzyme EcoRI.  The indicated 
DNA fragments from each digest were purified and ligated, resulting in untagged p110δ 
cDNA in pMX-neo. 
 
 
2.12.3 Vectors used in dual luciferase assays 
Murine  PIK3CD  exon  -2a  DNA  was  cloned  into  pGL3-Basic  (Figure  2.9),  which  is 
described in the following section (section 2.12.4).  DNA for HS21-Vav (Ogilvy, et al., 
1998)  had  previously  been  cloned  into  pGL2-Basic  vector  (Figure  2.10)  (Verrall  & 
Vanhaesebroeck, unpublished results).   
 
pGL3/pGL2-Basic  vector:  These  vectors  lack  a  eukaryotic  promoter  and  enhancer 
sequence, which allows maximum flexibility in assessing the promoter activity of putative 
regulatory sequences (Figure 2.9 and Figure 2.10).  Expression of luciferase activity in cells 
AmpR
MuLvLTR
Packaging 
signal
NeoR
pMX-neo-5’Myc-
p110δ
5’Myc-p110δ
EcoRI
EcoRI
EcoRI digest
EcoRI digest
AmpR
MuLvLTR
Packaging 
signal
NeoR
pMX-neo-p110δ-
3’CAAX
EcoRI
EcoRI
p110δ-3’CAAX
Ligation
pMX-neo-untagged 
p110δChapter 2 
108 
 
transfected with this vector depends on insertion of a functional promoter upstream of luc
+ 
(Firefly luciferase gene) (Promega, Technical Manual #TM033). 
 
 
Figure 2.9: pGL3-Basic vector (Promega, #E1751). 
   
 
Figure 2.10: pGL2-Basic vector (Promega, #E1611). 
 
pGL3-Promoter vector: This vector contains an SV40 promoter upstream of luc
+, and was 
used a positive control for luciferase activity in transfected cells (Figure 2.11). Chapter 2 
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Figure 2.11: pGL3-Promoter vector (Promega, # E1761). 
 
pGL3-Control vector: This vector contains an SV40 promoter upstream of luc
+ and an 
SV40  enhancer  sequence    located  downstream  of  luc
+  and  the  poly(A)  signal,  often 
resulting in strong expression of luc
+ in many cell types (Figure 2.12) (Promega, Technical 
Manual #TM033). 
 
Figure 2.12: pGL3-Control vector (Promega, # E1741). 
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pRL-SV40  vector:  This  vector  was  used  as  an  internal  control  reporter  and  was  co-
transfected  with  the  pGL3-reporter  vectors.  The  pRL-SV40  Vector  contains  the  SV40 
enhancer and early promoter elements to provide high-level expression of Renilla luciferase 
in co-transfected mammalian cells (Figure 2.13) (Promega, Technical Bulletin #TB239). 
 
Figure 2.13: pRL-SV40 (Renilla) vector (Promega, # E2231). 
 
2.12.4 Cloning of exon -2a into the pGL3-Basic vector 
PCR  was  first  performed  to  amplify  exon  -2a  from  p110δ-2a  in  the  pCMV.Sport6 
expression  vector.  PCR  products  were  run  on  an  agarose  gel  and  the  gel  fragments 
containing the amplified exon -2a cDNA excised.  DNA was purified from the agarose gel 
and ligated into the pGEM
®-T Easy vector (Figure 2.14).  Transformed competent cells 
were plated on LA/ampicillin/IPTG/X-Gal plates.  Plates were incubated at 37
oC overnight 
and white colonies picked the following day. Cultures were expanded and a small scale 
DNA preparation carried out.  DNA was digested with the restriction enzymes Xho I and 
Bgl II to cleave exon -2a cDNA from the pGEM
®-T Easy vector. The pGL3-Basic (Figure 
2.9) was also digested with Xho I and Bgl II. The restriction digest products from the pGL3-
Basic and the pGEM
®-T Easy vector-exon -2a digest were run on an agarose gel and the 
required DNA fragments excised and purified for ligation of exon -2a into the pGL3-Basic 
vector. 
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2.12.4.1 Primers to amplify exon -2a 
Forward primer incorporating Xho I restriction site 
5‟ GACTCTCGAGCCGGAATTCCCGGGATATCGTCGACGAGCTC 3‟  
 
Reverse primer incorporating Bgl II restriction site:  
5‟ GACTAGATCTGATGTCGGTCCAGCAGCTGGGTCCGCGG 3‟  
 
2.12.4.2 pGEM
®-T Easy vector  
 
Figure 2.14: pGEM
®-T Easy vector (Promega, #A1380). 
 
2.13 CRYSTAL VIOLET STAINING 
Cells were fixed by incubation with 4% PFA for 15 min at room temperature.  0.1% crystal 
violet solution made in 25% methanol was left on cells for 10 min at room temperature.  
Cells were washed three times with ddH2O and plates left to dry. 
 
2.14 MAY-GRUNWALD/GIEMSA STAINING OF BMMC CYTOSPIN SLIDES 
150 μl of BMMCS at a concentration of 0.5 x 10
6 cell/ml were loaded onto cytoslides 
(Cytoslide, Double Circle, Coated, Thermo Scientific, #5991055) using the Shandon EZ 
Double Cytofunnel (Thermo Scientific).  Cytoslides were spun for 5  min at 1000 rpm.  
BMMCs were fixed in 100% methanol for 15 min.  After this time, slides were immersed in 
May-Grunwald stain for 5 min (undiluted), followed by immersion in 10 % Giemsa stain 
(diluted in ddH20, pH 6.8) for 10 min.  Slides were rinsed briefly in water and excess dye Chapter 2 
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wiped  off  the  back  of  the  slide.    Coverslips  were  wet-mounted  onto  the  slides  using 
VectorMount
®. 
 
2.15 DNA SYNTHESIS AND CELL EXPANSION ASSAYS 
2.15.1 BMMCs  
DNA synthesis: Following 24 h starvation in culture media without IL-3 and SCF, 1x10
5 
cells were seeded / well in a 96 well plate, in triplicate, with 20 ng/ml IL-3 and/or 20 ng/ml 
SCF, together with 0.5 μCi [
3H]-Thymidine (Amersham).  Cells were harvested 24-72 h 
later  cells  were  harvested  and  [
3H]-Thymidine  incorporated  into  DNA  measured  by 
scintillation counting (Perkin-Elmer Microbeter counter). 
 
Cell expansion: Following 24 h starvation in culture media without IL-3 and SCF, cells 
were seeded at a concentration of 0.5x10
6 cells/ml in media containing 20 ng/ml IL-3 and 
20 ng/ml SCF.  Viable cell numbers were determined every 24 – 72 h using a Casy cell 
counter (Scharfe System).  Cell media containing 20 ng/ml IL-3 and 20 ng/ml SCF was 
replaced every 3 days. 
 
2.15.2 Cell lines  
DNA synthesis: Cells were incubated at 2   10
5 cells per well in 96-well plate, in cell 
culture media without FBS for 24 h.  After this time cell culture media was replaced with 
media containing 10% FBS together with 0.5 μCi [
3H]-Thymidine. Cells were harvested 
24-72 h later cells were harvested and [
3H]-Thymidine incorporated into DNA measured by 
scintillation counting (Perkin-Elmer Microbeter counter). 
 
2.16 FACS ANALYSIS OF c-KIT and FcεRI EXPRESSION ON BMMCs 
100,000 cells were used per FACS tubes.  BMMCs were washed two times in PBS, at 1400 
rpm for 5 min.  Cells were resuspended in FACS buffer and 100 μl distributed per FACS 
tube.    In  general,  the  antibody  incubations  were  as  follows:  1)  anti-c-kit-PE  (BD 
PharMingen, # 553355), 2) purified mouse IgE (BD PharMingen, #553413) + anti- mouse 
IgE-FITC (BD PharMingen, #553415), 3) anti-IgE-FITC alone and 4) unstained cells.  For 
detection of FcεRI, 20 μl of purified IgE was added per FACS tube and samples left for 20 
min at 4
oC.  Subsequently, 5 μl of anti-IgE-FITC was added per tube and samples incubated 
for a further 30 min at 4
oC in the dark.  For detection of c-kit, 2.5 μl of anti-c-kit conjugated 
to Phycoerythrin (anti-c-kit-PE) was added per FACS tube and samples incubated for 30 
min at 4
oC in the dark.  To determine the background fluorescence for FITC, 5 μl of anti-Chapter 2 
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IgE-FITC (without the addition of purified IgE) was added to tubes and samples incubated 
for 30 min at 4
oC in the dark.  Cells were washed once with FACS buffer and resuspended 
in 400 μl FACS buffer per FACS tube. 
 
2.17 MASS SPECTROMETRY 
I  carried  out  the  colloidal  Coomassie  staining  of  acrylamide  gels  and  preparation  of 
peptides for mass spectrometry analysis, however the actual mass spectrometry analysis 
was performed by Dr. Pedro Cutillas (Barts & The London School of Medicine, Queen 
Mary).  
 
2.17.1 Colloidal Coomassie staining of acrylamide gel 
Colloidal Coomassie staining of acrylamide gels was performed using GelCode
® Blue stain 
reagent according to the manufacturer‟s protocol (Pierce, 24592).  Briefly, acrylamide gels 
were fixed in 40% ethanol/10% acetic acid for 1 h to overnight.  Gels were subsequently 
washed 3-5 times with excess ddH2O and 20 ml of GelCode
® Blue was added for 1 h.  Gels 
were washed in ddH2O for a further 1 h to decrease background staining. 
 
2.17.2 Preparation of peptides for mass spectrometry analysis 
To minimise protein contamination, sample preparations were performed in a ventilated 
hood.  Colloidal Coomassie-stained gel bands were excised from the acrylamide gel and cut 
into small pieces and placed into 0.625 ml siliconised tubes.  Gel pieces were washed and 
dehydrated by the addition of 50% acetonitrile (ACN) three times.  Gel loading tips were 
used to aspirate ACN between washes. The gel pieces were dried in a speed vacuum for 
approximately 1 h.  Protein disulphide bridges were reduced by adding a sufficient volume 
of 10 mM DTT in 25 mM ammonium bicarbonate (AmBic) pH 8.0, to cover gel pieces, and 
incubating for 45 min at 50
oC.  For alkylation of cysteine residues, a sufficient volume of 
50 mM iodoacetamide in 25 mM to cover gel pieces and the reaction incubated for 1 h at 
room temperature in the dark.  Following this, gel pieces were washed twice in 50% ACN 
and fully dried in a speed vacuum for approximately 1 h. 
 
To  digest  the  peptides,  25  mM  AmBic  pH8  containing  150  ng  /  sample  of  trypsin 
(Promega, 608-274-4330) was added to cover the gel pieces.  After 5 min, this was overlaid 
with 25 mM AmBic to completely cover the gel pieces and incubated at 37
oC overnight.  
The following day, samples were centrifuged to spin down liquid from tube lid.  20 μl of 
50%  ACN  5%  trifluoroacetic  acid  was  added  to  the  samples  and  the  total  supernatant 
removed to a fresh tube.  80 μl of 50% ACN 5% trifluoroacetic acid was then added to the Chapter 2 
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gel pieces again, the sample vortexed, centrifuged and the supernatant removed to the fresh 
tube.  This was repeated one more time to extract as much of the digested peptides from the 
gel pieces as possible.  The extracted peptides were concentrated by drying samples in a 
speed vacuum and resuspending in 5 μl 0.1% formic acid. 
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3. DOES CELL TRANSFORMATION ALTER P110 COUPLING TO TYROSINE 
KINASE RECEPTORS? 
 
3.1 Introduction 
The question addressed in this part of my thesis is whether coupling of class IA PI3Ks to 
tyrosine kinase receptors remains the same under normal and transformed cellular states.  
The  reasoning  behind  this  work  is  that  in  primary,  untransformed  cells,  a  single  PI3K 
isoform often appears to carry most PI3K activity downstream of a given receptor.  This is 
evidenced by the observation that blockade of a single PI3K isoform downstream of a given 
tyrosine  kinase  receptor  often  results  in  a  severe  impact  on  the  biological  responses 
controlled by this tyrosine kinase receptor.  For example, in primary leukocytes, p110 is 
often the 'dominant' class IA isoform, with p110δ inhibition having a major impact on, for 
example, the c-kit receptor and antigen receptor signalling.   In transformed leukocytes, 
however, the relative contribution of p110 appears to become less important, with p110δ 
inhibition having less of an impact compared to that in primary cells.  For example, in 
primary macrophages, CSF-1 receptor signalling is dependent on p110δ activity, whereas in 
immortalized macrophage cell lines, p110ʱ is the principle PI3K isoform downstream of 
the CSF-1 receptor (Papakonstanti, et al., in preparation). One possible explanation could 
be that coupling of class IA PI3Ks to tyrosine kinase receptors is altered in normal and 
transformed cellular states. I have investigated this question, focusing on the coupling of 
p110δ to the tyrosine kinase receptor, c-kit, in bone marrow-derived mast cells (BMMCs).   
  
To investigate whether p110δ remains the principal p110 isoform activated downstream of 
c-kit in a „transformed‟ mast cell, three approaches were used to experimentally transform 
or immortalize primary wild-type (WT) BMMCs, namely by introduction of the HOX11 
homeobox gene or the polyoma middle T antigen (PMT).  The third approach was to assess 
whether in p110δ
D910A/D910A BMMCs, another p110 isoform than p110δ is able to signal 
downstream of c-kit to substitute for the kinase-dead p110δ, to restore c-kit signalling. This 
could  perhaps  be  referred to  as  a „spontaneous transformation‟ phenomenon.  Previous 
findings (Ali & Vanhaesebroeck, unpublished results) have indicated that such a change 
may occur in long-term cultured p110δ
D910A/D910A BMMCs, possibly leading to a switch in 
p110 recruitment to c-kit, with p110ʱ being the most likely candidate.  The main finding 
that led to this conclusion was that p110δ
D910A/D910A BMMCs maintained in culture for more 
than 6 weeks were often found to have increased p110ʱ protein expression associated with 
increased  p110ʱ  kinase  activity  compared  to  WT  BMMCs  (Ali  &  Vanhaesebroeck, 
unpublished results).  Chapter 3 
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3.2  HOX11  immortalisation  of  BMMCs  results  in  a  less  differentiated  mast  cell 
phenotype 
The HOX11 homeobox gene encodes an oncogenic transcription factor that is frequently 
activated  in  a  subset  of  T-cell  acute  lymphoblastic  leukaemia  (Riz  &  Hawley,  2005).  
HOX11 transfection is frequently used in our laboratory to immortalise leukocyte cell lines.  
Using a retroviral infection method, HOX11 was introduced into primary WT BMMCs 6 
weeks after isolation.  Cells stably expressing HOX11 were selected using neomycin and 
HOX11 expression determined by western blot (Figure 3.1).   
 
Figure 3.1: HOX11 expression in HOX11-infected BMMCs. HOX11 expression was 
assessed in WT BMMCs after selection with neomycin.  Cell lysates were separated by 
SDS-PAGE and immunoblotted for HOX11. 
 
Cells expressing HOX11 were fixed and stained using May-Grünwald and Giemsa stain to 
assess cell morphology (Figure 3.2).  It was observed that HOX11-expressing cells had a 
less differentiated „early progenitor-like‟ appearance, with less granular cells and a large 
round nucleus.   
 
Figure 3.2: Cell morphology of WT BMMCs transfected with HOX11.  Cells were 
fixed and stained with May Grünwald and Giemsa.  HOX11-expressing cells have a less 
differentiated morphology compared to WT BMMCs.  Arrows indicate cells with an early 
progenitor-like appearance with large rounded nuclei. 
 
WT BMMCs WT BMMCs + HOX11Chapter 3 
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To establish if WT BMMCs expressing HOX11 still maintained mast cell characteristics, 
the levels of c-kit and FcεRI expression were determined by FACS (Figure 3.3).  Only a 
small proportion of WT HOX11-expressing cells (15%) expressed c-kit compared to non-
transfected cells, which had almost 100% expression of c-kit.  Expression of FcεRI was 
also reduced in HOX11-positive BMMCs, with only 20% of cells expressing this receptor 
compared  to  95%  of  non-transfected  cells.    These  results  indicate  that  expression  of 
HOX11 in BMMCs results in cells that no longer express characteristic mast cell markers.   
 
 
Figure  3.3:  c-kit  and  FcεRI  expression  in  HOX11-immortalised  BMMCs.    The 
expression  of  (a)  c-kit  and  (b)  FcεRI  was  determined  by  FACS  analysis.  Cells  were 
incubated with a PE-conjugated anti-c-kit antibody, or with purified  IgE followed by a 
FITC-conjugated anti-IgE antibody.  
 
To study the effect of HOX11-immortalisation on c-kit signalling, a larger population of c-
kit-positive  cells  was  required.    The  15%  of  HOX11-expressing  WT  BMMCs  that 
expressed c-kit were separated from the c-kit-negative cell population by FACS in order to 
expand this cell population for further studies.  However, after continued culture of the 
sorted cells, further FACS analysis on this theoretically „100% c-kit-positive‟ population 
revealed that only 12% of cells expressed c-kit  and 15% of cells expressed FcεRI (Figure 
3.4).  In other words, HOX11-positive cells had a tendency to lose expression of the c-kit 
receptor, most likely an effect of HOX11 on cell differentiation, causing what were thought 
of  as  terminally  differentiated  mast  cells  to  take  on  less  differentiated  progenitor  cell 
characteristics.  Importantly, for this study, HOX11-expressing cells no longer expressed 
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the c-kit receptor and could therefore not be used to study coupling of p110δ to the c-kit 
receptor. 
 
Figure 3.4: Expression of c-kit and FcεRI in HOX11-transduced BMMCs, following 
sorting for expression of c-kit and two weeks culture.   HOX11-transfected BMMCs 
were sorted on the basis of c-kit expression.  c-kit-positive cells were expanded for two 
weeks, followed by determination of (a) c-kit and (b) FcεRI expression by FACS analysis.  
 
3.3 Transformation of BMMCs with PMT 
The  Polyoma  middle  T  antigen  (PMT)  has  been  shown  to  be  responsible  for  the 
oncogenicity of the virus in susceptible cells. PMT associates with and activates Src family 
tyrosine kinases.  Tyrosine kinases of the Src family play an essential role in cell signalling, 
regulating cell growth, differentiation and morphology (Dunant & Ballmer-Hofer, 1997; 
Gottlieb & Villarreal, 2001).  Phosphorylation of tyrosine 527 on Src kinase (by members 
of the Csk family kinases) permits an intramolecular interaction between this C-terminal 
phosphotyrosine  residue  and  the  SH2  domain  causing  a  closed  catalytically  inactive 
conformation of Src.  When this intramolecular interaction is disrupted and the protein is in 
an open conformation, the Src kinase is active (Dunant & Ballmer-Hofer, 1997).   PMT 
associates more efficiently with the active conformation of Src at the catalytic domain, 
which  has  led  to  the  proposition  that  PMT  increases  Src  kinases  activity  through 
stabilisation of active Src molecules in this open conformation (Dunant & Ballmer-Hofer, 
1997).   
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PMT activation of Src kinases gives rise to phosphorylation of specific tyrosine residues in 
PMT as well as in other molecules in the PMT-complex.  Phosphorylated-tyrosine residues 
on PMT act as docking sites for intracellular signalling molecules. The phosphorylated 
tyrosine residue 315 associates with one of the SH2 domains of p85,  most likely leading to 
recruitment  of  PI3K  to  the  membrane  (Dunant  &  Ballmer-Hofer,  1997;  Gottlieb  & 
Villarreal, 2001). 
 
3.3.1 Expression of PMT does not affect mast cell differentiation 
Using a retroviral infection method, WT BMMCs were infected with PMT with the aid of 
retronectin.  Infected BMMCs were selected using neomycin and cell cultures expanded.   
PMT expression was assessed by western blot and found to be highly expressed in infected 
cells (Figure 3.5). 
 
 
Figure 3.5: PMT expression in PMT-infected BMMCs.  PMT expression was assessed 
in WT BMMCs cells selected with neomycin.  Cell lysates were separated by SDS-PAGE 
and immunoblotted for PMT. 
 
To give an insight if PMT-expressing cells maintained mast cell characteristics, cells were 
fixed and stained with May Grünwald  and Giemsa to look at cell morphology.  PMT-
expressing cells appeared to have a similar morphology to uninfected cells (Figure 3.6), 
maintaining a granular appearance and a similar size and shape to uninfected BMMCs.  
Importantly, PMT-expressing cells maintained a similar level of c-kit and FcεRI expression 
to uninfected BMMCs.  FACS analysis showed that almost 100% of both WT and PMT-
expressing BMMCs expressed both the c-kit receptor and FcεRI (Figure 3.7).   
 
Overall,  these  data  suggest  that  unlike  HOX11,  PMT  does  not  affect  BMMC 
differentiation.  Given that PMT-expressing cells retain c-kit expression, they could be used 
to investigate p110 coupling to c-kit. Chapter 3 
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Figure 3.6: Cell morphology of WT and PMT-expressing BMMCs.  Cells were fixed 
and stained with May Grünwald and Giemsa.   
 
 
Figure 3.7: Expression of c-kit and FcεRI in PMT-expressing BMMCs.  The expression 
of (a) c-kit (b) and FcεRI was determined by FACS analysis. Cells were incubated with a 
PE-conjugated anti-Kit antibody, or with purified IgE followed by a FITC-conjugated anti-
IgE antibody. 
 
3.3.2 PMT-expressing BMMCs maintain IL-3-dependence 
IL-3 is an essential component of the culture media required for proliferation of BMMCs. 
To  assess  whether  PMT  expression  in  BMMCs  resulted  in  cell  transformation,  which 
would  be  expected  to  render  cells  independent  of  IL-3,  a  cell  expansion  assay  was 
performed on WT and PMT-expressing cells in media with or without IL-3 (Figure 3.8).  In 
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the complete absence of IL-3, both WT and PMT-expressing BMMCs failed to expand 
(Figure 3.8a), indicating that PMT-expressing BMMCs were still dependent on IL-3 for cell 
growth.  However, they showed increased cell growth in media containing 5 ng or 20 ng/ml 
IL-3, compared to WT BMMCs (Figures 3.8b, c).  Therefore, although PMT-expressing 
BMMCs appeared to not be „fully‟ transformed (in that they are not cytokine-independent), 
they had a proliferative advantage over WT cells.   
 
 
Figure 3.8:  Effect of IL-3 on cell expansion of WT and PMT-expressing BMMCs. WT 
and PMT-expressing BMMCs were seeded at the same density in  (a) media alone, (b) 
media containing 5 ng/ml IL-3, or (c) media containing 20 ng/ml IL-3. Cell counts were 
performed over a period of 10 days, during which media was replaced every 2 days.   
 
 
3.3.3  PMT-expressing  BMMCs  do  not  have  increased  basal  or  SCF-induced  Akt 
phosphorylation 
The effect of PMT expression on PI3K signalling in BMMCs was assessed by examining 
basal and SCF-induced Akt phosphorylation.  PMT-positive cells did not show an increase 
in basal phosphorylation of Akt compared to WT cells (Figure 3.9).  Furthermore, SCF-
induced phosphorylation of Akt appeared somewhat lower in PMT-expressing BMMCs 
compared to WT BMMCs.  This result is surprising given that expression of PMT results in 
activation of Src, which in turn activates PI3K.  However, this result does help explain the 
finding  that  PMT-positive  BMMCs  are  not  cytokine-independent  for  cell  growth.  In 
conclusion, PMT-infection of BMMCs appears to result in a „semi-transformed‟ state, in 
which  PMT-expressing  cells  have  a  proliferative  advantage  over  uninfected  cells,  but 
remain cytokine-dependent and do not have constitutive Akt activation.   Chapter 3 
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Figure 3.9: Levels of Akt phosphorylation under basal and SCF-stimulated conditions 
in  WT  and  PMT-expressing  BMMCs.    WT  and  PMT-expressing  BMMCs  were 
stimulated with 20 ng/ml SCF for 5 min.  Cell lysates were separated by SDS-PAGE and 
immunoblotted for P-Akt and PMT. 
 
3.3.4 c-kit remains dependent on p110δ in PMT-expressing BMMCs 
Given that cell numbers were a limiting factor and that a large number of cells was required 
for successful c-kit immunoprecipitation, to investigate whether functional c-kit coupling to 
p110δ is  affected in  cells  „semi-transformed‟ by  PMT, isoform-specific inhibitors  were 
used to assess the dependence of the c-kit receptor on individual p110 isoform to induce 
Akt phosphorylation (Figure 3.10). Cells that had been in culture for 12 weeks were used in 
this study, which is considered a long period for primary cells to be maintained in culture.  
However, due to the number of cells required for the experiment and the relatively slow 
proliferative rate of BMMCs, a 12 week culture time was necessary.  
 
In WT BMMCs, the p110δ inhibitor (IC87114) reduced SCF-induced Akt phosphorylation 
to almost the same extent as LY294002 (Figure 3.10), supporting previous findings that 
p110δ is the primary p110 isoform downstream of c-kit activation (Ali, et al., 2004).  In 
PMT-expressing BMMCs, p110δ appeared to remain the principle isoform downstream of 
c-kit as IC87114 treatment also inhibited SCF-induced Akt phosphorylation to the same 
extent  as  LY294002.    In  PMT-expressing  BMMCs,  inhibition  of  p110γ  reduced  SCF-
induced Akt phosphorylation to  around 40% of the maximal  response, whereas  in  WT 
BMMCs, inhibition of p110γ (AS604850 treatment) had no effect on Akt phosphorylation.  
This result indicates p110γ may be playing a role downstream of c-kit in PMT-expressing 
cells.  Treatment of both WT and PMT-expressing cells with the p110β inhibitor (TGX115) 
at 0.5 μM reduced SCF-induced Akt phosphorylation by around 40%.  It is possible that 
this is an off-target effect of TGX115, as this inhibitor has also been shown to inhibit p110δ 
at this concentration (see Table 2.1, section 2.1.5, for IC50 values of PI3K inhibitors). Chapter 3 
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Figure 3.10: Effect of PI3K inhibition on SCF-induced Akt phosphorylation in WT 
and PMT-expressing BMMCs. WT and PMT-expressing BMMCs that had been cultured 
for 12 weeks, were incubated with a p110 inhibitor or DMSO for 1 h prior to stimulation 
with  20  ng/ml  SCF.    The  p110β  inhibitor,  TGX115,  was  used  at  0.5  µM,  the  p110δ 
inhibitor, IC87114, was used at 5 µM and the p110γ inhibitor, AS604850, was used at 1 
µM. The pan-PI3K inhibitor, LY294002 was used at 10 µM. 
 
Collectively, these data indicate that c-kit remains dependent on p110δ in PMT-expressing 
cells to induce Akt phosphorylation, suggesting that p110 isoform recruitment to the c-kit 
receptor is not significantly altered.  Experiments need to be repeated in order to comment 
on a possible role of p110γ in  PMT-expressing  BMMCs.   These data do not  however 
provide information regarding c-kit-p110 coupling in fully transformed BMMCs.   
 
3.4 Spontaneous transformation of p110δ
D910A/D910A BMMCs in long-term culture 
As  mentioned  in  the  introduction,  it  has  been  observed  that  p110δ
D910A/D910A  BMMCs 
maintained in culture for over 6 weeks become more responsive to SCF.  Given that p110δ 
is kinase-dead in these cells, it is likely that another p110 isoform is signalling downstream 
of c-kit.  It was hypothesised that an adaptation of p110δ
D910A/D910A BMMCs may occur that 
enables them to become responsive to SCF, which from previous findings may involve 
p110ʱ (Ali & Vanhaesebroeck, unpublished results). 
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3.4.1  Upregulation  of  p110ʱ  isoform  expression  in  p110δ
D910A/D910A  BMMCs 
maintained in long-term culture 
After  36  days  in  culture,  both  WT  and  p110δ
D910A/D910A  BMMCs  had  similar  p110 
expression profiles (Figure 3.11).   
 
 
Figure 3.11: p110 isoform expression in WT and p110δ
D910A/D910A BMMCs over a time 
period  of  36  days  after  isolation.    Total  cell  lysates  were  taken  from  WT  and 
p110δ
D910A/D910A BMMCs at days 11, 25 and 36 after isolation.  Cell lysates were separated 
by SDS-PAGE and immunoblotted for p110ʱ, p110β and p110δ.   
 
11 days after isolation, p110δ
D910A/D910A BMMCs appeared to have a higher level of p110ʱ 
expression compared to WT BMMCs, however after 36 days, when the mast cells are fully 
differentiated,  both  WT  and  p110δ
D910A/D910A  BMMCs  had  a  similar  level  of  p110ʱ 
expression (Figure 3.11).  p110δ expression increased in both WT and p110δ
D910A/D910A 
BMMCs at each time point after isolation, which correlates with the high levels of p110δ 
found in fully differentiated mast cells.  When immunoblotting for p110β, two bands are 
detected with the p110β antibody used and it is the upper band which has been verified as 
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p110β (Guillermet-Guibert, et al., 2008).  In contrast to p110δ, p110β expression appeared 
to  decrease  in  both  WT  and  p110δ
D910A/D910A  BMMCs  after  36  days  in  culture.    The 
important finding from this study is that at day 36, when the haematopoietic progenitors are 
fully differentiated into mast cells, p110ʱ, p110β and p110δ are expressed at similar levels 
in WT and p110δ
D910A/D910A BMMCs (Figure 3.11). 
 
It was thought that for an adaptation to occur in p110δ
D910A/D910A BMMCs, cells may need 
to be cultured for a time period exceeding 36 days.  Two further independent batches of 
BMMCs (subsequently referred to as batch B and batch C) were isolated and maintained in 
culture for longer time periods, 77 and 54 days, respectively.    At both of these later time 
points,  increased  p110ʱ  expression  was  observed  in  WT  and  p110δ
D910A/D910A  BMMCs 
(Figure 3.12).  The increase in p110ʱ expression was more apparent in p110δ
D910A/D910A 
BMMCs and appeared to correlate with a decrease in p110δ expression.  p110β expression 
was undetectable in all cell lysates taken from BMMCs in batch B, however a noticeable 
decrease in p110β expression was observed at day 54 in batch C compared to day 25 in WT 
and p110δ
D910A/D910A BMMCs.   
 
Collectively, the data suggests that long-term culture of p110δ
D910A/D910A BMMCs results in 
upregulation of p110ʱ expression and a concomitant decrease in both p110β and p110δ 
expression,  which  suggests  cells  may  be  adapting  to  expressing  a  kinase-dead  p110δ 
isoform through upregulation of p110ʱ.  Although an increase in p110ʱ expression was 
also  observed  in  WT  BMMCs  after  long-term  culture,  this  was  not  associated  with  a 
decrease in  p110δ expression, which suggests that in  WT BMMCs,  p110δ remains  the 
principal p110 isoform. 
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Figure 3.12: p110 isoform expression in WT and p110δ
D910A/D910A BMMCs over a time 
period of 77 and 54 days after isolation.  Total cell lysates were taken from WT and 
p110δ
D910A/D910A BMMCs at days 25 and 77 for batch B and days 25 and 54 for batch C 
after isolation.  Cell lysates were separated by SDS-PAGE and immunoblotted for p110ʱ, 
p110β and p110δ.   
 
3.4.2 p110ʱ isoform upregulation in p110δ
D910A/D910A BMMCs does not correlate with 
increased cell proliferation 
To investigate whether long-term cell culture affects cell proliferation in p110δ
D910A/D910A 
BMMCs, cell counts were performed over a period of 78 days after isolation for BMMCs 
from  batch  B  (Figure  3.13).    The  initial  drop  in  cell  numbers  of  both  WT  and 
p110δ
D910A/D910A BMMCs reflects the selection and differentiation period for mast cells 
progenitors from the heterogenous haematopoietic progenitor population initially isolated 
from the bone marrow. 
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Figure  3.13:  Cell  counts  of  WT  and  p110δ
D910A/D910A  BMMCs  up  to  78  days  after 
isolation.  BMMCs were counted over a period of 78 days after isolation.  Cells isolated 
from the bone marrow of mouse femurs were cultured in media containing 10 ng/ml SCF 
and 10 ng / ml IL-3 for selection and differentiation of mast cells. 
 
Despite the apparent upregulation in p110ʱ expression in p110δ
D910A/D910A BMMCs, cell 
expansion of  p110δ
D910A/D910A  BMMCs  remained substantially lower than WT BMMCs 
throughout the 78 day course of cell counts.  After 60 days in culture, WT BMMC numbers 
began to decrease indicating cell death.  However, in p110δ
D910A/D910A BMMCs, although 
cells did not appear to be readily expanding, cells did not appear to be dying either (Figure 
3.13).  The data suggest that if p110δ
D910A/D910A BMMCs are adapting when maintained in 
long-term culture through upregulation of p110ʱ, this does not translate into increased cell 
proliferation but may protect the cells from cell death. 
 
3.4.3 Restoration of SCF-induced phosphorylation of Akt in p110δ
D910A/D910A BMMCs 
upon long-term culture 
An  almost  complete  abrogation  of  SCF-induced  Akt  phosphorylation  was  reported  in 
p110δ
D910A/D910A  mast  cells  cultured  for  6  weeks  (Ali  et  al.,  2004).    Remarkably  in 
p110δ
D910A/D910A BMMCs that had been maintained in culture for 12 weeks, SCF induced 
Akt phosphorylation (Figure 3.14).  This result raised the possibility that a switch in c-kit-
p110 receptor coupling had occurred, with p110ʱ as the most likely candidate from the data 
shown in Figure 3.12. 
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Figure  3.14:  Effect  of  PI3K  inhibition  on  SCF-induced  Akt  phosphorylation  in 
p110δ
D910A/D910A BMMCs. p110δ
D910A/D910A BMMCs were incubated with a p110 inhibitor 
or DMSO for 1 h prior to stimulation with 20 ng/ml SCF.  The p110β inhibitor, TGX115, 
was  used  at  0.5  µM,  the  p110δ  inhibitor,  IC87114,  was  used  at  5  µM  and  the  p110γ 
inhibitor, AS604850, was used at 1 µM. The pan-PI3K inhibitor, LY294002, was used at 
10 µM. 
 
Due to the lack of p110ʱ-specific inhibitor at the time of this study, the dependency of c-kit 
on p110ʱ to induce Akt phosphorylation in response to SCF could not be tested.  However 
c-kit dependency on p110β, p110δ and p110γ could be investigated.  As shown in Figure 
3.14, the p110β inhibitor and surprisingly the p110δ inhibitor had the greatest effect on 
reducing  SCF-induced  Akt  phosphorylation  besides  the  pan  PI3K  inhibitor  LY294002.  
Since p110δ in p110δ
D910A/D910A BMMCs is kinase-dead, the inhibitory effect induced by 5 
μM IC87114 treatment is most likely the result of off-target p110β inhibition (see Table 2.1 
for the IC50 values of the PI3K-specific inhibitors).  Evidence to support off-target p110β 
inhibition  by  IC87114  has  been  found  in  NIH  3T3,  a  cell  line  that  expresses  low 
endogenous levels of p110δ.  Treatment of NIH 3T3 cells with 5μM IC87114 reduces LPA-
induced Akt phosphorylation to a similar extent as that for the p110β inhibitor (Guillermet-
Guibert & Vanhaesebroeck, unpublished results). 
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3.4.4 Association of p110ʱ and p110δ with c-kit in WT and p110δ
D910A/D910A BMMCs 
upon SCF stimulation 
To investigate if there is a p110 isoform switch in recruitment to the c-kit receptor in long-
term cultured BMMCs, an immunoprecipitation with an anti-Kit antibody was performed 
on  long-term  cultured  (16  weeks)  BMMCs  and  p110  recruitment  to  the  c-kit  receptor 
analysed (Figure 3.15). 
 
 
Figure 3.15: Recruitment of p110 isoforms to c-kit upon SCF-stimulation in WT and 
p110δ
D910A/D910A BMMCs. Long-term cultured WT BMMCs and p110δ
D910A/D910A BMMCs 
were stimulated with 20 ng / ml SCF for 10 min.  An immunoprecipitation was performed 
on  cell  lysates  with  c-kit  antibody.    Cell  lysates  were  separated  by  SDS-PAGE  and 
immunoblotted with specific p110 antibodies or antibodies to c-kit. 
  
In WT BMMCs, p110ʱ was constitutively bound to c-kit with additional p110ʱ recruitment 
upon SCF stimulation (Figure 3.15).  p110β and p110γ did not constitutively bind to c-kit 
and  were  not  recruited  to  the  receptor  upon  SCF  stimulation  like  p110ʱ.    p110δ  was 
constitutively bound to c-kit with no obvious additional recruitment to the receptor upon 
SCF stimulation.   
 
In p110δ
D910A/D910A BMMCs, p110ʱ and p110δ also constitutively bound to c-kit, but at 
lower levels compared to WT BMMCs. However in p110δ
D910A/D910A BMMCs, there was 
considerable recruitment of p110ʱ and p110δ to the c-kit receptor upon SCF stimulation.  
The level of recruitment of p110ʱ to c-kit appeared to be greater than the level of p110δ Chapter 3 
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recruitment.  As was observed in WT BMMCs, p110β or p110γ did not bind to c-kit in 
p110δ
D910A/D910A BMMCs. 
 
3.5 Discussion 
3.5.1  Expression  of  HOX11  or  PMT  in  WT  BMMCs  does  not  result  in  full  cell 
transformation  
Overall, my findings, in conjunction with the study by Ali et al, 2004, have shown that 
p110δ is the critical p110 isoform downstream of c-kit in WT BMMCs.  My aim was to 
assess whether transformation of BMMCs resulted in a switch of p110 isoform recruitment 
to c-kit.  Immortalising BMMCs with HOX11 resulted in the cells losing their mast cell 
characteristics and displaying a less differentiated phenotype.    Homeobox genes encode 
transcription factors which appear to play managerial roles in embryonic development and 
also in many subsequent differentiation processes (Perkins & Cory, 1993).  HOX-2.4 and 
HOX11 have strong immortalisation potential for bone marrow as well as embryonic stem 
cell-derived haematopoietic cells (Hawley, et al., 1994; Perkins & Cory, 1993).  Primitive 
hemopoietic  cells  are  more  susceptible  to  immortalization  by  HOX-2.4  compared  to 
differentiated hemopoietic cell lineages (Perkins & Cory, 1993).  It is possible that at the 
time  of  transfection  of  BMMCs  with  HOX11,  a  small  population  of  undifferentiated 
hemopoietic  progenitors  were  present  that  were  preferentially  transfected  over 
differentiated mast cells.  It is possible that increased expansion of this cell population over 
the differentiated mast cell population subsequently resulted in loss of c-kit expression.   
Alternatively,  HOX11  expression  in  BMMCs  may  have  a  direct  effect  on  BMMC 
differentiation,  forcing  cells  to  take  on  a  less  differentiated  state.    HOX11  is  a  potent 
repressor of transcription from a wide
 range of natural promoters in cells of human and 
murine origin and it has been proposed that  HOX11-mediated transcriptional activation 
and/or  repression
  of  downstream  targets  may  negatively  regulate  haematopoietic
 
differentiation  programs  (Owens,  et  al.,  2003).  For  the  purpose  of  this  study,  the 
mechanism by which HOX11 induces a less differentiated mast cell phenotype was not 
considered of critical importance.  The key finding was that HOX11-transfected cells no 
longer expressed c-kit and therefore could not be used to study p110 coupling to the c-kit 
receptor. 
 
Transfection  of  BMMCs  with  PMT  resulted  in  a  cell  line  that  maintained  mast  cell 
characteristics  and  expressed  the  c-kit  receptor  to  the  same  extent  as  untransfected 
BMMCs.  However, PMT-transfection of BMMCs did not result in cytokine-independent 
cell growth, which indicated that PMT expression in  BMMCs  did  not lead to  full  cell Chapter 3 
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transformation.  An unexpected finding was that PMT expression was not associated with 
increased Akt phosphorylation.  This was surprising given that PI3K signalling is one of the 
key pathways activated downstream of PMT-induced Src activation at least in fibroblasts 
(Meili, et al., 1998; Penuel & Martin, 1999).  The reason for this is unclear, it is possible 
that this PMT-effect is cell-type dependent.  In order to gain more insight into this, it would 
be of interest to assess if Src is activated in BMMCs upon expression of PMT.  It is also 
possible  that  PI3K  is  recruited  to  the  PMT  complex  and  activated  but  that  this  is  not 
reflected  in  the  phosphorylation  state  of  Akt.    Indeed,  in  some  instances  stable 
overexpression of a membrane-targeted PI3K does not result in constitutive activation of 
Akt (Auger, et al., 2000).  
 
In PMT-expressing BMMCs, p110δ remained the principal isoform downstream of c-kit 
activation.  However given that the cells were not fully transformed by PMT, it is likely 
that this is the main reason that c-kit selectivity for p110δ was retained.  The aim of the 
study, to create a transformed mast cell line, was not met through PMT-infection and so it 
is not possible to ascertain whether p110δ would remain the principal isoform downstream 
of c-kit in transformed cells.  A potentially useful finding from this line of investigation is 
that PMT-expressing BMMCs may be advantageous over WT BMMCS to screen p110δ 
inhibitors as they have an increased growth rate compared to WT BMMCs, requiring a 
lower concentration of IL-3, whilst remaining dependent on p110δ downstream of c-kit. 
 
3.5.2  SCF-induced  Akt  phosphorylation  in  long-term  cultured  p110δ
D910A/D910A 
BMMCs may be the result of p110ʱ upregulation 
It has been reported that c-kit-induced Akt phosphorylation in p110δ
D910A/D910A BMMCs is 
completely abrogated (Ali, et al., 2004), highlighting the essential role of p110δ in c-kit 
signalling. Investigation into the possibility that „spontaneous transformation‟ may occur in 
p110δ
D910A/D910A  BMMCs  maintained  in  long-term  culture,  led  to  the  finding  that  SCF 
could  indeed  induce  Akt  phosphorylation  in  p110δ
D910A/D910A  BMMCs    maintained  in 
culture for over 12 weeks.  Given that p110δ in p110δ
D910A/D910A BMMCs is kinase-dead, 
another p110 isoform must be acting downstream of c-kit.  After 6 weeks in culture, both 
WT and p110δ
D910A/D910A BMMCs displayed a similar expression profile of class IA p110 
subunits,  however  after  continued  culturing  of  the  cells  a  clear  upregulation  of  p110ʱ 
expression  associated  with  a  downregulation  of  both  p110δ  and  p110β  expression  was 
observed in p110δ
D910A/D910A BMMCs.  This result suggests that p110ʱ may be mediating 
SCF-induced c-kit signalling.   Chapter 3 
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The upregulation of p110ʱ in p110δ
D910A/D910A BMMCs was not associated with increased 
cell expansion, however unlike WT BMMCs whose numbers began to drop after 9 weeks 
of being in culture, the numbers of p110δ
D910A/D910A BMMCs were maintained, albeit at a 
much  lower  level  compared  to  WT  BMMCs,  for  up  to  12  weeks.    It  is  possible  that 
upregulation of p110ʱ in p110δ
D910A/D910A BMMCs protects the cells from apoptosis or 
alternatively induces cells to enter senescence.  
 
3.5.3 p110δ and p110ʱ are constitutively bound to c-kit in WT and p110δ
D910A/D910A 
BMMCs 
Immunoprecipitation  of  cell  lysates  from  long-term  cultured  WT  and  p110δ
D910A/D910A 
BMMCs  with  an  antibody  against  c-kit,  revealed  that  both  p110δ  and  p110ʱ  were 
constitutively bound to c-kit in WT and p110δ
D910A/D910A BMMCs.  p110β and p110γ were 
not found constitutively bound or recruited to the c-kit receptor upon SCF stimulation, in 
both WT and p110δ
D910A/D910A BMMCs.  These data indicate that in addition to p110δ, 
p110ʱ could also potential signal directly downstream of c-kit in WT BMMCs. However, 
since inhibition of p110δ in WT BMMCs reduced SCF-induced Akt phosphorylation to that 
of the pan-PI3K inhibitor LY294002, it appears as though p110ʱ does not does not play a 
role in c-kit signalling.  This raises the question of what role p110ʱ is playing, given that it 
is coupled to c-kit, if it is not involved in c-kit signalling.  
 
The finding that  in  addition  to  p110δ,  p110ʱ  was also  constitutively  bound to  c-kit in 
p110δ
D910A/D910A BMMCs and was further recruited to c-kit upon SCF-stimulation, suggests 
p110ʱ is indeed the principal PI3K isoform mediating SCF-induced Akt phosphorylation in 
cells expressing a kinase-dead p110δ.  It is possible, given that both p110δ and p110ʱ are 
bound to c-kit, that a switch from p110δ to p110ʱ isoform signalling downstream of c-kit in 
p110δ
D910A/D910A BMMCs occur.  It is unclear how this switch in p110 isoform signalling 
occurs since it does not appear to be due to a switch in p110 binding to c-kit.   It would be 
interesting to investigate whether after maintaining p110δ
D910A/D910A BMMCs in long-term 
culture, another signalling molecule is selectively recruited to the activated c-kit receptor 
complex.  This could be investigated through immunoprecipitating SCF-stimulated c-kit 
receptors in short-term and long-term cultured p110δ
D910A/D910A BMMCs, followed by mass 
spectrometry  analysis  of  recruited  proteins.    This  experiment  would  however  require  a 
substantial  number  of  cells  to  obtain  a  high  enough  concentration  of  c-kit  protein 
complexes  that  when  separated  by  SDS-PAGE  are  visible  by  Coommassie  colloidal 
staining. Chapter 3 
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To  investigate  whether  p110ʱ  kinase  activity  is  required  in  long-term  cultured 
p110δ
D910A/D910A  BMMCs  to  mediate  c-kit  signalling,  BMMCs  isolated  from 
p110δ
D910A/D910A/p110ʱ
D933A/WT  mice could  be used to  assess whether c-kit signalling is 
compromised  by  reduced  p110ʱ  kinase  activity  in  these  cells  after  long-term  culture.  
Progress has also been made in the development of a p110ʱ-selective inhibitor (Hayakawa, 
et al., 2007a; Hayakawa, et al., 2007b; Hayakawa, et al., 2007c; Knight, et al., 2006), 
which could be used to assess whether in long-term cultured p110δ
D910A/D910A BMMCs, 
p110ʱ inhibition abrogates SCF-induced Akt phosphorylation. 
 
The absence of p110γ binding to c-kit was not unexpected since p110γ is known to be 
activated downstream of GPCRs as opposed to tyrosine kinase receptors.  Given that the 
p110β inhibitor reduced SCF-induced Akt phosphorylation in p110δ
D910A/D910A BMMCs it 
was  expected  that  p110β  may  be  recruited  to  c-kit  in  these  cells.    p110β  was  neither 
constitutively bound nor recruited to c-kit upon SCF-stimulation, indicating that it does not 
play a direct role in c-kit signalling.  There is a growing body of evidence that p110β is also 
predominantly activated downstream of GPCRs (Guillermet-Guibert, et al., 2008; Kurosu, 
et al., 1997), which is corroborated by the finding that the tyrosine kinase receptor, c-kit, 
does not bind p110β.  It is possible that p110β is activated downstream of c-kit through the 
action of an autocrine loop by GPCR agonists.  However, since p110β appeared to be 
downregulated in long-term cultured p110δ
D910A/D910A BMMCs, this seems to contradict the 
idea that p110β, in addition to p110ʱ, may also play a role in c-kit signalling.   
 
Overall, the data indicate that long-term culture of p110δ
D910A/D910A BMMCs may indeed 
result  in  a  type  of  „spontaneous  transformation‟,  in  which  cells  adapt  to  the  loss  of 
catalytically active p110δ by a switch to p110ʱ isoform signalling downstream of c-kit.  
The  switch  in  p110-isoform  signalling  does  not  appear  to  be  entirely  regulated  by 
differential  p110  coupling  to  c-kit,  and  does  not  result  in  a  highly  proliferative  cell 
population,  indeed  p110δ
D910A/D910A  BMMC  expansion  remained  considerably  low 
throughout  3  months  of  culturing  the  cells.    The  slow  rate  of  cell  expansion  for 
p110δ
D910A/D910A BMMCs made it extremely difficult to obtain large enough cell numbers 
for detailed biochemical studies to be carried out.  The cost of maintaining cells in culture 
for this time period was also an issue, since BMMCs are cultured in media containing the 
cytokines IL-3 and SCF, which needs to be replaced frequently. Although this approach 
generated  some  potentially  interesting  areas  for  further  investigation,  it  is  not  a Chapter 3 
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straightforward model to investigate p110-coupling to tyrosine kinase receptors and it was 
decided against pursuing this line of investigation any further. Chapter 4 
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4. OVEREXPRESSION OF P110δ IN A MAMMALIAN CELL LINE 
4.1 Introduction 
To investigate the isoform-specific signalling role of p110δ, we used the approach of stable 
overexpression in a mammalian cell line.  As described in the introduction (section 1.6.2), a 
number of investigations  into the isoform-specific roles  of PI3K have been carried out 
through overexpression studies.  However, the majority of these studies have employed 
transient transfection of the p110 isoforms, which can provide limited information about 
the full functional consequences of p110 overexpression.   
 
Unlike  p110ʱ  and  p110β,  p110δ  has  a  more  restricted  tissue  distribution  and  is  most 
abundantly  expressed in leukocytes.  However, there  are instances  where  cells  of non-
haematopoietic  origin  have  high  levels  of  p110δ  expression,  such  as  breast  cells, 
melanocytes,  microglia,  ovarian  carcinoma  and  primary  synoviocytes  (Knobbe  & 
Reifenberger, 2003; Mizoguchi, et al., 2004; Sawyer, et al., 2003).  The role that p110δ 
may be playing in these cells was investigated by attempting to stably overexpress p110δ in 
a mammalian cell line that has low endogenous levels of p110δ expression.   This was done 
by transfection of standard mammalian expression vectors or by a retroviral expression 
system in which p110δ expression is under the control of a strong promoter. 
 
At the time when I initiated these studies, our laboratory had discovered the presence of 
upstream untranslated exons in the p110δ gene (Verrall & Vanhaesebroeck, unpublished 
results).  We speculated that the presence of these 5‟ untranslated exons could possibly be 
important for effective expression of p110δ. 
 
4.2 Transfection of full length p110δ cDNA 
4.2.1 Multiple p110δ transcripts exist which encode upstream untranslated exons  
Rapid amplification of 5‟ cDNA ends (5‟RACE) on both human and mouse p110δ mRNA 
has identified several potential transcriptional start sites  (Kok, et al., in preparation; Verrall 
& Vanhaesebroeck, unpublished results).   An in-frame stop codon, present immediately 
upstream of the published translational start site, rules out the possibility that the newly 
identified upstream exons are translated as part of the p110δ protein.  To date five distinct 
upstream exons have been identified in the murine p110δ gene (termed exons -1, -2a, -2b, -
2c and -2d) and three distinct upstream exons in the human p110δ gene (termed exons -1, -
2a and -2b), shown schematically in Figure 4.1.  The coding region for p110δ is around 
90%  homologous  for  the  murine  and  human  p110δ  gene,  however,  the  upstream Chapter 4 
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untranslated exons exhibit little or no homology.  Exon  -1 is around 60% homologous 
between human and mouse, exon -2a has overlapping regions of high homology (illustrated 
in Figure 5.2, Chapter 5), and exon -2b displays no sequence homology between the two 
species. 
 
Figure 4.1:  Murine and human p110δ transcripts as revealed by 5’RACE.  Exon 1, 
which contains the ATG translational start site, is represented by the blue boxes; upstream 
unstranslated exons are shown as black boxes.   
 
All the upstream exons identified have a classical splice donor (GT) and splice acceptor 
(AG) sequence with the exception of the -2 exons which only have a splice donor sequence, 
which is in line with the observation that p110δ transcripts only contain a single -2 exon 
spliced onto exon -1.  Quantification of the amount of each p110δ mRNA transcript in 
murine cell lines has revealed that leukocytes express significantly higher amounts of the 
different  p110  transcripts  compared  to  non-leukocytes,  with  the  p110δ  transcript 
containing exon -1 with exon -2a being the most abundant (Kok, et al., in preparation).   A 
great deal of time has been invested in our laboratory to identify the role of these upstream 
exons  and  whether  they  are  involved  in  the  restricted  leukocyte  expression  of  p110δ.  
Indeed, recently exon -2a has been identified as having a condensed transcription factor 
binding cluster correlating with a high TSS prediction score (Kok, et al., in preparation), 
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which indicated this region as a putative PIK3CD promoter.  Promoter analysis of this 
region is described in the following chapter.   
At the start of my PhD work, the information about exon -2a as a potential p110δ promoter 
was not known.  It was thought however that the upstream exons may provide mRNA 
stability or some other function that enables stable overexpression of p110δ.  To investigate 
this, p110δ cDNAs containing the upstream exon -1 with exon -2a (referred to p110δ-2a) or 
exon -1 with exon -2b (referred to as p110δ-2b) were cloned into mammalian expression 
vectors and transfected into mammalian cell lines.  
 
4.3 Stable transfection of expression vectors containing full length p110δ cDNA in NIH 
3T3 cells 
4.3.1 p110δ-2a mRNA makes up approximately 80% of the total p110δ mRNA found 
in A20 cells 
To determine the absolute levels of p110δ-2a and p110δ-2b mRNA compared to the total 
p110δ mRNA levels in the A20 leukocyte cell line, quantitative real-time PCR (a detailed 
description of the method is described in section 2.8) was used.  p110δ-2b only contributed 
to  approximately  10%  of  the  total  p110δ  mRNA  levels,  whereas  p110δ-2a  mRNA 
contributed to approximately 80% (Figure 4.2).  It is likely that the other identified p110δ 
transcripts make up the remaining 10% of total p110 mRNA.   
 
 
Figure 4.2: Absolute amounts of p110δ-2a and p110δ-2b mRNA in A20 cells relative 
to total p110δ mRNA.  p110δ-2a mRNA and p110-δ-2b mRNA was compared to total 
p110δ mRNA levels in A20 cells assessed by quantitative real time PCR. 
 Chapter 4 
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4.3.2 The murine fibroblast cell line, NIH 3T3, is a suitable mammalian cell line for 
transfection of p110δ cDNA 
To investigate the biological impact of introducing p110δ into cells, a cell line that has low 
endogenous  p110δ  expression  was  required.    It  is  known  that  p110δ  is  predominantly 
expressed in leukocytes, therefore a non-leukocyte cell line was an obvious candidate for 
expressing low levels of p110δ.  Western blot analysis was performed on total cell lysate 
extracted from the murine A20 leukocyte cell line, the WEHI-231 pre-B cell line, and the 
murine NIH 3T3 fibroblast cell line and analysed for p110δ protein expression.  The p110δ 
mRNA levels in these cell lines was also assessed using quantitative real time PCR.  As 
expected, the murine fibroblast cell line NIH 3T3 expressed low levels p110δ protein and 
p110δ mRNA compared to the leukocyte cell lines (Figure 4.3). 
 
In  addition  to  expressing  low  levels  of  p110δ,  NIH  3T3  cells  have  a  reasonably  high 
transfection  capability and are  easily maintained in  culture.  Therefore, NIH 3T3  were 
considered  a  suitable  candidate  cell  line  to  examine  the  functional  consequences  of 
introducing and stably overexpressing p110δ.   
 
 
Figure 4.3:  p110δ mRNA and protein expression in NIH 3T3 cell line versus leukocyte 
cell lines. Relative expression of (a) p110δ mRNA and (b) p110δ protein in NIH 3T3 cells 
compared to A20 and WEHI-231 cells. 
 
 
4.3.3 In vitro translation of p110δ-2a, p110δ-2b and p85 expression vectors 
To assess the functionality of PI3K-containing vectors, in vitro translations of the plasmids 
containing  cDNAs  for  p110δ-2a,  p110δ-2b,  p85ʱ  and  p85β  (vector  maps  and  cloning 
strategies can be found in section 2.12.1) were performed using SP6 and T7 TNT
® Quick 
Coupled Translation Systems.  The results indicated that p110δ could be translated from 
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both  the  p110δ-2a  and  p110δ-2b  expression  vectors,  although  pcDNA3.1(+)  containing 
p110δ-2b  cDNA  may  not  be  as  effective  as  pCMV.Sport6  containing  p110δ-2a  cDNA 
(Figure  4.4).  p85ʱ  was  also  successfully  translated  from  pCMV.Sport6,  however  there 
appeared to be a problem with pCMV.Sport6 containing p85β as no 85  kDa band was 
detected from this in vitro translation, suggesting this expression vector is not functional. 
 
 
Figure 4.4:  In vitro translation of p110δ and p85 cDNAs from expression vectors. In 
vitro translations were performed on the p110δ-2a, p110δ-2b, p85ʱ and p85β plasmids to 
ensure the cDNAs could be translated into the expected proteins.  Reaction mix where no 
plasmid DNA were used as negative controls.   
 
4.3.4 No evidence for counter selection of NIH 3T3 clones expressing p110δ-2a cDNA 
p110δ-2a in the vector pCMV.Sport6 was cotransfected in NIH 3T3 cells with a vector 
encoding neomycin resistance (NeoR) (pIRES, Figure 2.5).  Control transfections included 
pCMV.Sport6 vector alone to ensure only cotransfection with the NeoR vector conferred 
neomycin-resistance and transfection of pCMV.Sport6 without the p110δ cDNA insert to 
assess whether transfection of p110δ altered the number of neomycin-resistant colonies 
obtained.  After 14 days in growth media containing neomycin, neomycin-resistant cell 
colonies were stained using methylene blue.  Approximately the same number of colonies 
were obtained for p110δ and control transfected NIH 3T3 cells (Figure 4.5), suggesting 
there was no counter-selection upon transfection of p110δ expression constructs. 
Negative 
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Figure 4.5: Colony formation of NIH 3T3 cells transfected with p110δ-2a. (a) NIH 3T3 
cell  colonies  transfected  with  pCMV.Sport6,  pCMV.Sport6  +  NeoR  or  p110δ-2a  in 
pCMV.Sport6 + NeoR, visualized by staining with methylene blue.  Colony staining was 
carried out in duplicate. (b) Graphical representation of the number of colonies formed. 
 
4.3.5 Increased  p110δ-2a mRNA in  p110δ-2a-transfected  NIH  3T3  clones  does  not 
correlate with increased p110δ protein expression  
Seven individual neomycin-resistant colonies transfected with p110δ-2a were expanded and 
the remaining colonies pooled.  Total RNA was then extracted and reverse transcribed to 
cDNA, followed by determination of the level of p110δ cDNA by quantitative real time 
PCR.  Primers specific for exon  -2a or the p110δ coding region were used to amplify 
p110δ-2a cDNA or total p110δ cDNA, respectively.  p110δ-2a-transfected clones expressed 
varying levels of p110δ mRNA compared to untransfected and vector control-transfected 
NIH 3T3 cells (Figure 4.6). This difference is likely to be dependent on the location in the 
genome in which the p110δ gene is incorporated since some loci are transcriptionally more 
active  than  others.    Also,  as  cell  resistance  to  neomycin  was  achieved  through 
cotransfection of p110-2a with pIRES, it is possible that some colonies may have only 
integrated the gene conferring neomycin-resistance without p110δ-2a. 
 
Clones  1,  2  and  7  displayed  the  largest  increase  in  p110δ-2a  mRNA,  with  clone  1 
expressing  approximately  10-fold  more  p110δ-2a  mRNA  compared  to  the  control 
transfected cells  (Figure 4.6a),  which  correlated  with  a 10-fold increase in  total p110δ 
mRNA (Figure 4.6b).  Although the level of p110δ-2a and total p110δ mRNA in this clone Chapter 4 
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was increased, it did not reach the level of that found in the A20 leukocyte cell line.  The 
pCMV.Sport6-control  transfected cells  expressed the same  amount of  p110δ mRNA as 
untransfected NIH 3T3 cells, indicating that the transfection process itself did not have any 
effect on p110δ mRNA levels. 
 
Figure  4.6:  Level  of  p110δ-2a  mRNA  and  total  p110δ  mRNA  in  NIH  3T3  clones 
transfected with p110δ-2a. (a) Relative amounts of p110δ-2a mRNA in transfected clones 
compared to untransfected NIH 3T3 cells.  For pCMV.Sport6 vector control transfected 
cells, either a single colony that was expanded (clone 1) or colonies were pooled (pool).  
A20 mRNA was used as a positive control. (b) Relative amounts of total p110δ mRNA. 
 
Next, total cell lysates were analysed for p110δ protein levels by western blot.   There 
appeared  to  be  no  significant  increase  in  p110δ  expression  in  any  of  the  transfectants 
(Figure 4.7).  Thus, despite clones 1, 2 and 7 expressing increased levels  of p110δ-2a 
mRNA, this did not lead to a concomitant increase in p110δ protein levels. Chapter 4 
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Figure 4.7: p110δ protein levels in NIH 3T3 p110δ-2a clones. Total cell lysate from the 
indicated cell lines were separated by SDS-PAGE and immunoblotted for p110δ and pan-
p85.    100  μg  of  total  cell  lysate  was  loaded  for  the  NIH  3T3  cells  and  p110δ-2a 
transfectants whereas 40 μg of WEHI-231 total cell lysate, used as a positive control, was 
loaded. 
 
4.3.6  Proteasomal  inhibition  leads  to  p110δ  protein  expression  in  NIH  3T3  cells 
transfected with p110δ-2a cDNA 
The data above indicate that stable overexpression of p110δ-2a mRNA is possible although 
this does not result in increased p110δ protein expression.  This could be due to the failure 
of  protein  being  translated  from  mRNA  or  the  translated  protein  being  subsequently 
degraded.  Protein substrates can be marked for destruction by the covalent addition of a 
poly-ubiquitin tail, which is recognized by a proteasome complex that digests the protein.  
Cells from p110δ-2a clone 1 (the clone expressing the highest level of p110δ-2a mRNA) 
were treated with a tripeptide aldehyde proteasome inhibitor, N-Ac-Leu-Leu-norLeucinal 
(LLnL) for 24 and 48 h.  Treatment of p110δ-2a clone 1 with LLnL for 24 h or 48 h 
resulted in a 2-fold and 3-fold increase in p110δ protein expression relative to the DMSO 
control,  respectively.  (Figure  4.8)  The  expression  of  cyclin  D2,  which  was  used  as  a 
positive control for proteasome inhibition, was increased in the control-transfected cells 
after 24 h or 48 h LLnL treatment, indicating successful proteasome inhibition.  Cyclin D2 
levels also increased after 24h LLnL treatment in p110δ-2a clone 1, however cyclin D2 
expression surprisingly decreased upon 48 h of LLnL treatment.  These data suggest that 
induced  p110δ  expression  may  have  an  effect  on  cyclin  D2  expression.  Treatment  of 
control-transfected cells with LLnL for either 24 h or 48 h had no effect on p110δ protein 
expression,  indicating  that  only  exogenously  expressed  p110δ  can  be  induced  upon 
proteasome inhibition (Figure 4.8).   
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In general, these results indicate that the increase in p110δ mRNA expression in p110δ-2a 
clone  1  can  indeed  lead  to  an  increase  p110δ  protein  expression  upon  proteasome 
inhibition.  This suggests that one reason for the failure of p110 protein expression under 
normal  cell  culture  conditions  in  cells  expressing  high  p110δ  mRNA,  is  due  to  p110δ 
protein instability and subsequent degradation.  
 
Figure 4.8: Analysis of p110δ protein expression in p110δ-2a clone 1 upon proteasome 
inhibition. Cells were treated with 50 μM LLnL or vehicle control (DMSO) for 24 h or 48 
h, followed by separation of cell lysates by SDS PAGE and immunoblotting for p110δ and 
cyclin D2.   
 
To find out how the 3-fold increase in p110δ protein levels after 48 h LLnL treatment 
compared to p110δ protein levels in a leukocyte cell line, the experiment was repeated with 
total cell lysate from the A20 leukocyte cell line separated by SDS PAGE alongside the 
other samples.  After 24 h of LLnL treatment, a clear induction of p110δ expression was 
observed in p110δ-2a clone 1, which corresponded to approximately half of that expressed 
in A20 cells (Figure 4.9).  It should be noted however, that since the loading control (β-Chapter 4 
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actin)  was  seen  to  decrease  in  p110δ-2a  clone  1  after  24  h  of  LLnL  treatment,  p110δ 
expression  has  not  been  normalised  to  β-actin.    Such  normalisation  would  give  an 
exceptionally high and misleading value for p110δ expression in p110δ-2a clone 1, which 
is likely to be a false readout since LLnL treatment did not reduce β-actin expression in 
untransfected and control transfected cells.  This infers that the low β-actin expression in 
p110δ-2a clone 1 is likely to be an immunoblotting technical problem. 
 
 
Figure 4.9: Analysis of p110δ protein expression in p110δ-2a clone 1 upon proteasome 
inhibition in comparison with p110δ expression in a leukocyte cell line. Cells were 
treated with 50 μM LLnL or vehicle control (DMSO) for 24 h, followed by separation of 
cell lysates by SDS  PAGE and immunoblotting for p110δ.  A20 total cell lysate from 
untreated cells was run on the same gel to compare p110δ expression. 
 
4.3.7  Increased  p110δ-2b  mRNA  in  transfected  clones  does  not  correlate  with 
increased p110δ protein expression 
Exon -2b of p110δ mRNA has been found in all leukocyte cell lines screened so far and is 
absent or present in extremely low amounts in non-leukocyte cell lines (Kok, et al., in 
preparation).   Although p110δ-2b mRNA was found to make up approximately only 10% 
of the total p110δ mRNA in the leukocyte cell line A20 (Figure 4.2), it is feasible that these 
low  levels  play  a  critical  role  in  p110δ  protein  expression.  p110δ-2b  cDNA  in Chapter 4 
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pcDNA3.1(+) under the control of a CMV promoter was transfected in NIH 3T3 cells (see 
section  2.12.1  for  vector  maps).    pcDNA3.1(+)  encodes  a  gene  conferring  neomycin-
resistance, enabling transfected cells to be selected in neomycin, thus circumventing the 
need to cotransfect the cells with a separate vector conferring resistance neomycin (as was 
the  case  for  transfection  p110δ-2a  cDNA).    Neomycin-resistant  transfectants  were 
expanded and quantitative real time PCR was performed to assess p110δ-2b mRNA levels 
(Figure 4.10).  
 
 
Figure 4.10: Levels of p110δ-2b mRNA and total p110δ mRNA in NIH 3T3 p110δ-2b 
clones. (a) Amounts of p110δ-2b mRNA in transfected clones relative to vector control 
transfected cells and compared to A20 cells.  (b) Relative amounts of total p110δ mRNA 
p110δ-2b mRNA in transfected clones compared to vector control transfected cells and A20 
cells. 
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Similarly, as was seen for the transfection with p110δ-2a cDNA, clones expressing varying 
levels of p110δ-2b mRNA were obtained (Figure 4.10a).  Clone 3 expressed the highest 
levels of p110δ-2b mRNA, with a greater than 100-fold increase compared to the control 
transfected cells, correlating to approximately 2-fold more than the A20 leukocyte cell line 
(Figure 4.10a).  However, and relevantly, this 100-fold increase in p110δ-2b mRNA in 
clone 3 was not reflected in a concomitant increase in the levels of total p110δ mRNA.  
Clone  3  had  only  a  3-fold  increase  in  total  p110δ  mRNA  compared  to  vector  control 
transfected  NIH  3T3  cells  representing  approximately  25%  of  that  found  in  A20  cells 
(Figure 4.10b). 
Taking into consideration that the total level of p110δ mRNA in NIH 3T3 cells represents 
only 5% of that in A20 cells (Figure 4.3a) and that in this pool of p110δ mRNA, p110δ-2b 
mRNA is likely to make up around 10%, (Figure 4.2) it is not surprising that although NIH 
3T3 p110δ-2b clone 3 expresses 100-fold more p110δ-2b mRNA than vector control cells 
and 2-fold more than p110δ-2b mRNA in A20 cells, this only corresponds to around 20% 
of the total p110δ mRNA in A20 cells.  This information is represented graphically and 
hopefully simplified in Figure 4.11. 
 
Figure 4.11: Diagram to illustrate the amount of p110δ-2b mRNA contributing to the 
total amount of p110δ mRNA in A20, NIH 3T3 cells transfected with p110δ-2b and 
WT NIH 3T3 cells.  
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To asses if the increase in p110δ mRNA in the p110δ-2b-transfected clones gave rise to an 
increase  in  p110δ  protein,  total  cell lysates  from  clone  3,  pooled  p110δ-2b  clones  and 
control-transfected NIH 3T3 clones were immunoblotted for p110δ.   Neither clone 3 nor 
the pooled p110δ-2b clones expressed an increase in p110δ protein compared to the control 
transfectants (Figure 4.12).  It is possible that the 3-fold increase in total p110δ mRNA in 
clone 3 is not sufficient to induce protein expression. 
 
Figure 4.12: p110δ protein levels in NIH 3T3 p110δ-2b clones. Total cell lysate from 
untransfected, pcDNA3.1(+) control-transfected and p110δ-2b-transfected NIH 3T3 cells 
were separated by SDS-PAGE and immunoblotted for p110δ. A20 and WEHI-231 total cell 
lysate were ran on the same gel to use as a positive control for p110δ expression. 
 
4.3.8 Stable coexpression of p85ʱ and p110δ-2a cDNAs does not induce p110δ protein 
expression 
Since p110 subunits of PI3K are more stable when in complex with the regulatory subunit 
(Yu et al., 1998a), it was thought that cotransfection of a regulatory subunit with p110δ 
may  promote  stable  p110δ  overexpression.  As  there  are  three  separate  genes  encoding 
regulatory  subunits  capable  of  binding  p110δ,  we  first  investigated  if  an  increase  in  a 
specific PI3K regulatory subunit mRNA correlated with the high p110δ mRNA expression 
in  leukocytes.    This  would  give  an  indication  of  which  p85  may  be  the  most  likely 
candidate to stabilise p110δ. Quantitative real  time PCR was  carried  out  on NIH 3T3, 
WEHI-231  and  A20  cell  lines  to  determine  the  mRNA  levels  of  the  different  PI3K 
regulatory subunits compared to the p110 subunits (Figure 4.13).  
 
These  experiments  revealed  that  there  is  approximately  1.6-fold  more  p85ʱ  mRNA 
expressed in WEHI-231 and A20 cells compared to NIH 3T3.  Given that A20 and WEHI-
231 cells expressed approximately 20-fold more p110δ mRNA than NIH 3T3 cells, this 
indicates p85ʱ is unlikely be the stabilising regulatory subunit for p110δ.  Assuming that Chapter 4 
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the level of mRNA directly correlates with protein expression, it seems unlikely that a 1.6-
fold increase in p85ʱ mRNA expression would be sufficient to stabilise a 20-fold increase 
in p110δ mRNA.  p85β mRNA was the most highly expressed of all class IA regulatory 
subunits in all of the three cell lines.  If p110δ was preferentially stabilised by p85β then 
one might expect that WEHI-231 and A20 cells to express more p85β mRNA than NIH 
3T3 cells, however this was not the case.  In fact, NIH 3T3 cells expressed approximately 
the same level of p85β mRNA as WEHI-231 cells.  All three cell lines examined express 
very  little  p55γ,  although  NIH  3T3  cells  expressed  approximately  10  times  more  than 
WEHI-231 and A20 cells.  
 
 
Figure 4.13: Quantitative real time PCR using primers specific for class IA PI3Ks on 
cDNA isolated from WEHI-231, A20 and NIH3T3 cells.  Absolute quantification of class 
IA  PI3K  isoforms  was  achieved  by  comparing  endogenous  mRNA  levels  with  known 
amounts of plasmid DNA containing cDNA for each class IA subunit.  The values were 
standardized  using  GAPDH  and  expressed  relative  to  the  mRNA  amount  of  the  least 
expressed class IA PI3K subunit, which was p55γ in WEHI-231 cells. 
 
This quantitative real time PCR data has been in used in combination with absolute protein 
quantification of p110 and p85 subunits from NIH 3T3 and WEHI-231 cells using mass 
spectrometry.  A reasonably good correlation between mRNA and protein levels was found 
for each class IA PI3K isoform indicating that p110 and 85 protein expression is at least 
partly regulated at the transcriptional level (Geering, et al., 2007b).  
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Overall, these data did not give a clear indication of which specific p85 would be favoured 
to transfect p110δ-2a clone 1 in an attempt to stabilise and induce p110δ expression.  Given 
that an in vitro translation of the vectors encoding p85ʱ and p85β revealed that only the 
vector encoding p85ʱ was functional (Figure 4.4) and taking into consideration the real 
time PCR results, it was decided to use p85ʱ for cotransfection with p110δ.  
 
Transfection of NIH 3T3 p110ʴ-2a clone 1 with expression vector for p85ʱ  
NIH 3T3 p110δ-2a clone 1, which expressed the highest amount of p110δ mRNA of all the 
NIH 3T3 clones transfected with p110δ expression plasmids (Figure 4.6), was selected for 
transfection with p85ʱ.  cDNA for murine p85ʱ in pCMV.Sport6 vector was cotransfected 
with a vector conferring hygromycin-resistance (pBabe-Hygro) in p110δ-2a clone 1 cells.  
Individual  hygromycin-resistant  clones  were  selected  and  expanded.    Total  RNA  was 
extracted from and reversed transcribed to cDNA for use in quantitative real time PCR 
using primers specific for p85ʱ.  Real time PCR showed that clones 4 and 5 transfected 
with p85ʱ had the greatest increase in p85 mRNA expression (Figure 4.14).  Total p85 and 
p110δ protein expression was therefore assessed in these clones (Figure 4.15).   
Figure 4.14: p85ʱ mRNA expression in NIH 3T3 p110δ-2a clone 1 transfected with an 
expression vector for p85ʱ. Quantitative real time PCR was carried out using primers 
specific for p85ʱ from clones expanded from NIH 3T3 p110δ-2a clone 1 stably expressing 
p85ʱ. 
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Although clones 4 and 5 showed increase p85ʱ mRNA expression, western blot analysis 
revealed  no  change  in  p110δ  or  total  p85  protein  levels  (Figure  4.15).  Since  stable 
overexpression of p85ʱ protein was not achieved, it is not surprising that clones 4 and 5 
have unaltered p110δ protein expression.  
 
Figure  4.15:  p110δ  and  p85  protein  expression  in  NIH  3T3  p110δ-2a  clone  1 
transfected with an expression vector for p85ʱ. Total cell lysate from clones expanded 
from  pCMV.Sport6-transfected  and  p85ʱ-transfected  NIH  3T3  p110δ-2a  clone  1  were 
separated by SDS-PAGE and immunoblotted for p110δ and pan-p85.  
 
4.4 Transient transfection of expression vectors containing full length p110δ cDNA in 
NIH 3T3 cells 
4.4.1 Introduction 
Results presented in the previous section have demonstrated that it not possible to generate 
a  NIH  3T3  stable  cell  line  expressing  significantly  increased  levels  of  p110δ  protein 
through transfection of full length p110δ cDNA containing either upstream exon -2a or 
exon -2b in pCMV.Sport6 or pcDNA3.1(+).  This work did however reveal that a stable 
increase in p110δ mRNA could be achieved and that a moderate increase in p110δ protein 
expression could be accomplished in p110δ-2a transfectants by treating the cells with a 
proteasome inhibitor.   This raised the possibility that p110δ exogenously expressed in NIH 
3T3 is targeted for proteasomal degradation. 
 
Although the generation a stable NIH 3T3 cell line expressing high levels of p110δ was the 
ultimate objective of this part of our work, transient transfection of p110δ-2a or p110δ-2b 
cDNA was also considered worthwhile.  In a transient transfection, the DNA introduced 
into the cell is not integrated into the chromosomal DNA (as in stable transfections) but is 
present at higher copies in the nucleus, typically generating higher protein expression than 
in  a  stable  transfection.    This  approach  may  permit  a  substantial  increase  in  p110δ Chapter 4 
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expression, albeit transiently, thereby avoiding complete degradation by the proteasome.  In 
this way, we can ascertain whether full length p110δ constructs can at least give rise to a 
temporary increase p110δ expression. 
 
HEK293T  cells  are  commonly  used  for  transient  transfections  as  they  are  highly 
transfectable and stably express polyoma large T antigen, which leads to amplification of 
genes in plasmids containing an SV40 origin of replication (Pear, et al., 1993).  For these 
reasons,  these  cells  were  used  in  transfection  experiments  as  a  control  for  transfection 
efficiency and protein expression.   
 
4.4.2  Transient  transfection  of  p110δ-2a  cDNA  and  p110δ-2b  cDNA  results  in 
increased p110δ mRNA expression in both NIH 3T3 and HEK293T cells 
cDNAs for p110δ-2a or p110δ-2b were transfected into NIH 3T3 or HEK293T cells with or 
without  a  plasmid  encoding  p85ʱ.    The  mRNA  levels  of  p110δ  and  p85ʱ  were  first 
determined  in  the  transfectants.    Total  RNA  was  extracted  and  reverse  transcribed  to 
cDNA, followed by determination of p110δ cDNA levels by quantitative real time PCR.  
Primers specific for exon -2a, exon -2b or primers that bound in the coding region of p110δ 
were used to amplify p110δ-2a cDNA, p110δ-2b cDNA or total p110δ cDNA, respectively.  
The level of p85ʱ mRNA was also determined using primers specific for p85ʱ cDNA. 
 
In comparison to untransfected cells, NIH 3T3 and HEK393T cells transiently transfected 
with p110δ constructs and/or a p85ʱ expression plasmid expressed a substantial increase in 
p110δ and/or p85ʱ mRNA, respectively (Figure 4.16).   In both cell types, transfection of 
p110δ  constructs  resulted  in  a  level  of  p110δ  mRNA  significantly  higher  than  the 
endogenous level of p110δ mRNA found in the leukocyte cell line, A20.  In NIH 3T3 cells, 
transfection of p110δ-2a cDNA gave rise to around 20,000-fold more p110δ-2a and total 
p110δ mRNA compared to the endogenous levels of p110δ mRNA in A20 cells (Figure 
4.16a).   
 
Surprisingly, cotransfection of p85ʱ with p110δ-2a cDNA in NIH 3T3 cells resulted in 
reduced  p110δ-2a  mRNA  expression  compared  to  transfection  of  p110δ-2a  alone.  
Nonetheless, p110δ-2a mRNA expression in NIH 3T3 cells coexpressing p110δ-2a and 
p85ʱ expression plasmids was still 3000-fold more than endogenous p110δ-2a mRNA in 
A20 cells. Moreover, total p110δ mRNA expression in NIH 3T3 cells coexpressing p110δ-
2a and p85ʱ was 400-fold more than endogenous total p110δ mRNA in A20 cells.  In 
comparison to stable expression of p110δ-2a in NIH 3T3 cells (described in section 4.3.5), Chapter 4 
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which  resulted  in  a  10-fold  increase  in  p110δ  mRNA  compared  to  untransfected  cells, 
corresponding to around half of that found in A20 cells, a 400-fold increase in total p110δ 
mRNA is a vast amplification in p110δ mRNA expression.   
 
 
Figure 4.16: Levels of p110δ and p85ʱ mRNA in NIH 3T3 and HEK293T transient 
transfectants. Relative amounts of total p110δ, p110δ-2a, p110δ-2b and p85ʱ mRNA in 
transiently transfected a) NIH 3T3 cells and b) HEK293T cells relative to untransfected 
A20 cells. Cells were transfected with  a total of 10 μg of the indicated cDNAs. Fold-
increase values of mRNA with respect to A20 cells are given. N/A indicates the mRNA 
levels were not measured. 
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Transfection of p110δ-2b cDNA in NIH 3T3 cells gave rise to 1500-fold more total p110δ 
mRNA and 2500-fold more p110δ-2b mRNA compared to the endogenous levels of p110δ 
mRNA  in  A20  cells.    Similar  to  cotransfection  of  p85ʱ  with  p110δ-2a  cDNA, 
cotransfection of p85ʱ  with  p110δ-2b cDNA resulted in  a decrease in total  p110δ and 
p110δ-2b mRNA expression compared to transfection of p110δ-2b alone.  Despite this 
decrease, total p110δ and p110δ-2b mRNA levels in NIH 3T3 cells cotransfected with p85ʱ 
and p110δ-2b  cDNA  were  around 400-fold more than the  endogenous levels  of p110δ 
mRNA in A20 cells. 
 
Cotransfection of p110δ-2a cDNA with p110δ-2b cDNA in NIH 3T3 cells resulted in a 
decrease in p110δ-2a and p110δ-2b mRNA expression compared to transfection of each 
p110δ cDNA alone, although this still corresponded to 2700-fold (for p110δ-2a) and 1000-
fold (for p110δ-2b) more than the endogenous levels of p110δ mRNA in A20 cells (Figure 
4.16a). 
 
Compared to transfections in NIH 3T3 cells, transfection of either p110δ-2a or p110δ-2b 
cDNAs in HEK293T cells, gave rise to an even higher increase in p110δ mRNA expression 
relative  to  the  endogenous  levels  of  p110δ  mRNA  in  A20  cells    (Figure  4.2.16b).  
Transfection of p110δ-2a cDNA in HEK293T cells resulted in around 280,000-fold more 
p110δ-2a mRNA and 260,000-fold more total p110δ mRNA compared to untransfected 
A20 cells.  Transfection of p110δ-2b resulted in 600,000-fold more total p110δ mRNA and 
960,000-fold more p110δ-2b mRNA relative to the endogenous p110δ levels in A20 cells.  
Since the vector backbone of p110δ-2b is pcDNA3.1(+), which contains an SV40 origin of 
replication, whereas the vector backbone of p110δ-2a (pCMV.Sport.6) does not contain an 
SV40 origin of replication, it was expected that HEK293T cells would amplify p110δ-2b 
mRNA expression to a greater extent than p110δ-2a mRNA. 
 
In agreement with the data on cotransfecting p85ʱ with p110δ cDNA in NIH 3T3 cells, 
cotransfection of p85ʱ with p110δ-2a or p110δ-2b in HEK293T cells reduced total p110δ 
and  p110δ-2a  or  p110δ-2b  mRNA  expression  compared  to  transfection  of  the  p110δ 
constructs alone (Figure 4.16b).  These data highlight that transient transfection of cDNAs 
results in substantially more mRNA expression compared to stable transfections and that 
HEK293T cells are capable of producing excessive levels of exogenous mRNA compared 
to NIH 3T3 cells. 
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4.4.3  Transient  transfection  of  p110δ-2a  cDNA  but  not  p110δ-2b  cDNA  results  in 
increased p110δ protein expression in both NIH 3T3 and HEK293T cells 
To assess whether the increased p110δ and p85ʱ mRNA expression gave rise to increased 
p110δ  and  p85  protein  levels,  total  cell  lysates  were  extracted  from  transfectants  and 
protein levels assessed by western blot (Figure 4.17).   
Figure 4.17: Analysis of p110δ and p85 protein expression in NIH 3T3 and HEK293T 
cells transiently transfected with p110δ-2a, p110δ-2b and p85ʱ. Cells were transfected 
with a total of 10 μg of the indicated cDNAs.  Cell lysates were separated by SDS PAGE 
and immunoblotted for p110δ and pan p85.  A20 total cell lysate from untreated cells was 
run on the same gel to compare p110δ expression. 
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Transfection of p110δ-2a cDNA alone, in both NIH 3T3 and HEK293T cells gave rise to 
around  a  3-fold  increase  in  p110δ  protein  expression  (lanes  6  and  14,  respectively) 
compared to p110δ expression in untransfected cells (lanes 2 and 11).   
In  NIH  3T3  cells,  cotransfection  of  p85ʱ  cDNA  with  p110δ-2a  cDNA  reduced  p110δ 
protein expression (lane 7), whereas in HEK293T cells cotransfection of p85ʱ cDNA with 
p110δ-2a cDNA further enhanced p110δ expression (lane 15).  Interestingly, transfection of 
p85ʱ cDNA only increased the total p85 protein expression in HEK293T cells (lanes 15 
and 17) and not in NIH 3T3 cells (lanes 7 and 9).  Since transfection of p85ʱ cDNA in NIH 
3T3 cells does not give rise to increased p85 protein expression, it is reasonable that the 
expression of p110δ is not enhanced. 
Transfection of p110δ-2b cDNA (alone or cotransfected with p85ʱ cDNA) did not result in 
increased p110δ expression in either NIH 3T3 or HEK293T cells (lanes 8 and 9 in NIH 3T3 
cells and lanes 16 and 17 in HEK293T cells).  This was a surprising result considering the 
substantial increase in total p110δ mRNA in HEK293T cells transfected with p110δ-2b 
cDNA. 
 
4.4.4 Proteasome inhibition or varying cDNA concentrations does not substantially 
increase p110δ protein expression in HEK293T cells transiently transfected with a 
p110δ-2b expression plasmid 
Transfection of 10 μg p110δ-2b cDNA did not result in increased p110δ expression in 
either NIH 3T3 or the more easily transfected cell line HEK293T.  10 μg of cDNA is a 
relatively high concentration of cDNA to be used in transfections, and it is possible that this 
concentration  is  inhibiting  p110δ  protein  expression  in  p110δ-2b  transfectants.  
Transfections of lower concentrations p110δ-2b cDNA in HEK293T cell were performed, 
to investigate whether a lower concentration of p110δ-2b cDNA could indeed induce p110δ 
protein expression.   In parallel, the effect of proteasome inhibition on p110δ expression in 
HEK293T cells transiently transfected with p110δ-2b cDNA was also investigated.  
 
There  was  little  change  in  p110δ  protein  expression  across  all  p110δ-2b  cDNA 
concentrations transfected (Figure 4.18).  The only induction of p110δ protein expression 
was observed upon cotransfection of 2 μg p110δ-2b cDNA with 1 μg p85ʱ cDNA after 
treatment with a proteasome inhibitor (lane 11).  The exogenously expressed murine p110δ 
protein  is  of  a  slightly  higher  molecular  weight  that  the  endogenous  human  p110δ  in 
HEK293T cells, therefore induction of p110δ-2b protein expression appeared as a doublet.  Chapter 4 
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These  results  indicate  that  some  of  the  exogenously  expressed  p110δ-2b  mRNA  is 
translated  into  p110δ  protein  but  the  protein  is  subsequently  targeted  for  proteasomal 
degradation. 
 
Figure 4.18: Analysis of p110δ expression in HEK293T cells transiently transfected 
with p110δ-2b cDNA. Cells were transfected with a total of 10 μg of the indicated cDNAs.  
Cells were treated with 50 μM LLnL for 48 h. Cell lysates were separated by SDS PAGE 
and immunoblotted for p110δ and pan p85.  A20 total cell lysate from untreated cells was 
run on the same gel to compare p110δ expression. 
 
Cotransfection  of  p110δ-2a  cDNA  with  p85ʱ  cDNA,  in  the  absence  of  proteasome 
inhibition, induced a substantially greater increase in p110δ proteins expression compared 
to any of the p110δ-2b cDNA transfections (lane 15), emphasizing that p110δ-2a mRNA is 
much more efficient in increasing p110δ protein expression compared to p110δ-2b mRNA. 
 
4.4.5  Proteasome  inhibition  increases  p110δ  protein  expression  in  NIH  3T3  cells 
transiently transfected with p110δ-2a cDNA but not p110δ-2b cDNA  
To further investigate the induction of p110δ protein expression by proteasome inhibition, 
NIH 3T3 cells transiently transfected with p110δ-2a or p110δ-2b cDNA (+/- p85ʱ cDNA) 
were treated with the proteasome inhibitor LLnL for 24 h or 48 h (Figure 4.19).   In all 
conditions tested, transfection of p110δ-2b cDNA had no effect on the protein expression 
of p110δ (lanes 7-12) in comparison to untreated untransfected NIH 3T3 cells (lane 2).  On 
the contrary, transfection of p110δ-2a cDNA resulted in increased p110δ protein expression 
compared  to  untransfected  NIH  3T3  cells  (lane  17  compared  to  lane  2),  which  was 
increased further upon 24 h of LLnL treatment (lane 14) and also 48 h of LLnL treatment 
(lane  13).    This  increase  in  p110δ  expression  was  not  associated  with  increased  p85 
expression.  Cotransfection of p85ʱ cDNA with p110δ-2a cDNA did not further increase 
p110δ expression upon LLnL treatment (lanes 15 and 16).  Together these results further 
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corroborate the previous finding that p110δ-2a mRNA is much more efficient in increasing 
p110δ  protein  expression  compared  to  p110δ-2b  mRNA  and  that  in  NIH  3T3  cells 
transfection of p85 cDNA does not enhance p110δ expression. 
 
Figure  4.19:  Analysis  of  p110δ  and  p85  expression  in  NIH  3T3  cells  transiently 
transfected  with  cDNAs  encoding  p110δ-2a,  p110δ-2b  and  p85ʱ  treated  with  or 
without  a  proteasome  inhibitor.  Cells  were  transfected  with  a  total  of  3  μg  of  the 
indicated cDNAs.  Cells were treated with 50 μM LLnL or DMSO vehicle control for 24 h 
or 48 h. Cell lysates were separated by SDS PAGE and immunoblotted for p110δ and pan 
p85.  A20 total cell lysate from untreated cells was run on the same gel to compare p110δ 
expression. 
 
Interestingly,  only  after  48  h  of  LLnL  treatment  was  increased  p85  protein  expression 
observed in NIH 3T3 cells in which p85ʱ cDNA had been cotransfected with either p110δ-
2a or p110δ-2b cDNA (lanes 9 and 15, respectively).  No increase in p85 protein expression 
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was observed in untreated cells or cells treated for 24 h with LLnL in which p85ʱ cDNA 
had been cotransfected  with  p110δ (lanes  10, 12, 16 and 18).   This  suggests that the 
exogenously expressed p85ʱ is also targeted for proteasomal degradation in NIH 3T3 cells 
and  despite  low  levels  of  p110δ  protein  expression,  in  the  presence  of  a  proteasome 
inhibitor high levels of exogenous p85ʱ expression can be achieved (as shown in lane 9). 
 
4.5 Discussion 
4.5.1 Transfection of full length murine p110δ cDNA in NIH 3T3 cells does not result 
in stable constitutive p110δ overexpression 
Multiple transcripts exist for p110δ with untranslated exons upstream of the first coding 
exon in both human and murine PIK3CD.  During the course of my PhD work, the nature 
of  these  upstream  exons  has  been  investigated  in  an  effort  to  elucidate  their  function.  
Although some progress has been made, the precise purpose of these 5‟ untranslated exons 
still remains unclear. 
 
Previous attempts to stably overexpress p110δ in mammalian cells in the laboratory were 
unsuccessful.    The  identification  of  multiple  p110δ  transcripts,  particularly  highly 
expressed in leukocytes, raised the possibility that the untranslated upstream exons could be 
important in effective p110δ expression.  It was hypothesized that transfection of full length 
p110δ cDNA, which incorporated the upstream exon -1 together with exon -2a (p110δ-2a) 
or exon  -2b (p110δ-2b), may permit  p110δ expression, for  example through increasing 
p110δ  mRNA  stability.    It  is  now  known  that  the  high  expression  of  p110δ  found  in 
leukocyte cell lines does not result from increased p110δ mRNA stability, although the 
stability of each individual p110δ mRNA transcript has not been investigated (Kok, et al., 
in preparation). 
Stable transfection of either p110δ-2a or p110δ-2b cDNA in the murine fibroblast cell line 
NIH 3T3 did not result in overexpression of p110δ protein despite an increase in p110δ 
mRNA expression in both cases.  Transfection of p110δ-2a cDNA increased p110δ mRNA 
levels  approximately  10-fold,  however  increased  p110δ  protein  expression  was  only 
observed  after  treatment  of  cells  with  a  proteasome  inhibitor.    This  suggests  that 
exogenously expressed p110δ is subsequently degraded by the proteasome.  The stability of 
p110s is increased when they are part of a heterodimer with p85s (Yu, et al., 1998b).  To 
assess if p110δ expression could be increased through such heterodimer formation, p85ʱ 
cDNA was cotransfected with p110δ-2a cDNA.  Despite an increase in p85ʱ mRNA levels, Chapter 4 
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expression of total p85 protein was not increased in p85ʱ stable transfectants and most 
likely as a result of this, transfection of p85ʱ cDNA did not affect p110δ expression in 
p110δ-2a transfectants.   
It is possible that the level of stably incorporated p110δ and p85ʱ cDNA is not high enough 
to drive p110δ and p85ʱ protein expression, respectively.  At low levels of p110δ and p85 
protein expression it is possible that that a third binding partner acting as a chaperone 
protein is necessary for efficient heterodimer formation, which would stabilise and protect 
p110 from degradation (Figure 4.20a).  In the absence of a chaperone protein, which might 
not be expressed in cells that normally do not express high levels of p110δ, such as NIH 
3T3 fibroblasts, p110δ and p85ʱ monomers are targeted for proteasome degradation.  
 
Figure 4.20: Hypothetical models to illustrate why increased p110δ and p85ʱ mRNA 
expression is not associated with increased p110δ and p85ʱ protein expression. (a) A 
third binding partner „x‟ is required for the association of p110δ with p85 in NIH 3T3 cells, 
which may act to stabilise the heterodimer or offer a protective role to prevent p110 / p85 
degradation.  In  the  absence  of  chaperone  protein  „x‟  p110δ  and  p85  monomers  are 
degraded. (b)  Transfected p85ʱ and p110δ bind each other to form heterodimers, however 
the proteins are cleaved and are subsequently degraded by proteases present in NIH 3T3 
cells. 
 
Alternatively,  transfected  p85  and  p110  proteins  may  form  heterodimer  complexes  but 
complexes are also degraded by the proteasome (Figure 4.20b).  It seems unlikely however 
that all exogenously expressed p110δ-p85ʱ heterodimers, which form stable complexes, 
would be degraded.   
p110δ-2a 
mRNA
p85α
mRNA
+/-
p85 p110δ
x
a
p85 p110δ
b
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Overall, we can conclude that the presence of the upstream exons -2a or -2b did not alter 
the  expression  level  of  p110δ  protein,  as  compared  to  cDNAs  which  lacked  these  5‟ 
untranslated exons. 
 
4.5.2  Transient  transfection  of  p110δ-2a  cDNA  but  not  p110δ-2b  cDNA  results  in 
p110δ overexpression 
As expected, in transient transfections of p110δ-2a or p110δ-2b, more substantial increases 
in p110δ mRNA expression were achieved in both NIH 3T3 cells and HEK293T cells 
compared  to  stable  transfections.    In  particular,  transfection  of  p110δ-2b  cDNA  in 
HEK293T cells resulted in massive increases of both p110δ-2b and total p110δ mRNA.  
This is due to the presence of an SV40 origin of replication in the p110δ-2b mammalian 
expression vector.  In spite of this finding, only transfection of p110δ-2a cDNA and not 
p110δ-2b cDNA resulted in p110δ overexpression in HEK293T or NIH 3T3 cells.  The 
data indicate that exon -2a is mediating a positive effect on p110δ expression which is not 
observed for exon -2b.  Transfection of various concentrations of p110δ-2b cDNA and 
treatment of cells with a proteasome inhibitor only resulted in a marginal increase in p110δ 
protein expression in HEK293T cells only.  Indeed, analysis of the contribution p110δ-2a 
and  p110δ-2b  transcripts  make  to  the  total  amount  of  p110δ  transcripts  in  the  A20 
leukocyte cell line, revealed that p110δ-2a contributes to 80% of the total p110δ mRNA, 
with p110δ-2b contributing to just 10%.  It is possible that the high level of p110δ-2a 
mRNA expression in leukocytes is partly responsible for high p110δ protein expression.  
However, it is clear from the stable transfections of p110δ-2a that in non-leukocyte cell 
lines  expression  of  p110δ-2a  cDNA  alone  is  not  sufficient  for  constitutive  p110δ 
overexpression. 
 
In HEK293T p110δ-2a-transfectants, p110δ protein levels could be further increased upon 
transfection  of  p85ʱ  cDNA,  whereas  in  NIH  3T3  p110δ-2a-transfectants,  proteasome 
inhibition  enhanced  p110δ  protein  levels.    This  corroborated  the  findings  from  stable 
transfection of p110δ-2a cDNA, that exogenously expressed p110δ is also regulated at the 
protein  level  through  stabilisation  by  p85  and  proteasomal  degradation,  supporting  the 
model proposed in Figure 4.20a.  Indeed, the models proposed in Figure 4.20 for the failure 
of p110δ expression in stable p110δ-2a transfections of NIH 3T3 cells, could also explain 
the findings from transient transfection of p110δ-2a.  In addition, the proposal that a high 
level  of  transfected  p110δ  and  p85ʱ  cDNA  is  required  to  drive  protein  expression  is Chapter 4 
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supported  by  the  finding  that  in  transient  transfections,  unlike  stable  transfections,  a 
substantial increase in p110δ and/or p85 cDNA led to effective protein overexpression. 
 
Interestingly, overexpression of p110δ protein in p110δ-2a transient transfectants, was not 
associated with an increase in endogenous levels of p85.  There are at least three possible 
scenarios which can explain this phenomenon.  The first is that exogenously expressed 
p110δ does not form heterodimers with p85 but exists as a monomer (Figure 4.21a).  This 
possibility implies that p110δ expression does not absolutely require p85, but can exist at 
least transiently as a monomer, which does not discount the idea that binding of p85 would 
stabilise p110δ.   
 
 
Figure  4.21:  Hypothetical  models  showing  why  increased  p110δ  expression  is  not 
associated with increased p85 expression. (a) p110δ can transiently exist as a monomer 
giving rise to increased p110δ protein expression. (b) Exogenously expressed p110δ titrates 
endogenous expressed p110ʱ and/or p110β from their regulatory subunit resulting in free 
p85 to which p110δ can bind. Monomeric p110ʱ and p110β are subsequently degraded. c) 
Exogenously  expressed  p110δ  downregulates  p110ʱ  and/or  p110β  expression  at  the 
transcriptional level resulting in increased p85 to which p110δ binds. 
 
The  second  possibility  is  that  the  exogenously  expressed  p110δ  titrates  endogenously 
expressed class IA p110s from their regulatory subunit, resulting in free p85 to bind p110δ 
(Figure  4.21b).    Monomers  of  titrated  p110  are  likely  to  be  subsequently  degraded, 
resulting in downregulation of p110ʱ and p110β protein expression. This possibility seems 
unlikely given that the binding of p110s to p85 has been shown to be extremely strong and 
can withstand high concentrations of urea, salt or detergent (Fry, et al., 1992).  A third 
scenario is that expression of exogenous p110δ results in downregulation of other class IA 
p110s at the transcriptional level resulting in decreased endogenous p110 expression but Chapter 4 
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not p85 expression.  Decreased protein expression of other class IA p110s would also result 
in  increased  free  p85  that  can  bind  and  stabilise  p110δ  (Figure  4.21c).    Transient 
overexpression of p110δ has indeed been found to result in downregulation of p110ʱ and 
p110β in chicken embryo fibroblasts (Kang, et al., 2006) and taking into consideration 
results  obtained  through  retroviral  infection  of  5‟Myc-p110δ  cDNA  in  NIH  3T3  cells 
(described in chapter 6), this possibility seems the most plausible. 
 
4.5.3 Transient or stable transfection of p85ʱ does not result in p85 overexpression 
NIH 3T3 cells 
As mentioned in section 4.5.1, stable overexpression of p85ʱ protein in NIH 3T3 cells was 
not possible despite an increase in p85ʱ mRNA levels.  Transient transfection of p85ʱ 
cDNA in NIH 3T3 also failed to result in p85 overexpression.  Increased p85 expression 
was only observed in NIH 3T3 cells transiently transfected with p85ʱ cDNA after 48 h of 
proteasome inhibition.  Interestingly, although the expression vector in which p85ʱ was 
expressed did  not  contain an SV40 origin  of replication, clear p85 overexpression was 
observed in HEK293T cells.  HEK293T cells are more readily transfected than NIH 3T3 
cells  and  indeed,    quantitative  real  time  PCR  revealed  that  HEK293T  cells  expressed 
37,000-fold more p85ʱ mRNA relative to A20 cells, whereas NIH 3T3 expressed 260-fold 
more.  It is possible that a certain threshold of mRNA expression first has to be reached in 
order for expression of exogenous p85 at such a level that it escapes complete proteasome 
degradation. 
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5  ANALYSIS  OF  THE  PROMOTER  ACTIVITY  OF  THE  UPSTREAM 
UNTRANSLATED EXON -2A OF MURINE PIK3CD 
 
5.1 Introduction 
It has been well documented that p110δ is predominantly expressed in leukocytes, however 
the mechanism by which leukocyte-restricted p110δ expression is achieved it is not known.   
Before starting and throughout the course of my PhD work, members of the laboratory have 
investigated the regulation of p110δ gene expression, in an effort to gain some insight into 
the leukocyte-specific nature of p110δ expression (Kok, et al., in preparation; Verrall & 
Vanhaesebroeck, unpublished results). These investigations have, for the most part, led to 
negative  data  regarding  the  manner  by  which  p110δ  gene  expression  is  regulated.    In 
summary,  p110δ  expression  does  not  appear  to  be  regulated  by  acute  stimulation  in  a 
variety of stimuli tested (TNFʱ, osmotic stress, UV radiation, proteasomal inhibition and 
aldosterone) in NIH 3T3 fibroblasts, or by DNA methylation and histone acetylation in the 
L929 fibrosarcoma cell line.  In addition, high p110δ expression in leukocytes does not 
appear to be due to increased p110δ mRNA stability compared to non-leukocytes (Kok, et 
al., in preparation). However, these investigations have led to the identification of multiple 
p110δ transcripts, as previously described in section 4.2.1.  The newly identified transcripts 
contain untranslated 5‟ upstream exons as far as 36 Kb from the ATG translational start site 
in  murine  exon  1  (Figure  4.1).    Investigations  into  locating  putative  leukocyte-specific 
promoter regions upstream of the untranslated exons have been carried out to offer some 
mechanism for tissue-restricted p110δ gene expression. 
 
5.2 In silico promoter analysis of the 5’ UTR of PIK3CD genomic DNA 
Although this work has been carried out by Dr. Elizabeth Verrall with the help of Klaartje 
Kok, it is important to summarise their findings to put the results I have obtained in this 
chapter into context.  In silico analysis of the 5‟UTR genomic sequence of murine PIK3CD 
identified  regions  of  high  homology  with  8  other  species,  which  is  indicative  of 
functionally conserved DNA sequences (Figure 5.1a).  Some of these regions colocalized 
with CpG islands, which as discussed in section 1.9.3 are frequently found in promoter 
regions.    DNA  fragments  upstream  of  exon  1  and  the  untranslated  exons,  in  genomic 
regions of DNA indicated in Figure 5.1a, were cloned into a luciferase reporter vector and 
expressed in the mouse A20 leukocyte cell line and the NIH 3T3 fibroblast cell line in an 
effort to identify a leukocyte-specific PIK3CD promoter.  The findings of the promoter 
activities of the different PIK3CD fragments are summarised below: Chapter 5 
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  Transfection of 6 fragments ranging from 58 bp to 2 Kb upstream of exon -2b 
 Low promoter activity was detected in both cell lines in transient transfections 
for  all  DNA  fragments.    In  stable  transfections,  a  modest  increase  in  promoter 
activity was detected in NIH 3T3 cells, although not in A20 cells, with the 58 bp 
DNA fragment. 
  Transfection of 7 fragments ranging from 36 bp to 2 Kb upstream of exon -2a 
  Transient  and  stable  transfections  resulted  in  similar  low  promoter  activity 
detected in both NIH 3T3 and A20 cell lines for all DNA fragments.  
  Transfection of 7 fragments ranging from 185 bp to 2 Kb upstream of exon -1 
 In transiently transfected cells the largest DNA fragment of 2 Kb gave rise to an 
unexpected significant increase in promoter activity in NIH 3T3 cells compared to 
A20  cells.    In  contrast,  the  smallest  DNA  fragment  of  185  bp  gave  rise  to  a 
significant increase in promoter activity in A20 cells compared to NIH 3T3 cells.  
However,  in  both  instances  the  promoter  activity  detected  was  relatively  low 
compared to the positive promoter control (SV40).  
  Transfection of 9 fragments ranging from 56 bp to 2 Kb upstream of exon 1    
 In transiently transfected cells high promoter activity was detected in both cell 
lines for most of the fragments, with no obvious difference between NIH 3T3 and 
A20 cells. 
 
On the basis of these results, it was not possible to delineate specific sites in the genomic 
DNA  which  accounts  for  the  tissue-specific  regulation  of  PIK3CD  (Verrall  & 
Vanhaesebroeck, unpublished results).   
 
5.2.1 Transcription factor binding cluster identified in mouse PIK3CD exon -2a 
In silico analysis of TF binding sites within a 600 bp region flanking the 5‟ untranslated 
exons (500 bp upstream and 100 bp downstream) in murine PIK3CD, identified a cluster of 
TF binding sites within exon -2a (Figure 5.1b) (Kok, et al., in preparation).  In comparison 
to  the  other  upstream  exons,  the  cluster  of  TF  binding  sites  was  tightly  packed  and 
correlated with a high TSS score.  From the previously described in silico analysis of the 
5‟UTR of murine PIK3CD, it was observed that a region of high homology in the 9 species 
analysed in addition to a CpG island surrounds exon -2a.  Collectively these data indicate a 
putative promoter region surrounding mouse exon -2a. 
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The TFs that bind in the identified cluster in mouse exon -2a are shown in Table 5.1 with 
their  DNA  binding  sequences  illustrated  in  Figure  5.2.  The  region  containing  the  TF 
binding cluster (TFB cluster), is highly conserved between species (Figure 5.2a), with at 
least  4  of  the  identified  TFs  being  associated  with  leukocyte  gene  expression,  namely 
ETSF, IRFF, NFAT and LEFF, which are discussed further in section 5.5.1.  Collectively, 
these findings strongly supported the hypothesis that this TFB cluster may act as a tissue-
specific promoter for PIK3CD gene expression.  This region of DNA had not been analysed 
for promoter activity previously as it is contained within exon -2a itself, and only regions 
upstream  of  the  untranslated  exons  were  previously  cloned  into  the  luciferase  reporter 
vector.  It is unusual, but not unheard of, that promoter regions are contained within exons.  
Recent  work  from  the  ENCODE  project  (http://www.genome.gov/10005107  and 
http://genome.cse.ucsc.edu/ENCODE/)  has  revealed  that  proximal  TF  binding  sites  fall 
within 1 Kb of both sides, 5‟ and 3‟, on the TSS (Kok, et al., in preparation).  Alignment of 
genomic PIK3CD DNA from human and mouse reveals that in actual fact, the TFB cluster 
is  located  53  bp  upstream  of  human  exon  -2a  (Figure  5.2b),  which  fits  in  with  the 
conventional idea of promoter location in relation the to the TSS. 
 
TF Abbreviation  TF full name 
IRFF  Interferon regulatory factor 
FKHD  Forkhead 
NFAT  Nuclear factor of activated T-cells 
LEFF  Lymphoid enhancer factor-1 and T-cell factor 
NKXH  NKX homeodomain factors 
ETSF  ETS/Elk family [named after E26 (E twenty six)  leukemogenic chicken virus] 
RBPF  Mammalian transcription repressor RBP-Jkappa/CBF 
Table 5.1: Transcription factor binding sites in mouse PIK3CD exon -2a. 
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The location of the TFB cluster in relation the translational start site in PIK3CD in species 
other than human and mouse is illustrated in  Figure 5.3.  If the TFB cluster acts as  a 
promoter for PIK3CD in these other species, it is likely that untranslated upstream exons 
also exist in these genomic sequences given that the TFB cluster lies up to 60 Kb upstream 
of the translational start site.  The presence of upstream exons in PIK3CD species other 
than human and mouse has not yet been investigated, although the similar locations of the 
TFB cluster in human compared to chimp, and mouse compared to rat PIK3CD, in relation 
to the ATG start site, strongly supports their existence. 
 
 
Figure 5.3: Location of TFB cluster relative to the translation start site of PIK3CD in 
six  species.  (a)  Schematic  to  show  the  location  of  the  TFB  cluster    in  relation  to  the 
translational start site in mouse, human, rat, chimp, cow and dog PIK3CD genomic DNA 
and also  in relation to  exon  -2a in  mouse and human.  (b)  Table to  show the distance 
between the TFB cluster and exon 1 and untranslated exons. 
exon 1 
(ATG)          
-2a
-2a
-1 24 kb  11kb  Mouse
Human
-1 40 kb  19kb 
34 kb  Rat
Chimp 60 kb 
47 kb 
Cow
40 kb 
Dog
= TFB cluster: CCTGTTATCTGTAGAAAGGAAACAAAGTGGGAAGTGGAGTGTGCGGAC
Exon1 Exon-1 Exon-2a
Mouse
Human
Rat
Chimp
Cow
Dog
35 kb
60 kb
34 kb
60 kb
47 kb
40 kb
24 kb
40 kb
0 b
53 b
U
U
U
U
U
U
U
U
U = Unknown
Distance of TFB cluster upstream of PIK3CD untranslated exons
a
bChapter 5 
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Two  additional  TF  binding  sites  immediately  upstream  of  the  TFB  cluster  were  also 
identified; MyoD, a member of a family of proteins known as myogenic regulatory factors 
that are involved in muscle differentiation, and SP1, a widely expressed activator of gene 
transcription in many cell types (Figure 5.4). 
 
Considering  the  high  conservation  of  the  DNA  sequence  comprising  the  TFB  cluster 
between species, the leukocyte-nature of certain TF binding sites located within the cluster, 
the high TSS score and the location of CpG islands in and surrounding the TFB cluster, the 
decision was taken to investigate the promoter activity of this region in leukocyte compared 
to non-leukocyte cells. 
 
 
Figure 5.4:  Interspecies homology  of TF binding sites  immediately  upstream of the 
TFB cluster. Alignment of TFB cluster identified in mouse exon  -2a with rat, human, 
chimp, dog, cow, elephant and tenrec genomic DNA identified two additional TF binding 
sites, MyoD and SP1F, 82 bp and 41 bp upstream of the TSS of mouse PIK3CD exon -2a, 
respectively.   
 
 
5.3 Cloning of mouse PIK3CD exon -2a into a luciferase reporter vector 
Using the mammalian expression vector containing the mouse p110δ-2a cDNA sequence 
(used for p110δ overexpression studies described in Chapter 4), exon -2a was amplified by 
PCR and cloned into the pGL3-Basic luciferase reporter vector (Figure 5.5 and described 
further  in  section  2.12.4).  The  pGL3-Basic  vector,  together  with  the  other  luciferase 
vectors used in the reporter assays, are described in section 2.12.3 and a vector map for 
pGL3-Basic is depicted in Figure 2.9.   
 
 
Mouse-2a
1.0
0.0
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Mouse
Rat
Human
Chimp
Dog
Cow
Elephant
Tenrec
>------MYOD----->                        >---SP1F---->
gaaggcacctgctggtgctaccctcgcagggcccgctgggcttggggcggggctggagaggcgtagaggatcagttgtttttCCT
aaaggcacctgc-ggcgctactcttgcagggcccgctgggcttggggcggggctggagaggcgtaggggaccagttgtttttCCT
caaggcacctggtgatgcccctctagcggggcgaactggggagtgtgggcggcgggggaagcctggaggacctgttgtttttCCT
caaggcacctggtgatgcccctctagcggggcgaactggggggtgtgggcggcgggggaagcctgggggacctgttgtttttCCT
caa--cacctggtgctgctcctccagcggggggtggagaggagggtggggggtgggggggggaggaggacctgttgttttttCCT
caaggcacctggtgacgcccctccagcgggggcaggcgaggcaggcggagggttagaagaagcaggaggacctgctgtttttCCT
-----cacctgc-gatacccttccatcag-------------ggcctgggggcgggaccagacaagagggccggttcttttcCCT
-----cacctgc-gatgcccctccagcag-------------ggg-tgggggcggg-cgaaggtagagga---gctgtttttCCT
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Figure 5.5: Cloning strategy used to obtain firefly luciferase in pGL3-Basic under the 
control of the putative mouse exon -2a PIK3CD promoter. (1) Mouse PIK3CD exon -2a 
was  amplified  from  pCMV.sport6  mammalian  expression  vector  containing  p110δ-2a 
cDNA.  PCR primers incorporated DNA sequences containing restriction enzyme digest 
sites for Xho I and Bgl II.  (2) Amplified exon -2a was ligated into pGEM
®T-Easy vector 
and used for transformation of competent cells. Transformation cultures were plated onto 
LB/ampicillin/IPTG/X-Gal plates and white colonies, containing ligation product, selected.  
(3) pGEM
®T-Easy containing exon -2a and pGL3-Basic were digested with the restriction 
enzymes Xho I and Bgl II.  (4) exon -2a was ligated into pGL3-Basic upstream of firefly 
luciferase. 
 
 
5.4 Mouse PIK3CD exon -2a has enhanced promoter activity in leukocyte cell lines 
compared to non-leukocyte cell lines 
Firefly luciferase under the control of the SV40 promoter (pGL3-Promoter, Figure 2.11), 
the putative exon -2a PIK3CD promoter (pGL3-Exon -2a, Figure 5.5) or the leukocyte-
specific Vav promoter (pGL2-Vav, Figure 2.10) were  transfected into the macrophage cell 
line, RAW 264.7 or the fibroblast cell line NIH 3T3.  The pGL3-Basic vector which did not 
contain any promoter sequence upstream of firefly luciferase was used for transfections to 
assess the basal level of luminescence. 
 
The  luminescence  detected,  which  acts  as  a  readout  for  promoter  activity,  from  cells 
transfected  with  pGL3-Exon  -2a  or  pGL2-Vav  has  been  expressed  as  a  %  of  the 
CCTGTTATCT GTAGAAAGGAAACAAAGTGGGAAGTGGAGTGTGCGGACTGT CAGT AGGCGGGC T G T CCCGC T GCGCGCCCCGC CTCTGGCTCAC TCGCGCCT AGCC T TGGGGCTGCCAGCT– CCGCGGACCC AGCT GCTGGAC
1 40 142
Bgl II
Exon -2a
p110δ
pCMV.sport6
Xho I
1.
Exon -2a
luc +
Xho I
Bgl II
pGL3-Basic
2. Exon -2a
luc +
pGL3-Basic
4.
TFB cluster
Xho I
Bgl II
Exon -2a
Exon -2a
pGEM®T-
Easy
Xho I
Bgl II
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luminescence detected for pGL3-SV40.  In all three transfections (pGL3-SV40, pGL2-Vav, 
pGL3-Exon -2a) the basal luminescence from pGL3-Basic has been subtracted (Figure 5.6). 
 
In two independent  experiments,  in  which transfection of each promoter construct  was 
carried  out  in  triplicate,  exon-2a  had  increased  promoter  activity  in  RAW  264.7  cells 
compared to NIH 3T3 cells (Figure 5.6a).  In RAW 264.7 cells, the promoter activity of 
exon -2a was around 75% of that observed for SV40, whereas in NIH 3T3 the promoter 
activity of exon -2a was around 15%.   The leukocyte-specific Vav promoter produced 15% 
promoter activity in RAW 264.7 cells, whereas in NIH 3T3 cells no promoter activity was 
detected (Figure 5.6a).  These results indicate that mouse exon -2a acts as a promoter in 
both cell types, however, promoter activity is enhanced in RAW 264.7 cells compared to 
NIH 3T3. 
 
 
Figure 5.6: Promoter activity of mouse PIK3CD exon -2a in leukocyte versus non-
leukocyte cell lines. The promoter activity of exon-2a and the Vav promoter is expressed as 
%  of  SV40  promoter  activity  after  basal  luminescence  has  been  subtracted.    Each 
transfection was carried out in triplicate with the error bars indicating the standard deviation 
between these triplicates.  Leukocyte cell lines are indicated by black bars. (a) Promoter 
activity in RAW 264.7 and NIH 3T3 cells expressed as an average over two independent 
experiments.  (b)  Promoter  activity  in  Thp1,  HEK  293  and  CT26  cells  from  a  single 
experiment.   
 
To analyse if exon -2a had increased promoter activity in an additional leukocyte cell line, 
the luciferase constructs were transfected in the monocytic cell line, Thp 1, and two non-
leukocyte  cell  lines,  HEK  293  (human  embryonic  kidney  cells)  and  CT26  (a  mouse 
carcinoma cell line) which both express low endogenous levels of p110δ.  Similarly to exon 
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-2a promoter activity in RAW 264.7 cells, the promoter activity of exon -2a was around 
75% of that observed for SV40 in Thp 1 cells (Figure 5.6b).  Fittingly, the promoter activity 
of exon -2a was much lower in the non-leukocyte cell lines, around 15% in HEK 293 and 
undetectable in CT26 cells.  Transfection of the leukocyte-specific Vav promoter resulted in 
10% promoter activity in Thp 1 cells, whereas in HEK 293 and CT26 cells no promoter 
activity was detected (Figure 5.6b).  Collectively, these data indicate that exon -2a, and 
most  likely  the  TFB  cluster  identified  within  this  region,  may  predominantly  promote 
p110δ expression in leukocytes. 
 
 
5.5 Discussion 
 
5.5.1 Characterisation TFs identified in the putative PIK3CD promoter surrounding 
exon -2a  
After a great deal of time invested in identifying a leukocyte-specific promoter for PIK3CD 
gene  expression,  the  identification  of  a  TFB  cluster  in  mouse  exon  -2a  as  a  putative 
PIK3CD  promoter  has  offered  some  insight  into  the  leukocyte-restricted  expression  of 
p110δ.    Transfection  of  firefly  luciferase  under  the  control  of  the  putative  exon  -2a 
PIK3CD promoter in leukocyte and non-leukocyte cell lines indicated that exon -2a has 
promoter activity in both cell types, with enhanced promoter activity in leukocyte cells.  
These  results  suggest  that  the  TFB  cluster  contains  TF  binding  sites  for  ubiquitously 
expressed TFs, which are able to drive PIK3CD gene expression in many cell types, in 
addition  to  TFs  predominantly  expressed  in  leukocytes,  which  enhances  PIK3CD  gene 
expression in this cell type only.  Indeed, 4 of the 7 different TFs identified in the TFB 
cluster,  namely  ETSF,  IRF,  NFAT  and  LEFF,  are  associated  with  regulation  of 
haematopoiesis and expression of leukocyte specific genes and are discussed in more detail 
below. 
 
ETS  family:  Nearly  30  members  of  the  ETS  family  have  been  identified,  which  are 
implicated  in  a  wide  range  of  physiological  and  pathological  processes  (Bartel,  et  al., 
2000).   Although the precise role of ETS-family members has not yet been delineated, TFs 
of the ETS family have been shown to be important for diverse cellular functions such as 
haematopoiesis,  haemostasis  and  lymphoid  development,  in  addition  to  endothelial  cell 
differentiation, angiogenesis, extraembryonic development and neurogenesis (Bartel, et al., 
2000; Bassuk & Leiden, 1997; Dejana, et al., 2007; Graves & Petersen, 1998; Orkin, 1998). 
Most  ETS  proteins  activate  gene  transcription,  although  a  few  members  exhibit 
transcriptional  repression  and  some  display  both  activating  and  repressing  functions, Chapter 5 
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however all bind the same DNA consensus motif.  The regulation of ETS function depends 
upon the expression profile, activity and interplay between ETS family members, other TFs 
and regulatory proteins within the cell.  It is apparent from ETS gene-targeting studies that 
a number of ETS TFs (PU.1, ETS1, Spi-B, Fli1, and TEL1) play an important role in the 
regulation of haematopoiesis (Bories, et al., 1995; Hart, et al., 2000; Iwama, et al., 1998; 
Muthusamy, et al., 1995; Scott, et al., 1997; Su, et al., 1997; Wang, et al., 1997).  PU.1 is 
expressed  specifically  in  haematopoietic  tissues,  with  high  levels  of  expression  in 
monocytic,  granulocytic,  and  B  lymphoid  lineages  (Chen,  et  al.,  1995;  Hromas,  et  al., 
1993). Mutation of the PU.1 gene results in a block of the development of lymphoid and 
myeloid lineages in the fetal liver and yolk sac (Scott, et al., 1997; Scott, et al., 1994).  
ETS1  is  expressed  predominantly  in  lymphoid  cells  in  adult  mice  where  it  has  been 
implicated in regulating transcription of lymphocyte-specific genes.  In particular, ETS1 
deficiency has dramatic, but different, effects on development and function of T- and B-
lineage cells.  Reduced numbers of ETS1-deficient splenic T cells are observed that are 
highly susceptible to cell death  in  vitro, whereas ETS1-deficient B cells are present in 
normal numbers but many show abnormal differentiation to  IgM-secreting plasma cells 
(Bories,  et  al.,  1995).    Furthermore,  ETS1-deficient  murine  T  cells  display  a  severe 
proliferative defect in response to multiple activational signals (Muthusamy, et al., 1995).   
 
IRF family: There are 9 mammalian IRFs, which have been shown to be transcriptional 
mediators of many biological processes, such as the development of innate and adaptive 
immunity, cell growth, apoptosis and haematopoietic development (Takaoka, et al., 2008).  
In particular, IRF TFs play a pivotal role in the induction of type I IFN signalling pathways 
providing a principal basis for host resistance against pathogens (Ozato, et al., 2007). IRF 
family members are highly expressed, but not exclusively, in cells of the immune system 
and  in  addition  to  promoting  IFN  gene  transcription,  IRF  family  members  stimulate 
expression  of  IFN  responsive  genes,  proinflammatory  cytokines,  and  expression  of 
macrophage and B cell specific genes (Ozato, et al., 2007; Paun & Pitha, 2007). 
 
NFAT family:  Five different NFAT family proteins have been characterised, which are 
mainly found in T cells and other cells of the immune system, such as mast cells, NK cells 
and monocytes (Rao, 1994).  NFAT was initially identified as an inducible factor that could 
bind to the promoter of IL-2 in activated T-cells (Shaw, et al., 1988).  Since this discovery, 
NFAT TFs have been shown to play a role in the regulation of various cytokines, including 
those involved in the regulation of haematopoietic cells such as granulocyte-macrophage 
colony stimulating factor, IL-4, IL-3, IL-13 and IL-5 (De Boer, et al., 1999).  Chapter 5 
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LEF family: Although there are only four members of the LEF/TCF family in vertebrates, 
extensive  patterns  of  alternative  splicing,  alternative  promoter  usage  and  activities  of 
repression, add to the complexity of LEF family TFs (Arce, et al., 2006). LEF proteins 
frequently activate LEF target genes in association with the TF β-catenin (Behrens, et al., 
1996), although LEF activation of target genes can also be independent of β-catenin (Hsu, 
et al., 1998). β-catenin is an important effector in the Wnt signalling pathway involved in 
various  cellular  processes  such  as  cell  differentiation  and  development.  Wnt  signals 
stabilise β-catenin in the cytosol and result in the accumulation and nuclear translocation of 
β-catenin (Eastman & Grosschedl, 1999).  LEF-1/TCF proteins associated with β-catenin 
mediate a transcriptional response to Wnt signalling (Arce, et al., 2006). 
 
LEF-1  was  originally  identified  as  a  gene  expressed  specifically  in  pre-B  and  T 
lymphocytes, encoding a nuclear protein that binds to a functionally important site in the 
TCRʱ enhancer conferring maximal enhancer activity (Travis, et al., 1991). This suggested 
that LEF-1 was a regulatory participant in lymphocyte gene expression and differentiation.  
Subsequently,  LEFs  have been linked to  the regulation  and expression of a number of 
lymphoid-specific genes.  For example, the recombination-activating gene (RAG)-1 and 
RAG-2 are expressed specifically in immature B or T lineage cells undergoing Ig or TCR 
gene  rearrangements.  The failure of functional expression of  RAG causes defect  in  the 
formation  of  functional  antigen  receptor  of  lymphocytes,  and  the  block  of  lymphocyte 
development in mouse and human (Mombaerts, et al., 1992; Shinkai, et al., 1992).  In 
immature B-cells, interaction of LEF-1 with β-catenin was found to be important for RAG-2 
expression, in concert with two additional TFs, implicating Wnt signalling and LEF-1 as 
important mediators in RAG transcription in B cells (Jin, et al., 2002).  The importance of 
LEF-1 expression in B cell maturation is also emphasized in LEF-1 deficient mice, which 
display defects of proliferation and survival of pro-B cells (Reya & Grosschedl, 1998).  
Regarding  the  regulation  of  T  lymphocyte-specific  genes  during  T  lymphocyte 
development,  additional  binding  sites  for  LEF-1  have  been  identified  in  transcriptional 
control regions of several T lymphocyte-specific genes, including those encoding adenosine 
deaminase (Brickner, et al., 1995), CD4 (Sawada & Littman, 1991), TCRβ, and TCRδ 
(Leiden & Thompson, 1994).  
LEF-1  has  also  been  identified  as  a  decisive  transcription  factor  in  granulopoiesis,  the 
haematopoiesis  of  granulocytes  (neutrophils,  eosinophils  and  basophils),  controlling 
proliferation,  proper  lineage  commitment,  and  granulocytic  differentiation  (Skokowa  & Chapter 5 
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Welte,  2007).  Indeed,  myeloid  progenitor  cells  of  patients  with  severe  congenital 
neutropenia  (abnormally  low  number  of  neutrophil  granulocytes)  show  a  severe 
downregulation of LEF-1 and its target genes expression (Skokowa, et al., 2006). 
 
The  leukocyte-specific  nature  of  the  TF  binding  sites  identified  in  the  TFB  cluster 
identified in mouse exon -2a strongly supports the proposal that this region of DNA acts as 
leukocyte-specific  promoter  for  PIK3CD  gene  expression.    Moreover,  the  high 
conservation of the TFB cluster DNA sequence between species and its location within a 
CpG island further indicate this region as a gene promoter.  It would be interesting to assess 
the importance of individual TF binding sites within the TFB cluster in driving leukocyte-
specific  gene  expression,  by  mutational  analysis.    LEF-1  has  been  shown  to  have  no 
transcriptional  activation  potential  by  itself,  but  act  as  an  architectural  protein  in  the 
assembly of multiprotein enhancer complexes  (Giese, et al., 1995).  This opens up the 
possibility that a complex of TFs is required for the leukocyte-specific promoter activity.    
 
Two other TF binding sites, MyoD and SP1, were identified immediately upstream of the 
TFB cluster in mouse exon -2a.  SP1 is a widely expressed TF that was originally found to 
recognize  and  specifically  bind  to  GC-rich  sites  within  the  SV40  promoter  via  three 
Cys2His2  zinc-finger  motifs.  Although  widely  expressed,  SP1  is  involved  in  regulated 
tissue-specific  gene  expression  such  as  the  differentiation  of  myeloid  cells,  and  LPS-
induced gene expression in macrophages and monocytes (Chanteux, et al., 2007; Hirata, et 
al.,  2008;  Liu,  et  al.,  2007;  Resendes  &  Rosmarin,  2004).  Characterisation  of  core 
promoters,  which  typically  encompass  the  site  of  transcription  initiation  and  extends 
approximately 35 nucleotides upstream or downstream, are commonly thought to contain 
TATA-like elements.  For PIK3CD no TATA-like motifs were identified through in silico 
analysis.  Interestingly, a genome-scale computational analysis has indicated that   76% of 
human core promoters lack TATA-like elements, have a high GC content, and are enriched 
in  SP1-binding  sites  (Yang,  et  al.,  2007).    Furthermore,  in  TATA-less  promoters,  SP1 
binding has been found to have a pivotal role in initiating transcription (Chen, et al., 1997; 
Colgan & Manley, 1995; Zenzie-Gregory, et al., 1993; Zhang, et al., 1994).  Although the 
SP1  TF  binding  site  was  not  included  in  the  DNA  region  cloned  into  pGL3-basic  for 
promoter analysis, it possible that it may enhance PIK3D gene expression.  It would be 
interesting  to  investigate  whether  including  the  SP1  TF  binding  site  would  enhance 
promoter  activity  in  an  in  vitro  reporter  assay,  and  whether  this  would  augment  the 
leukocyte-specific nature of the promoter. Chapter 5 
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5.5.2 PIK3CD core promoter elements 
As mentioned in the introduction (section 1.9.3), the core promoter is the minimal stretch of 
DNA sequence that is sufficient to direct accurate initiation of transcription, which typically 
encompasses the TSS within the initiator (Inr) sequence and several other motifs including  
the TFIIB recognition element, a TATA box and downstream promoter element (DPE) 
(Figure 1.15).  As previously stated, for PIK3CD no TATA-like motifs were identified 
through in silico analysis. DPE motifs commonly occur with TATA-less promoters located 
28-32 bp downstream of the TSS.  Downstream of the mouse exon -2a TSS, three possible 
DPE motifs exist (Figure 5.7), all of which have one nucleotide mismatch from one of the 
commonly occurring DPE sequence; AGTC/TG.  13 bps downstream of the human TSS for 
exon  -2a,  an  exact  match  for  the  commonly  found  DPE  sequence,  AGTCG,  is  found. 
However further investigation would be required to assess whether these sequences are in 
fact important for transcription initiation, indeed in drosophila, DPE sequences are usually 
located precisely at 28-32 bp downstream of the TSS (Burke & Kadonaga, 1996), therefore 
in this respect the sequences identified do not fit the conventional characteristics of DPEs. 
 
The initiator sequence typically encompasses the TSS with the consensus Py-Py(C)-A+1-N-
T/A-Py-Py, where A+1 represents the common nucleotide at which transcription is initiated 
(Javahery,  et  al.,  1994).  However,  the  TSS  may  occur  in  the  vicinity  of  Inr  at  not 
necessarily at A+1 (Butler & Kadonaga, 2002).  A possible Inr sequence (TCAGTTG) that 
differed only by the last nucleotide from the consensus, was found 5 bp upstream of the 
mouse exon -2a TSS (Figure 5.7).  Interestingly, the adenine (A) nucleotide, which is the 
only specified nucleotide in the Inr consensus, within this putative Inr sequence, was not 
present in the human PIK3CD genomic sequence.  This finding offers some explanation for 
the differing TSSs of mouse and human exon -2a.  A putative Inr sequence, TCACTCG, 
that contains the TSS of human exon -2a was found that also differs by the last nucleotide 
from the consensus Inr. 
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Figure  5.7:  Location  of  putative  core  promoter  elements  for  mouse  and  human 
PIK3CD transcripts containing exon -2a.   The location of putative Inr, DPE and TFBII 
sites surrounding the TSS for mouse and human exon -2a. 
 
The mechanism of transcriptional initiation from apparently TATA-less promoters is not 
firmly  established,  however  it  has  been  demonstrated  that  both  TATA-containing  and 
TATA-less promoters require the same basal transcription factors (Aso, et al., 1994).  A Chapter 5 
178 
 
possible TFIIB binding site was present on both mouse and human PIK3CD sequences, 
however given that it lies upstream of the putative Inr sequence and TSS of human exon -2a 
only, if this element is indeed functional, it is likely to only regulation transcription of 
human PIK3CD containing exon -2a and not mouse (Figure 5.7). 
 
5.5.3 The TFB cluster in mouse exon -2a is the principal PIK3CD promoter region 
driving leukocyte-specific p110δ expression  
Previous  investigations  have  identified  other  DNA  regions  upstream  of  exon  1  and 
untranslated  exons  with  relatively  high  promoter  activity  (Verrall  &  Vanhaesebroeck, 
unpublished results).  A DNA fragment 185 bp upstream of the TSS in mouse exon -1 was 
found to be the most promising leukocyte-specific promoter.  This region has TF binding 
sites  for PU.1 (an ETS TF) and  NFAT, described above,  and for Oct1, a ubiquitously 
expressed TF that is important for B cell development (Brunner & Wirth, 2006; Pfisterer, et 
al., 1994).  In contrast, regions of genomic DNA upstream of exon 1 were found to have 
high  promoter  activity  in  both  leukocytes  and  fibroblasts.    It  is  possible  that  multiple 
promoters upstream or within untranslated exons exert leukocyte-restricted PIK3CD gene 
expression.  However, PIK3CD transcripts containing exon -1 or exon -2a are the most 
abundantly expressed in a number of leukocyte cell lines tested and given that the level of 
PIK3CD transcripts containing exon -2a is almost equal to the level of PIK3CD transcripts 
containing translated exon 1 (Kok, et al., in preparation), this suggests that the majority of 
PIK3CD  transcripts  containing  exon  -1  also  contain  exon  -2a.    Corroborating  these 
findings,  quantitative  real-time  PCR  results  described  in  Chapter  4,  demonstrated  that 
mouse p110δ mRNA containing exon -2a contributed to ~80% of the total p110δ mRNA 
detected in the leukocyte cell line, A20 (Figure 4.2).  These data indicate that the promoter 
region identified in mouse exon -2a is likely to be sufficient in mediating the majority of 
leukocyte-specific PIK3CD gene expression. 
 
5.5.4 Possible regulation of p110δ expression by acute stimuli 
The  identification  of  leukocyte-associated  TFs  in  the  PIK3CD  promoter  raises  the 
possibility that p110δ expression may be regulated by acute stimulation.  Investigation into 
this area has previously been carried out, with the conclusion that p110δ is not regulated by 
acute stimulation.  However, stimuli that regulate the expression and/or activation of the 
specific TFs identified in the TFB cluster, were not thoroughly investigated.  Furthermore, 
it is conceivable that only certain cell types, which are capable of regulating the expression 
and/or activation of specific TFs that bind the TFB cluster are able to upregulate p110δ Chapter 5 
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expression.  Indeed, preliminary experiments in primary endothelial cells and endothelial 
cell lines have shown upregulation of p110δ (and not p110ʱ and p110β) in response to 
treatment with TNFʱ (Whitehead & Vanhaesebroeck, unpublished results).  Indeed, TNFʱ 
and other pro-inflammatory stimuli have been shown to upregulate IRF in endothelial cells 
to regulate the transcription of inflammatory markers, such as selectins (Dagia, et al., 2004; 
Neish, et al., 1995).  In addition, NFAT in endothelial cells has also been implicated in the 
upregulation  of  inflammatory  cell  adhesion  molecules  (Cockerill,  et  al.,  1995).    It  is 
tempting  to  speculate  from  these  data  that  PIK3CD  promoter  activity  is  increased  in 
endothelial  cells  through  increased  TF  binding  in  the  newly  identified  TFB  cluster,  in 
response to inflammatory stimuli, suggesting the role p110δ plays in inflammation is not 
limited to leukocytes.   
 
  
5.5.5 Targeting the PIK3CD promoter in cancer 
There are a number of instances where high expression levels of p110δ are observed in 
cells other than leukocytes, which are often associated with cancer, such as in breast tissue, 
melanoma and glioma (Sawyer, et al., 2003).  No somatic mutations in PIK3CD have been 
reported,  which  suggests  upregulation  of  p110δ  expression  occurs  by  some  other 
mechanism.    It  is  possible  that  upregulation  or  activation  of  leukocyte-associated  TFs 
which  bind  in  the  newly  identified  TFB  cluster,  increases  PIK3CD  promoter  activity 
resulting in high p110δ expression.  To support this hypothesis, LEF/TCF interaction with 
β-catenin has been implicated in tumorigenesis, and in particular breast cancer progression 
(Ayyanan, et al., 2006; Gebeshuber, et al., 2007; Hatsell, et al., 2003; Ravindranath, et al., 
2008).   In addition, other leukocyte-associated TFs identified in the TFB cluster in mouse 
exon -2a, have also been implicated in breast cancer progression.  For example, ETS-1 is 
overexpressed by invasive breast cancers and associated with poor prognosis (Span, et al., 
2002).  Recent investigations have found ETS-1 to increase the invasive potential of mouse 
mammary tumour cells, through promoting hepatocyte growth factor activation and c-Met 
receptor  overexpression  (Furlan,  et  al.,  2008).    ETS-2  mRNA  has  also  found  to  be 
upregulated in breast tissue carcinomas compared to normal breast tissue (Buggy, et al., 
2006).  The TF NFAT3 acts as a transcriptional coactivator of estrogen receptors (ERʱ and 
ERβ) and was found to enhance ER transcriptional activity in breast cancer cells and play 
an important role in regulation of breast cancer cell growth (Zhang, et al., 2005).  Recently, 
one study has implicated all 4 of the leukocyte-associated TFs identified in the TFB cluster 
in mouse exon -2a, in breast cancer progression.  Using a computer program to analyse 
alterations in gene transcription of TFs in breast cancer from 6 of the largest microarray Chapter 5 
180 
 
cancer datasets, NFAT, IRF, ETS2 and LEF1 were in the 20 most frequently mapped TFs 
with differential activation (Teschendorff, et al., 2007), although from this study it is not 
clear whether the alterations confer increased or decreased TF activation.   From these 
observations, it is feasible that high p110δ expression observed in breast cancer tissue may 
result from increased PIK3CD promoter activity due to increased TF activation and DNA 
binding.    
 
The  results  presented  in  this  chapter  shed  some  light  onto  the  leukocyte-restricted 
expression of p110δ, however they can only lead to speculation regarding the nature of 
p110δ regulation in disease settings.  Further investigations are needed to identify which TF 
binding sites are critical in driving PIK3CD gene expression.  It would be interesting to 
analyse the promoter activity of mouse exon  -2a in  breast  cancer cells and other non-
leukocyte cells which express high levels of p110δ, to examine whether these cells, unlike 
other  non-leukocyte  cells  tested,  are  able  to  utilize  this  promoter.    Regulation  of  the 
promoter activity of PIK3CD may offer a novel therapeutic target for cases of aberrant 
p110δ expression. 
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6. STABLE RETROVIRAL INFECTION OF HUMAN  P110δ cDNA IN THE NIH 
3T3 CELL LINE 
 
6.1 Introduction 
Retroviral-mediated transfection has been employed in a number of studies investigating 
the  effect  of  PI3K  overexpression.    For  example,  successful  overexpression  of  p110ʱ-
3‟CAAX and p110δ-3‟CAAX in BMMCs has been achieved using the retroviral vectors 
pBabe or pMX-neo (Kinashi, et al., 1999; Kinashi, et al., 2000).  Furthermore, stable NIH 
3T3 cell lines expressing a myristylated p110ʱ were created using the retroviral mammalian 
expression  vector  pLNCX  (Auger,  et  al.,  2000).    In  an  additional  study,  stable 
overexpression of myristylated p110ʱ, p110β, p110γ and p110δ in Rat1 fibroblasts has also 
been achieved (Link, et al., 2005), using the retroviral vector pWZL-Blast, which is based 
on pBabe.  It is interesting to note though that in each case of stable overexpression, the 
p110 subunit was modified by a membrane-localization signal. 
 
Recently, untagged p110β, γ, δ isoforms were successfully overexpressed using the avian 
retroviral RCAS system in primary cultures of chicken embryo fibroblasts (Kang, et al., 
2006).  All 3 isoforms were found to induce the formation of transformed cell foci.  Fusion 
of a myristylation signal to the N-terminus of p110 isoforms enhanced their oncogenic 
transforming ability, although p110δ and p110γ isoforms had potent transforming ability 
without the myristylation signal.  Although overexpression of all three p110 isoforms was 
achieved leading to cell transformation, this did not lead to full immortalisation of the cells, 
which could only be maintained in culture for approximately 3-4 weeks (Vogt, P., Personal 
communication to Bart Vanhaesebroeck). 
 
It is possible that the retroviral method of gene delivery into the cell induces higher gene 
expression  than  transfection  of  plasmid  cDNA,  therefore  leading  to  effective  protein 
expression.  The human p110δ gene in a retroviral expression vector system was available 
to us (a gift from Tatsuo Kinashi (Kinashi, et al., 2000)) for transfection of NIH 3T3 cells.  
This p110δ cDNA contained the coding region of p110δ (no 5‟ untranslated p110δ exons) 
with additional DNA sequences encoding an N-terminal Myc tag, which has the potential to 
stabilise p110 (Yu, et al., 1998a), and a membrane-targeting CAAX sequence at the C-
terminus. 
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6.2 Retroviral infection of 5’Myc-p110δ-3’CAAX and 5’Myc-p110ʱ-3’CAAX in NIH 
3T3 cells 
6.2.1 p110δ can be stably overexpressed through retroviral infection of 5’Myc-p110δ-
3’CAAX cDNA in NIH 3T3 cells 
5‟Myc-p110δ-3‟CAAX was introduced into NIH 3T3 cells in a pMX-neo retroviral vector 
(see  section  2.12.2  for  vector  maps)  through  retroviral  infection.    Infected  cells  were 
selected with neomycin and total cell lysate analysed for p110δ expression.  A significant 
increase in p110δ expression was observed in transfected NIH 3T3 cells compared to WT 
NIH 3T3 cells, which corresponded to around half of that found in bone marrow-derived 
macrophages  (Figure  6.1).  This  result  indicates  that  despite  the  previous  difficulties 
described in Chapter 4, stable overexpression of p110δ in NIH 3T3 cells is achievable, 
raising the question of whether this is as a result of the retroviral system used, the presence 
of a potentially stabilizing 5‟Myc tag, the presence of the membrane targeting 3‟CAAX 
motif, or a combination of all three. 
 
Figure 6.1: Stable expression of 5’Myc-p110δ-3’CAAX in NIH 3T3 cells by retroviral 
infection.  5‟Myc-p110δ-3‟CAAX in pMX-neo retroviral vector expressed in packaging 
cells was used for retroviral infection of NIH 3T3 cells.  Stable transfectants were selected 
with  neomycin  and  colonies  pooled.    Cell  lysates  were  separated  by  SDS-PAGE  and 
immunoblotted for p110δ.  Total cell lysate from wild type bone marrow-derived mast cells 
(WT BMMCs) was run on the same gel to compare p110δ expression. 
 
6.2.2 Stable overexpression of 5’Myc-p110δ-3’CAAX but not 5’Myc-p110ʱ-3’CAAX 
results in high levels of constitutive phosphorylation of Akt 
Packaging cells expressing 5‟Myc-p110ʱ-3‟CAAX in pMX-neo retroviral vector were also 
accessible to us (a gift from Tatsuo Kinashi).  To investigate whether this system could also 
give rise to p110ʱ overexpression, NIH 3T3 cells were retrovirally infected with 5‟Myc-Chapter 6 
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p110ʱ-3‟CAAX.    In  comparison  to  cells  overexpressing  5‟Myc-p110δ-3‟CAAX,  the 
exogenously expressed p110ʱ was not as easily detected (although still detectable) in total 
cell lysates as the exogenously expressed p110δ (Figure 6.2a).   
 
 
Figure 6.2: Stable expression of 5’Myc-p110δ-3’CAAX and 5’Myc-p110ʱ-3’CAAX in 
NIH  3T3  cells  by  retroviral  infection.    5‟Myc-p110δ-3‟CAAX  and  5‟Myc-p110ʱ-
3‟CAAX  in  pMX-neo  retroviral  vector  expressed  in  packaging  cells  were  retrovirally 
infected into NIH 3T3 cells.  Stable transfectants were selected with neomycin and colonies 
pooled.  (a) Cell lysates were separated by SDS-PAGE and immunoblotted for p110ʱ, 
p110δ and P-Akt.  P-Akt levels are also represented graphically.  (b) Cell lysates were 
subjected to an immunoprecipitation with an anti-Myc antibody and immunoblotted for 
p110ʱ and p110δ. 
 
Interestingly,  NIH  3T3  cells  stably  overexpressing  5‟Myc-p110δ-3‟CAAX  displayed 
considerably  high  basal  levels  of  phosphorylated  Akt  compared  to  pMX-neo  control 
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infected cells and 5‟Myc-p110ʱ-3‟CAAX infected cells.  NIH 3T3 cells overexpressing 
5‟Myc-p110δ-3‟CAAX also appeared to express lower levels of p110ʱ  compared to  pMX-
neo  control  infected  cells,  an  issue  which  is  further  discussed  in  section  7.2.1.    An 
immunoprecipitation with an anti-Myc antibody clearly showed overexpression of 5‟Myc-
p110ʱ or 5‟Myc-p110δ where the corresponding constructs had been infected, compared to 
control infected cells (Figure 6.2b).   
 
The activation of Akt in 5‟Myc-p110ʱ-3‟CAAX or 5‟Myc-p110δ-3‟CAAX infected cells 
was  further  investigated  under  serum-starvation  conditions  and  serum-stimulated 
conditions.  Similarly to under basal growing conditions, NIH 3T3 cells overexpressing 
5‟Myc-p110δ-3‟CAAX displayed the highest level of phosphorylated Akt under starvation 
conditions, which could be increased slightly further upon FBS stimulation (Figure 6.3).   
 
 
Figure 6.3: Akt phosphorylation in NIH 3T3 cells stably overexpressing of 5’Myc-
p110δ-3’CAAX or 5’Myc-p110ʱ-3’CAAX.  NIH 3T3 cells stably infected with pMX-neo 
control vector, 5‟Myc-p110ʱ-3‟CAAX or 5‟Myc-p110δ-3‟CAAX were starved of serum 
overnight.  The following day, cells were stimulated with 10% FBS for 5 min. Cell lysates 
were separated by SDS-PAGE and immunoblotted for P-Akt.   
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NIH 3T3 cells overexpressing 5‟Myc-p110ʱ-3‟CAAX displayed only a small increase in 
Akt phosphorylation under starvation and FBS stimulated conditions compared to pMX-
neo control infected cells (Figure 6.3).  These results indicate that expression 5‟Myc-p110δ-
3‟CAAX  in  NIH  3T3  cells  has  a  greater  impact  on  Akt  phosphorylation  compared  to 
5‟Myc-p110ʱ-3‟CAAX.    
 
6.3 Cloning of 5’Myc-p110δ, p110δ-3’CAAX, and untagged p110δ into the pMX-neo 
retroviral vector 
Retroviral infection of 5‟Myc-p110δ-3‟CAAX into NIH 3T3 cells gave rise to a substantial 
overexpression of p110δ.  To assess the importance of the 5‟Myc tag and the membrane-
targeting  3‟CAAX  motif,  untagged  p110δ,  5‟Myc-p110δ  and  p110δ-3‟CAAX  human 
cDNAs were cloned into the pMX-neo retroviral vector (Figure 6.4). 
 
 
Figure 6.4: Schematic of cloning strategy to insert untagged p110δ, 5’Myc-p110δ and 
p110δ-3’CAAXcDNA into the pMX-neo retroviral vector.  Construct number 4, 5‟Myc-
p110δ-3‟CAAX, was available expressed in pMX-neo, therefore no further cloning was 
required for this construct. A more detailed description of the cloning strategy for the other 
p110δ constructs can be found in material methods, section 2.12.2. 
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6.3.1 Retroviral infection of untagged p110δ and p110δ-3’CAAX gives rise to Gag-
p110δ fusion protein in GPE86 packaging cells and NIH 3T3 cells 
Once the p110δ constructs had been successfully cloned into pMX-neo (cloning strategies 
can be found in section 2.12.2), a viral packaging cell line (GPE86) stably expressing each 
of the constructs was created, for future retroviral infection of NIH 3T3 cells.  Total cell 
lysates  were  made  from  GPE86  cells  stably  expressing  each  p110δ  construct  to  check 
p110δ protein expression (Figure 6.5a).    
 
Figure  6.5:  p110δ  protein  expression  in  the  GPE86  packaging  cell  line  stably 
expressing untagged p110δ, 5’Myc-p110δ, p110δ-3’CAAX and 5’Myc-p110δ-3’CAAX 
in the pMX-neo retroviral vector. (a) Cell lysates from GPE86 cells stably expressing the 
indicated p110δ constructs were separated by SDS PAGE and immunoblotted for p110δ 
and P-Akt. The asterisk indicates the higher molecular weight protein that immunoblots 
with the anti-p110δ antibody (b) Cell lysates were subjected to an immunoprecipitation 
with an anti-p110δ antibody and immunoblotted for Myc and p110δ. (c) Cell lysates were 
subjected to an immunoprecipitation with an anti-Myc antibody and immunoblotted for 
p110δ. The asterisk indicates the presence of the higher molecular weight proteins that are 
detected with the p110δ antibody. 
 
Immunoblotting  the  total  cell  lysates  for  p110δ  revealed  substantial  overexpression  of 
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however it was also noticed that an additional band was present at around 130 kDa in 
GPE86 cells stably expressing untagged p110δ and p110δ-3‟CAAX (i.e. in the absence of a 
5‟Myc-tag).  This protein was also present in p110δ immunoprecipitates of GPE86 cells 
stably  expressing  untagged  p110δ  and  p110δ-3‟CAAX  only  (Figure  6.5b).  
Immunoprecipitation either with an antibody to p110δ or Myc confirmed the presence of 
the Myc tags in 5‟Myc-p110δ and 5‟Myc-p110δ-3‟CAAX transfected GPE86 cells (Figure 
6.5b, c).    
 
Similar  observations  were  made  in  NIH  3T3  cells  retrovirally  infected  with  the  p110δ 
constructs.  The appearance of a higher molecular weight band (~130 kDa) was detected 
after  immunoblotting  with  an  anti  p110δ  antibody  in  NIH  3T3  cells  stably  expressing 
untagged p110δ and p110δ-3‟CAAX constructs only (marked with * in Figure 6.6).  In fact, 
a second higher molecular weight protein (~120 kDa) could also be detected in NIH 3T3 
cells infected with untagged p110δ and p110δ-3‟CAAX constructs, (marked with ** in 
Figure 6.6), which was particularly apparent in cells expressing untagged p110δ.  However, 
this band was much less prominent than the band observed at ~130 kDa. 
 
Figure 6.6: p110δ protein expression in NIH 3T3 cells stably infected with untagged 
p110δ,  5’Myc-p110δ,  p110δ-3’CAAX  and  5’Myc-p110δ-3’CAAX  in  the  pMX-neo 
retroviral vector. Cell lysates from NIH 3T3 cells stably expressing the indicated p110δ 
constructs through retroviral infection were separated by SDS-PAGE and immunoblotted 
for  p110δ  and  pan-p85.  The  asterisks  indicate  the  higher  molecular  weight  proteins 
revealed upon immunoblotting with the anti-p110δ antibody.   
 
It was conceivable that the higher molecular weight protein that reacts with the p110δ 
antibody may have represented a modified p110δ protein, a modification that occurs at the Chapter 6 
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N-terminus of the protein that is prevented by the presence of a 5‟Myc tag.  To investigate 
the  nature  of  the  higher  molecular  weight  protein  and  the  possibility  of  a  p110δ 
modification,  the  130  kDa  protein  was  isolated  by  SDS-PAGE  and  analysed  by  mass 
spectrometry. 
 
 
Figure 6.7: Coomassie-stained gel of p110δ immunoprecipitates of the indicated cell 
lines. Cell lysates from NIH 3T3 cells stably expressing pMX-neo, untagged-p110δ and 
5‟Myc-p110δ  were  subjected  to  immunoprecipitation  using  a  p110δ  antibody  directed 
against the C-terminus, followed by separation by SDS-PAGE.  Immunoprecipitates were 
visualized by colloidal Coomassie blue staining.  The gel fragments indicated were excised 
and subjected to mass spectrometry analysis. 
 
The  four  gel  fragments  indicated  in  Figure  6.7  were  excised  and  subjected  to  mass 
spectrometry  analysis.    Fragment  1  represented  the  potential  modified  p110δ  protein, 
however it was revealed that this fragment actually consisted of transfected human p110δ 
and a viral Gag protein.  Closer inspection of the pMX-neo retroviral vector exposed a 
translational „ATG‟ start site in the viral packaging sequence that was in frame with the 
translational start site of p110δ.  This translational start site encodes 275 amino acids with a 
corresponding molecular weight of 30.7 kDa.  The protein resulting from this translational 
start site is in fact a viral Gag-p110δ fusion protein.  Where a 5‟Myc-tag is present in the 
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p110δ  insert,  the  „ATG‟  in  the  viral  packaging  sequence  is  no  longer  in  frame  of  the 
translational  start  site  of  p110δ,  preventing  the  formation  of  a  viral  Gag-p110δ  fusion 
protein.  As expected, excised fragments 2 and 3 were found by mass spectrometry to be 
untagged human p110δ and Myc-tagged p110δ, respectively.  Therefore, transfection of 
untagged p110δ in pMX-neo retroviral vector gives rise to two proteins; Gag-p110δ and 
untagged p110δ.  As anticipated, the two fragments excised in box 4, consisted of a mixture 
of p85ʱ and p85β.   
 
6.4 Cloning of untagged and p110δ-3’CAAXinto pMXs-neo 
An improved pMX-neo retroviral vector, called pMXs-neo, in which the ATG responsible 
for the translation of the viral Gag protein had been removed was provided for us by Tatsuo 
Kinashi (Kinashi, et al., 2000).   
 
Figure  6.8:  Schematic  of  cloning  strategy  to  introduce  the  packaging  sequence  of 
pMXs-neo into pMX-neo-p110δ constructs.  pMXs-neo and pMX-neo-p110δ constructs 
were  digested  with  the  restriction  enzymes  Sca  I  and  Age  I  and  the  packaging  signal 
sequence of pMXs-neo cloned into pMX-neo-p110δ constructs. 
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The group led by Tatsuo Kinashi had also experienced problems with the gene expression 
in  pMX-neo  retroviral  vector  leading  to  Gag-fusion  proteins,  which  had  led  to  the 
development of the improved pMXs-neo.  It was assumed that expression of the p110δ 
constructs in this vector would prevent the formation of viral Gag-p110δ fusion proteins.  
The sequence for pMX-neo and pMXs-neo only differ in the viral packaging portion of the 
vector, therefore rather than cloning the p110δ constructs into the new pMXs-neo vector, 
the viral packaging sequence of pMX-neo was replaced with the new pMXs-neo sequence 
(Figure 6.8).  
 
6.4.1 Overexpression of untagged and p110δ-3’CAAX in pMXs-neo in NIH 3T3 cells 
also gives rise to Gag-p110δ fusion protein expression 
The  new  pMXs-neo-p110δ  constructs  were  infected  into  NIH  3T3  cells.    Once  again, 
transfection of untagged or p110δ-3‟CAAX resulted in the expression of a higher molecular 
weight protein that immunoblotted with p110δ (marked by ** in Figure 6.9).  This protein 
had a molecular weight of around 120 kDa, as a opposed to the 130 kDa protein observed 
in the previous viral Gag-p110δ fusion protein product (marked by * in Figure 6.9).  In fact, 
a  protein  of  this  molecular  weight  (~120  kDa)  had  also  been  detected  in  previous 
transfections  of  NIH  3T3  cells  with  untagged  p110δ  and  p110δ-3‟CAAX  in  pMX-neo 
(indicated by ** in Figure 6.6), although not expressed as strongly.  
 
Analysis  of  the  new  pMXs-neo  packaging  sequence  uncovered  a  second  „ATG‟ 
translational  start  site  in  frame  with  the  translational  start  site  of  p110δ,  which  was 
downstream of the first detected viral Gag translational start site.  This second translational 
start site encoded 110 amino acids with a corresponding molecular weight of 12.3 kDa, 
which is consistent with the second 120 kDa protein being another viral Gag-p110δ fusion 
protein.  This finding was extremely disappointing especially as the formation of a second 
viral Gag-p110δ fusion protein could have been foreseen from previous NIH 3T3 p110δ-
transfections and by paying closer attention to the pMXs-neo DNA sequence.  In retrospect, 
more  time  should  have  been  spent  looking  into  the  potential  problems  of  using  the 
seemingly improved retroviral vector. 
 
The effect of this 12.3 kDa viral protein on p110δ function is unclear, and results obtained 
using cells overexpressing Gag-p110δ should be treated with caution.  However, NIH 3T3 
cells overexpressing 5‟Myc-p110δ (which do not express a viral Gag-p110δ) and NIH 3T3 
cells  overexpressing  untagged  p110δ  and  p110δ-3‟CAAX  (both  of  which  contain  viral 
Gag-p110δ fusion proteins) all have barely detectable levels of p110ʱ expression and high Chapter 6 
191 
 
basal levels of Akt phosphorylation (Figure 6.9), consistent with previous results illustrated 
in Figure 6.2.  This suggests that the presence of a Gag-fusion protein is not involved with 
the apparent downregulation of p110ʱ, but it is in fact as a result of overexpression of 
unmodified p110δ. 
 
 
Figure 6.9: p110δ expression in NIH 3T3 cells stably infected with untagged p110δ 
and p110δ-3’CAAX expressed in pMXs-neo and 5’Myc-p110δ-3’CAAX expressed in 
the pMX-neo retroviral vector. Cell lysates from NIH 3T3 cells stably expressing the 
indicated p110δ constructs were separated by SDS-PAGE and immunoblotted for p110δ, P-
Akt,  p110ʱ and pan-p85. Total cell lysate from NIH 3T3 cells expressing viral Gag-p110δ 
(Gag-p110δ)  was  included  as  a  positive  control  for  the  presence  of  Gag-p110δ  fusion 
protein.  *  indicates  the  first  viral  Gag-p110δ  found  and  **  indicates  the  second  lower 
molecular weight viral Gag-p110δ from the new pMXs-neo clones.  
 
6.4.2 Overexpression of Gag-p110δ in NIH 3T3 cells has a different impact on cell 
morphology compared to overexpression of 5’Myc-p110δ or 5’Myc-p110δ-3’CAAX  
As mentioned above, the effect of the 12.3 kDa viral protein has on p110δ function is not 
known and results obtained using cells overexpressing Gag-p110δ should be treated with 
caution.  However, before the nature of the p110δ „modification‟ was known, some studies 
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had  already  been  carried  out  looking  at  the  impact  of  p110δ  overexpression  on  cell 
morphology.   
 
The characterisation of NIH 3T3 cells overexpressing 5‟Myc-p110δ is discussed in detail in 
the next chapter, but is summarised briefly here.  In the presence of serum both 5‟Myc-
p110δ and 5‟Myc-p110δ-3‟CAAX overexpressing cells adhere over a greater surface area 
and display a more spread morphology compared to pMX-neo control infected cells (Figure 
6.10).  In contrast, NIH 3T3 cells expressing a Gag-p110δ fusion protein, either Gag-p110δ 
or  Gag-p110δ-3‟CAAX,  do  not  have  a  spread  morphology  but  more  closely  resemble 
pMX-neo control infected cells.  In cells expressing p110δ with both an N-terminus Gag 
fusion and C-terminus membrane CAAX motif, increased focal contacts were observed 
(assessed by expression of phosphorylated FAK) which colocalized with F-actin puncta.  
 
The difference between Gag-p110δ and 5‟Myc-p110δ expressing NIH 3T3 cells becomes 
more  apparent  under  serum-starvation  conditions  (Figure  6.11).  Gag-p110δ  expressing 
cells looked apoptotic with a rounded morphology.  Gag-p110δ expressing cells were found 
in  small  clusters,  which  displayed  high  levels  of  phospho-FAK  staining,  with  F-actin 
surrounding  the  nucleus  only.  In  contrast,  5‟Myc-p110δ  expressing  NIH  3T3  cells 
maintained a more spread morphology compared to pMX-neo control infected cells. 
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Figure 6.10: Cell cytoskeleton of Gag-p110δ and Gag-p110δ-3’CAAX overexpressing 
NIH 3T3 cells in normal growing conditions.  Cells were seeded in media containing 
10% FBS on glass coverslips in a 12-well plate and left to adhere overnight.  The following 
day cells were fixed and stained for focal adhesions (phospho-FAK), F-actin (phalloidin), 
DNA (DAPI). Chapter 6 
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Figure 6.11: Cell cytoskeleton of Gag-p110δ and Gag-p110δ-3’CAAX overexpressing 
NIH  3T3  cells  under  serum-starvation  conditions.    Cells  were  seeded  in  media 
containing 10% FBS on glass coverslips in a 12-well plate and left to adhere for 6 h.  After 
this time, media containing serum was replaced with starvation media (0% serum). The 
following day cells were fixed and stained for focal adhesions (phospho-FAK), F-actin 
(phalloidin), nuclear material (DAPI). 
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6.5 Discussion 
 
6.5.1 Stable overexpression of p110δ in NIH 3T3 cells using pMX-neo retroviral 
vectors  
Retroviral-mediated  transfection  has  proved  to  be  a  highly  successful  way  of  stably 
overexpressing PI3K isoforms (Auger, et al., 2000; Kang, et al., 2006; Kinashi, et al., 1999; 
Kinashi, et al., 2000;  Link, et al., 2005).  In all but one of these studies, a membrane 
targeting motif has been employed to investigate overexpression of a constitutively active 
p110.  Previous attempts to stably overexpress p110δ through transfection of full length 
p110δ cDNA in non-retroviral mammalian expression vectors were not hugely successful, 
as described in chapter 4.  Using the retroviral expression vector, pMX-neo, the ability of 
the retroviral system to overexpress p110δ has been investigated. 
 
Figure 6.12: The Mo-MuLV genome 
 
The pMX-neo retroviral vector contains the LTRs (long terminal repeats) of the Moloney 
murine leukaemia virus (Mo-MuLV).  The Mo-MuLV has a very simple genome, which 
can be divided into three transcriptional units: Gag, Pol and Env (Figure 6.12).  The LTR 
regions are found at either end of the gene and are important for initiating viral DNA 
synthesis and viral DNA integration into the host‟s genome (Barquinero, et al., 2004). The 
Gag region encodes genes that comprise the capsid proteins which encapsulate the viral 
genetic material.  In retroviral vectors, the viral genes located between the LTR regions are 
replaced with genes of interest.  Transfection of retroviral vectors into packaging cell lines, 
which  provide  all  the  viral  proteins  (Gag,  Pol  and  Env  gene  products)  results  in  the 
production of mature viral particles containing the gene of interest, which can subsequently 
be infected into mammalian cells (Paar, et al., 2007). 
 
Retroviral vector-mediated gene transfer is advantageous over other mammalian expression 
vectors in that they have superior gene transfer efficiency and provide a high degree of 
stable integration of exogenous DNA into the host‟s genome.  For the first time during the 
course  of  my  PhD  work,  introduction  of  a  p110δ  cDNA  gave  rise  to  a  substantial Chapter 6 
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constitutive overexpression of p110δ in NIH 3T3 cells.  To   ascertain whether stable p110δ 
overexpression was as result of the retroviral system used, the presence of a 5‟Myc tag or a 
3‟ membrane targeting CAAX motif, untagged p110δ, 5‟Myc-p110δ and p110δ-3‟CAAX 
were cloned into pMX-neo and also subsequently into the slightly modified pMXs-neo.  
Unfortunately,  both  retroviral  vectors  resulted  in  the  production  of  p110δ-Gag  fusion 
proteins when the p110δ cDNA used did not contain a 5‟Myc tag.   This was the result of 
viral Gag translational start sites being in frame with the translational start site of p110δ. 
 
All retroviral vectors contain a packaging signal, which is a region adjacent to the 5‟LTR 
which is involved in the packaging of viral genetic material into virions. The packaging 
signal for Mo-MuLV has been found to extend into the Gag region, indeed inclusion of a 
portion of the Gag region in different retroviral vectors has been found to increase the 
amount of vector RNA secreted by virus-producing cells (Bender, et al., 1987).  It is likely 
that the inclusion of a portion of the Gag sequence in the pMX-neo packaging signal was a 
feature intended to result in a high viral titer and enhanced viral infection of target cells.  
Irrefutably,  expression  of  p110δ  cDNA  in  pMX-neo  resulted  in  considerable  p110δ 
overexpression, however in the absence of a stop codon upstream of the translational start 
site of p110δ, a Gag-p110δ fusion protein was produced. 
 
In  hindsight,  more  careful  inspection  of  the  pMX-neo  and  pMXs-neo  sequences  and 
location of the p110δ cDNA inserts, could have avoided the time spent cloning p110δ 
constructs in pMXs-neo and analysing the nature of what was thought of as a potential 
p110δ modification. 
 
6.5.2 Expression of viral Gag-cellular fusion proteins in mammalian cells 
In  the  ASV16  oncovirus,  which  causes  rapidly  growing  hemangiosarcomas  in  young 
chickens  an  induces  oncogenic  transformation  in  cultured  chicken  embryo  fibroblasts 
(Chang, et al., 1997), a defective retrovirus codes for a single protein consisting of viral 
Gag sequences fused to a cell-derived insert.  The cellular sequence was found to contain 
most of the coding region for p110ʱ. The newly identified oncogenic Gag-p110ʱ fusion 
protein was termed P3K (Vogt, et al., 2006).  In addition to an N-terminal fusion with a 
partial Gag sequence, P3K also contains several point mutations (Chang, et al., 1997) and it 
was  considered  that  the  point  mutations  rather  than  Gag  may  confer  P3K  with  its 
oncogenicity, which led to  further investigations  into the oncogenic potential of p110ʱ 
(Aoki, et al., 2001; Aoki, et al., 2000; Kang, et al., 2005). Chapter 6 
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Studies in which the wild-type cellular p110ʱ sequence was cloned into the RCAS avian 
replication-competent  retroviral  expression  vector  and  introduced  into  chicken  embryo 
fibroblasts, did not induce generalize cell transformation but only the appearance of a few 
rare foci that emerged 2-3 weeks after incubation (Aoki, et al., 2000; Vogt, et al., 2006).  
Analysis  of  p110ʱ  in  these  foci  showed  that  in  every  case  the  cellular  sequences  had 
become fused to partial Gag sequences, the length of the Gag sequences differing from 
focus to focus (Aoki, et al., 2000; Vogt, et al., 2006).  In these transformation events, the 
oncogenicity  of  p110ʱ  derives  from  a  peculiarity  of  the  RCAS  vector  system  which 
generates random fusions between Gag and the cellular insert in the course of RCAS viral 
replication (Vogt, et al., 2006).  Using the RCAS avian replication-competent retroviral 
expression vector, the point mutations identified in p110ʱ were found to not be essential for 
oncogenic transformation, but rather the N-terminal fusion of p110ʱ to Gag (Aoki, et al., 
2000). 
 
Viral Gag proteins translocate to the plasma membrane and this seems to be the most likely 
function leading to activation of oncogenic p110ʱ.  Indeed, the addition of a myristylation 
signal to the N-terminus of cellular p110ʱ or the addition of a farnesylation signal to the C-
terminus, which both serve to target p110ʱ to the plasma membrane, lead to increased 
oncogenicity (Aoki, et al., 2000).  In oncogenic viral p110ʱ, deletion of the p85-binding 
region  and  mutational  inactivation  of  the  Ras-binding  domain  do  not  abolish  p110ʱ 
oncogenicity,  suggesting  that  membrane-bound  p110ʱ  is  constitutively  active  and  is 
independent of p85 or Ras (Aoki, et al., 2000; Vogt, et al., 2006).  
 
From the results presented in this chapter, the expression of Gag-p110δ in NIH 3T3 cells 
was  found  to  have  a  severe  impact  of  cell  morphology  under  conditions  of  serum-
starvation.    It  appears  that  this  effect  is  not  simply  the  result  of  plasma-membrane 
localization and constitutive activation of p110δ, given that expression of 5‟Myc-p110δ 
with a membrane targeting 3‟CAAX motif did not result in a similar phenotype.  In fact, 
expression of 5‟Myc-p110δ-3‟CAAX resulted in higher levels of basal Akt phosphorylation 
compared  to  cells  expressing  Gag-p110δ,  which  had  the  same  level  of  basal  Akt 
phosphorylation as cell expressing the cytoplasmic 5‟Myc-p110δ.  This indicates that the 
3‟CAAX  motif  is  more  efficient  at  targeting  p110δ  to  the  plasma  membrane  than  the 
presence of a 5‟Gag sequence.    
 
Surprisingly, in the absence of serum, the presence of Gag-p110δ in NIH 3T3 cells induced 
cell rounding, resembling an apoptotic phenotype, which is stark contrast the oncogenicity Chapter 6 
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observed for expression of Gag-p110ʱ in chicken embryo fibroblasts.  It is possible that this 
change in cell morphology is in fact indicative of cell transformation rather than cell death 
(Vogt, P., Personal communication).  It would be interesting to carry out colony formation 
experiments with these cells in reduced serum concentrations, to assess their oncogenicity 
compared to WT and 5‟Myc-p110δ-overexpressing NIH 3T3 cells.  
 
In the presence of serum, Gag-p110δ expression does not have a huge impact on the overall 
cytoskeletal cell morphology of NIH 3T3 cells, although the expression of Gag-p110δ with 
a 3‟CAAX motif did appear to result in increased focal adhesions associated with F-actin 
puncta, which possibly indicates increased invasive potential of these cells, although this 
would require further investigation.   
 
My initial aim was to investigate the biological effects of p110δ overexpression in NIH 3T3 
cells, and although the biological effects of N-terminus p110δ fusion to Gag appear to be 
interesting,  this  is  unlikely  to  represent  the  true  biological  consequences  of  p110δ 
overexpression.  If time was not a limiting factor, the effect of Gag-p110δ expression in 
NIH 3T3 cells could have been pursued, and cell growth, foci formation ability, cellular 
localization of Gag-p110δ and further investigation into the morphological consequences of 
Gag-p110δ expression considered.  However, as the overexpression of 5‟Myc-p110δ also 
resulted in phenotypically different cells compared to control infected cells, in the presence 
of  serum  and  under  serum-starvation  conditions,  the  decision  was  taken  to  further 
characterise these cells, which is described in the subsequent chapter.  
 
6.5.3  Overexpression  of  p110δ  but  not  p110ʱ  results  in  constitutive  Akt 
phosphorylation 
The presence of a 5‟Myc tag on the gene inserted into pMX-neo prevented the formation of 
a  Gag-fusion  protein.    Some  preliminary  comparisons  between  NIH  3T3  cells 
overexpressing  5‟Myc-3‟CAAX  versions  of  p110ʱ  and  p110δ  were  carried  out.  
Interestingly,  overexpression  of  5‟Myc-p110δ-3‟CAAX  but  not  5‟Myc-p110ʱ-3‟CAAX 
resulted in significantly increased basal and FBS-stimulated Akt phosphorylation compared 
to  control  cells.    This  is  a  finding  that  has  also  been  observed  in  other  investigations 
looking  into  the  effect  of  p110  overexpression.    Stable  overexpression  of  myristylated 
p110δ  in  rat  fibroblasts  triggers  Akt  phosphorylation  much  more  efficiently  than 
overexpression of myristylated p110ʱ, p110β or p110γ, in both serum-starved or serum-
stimulated conditions (Link, et al., 2005).  Similarly, overexpression of wild-type p110δ in 
chicken embryo fibroblasts results in high basal levels of Akt phosphorylation under serum-Chapter 6 
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starvation  conditions  compared  to  overexpression  of  wild-type  p110ʱ,  p110β  or  p110γ 
(Kang, et al., 2006).   
 
The relative enzymatic activity of p110ʱ is higher than that of the other p110 isoforms 
(Beeton, et al., 2000; Meier, et al., 2004), indicating that the low level of induced Akt 
activation in p110ʱ transfectants is not due to the relatively low kinase activity of p110ʱ.  It 
is possible that differences in the expression level of the exogenous p110 proteins may 
account for differences of p110s to trigger Akt phosphorylation.  Overexpression of p110ʱ 
but not p110δ may be toxic, which results in cells expressing low levels of exogenous 
p110ʱ  that  consequently  fails  to  induce  Akt  activation  (Kang,  et  al.,  2006).    Indeed, 
exogenously expressed p110δ was more easily detected in total cell lysates than p110ʱ, 
although  this  may  be  due  to  differences  in  sensitivities  of  isoform  detection  by 
immunoblotting.  Although the transfected p110ʱ and p110δ both contain an N-terminal 
Myc tag, the antibody against Myc can only be used for immunoprecipitation of Myc and 
not for Myc detection in total cell lysate by immunoblotting.   
 
It  should  be  considered,  however,  that  low  level  of  p110ʱ  protein  detection  by 
immunoblotting could result from differential cellular localization of p110ʱ compared to 
p110δ.  Exogenously  expressed  p110ʱ  may  predominantly  localize  in  the  membrane  or 
nuclear cell fraction compared to p110δ.  Subsequent cell lysis, using Triton X-100, may 
not result in full p110ʱ expression in total cell lysate supernatant. 
 
Another hypothesis to explain the ability of p110δ and not p110ʱ to efficiently activate Akt, 
is  that  fibroblasts  (which  have  been  used  in  all  the  studies  described)  express  low 
endogenous levels of p110δ compared to p110ʱ and p110β, it has been proposed that the 
introduction of exogenous p110δ to these cells elicits the activity of downstream effectors 
more potently than p110ʱ (Link, et al., 2005).   
 
6.5.4 Membrane-targeting of p110δ is not required for stable p110δ overexpression 
Although overexpression of different p110δ constructs in pMX-neo, aimed at investigating 
the necessity of a 5‟Myc tag or 3‟CAAX motif for successful stable overexpression, did not 
go entirely to plan, these investigations have revealed that the addition of a membrane 
targeting motif on p110δ is not essential for stable p110δ overexpression.  In fact, retroviral 
infection of 5‟Myc-p110δ in pMX-neo in NIH 3T3 cells resulted in levels of constitutive 
p110δ  overexpression  which  were  higher  than  that  observed  for  retroviral  infection  of 
5‟Myc-p110δ-3‟CAAX.    Since 5‟Myc-p110δ-3‟CAAX is likely to be expressed at the Chapter 6 
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plasma membrane is probable that a portion of 5‟Myc-p110δ-3‟CAAX will be lost from the 
cytoplasmic fraction of the total cell lysate taken for SDS-PAGE.  Nonetheless, retroviral 
infection of 5‟Myc-p110δ resulted in a substantial stable overexpression of p110δ. 
 
Expression of class IA p110 catalytic subunits is thought to be dependent on the availability 
of p85 regulatory subunits which stabilise p110s (Meier, et al., 2004; Ueki, et al., 2002a; 
Yu,  et  al.,  1998b).    However,  expression  of  5‟Myc-p110δ  was  achieved  without 
coexpression of a regulatory subunit.  Similarly, in other studies stable overexpression of 
p110s did not require exogenous p85 (Auger, et al., 2000; Kang, et al., 2006; Link, et al., 
2005).  It is possible that the 5‟Myc tag may be acting to stabilise p110δ since for p110ʱ the 
addition of a bulky N-terminal tag has been shown to supplant the requirement of p110ʱ for 
p85 (Yu, et al., 1998b).  Therefore, it is possible that overexpressed 5‟Myc-p110δ may not 
be acting in  the same way  as  overexpressed untagged p110δ might.  The limitations of 
characterising NIH 3T3 cells overexpressing p110δ with an N-terminal Myc tag is further 
discussed in the following chapter. Chapter 7 
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7. CHARACTERISATION OF NIH 3T3 CELLS OVEREXPRESSING 5’MYC-P110δ  
Although it was  originally  anticipated to  characterise  NIH 3T3 cells  overexpressing an 
untagged p110δ cDNA, the problems encountered with regard to the generation of a viral 
Gag-p110δ fusion protein, severely limited the time available to generate new NIH 3T3 
clones overexpressing untagged p110δ.  Since the addition of a Myc tag at the N-terminus 
of p110δ prevented the formation of Gag-p110δ fusion protein, the decision was made to 
start characterising NIH 3T3 cells overexpressing 5‟Myc-p110δ.  Unlike the presence of a 
3‟ Myc tag on p110 catalytic subunits, the presence of a 5‟Myc tag does not alter the lipid 
substrate specificity of class I p110s (Bilancio & Vanhaesebroeck, unpublished results).  
However, the drawback of using a 5‟Myc tag is that it has been shown to have a stabilizing 
effect on p110 subunits (Yu, et al., 1998b).  In this respect, a 5‟Myc tag may alter the 
dependency  of  p110δ  on  p85.    The  description  of  the  phenotypes  observed  in  5‟Myc-
p110δ-overexpressing cells are described below and summarised in Table 8.1 on page 261. 
 
7.1 Exogenously expressed 5’Myc-p110δ forms heterodimers with endogenous p85 in 
NIH 3T3 cells 
The colloidal Coomassie staining of p110δ immunoprecipitates separated by SDS-PAGE, 
first shown in section 6.3.1 and again here (Figure 7.1), depicts p110δ immunoprecipitates 
from control infected, untagged p110δ (now known to be Gag-p110δ fusion protein) and 5-
Myc-p110δ-overexpressing  NIH  3T3  cells.    This  figure  is  included  a  second  time  to 
emphasize the p85-binding capacity of 5‟-Myc-p110δ.   
 
 
Figure  7.1:  Coomassie  staining  of  p110δ  immunoprecipitates  separated  by  SDS-
PAGE. The bands indicated by arrows were excised and subjected to mass spectrometry 
analysis. 
 
The fragments indicated were excised and subjected to mass spectrometry analysis.  This 
identified p110δ and a mixture of p85ʱ and p85β in each of the fragments, indicated in 
Figure 7.1.  Although this result does not prove that the presence of the 5‟Myc tag on p110δ 
does  not  alter  the  level  of  p85  binding,  it  does  indeed  show  that  5‟Myc-p110δ  is  still 
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capable of forming heterodimers with p85 regulatory subunits.  This result indicates that the 
presence of a 5‟Myc tag does not obliterate the need of p110δ to bind, and perhaps be 
stabilised by, p85. 
 
7.2  NIH  3T3  cells  stably  overexpressing  5’Myc-p110δ  have  altered  class  IA  p110 
isoform expression and increased lipid kinase activity 
 
7.2.1 Overexpression of 5’Myc-p110δ in NIH 3T3 cells results in reduced p110ʱ and 
p110β isoform expression  
It  has  been  observed  that  reduced  expression  or  overexpression  of  a  particular  PI3K 
isoform,  either  by  PI3K  overexpression  or  gene  deletion,  can  result  in  deregulation  of 
expression of the other PI3K isoforms (Fruman, et al., 2000; Kang, et al., 2006).  Stable 
overexpression of 5‟Myc-p110δ in NIH 3T3 cells resulted in severe attenuation of p110ʱ 
expression and a lack of detectable p110β expression, whereas total p85 expression remains 
largely unaltered (Figure 7.2), which could be an indication that a limiting amout of p85 in 
cells plays a role in downregulation of p110ʱ and p110β expression.   
 
 
Figure 7.2: Class IA p110 isoform expression and Akt phosphorylation in NIH 3T3 
cells stably expressing pMX-neo or 5’Myc-p110δ. Cells were treated with 5 μM IC87114 
(p110δ-specific  inhibitor),  50  nM  TGX221  (p110β-specific  inhibitor),  10  μM  Y-27632 
(ROCK inhibitor) or DMSO vehicle control for 1 h. Cell lysates were separated by SDS-
PAGE and immunoblotted for p110δ, p110ʱ, p110β, pan-85 and P-Akt. 
 
The finding that p110δ overexpression results in reduced level of p110ʱ expression had 
also been observed in NIH 3T3 cells infected with 5‟Myc-p110δ-3‟CAAX, described in the 
previous  chapter  (Figure  6.2).    Inhibition  of  p110δ  activity,  using  the  p110δ-specific 
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inhibitor IC87114 did not alter p110ʱ or p110β expression, indicating that the lipid kinase 
activity of p110δ is not critical for the impact on p110ʱ and p110β expression.  
 
7.2.2  Overexpression  of  5’Myc-p110δ  in  NIH  3T3  results  in  constitutive 
phosphorylation of Akt 
Consistent  with  observations  made  for  NIH  3T3  cells  stably  expressing  5‟Myc-p110δ-
3‟CAAX described in Chapter 6, 5‟Myc-p110δ-overexpressing NIH 3T3 cells were found 
to have high constitutive Akt phosphorylation compared to pMX-neo control-infected cells, 
which had no detectable Akt phosphorylation under basal growing condition (Figure 7.2).  
Akt phosphorylation in 5‟Myc-p110δ-overexpressing NIH 3T3 cells was reduced to non-
detectable levels after treatment with the p110δ-specific inhibitor, IC87114.  The p110β-
specific inhibitor, TGX221, also had some minor effect on Akt phosphorylation levels.  
This is likely to be an off-target effect of p110δ inhibition, as p110β expression was not 
detected in 5‟Myc-p110δ-overexpressing NIH 3T3 cells (see Table 2.1 for the IC50 values 
of PI3K isoform-selective inhibitors).  
 
The ROCK inhibitor, Y-27632, induced Akt phosphorylation in pMX-neo control-infected 
cells and further increased Akt phosphorylation in 5‟Myc-p110δ-overexpressing NIH 3T3 
cells.  ROCK is a downstream target of RhoA and it has been proposed that RhoA-induced 
ROCK activation in turn stimulates the phosphatase activity of PTEN, ultimately inhibiting 
PI3K  activity  (Li,  et  al.,  2005;  Papakonstanti,  et  al.,  2007).    If  under  normal  growing 
conditions, there is a basal level of RhoA activity, inhibition of ROCK would suppress 
PTEN leading to increased PIP3 levels and increased Akt activation.  The results indicate 
that under basal growing conditions, in both pMX-neo and 5‟Myc-p110δ-overexpressing 
NIH 3T3 cells, RhoA is indeed active to some degree and stimulating PTEN phosphatase 
activity.  In an extension of this model, proposed by Papakonstanti et al, 2007, p110δ is 
shown to be a negative regulator of RhoA activity.  However, it appears that in 5‟Myc-
p110δ-overexpressing NIH 3T3 cells, the high level of p110δ expression is not sufficient to 
inhibit RhoA activity under basal growing conditions, as if this was the case, the ROCK 
inhibitor would be expected to have no effect on Akt phosphorylation levels. 
 
These data demonstrate that although the level of Akt phosphorylation is high in 5‟Myc-
p110δ-overexpressing NIH 3T3 cells, this does not represent the maximal level of Akt 
phosphorylation as it can be further increased. 
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7.3  NIH  3T3  cells  stably  overexpressing  5’Myc-p110δ  exhibit  differences  in  cell 
morphology and cell adhesion compared to pMX-neo control-infected cells 
 
7.3.1 NIH 3T3 cells stably overexpressing 5’Myc-p110δ have an altered actin-based 
cytoskeleton structure, which is dependent on the presence of serum, compared to 
pMX-neo control-infected cells 
NIH  3T3  cells  stably  overexpressing  5‟Myc-p110δ  were  found  to  have  a  structurally 
different F-actin-based cytoskeleton compared to pMX-neo control cells in both normal 
growing conditions, i.e. in the presence of 10% serum, or under serum-starvation conditions 
(Figures 7.3, 7.4, 7.5).  In the presence of serum, 5‟Myc-p110δ-overexpressing cells appear 
to adhere to a greater surface area than control infected cells, with more actin stress fibres 
traversing the cytoplasm of the cell, often terminating with sites of focal contacts with the 
substrate (as assessed by P-paxillin staining) (Figures 7.3, 7.4).  The difference in the cell 
adhesion area between NIH 3T3 cells stably expressing pMX-neo or 5‟Myc-p110δ was 
extremely  apparent.    In  some  instances  it  was  necessary  to  decrease  the  microscope 
objective to simply capture an image which contained a complete cell (Figure 7.3b).  It 
should be emphasized, however, that although the majority of 5‟Myc-p110δ-overexpressing 
cells  had  a  greater  adhesion  surface  area  than  pMX-neo-expressing  cells,  only  a  small 
minority of cells displayed a huge surface adhesion area, an example of which is shown in 
Figure 7.3b. 
 
In pMX-neo control-expressing cells the majority of F-actin was tightly packed in bundles 
running along the cell periphery, indicated by strong phalloidin staining (Figure 7.4).  In 
5‟Myc-p110δ-overexpressing cells, although there was also strong staining of F-actin at the 
cell periphery, in comparison to pMX-neo control-expressing cells this appeared reduced.   
 
In general, 5‟Myc-p110δ overexpressing cells appeared to have an increase number of focal 
adhesions  compared  to  pMX-neo  control  infected  cells,  although  this  has  not  been 
numerically quantified.  From staining with N-cadherin, there appeared to be no obvious 
difference in the ability of pMX-neo control or 5‟Myc-p110δ overexpressing cells to form 
adherens junctions (Figure 7.3).   
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Figure 7.3: Cell cytoskeleton of NIH 3T3 cells stably expressing pMX-neo or 5’Myc-
p110δ in normal growing conditions.  Cells were seeded in media containing 10% FBS 
on glass coverslips in a 12-well plate.  Cells were left to adhere overnight.  The following 
day cells were fixed and stained for F-actin (phalloidin), adherens junctions (N-cadherin) 
and focal adhesions (P-paxillin). Images are shown for (a) 60x and (b) 40x magnifications.  
The white ellipses enclose a complete cell for pMX-neo control infected and 5‟Myc-p110δ-
overexpressing NIH 3T3 cells, highlighting an obvious difference in cell adhesion area 
observed.  It should be noted that the 5‟Myc-p110δ-overexpressing cell highlighted here 
was  selected  to  show  how  large  these  cells  can  become,  however  this  cell  has  an 
exceptionally large surface adhesion area and is not an accurate reresentative of 5‟Myc-
p110δ-overexpressing cells. Scale bar = 10 μM for both magnifications. 
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Figure 7.4: Cell cytoskeleton of NIH 3T3 cells stably expressing pMX-neo or 5’Myc-
p110δ in normal growing conditions.  Cells were seeded in media containing 10% FBS 
on glass coverslips in a 12-well plate.  Cells were left to adhere overnight.  The following 
day cells were fixed and stained for F-actin (phalloidin), DNA (DAPI) and focal adhesions 
(P-paxillin). Scale bar = 10 μM.  
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Upon  overnight  serum-starvation,  5‟Myc-p110δ-overexpressing  cells  displayed  striking 
differences in the actin-based cytoskeleton compared to normal growing conditions with 
10% serum (Figure 7.5).  Moreover, in the absence of serum, 5‟Myc-p110δ-overexpressing 
cells also displayed a different morphology compared to pMX-neo-expressing cells (Figure 
7.5).   
 
Under starvation conditions, 5‟Myc-p110δ-overexpressing cells did not contain actin stress 
fibres traversing the cell cytoplasm, which were observed in the presence of serum.   In 
fact, in the absence of serum the overall staining of F-actin bundles appeared to decrease in 
5‟Myc-p110δ-overexpressing cells compared to pMX-neo-expressing cells and compared 
to 5‟Myc-p110δ-overexpressing cells in 10% serum (Figure 7.5a).  As previously observed 
in the presence of serum, pMX-neo-expressing cells expressed prominent bundles of F-
actin  along  the  cell  periphery  under  serum-starvation  conditions.      In  5‟Myc-p110δ-
overexpressing cells, F-actin bundles were only observed running along the cell periphery, 
but in comparison to pMX-neo-expressing cells, F-actin staining appeared reduced (Figure 
7.5a, b). 
 
In terms of general cell morphology, 5‟Myc-p110δ-overexpressing cells had a more flat and 
spread  appearance  compared  to  pMX-neo-expressing  cells  under  starvation  conditions.  
Myc-p110δ-overexpressing cells had a more spherical overall cell shape, which may be a 
consequence of the lack of F-actin stress fibres which determine the typical fibroblast cell 
morphology observed in pMX-neo-expressing NIH 3T3 cells (Figure 7.5a, b).  
 
In  some  cells  overexpressing  5‟Myc-p110δ,  punctate  F-actin  staining  was  observed 
(indicated by white arrowheads, Figure 7.5a), which were not linked to the cytoskeleton by 
F-actin fibres.  F-actin puncta staining colocalized with P-paxillin staining, indicating that 
the  F-actin  puncta  are  associated  with  points  of  contact  of  the  cell  to  the  underlying 
substrate.  This type of staining is typical for podosomes or invadopodia (Linder, 2007), 
suggesting that 5‟ Myc-p110δ-overexpressing cells may be more invasive, compared to 
pMX-neo-expressing cells (discussed in more detail in section 7.5.6). 
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Figure  7.5:  The  cell  cytoskeleton  of  NIH  3T3  cells  stably  expressing  pMX-neo  or 
5’Myc-p110δ  under  serum-starvation  conditions.  (a)  Cells  were  seeded  in  media 
containing 10% FBS on glass coverslips in a 12-well plate.  Cells were left to adhere for 6 h 
before the media was replaced with media without FBS.  The following day cells were 
fixed  and  stained  for  F-actin  (phalloidin),  adherens  junctions  (N-cadherin)  and  focal 
adhesions  (P-paxillin).  White  arrowheads  indicate  punctate  F-actin  staining  in  5‟Myc-
p110δ-overexpressing cells. Images are shown for 60 x magnifications. Scale bar = 10 μM.  
(b) Z-stack slices of pMX-neo control-infected and 5‟Myc-p110δ-overexpressing NIH 3T3 
cells  under  serum-starvation  conditions.  Z-stack  slices  taken  at  0.5  micron  intervals, 
starting at the cell substrate (slice 1) and proceeding up to the top of the cell (slice 5). Scale 
bar = 10 μM. 
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Cross section images of control and 5‟Myc-p110δ-overexpressing cells taken at intervals of 
0.5  microns  (Z-stack  slices)  revealed  further  differences  in  the  structure  of  the  actin 
cytoskeleton (Figure 7.5b).  In pMX-neo-expressing cells, actin stress fibres were observed 
to run along the cell periphery and across the cell cytoplasm in all of the Z-stack slices.  In 
contrast, in 5‟Myc-p110δ-overexpressing cells, long bundles of F-actin fibres were only 
observed at the cell periphery.  Surrounding and appearing to cover the nucleus, short F-
actin fibres were observed.  In addition, the first Z-stack slice (the cross section of the cell 
taken at the level of cell contact with the underlying substrate) indicated that 5‟Myc-p110δ-
overexpressing cells have an increased number of cell contacts with the substrate as shown 
by P-paxillin staining. 
 
7.3.2 The p110δ-specific inhibitor, IC87114, partially reverses the altered cytoskeletal 
phenotype observed in NIH 3T3 cells overexpressing 5’Myc-p110δ, but only under 
serum-starvation conditions  
To investigate whether the cytoskeletal changes observed in 5‟Myc-p110δ-overexpressing 
cells could be attributed to increased p110δ lipid kinase activity, cells were treated with the 
p110δ-specific  inhibitor  IC87114  either  in  the  presence  of  serum  or  under  starvation 
conditions.  IC87114 treatment of NIH 3T3 cells stably expressing pMX-neo or 5‟Myc-
p110δ in the presence of serum induced a surprising result.  For pMX-neo-expressing cells, 
inhibition of p110δ caused the cells to form distinct cell clusters (Figure 7.6).  For 5‟Myc-
p110δ overexpressing cells, IC87114 treatment had a greater impact, causing the cells to 
form long „string-like‟ clusters.  This cluster formation could be mediated by longitudinal 
contraction of the cell, or by cell detachment from the substrate with cell-cell junctions 
remaining (indicated by N-cadherin staining of adherens junctions).  It is remarkable that 
IC87114 treatment had an impact on pMX-neo-expressing cells, since these cells express 
particularly low levels of p110δ protein expression.    These results are difficult to interpret, 
far from  reversing the cytoskeletal phenotype observed in 5‟Myc-p110δ overexpressing 
cells to that resembling pMX-neo-expressing cells, IC87114 treatment in the presence of 
serum actually exacerbates the difference between the cell lines.     
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Figure  7.6:  Effect  of  IC87114  on  the  cell  cytoskeleton  of  NIH  3T3  cells  stably 
expressing  pMX-neo  or  5’Myc-p110δ  in  10%  serum.    Cells  were  seeded  in  media 
containing 10%  FBS on glass coverslips in  a  12-well plate.  Cells  were left  to  adhere 
overnight.  The following day cells were treated with DMSO or 5 μM IC87114 for 1 h 
before fixation and staining for F-actin (phalloidin), adherens junctions (N-cadherin) and 
focal adhesions (P-paxillin). The white dashed elliptical lines enclose discrete cell clusters.  
Scale bar = 10 μM.  
 
Surprisingly, under serum-starvation conditions, IC87114 did not induce cell clustering as 
observed  in  cell  treatment  in  the  presence  of  serum  (Figure  7.7a).    In  fact,  IC87114 
treatment seemed to, at least to some extent, alter the overall cell morphology of 5‟Myc-
p110δ overexpressing cells so that it more closely resembled that of pMX-neo-expressing 
cells.  More specifically, the overall cell adherence area of 5‟Myc-p110δ overexpressing 
cells  seemed  to  be  reduced  (Figure  7.7a)  and  on  closer  inspection,  IC87114  treatment Chapter 7 
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induced the formation of F-actin stress fibres in 5‟Myc-p110δ overexpressing cells to levels 
comparable with pMX-neo-expressing cells (Figure 7.7b). 
 
 
 
Figure  7.7:  Effect  of  IC87114  on  the  cell  cytoskeleton  of  NIH  3T3  cells  stably 
expressing pMX-neo or 5’Myc-p110δ in the absence of serum.  (a) 40x magnification: 
Cells were seeded in media containing 10% FBS on glass coverslips in a 12-well plate and 
left to adhere for 6 h.  After this time, media was replaced with media without serum and 
cells  were  left  overnight.    The  following  day  cells  were  treated  with  DMSO  or  5  μM 
IC87114 for 1 h before fixation and staining for F-actin (phalloidin), adherens junctions (N-
cadherin) and focal adhesions (P-paxillin). Scale bar = 10 μM.  
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Figure  7.7:  Effect  of  IC87114  on  the  cell  cytoskeleton  of  NIH  3T3  cells  stably 
expressing pMX-neo or 5’Myc-p110δ in the absence of serum. (b) 60x magnification: 
NIH 3T3 cells stably expressing pMX-neo or 5‟Myc-p110δ treated with IC87114 in the 
absence of serum. Confocal images of cells fixed and stained for F-actin (phalloidin). Scale 
bar = 10 μM.  
 
 
To correlate the phenotype observed for IC87114 treatment of control infected cells and 
5‟Myc-p110δ-overexpressing with the level of Akt phosphorylation (indirectly assessing 
the lipid kinase activity of p110δ), cell lysates were taken after IC87114 treatment of cells 
in the presence of serum or under starvation conditions. 5‟Myc-p110δ-overexpressing cells 
were found to have higher basal levels of phosphorylated Akt in both serum and starvation 
conditions compared to pMX-neo-expressing cells (Figure 7.8).  Although in the absence of 
serum 5‟Myc-p110δ-overexpressing cells only expressed low levels of phosphorylated Akt, 
in control infected cells phosphorylated Akt was undetectable.  In the presence of serum the 
difference in Akt phosphorylation levels between the cell lines was more evident, with 
5‟Myc-p110δ-overexpressing  cells  expressing  around  12-fold  more  phosphorylated  Akt 
compared to pMX-neo-expressing cells (Figure 7.8). 
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Figure 7.8: Levels of Akt phosphorylation in NIH 3T3 cells stably expressing pMX-
neo or 5’Myc-p110δ.  Cells were seeded in media containing 10% FBS and left to adhere 
for 6 h.  After this time, media was replaced with media without serum for the samples 
indicated.  The following day cells were treated with DMSO or 5 μM IC87114 for 1 h.  Cell 
lysates were separated by SDS-PAGE and immunoblotting for P-Akt, total Akt and p110δ. 
 
 
IC87114 treatment completely abrogated out all phosphorylation of Akt in 5‟Myc-p110δ-
overexpressing cells in both serum and starvation conditions, whereas IC87114 treatment of 
pMX-neo-expressing cells reduced but did not completely abrogate Akt phosphorylation in 
the presence of serum.  This result corroborates the data indicating that p110δ has become 
the  principle  p110  isoform  in  5‟Myc-p110δ-overexpressing  cells  resulting  from 
downregulation of p110ʱ and p110β isoform expression (Figure 7.2), whereas in pMX-neo-
expressing cells p110ʱ and p110β expression remains high, allowing possibly some basal 
PI3K signalling. 
 
Since IC87114 treatment completely abrogates, what was previously a high level of basal 
Akt phosphorylation, in 5‟Myc-p110δ-overexpressing cells in serum, this could perhaps 
account  for  the  dramatic  change  in  cell  morphology  observed  under  these  conditions.  Chapter 7 
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Whereas  in  the  absence  of  serum,  the  level  of  Akt  phosphorylation  in  5‟Myc-p110δ-
overexpressing  cells  is  relatively  low,  indicating  low  basal  p110δ  activity,  therefore 
inhibition of p110δ is likely to result in a more subtle change in cell morphology.   
 
7.3.3 NIH 3T3 cells stably overexpressing 5’Myc-p110δ adhere to an increased surface 
area in normal culture conditions compared to control-infected cells 
It was observed from the confocal images that 5‟Myc-p110δ-overexpressing cells appear to 
spread out and adhere to a greater surface area compared to pMX-neo-expressing cells 
(Figure 7.3, 7.5).  To formally prove this, using confocal images and the computer software 
Image J the cell area was calculated by manually drawing around individual cells and using 
Image J to calculate the enclosed area.  Indeed, 5‟Myc-p110δ-overexpressing cells were 
found  to  spread  over  a  significantly  increased  surface  area  compared  to  pMX-neo-
expressing cells in the presence or absence of serum (Figure 7.9a, b).  There was a great 
deal of variability in cell area in 5‟Myc-p110δ-overexpressing cells, which can be seen 
from  the  outlying  values  indicated  in  the  box  whisker  plot.    The  high  degree  of 
heterogeneity in cell surface area may be as a result of pooling cells stably overexpressing 
5‟Myc-p110δ  rather  than  expansion  of  a  single  clone,  as  individual  cells  amongst  the 
independent  transfectants  are  likely  to  express  various  levels  of  5‟Myc-p110δ 
overexpression. 
 
7.3.4 IC87114 treatment in the absence of serum reduces cell adherence area of NIH 
3T3 cells stably overexpressing 5’Myc-p110δ  
To assess if IC87114 treatment of NIH 3T3 cells stably expressing 5‟Myc-p110δ could 
reduce cell adherence area, confocal images and Image J were again used to calculate cell 
area.  Since IC87114 treatment of cells in the presence of serum induced cell clustering 
(Figure  7.6),  quantification  of  cell  area  of  individual  cells  was  not  possible,  therefore 
quantification of cell area was carried out on cells treated with IC87114 under starvation 
conditions.  IC87114 treatment of NIH 3T3 cells stably expressing 5‟Myc-p110δ under 
starvation conditions resulted in a reduction of cell adherence area to a level comparable 
with pMX-neo-expressing cells (Figure 7.9b).  These data indicate that p110δ lipid kinase 
activity (at least under starvation conditions) mediates the increased cell adherence area 
observed in 5‟Myc-p110δ-overexpressing NIH 3T3 cells. Chapter 7 
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Figure 7.9: Cell area of NIH 3T3 cells stably expressing pMX-neo or 5’Myc-p110δ. 
Cell area was calculated from confocal images of cells stained for F-actin using Image J 
software. (a) Cell area in the presence of serum: Cells were seeded in media containing 
10% FBS and left to adhere overnight.  The following day cells were fixed and stained for 
F-actin. (b) Cell area under starvation conditions: Cells were seeded in media containing 
10% FBS and left  to  adhere for 6 h.  After this  time  media  was  replaced with  media 
containing 0% FBS and cells were left overnight.  The following day, cells were treated 
with 5 μM IC87114 or DMSO vehicle control for 1 h after which cells were fixed and 
stained  for  F-actin.  Median,  quartiles  and  highest  lowest  values  are  indicated  on  box 
whisker plots.  ** indicates P < 0.01 using the Mann-Whitney U-test, n > 75. 
 
7.3.5  NIH  3T3  cells  stably  overexpressing  5’Myc-p110δ  adhere  and  spread  more 
quickly on a variety of substrates compared to pMX-neo-expressing cells 
To investigate how 5‟Myc-p110δ overexpression affects cell adhesion, cells were detached 
and seeded onto glass coverslips.  Fixing and staining of cells after 30 min or 1 h, revealed 
that 5‟Myc-p110δ-overexpressing cells display a different cell morphology at both time Chapter 7 
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points compared to pMX-neo-expressing cells (Figure 7.10).  30 min after seeding, pMX-
neo-expressing cells exhibited multiple filopodia protrusions relatively evenly distributed 
around the cell periphery, whereas 5‟Myc-p110δ-overexpressing cells appeared to form less 
overall  filopodia  protrusions,  and  the  filopodia present  were  dispersed  more  irregularly 
around the cell periphery.  Furthermore, 5‟Myc-p110δ-overexpressing cells appeared to 
spread and adhere to larger surface area on the glass cover slip.  1 h after seeding the cells, 
there was no longer an obvious difference in cell adhesion area between the  cell lines, 
however  5‟Myc-p110δ-overexpressing  cells  displayed  increased  membrane  ruffling 
compared  to  control  infected  cells  and  again  displayed  less  filopodia  protrusions  but 
broader lamellipodia-like extensions. 
 
 
Figure 7.10: Cell adhesion of NIH 3T3 cells stably expressing pMX-neo or 5’Myc-
p110δ onto glass coverslips.  NIH 3T3 cells stably expressing either pMX-neo control 
vector or 5‟Myc-p110δ were starved for 12 h, detached using trypsin and treated with either 
5 μM IC87114 or vehicle control (DMSO).  Cells were left to adhere onto glass coverslips 
in  the  absence  of  serum  for  the  indicated  times  before  fixation  with  4%  PFA.  
Permeabilised cells were stained with phalloidin (F-actin) and DAPI (DNA). Scale bar = 10 
μM.  
 
 
Treatment of cells with IC87114, reduced cell spreading of 5‟Myc-p110δ-overexpressing 
cells at both 30 min and 1 h after seeding the cells, whereas in pMX-neo-expressing cells 
IC87114 treatment seemed to have little effect on cell spreading, although organisation of 
filopodia  protrusions  was  affected  (Figure  7.10).    This  suggests  that  in  5‟Myc-p110δ-
overexpressing cells, p110δ is playing an essential role in cell adherence and cell spreading, 
whereas in control infected cells p110δ appears to not have such an essential role although 
it does appear to be involved in organisation of filopodia extensions.  Chapter 7 
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To investigate cell adherence on different substrates, glass coverslips were coated with 
either fibronectin or gelatin and cells, which had been starved of serum overnight, were left 
to adhere for 30 min, 2 h or 6 h in media without serum.  At each time point, 5‟Myc-p110δ-
overexpressing cells appeared to spread over an increased surface area compared to pMX-
neo-expressing  cells  (Figure  7.11).    Quantification  of  cell  area  revealed  a  significant 
difference  between  5‟Myc-p110δ-overexpressing  cells  and  pMX-neo-expressing  cells  at 
every time point and on both substrates (Figure 7.12).   
 
30  min  after  seeding  the  cells,  5‟Myc-p110δ-overexpressing  cells  displayed  broad 
lamellipodia protrusions compared to the slender filopodia protrusion observed in pMX-
neo-expressing cells on both fibronectin and gelatin.  At 2 h and 6 h after seeding, 5‟Myc-
p110δ-overexpressing cells also displayed mutiple filopodia protrusions similar to pMX-
neo-expressing cells.  These data suggest that initiation of cell adherence and cell spreading 
is largely dependent on Rac activity in 5‟Myc-p110δ-overexpressing cells indicated by the 
presence of lamellipodia (Kozma, et al., 1995; Ridley, et al., 1992).  At later time points, 
Cdc42 appears to play a role in cell adhesion, indicated by the presence of filopodia.  In 
contrast, in pMX-neo-expressing cells, initial cell spreading appears to be mediated largely 
by Cdc42 activity, indicated by the presence of multiple filopodia extensions at the early 
time point of cell-fixation (Kozma, et al., 1999).   
 
Overall, the data indicate that p110δ plays a role in cell adhesion and spreading on a variety 
of  substrates  and  is  likely  to  mediate  this  function  through  activation  of  small  Rho 
GTPases, specifically Rac. 
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Figure 7.11: Cell adhesion and cell spreading of NIH 3T3 cells stably expressing pMX-
neo or 5’Myc-p110δ on fibronectin- or gelatin-coated coverslips.  NIH 3T3 cells stably 
expressing either pMX-neo control vector or 5‟Myc-p110δ were starved for 12 h, detached 
using trypsin and seeded on (a) fibronectin- or (b) gelatin-coated coverslips in the absence 
of serum.  After the indicated times, cells were fixed with 4% PFA.  Permeabilised cells 
were stained with phalloidin (F-actin), DAPI (DNA) and vincullin. Arow heads indicate 
broad lamellipodia and asterisks indicate slender filopodia protrusions. Scale bar = 10 μM.  
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Figure 7.12: Quantification of cell spreading of NIH 3T3 cells stably expressing pMX-
neo  or  5’Myc-p110δ  on  fibronectin  or  gelatin-coated  coverslips.  Cell  area  was 
calculated from confocal images of cells adhering to (a) fibronectin- or (b) gelatin-coated 
coverslips,  using  Image  J  software.  Median,  quartiles  and  highest  lowest  values  are 
indicated on box whisker plots. * indicates  P<0.1 and ** indicates P < 0.01 using the 
Mann-Whitney U-test, n > 75. 
 
7.3.6  p110δ  may  play  a  role  in  mediating  cell-cell  junction  formation  and  in  the 
formation of focal adhesions  
Adherens junctions are calcium-dependent cell–cell contacts that link neighbouring cells 
through cadherin receptors. The formation of cell junctions requires regulation of the actin 
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cytoskeleton by Rho GTPases.  In epithelial cells, Rac activation promotes E-cadherin-
mediated cell-cell adhesion (Hordijk, et al., 1997; Sander, et al., 1998).  In fibroblasts Rac 
activation  has  also  been  shown  to  induce  an  epithelial-like  morphology  through  the 
formation  of  adherens  junctions  mediated  by  N-  and  P-cadherin  (as  these  cells  do  not 
express E-cadherin) (Reynolds, et al., 1996; Sander, et al., 1999).  In cells that had been 
starved overnight, N-cadherin was found to localize at points of cell-cell contact in both 
pMX-neo-expressing  and  5‟Myc-p110δ-overexpressing  cells.    A  possible  increased  N-
cadherin staining in 5‟Myc-p110δ-overexpressing cells compared to pMX-neo-expressing 
cells was observed, although this was not an obvious difference and would be difficult to 
quantify  (Figure  7.13).      Upon  PDGF  stimulation,  increased  N-cadherin  staining  was 
observed  for both  pMX-neo-expressing  and 5‟Myc-p110δ-overexpressing  cells,  with  no 
obvious difference between the cell lines, although some kind of quantification would need 
to be carried out to formally prove this (Figure 7.13).  These results indicate that p110δ 
may possibly play a role in adherens junction formation under serum-starvation conditions, 
although this is not a major role.  Likewise, overexpression of p110δ does not affect PDGF-
induced N-cadherin expression and adherens junction formation. 
 
PDGF  stimulation  induced  focal  adhesions  in  pMX-neo-expressing  and  5‟Myc-p110δ-
overexpressing NIH 3T3 cells (Figure 7.13).  As observed previously (Figures 7.4,7.5),  
5‟Myc-p110δ-overexpressing cells appeared to have an increased number of sites of focal 
contact with the underlying substrate than pMX-neo-expressing cells, in both starved and 
PDGF-stimulated conditions, suggesting p110δ has a role in mediating focal contacts. 
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Figure 7.13: Cell-cell junction formation in NIH 3T3 cells stably expressing pMX-neo 
or 5’Myc-p110δ. NIH 3T3 cells stably expressing either pMX-neo or 5‟Myc-p110δ were 
seeded on glass coverslips and starved for 12 h.  Cells were stimulated with 50 ng/ml 
PDGF for 7 min before fixation with 4% PFA.  Permeabilised cells were stained with 
phalloidin (F-actin) P-paxillin (focal adhesions) and N-cadherin (adherens junctions). Scale 
bar = 10 μM. 
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7.4  NIH  3T3  cells  stably  overexpressing  5’Myc-p110δ  have  altered  Rho  GTPase 
activity compared to control-infected cells 
The data presented clearly show that 5‟Myc-p110δ-overexpressing cells display an altered 
actin cytoskeleton and overall cell morphology compared to pMX-neo-expressing cells and 
this morphology differs depending on whether cells are in the presence of serum or under 
serum-starvation conditions.  As central regulators of the cell cytoskeleton, the activities of 
the three best characterised Rho GTPases; RhoA, Rac1 and Cdc42, were investigated in 
these cells, by performing pull downs of the GTP-loaded Rho GTPase (Figure 7.14).  The 
effect of p110δ inhibition, the effect of serum-starvation and the effect of acute serum-
stimulation on Rho GTPase activity was analysed. The activity of RhoA, Rac1 and Cdc42 
was determined.  These results are described below and summarised in Table 8.1 on page 
261. 
 
7.4.1 p110δ appears to be both a positive and negative regulator of RhoA activity in 
the presence of serum in NIH 3T3 cells stably overexpressing 5’Myc-p110δ 
The basal level of active RhoA in the presence of serum was found to be approximately 5-
fold higher in 5‟Myc-p110δ-overexpressing cells compared to pMX-neo-expressing cells 
(Figure 7.15a).  This was an unexpected finding since p110δ has previously been found to 
be  a  negative  regulator  of  RhoA  activity  in  macrophages  (Papakonstanti,  et  al.,  2007), 
overexpression of p110δ was  therefore  expected to  result in  a decrease in  basal  RhoA 
activity.  This result indicates that p110δ may be positively regulating basal RhoA activity 
in the presence of serum, in NIH 3T3 cells.   
 
In  agreement  with  previous  findings,  inhibition  of  p110δ  activity  (through  IC87114 
treatment) increased the level of GTP-loaded RhoA in 5‟Myc-p110δ overexpressing cells 
by approximately 2-fold, indicating that p110δ is indeed having some role in negatively 
regulating  RhoA  activity.    The  tendency  of  5‟Myc-p110δ-overexpressing  cells  to  have 
increased  basal  RhoA-GTP  in  serum  compared  to  pMX-neo-expressing  cells,  which  is 
further increased upon p110δ inhibition, was highly reproducible illustrated in two further 
independent experiments (Figures 7.16a, b).   
 
Although  pMX-neo-expressing  NIH  3T3  express  little  endogenous  p110δ,  IC87114 
treatment also increased RhoA activity by approximately 2-fold, suggesting that even low 
levels of p110δ expression is sufficient to negatively regulate basal RhoA activity (Figure 
7.15a).   Chapter 7 
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In the absence of serum, 5‟Myc-p110δ overexpressing cells expressed higher basal RhoA 
activity compared to pMX-neo-expressing cells, although this increase is substantially less 
than the increase observed in the presence of serum (Figure 7.15a).  This suggests, that 
under starvation conditions alternative signalling pathways are operating compared to in the 
presence of serum, in which p110δ does not exert such a marked positive effect on RhoA 
activation.  This inference is corroborated by the finding that IC87114 treatment of both 
pMX-neo-expressing and 5‟Myc-p110δ  overexpressing cells  under starvation conditions 
had  only  a  slight  increase  on  RhoA  activity  compared  to  the  increase  observed  in  the 
presence of serum. 
 
 
Figure 7.14: Effect of p110δ inhibition on Rho GTPase activity under basal growing, 
serum-starvation or serum-stimulated conditions in NIH 3T3 cells stably expressing 
pMX-neo  or  5’Myc-p110δ.  pMX-neo  control  infected  or  5‟Myc-p110δ-overexpressing 
cells were seeded either in media containing 10% serum or media without serum and left 
overnight.  The following day cells were treated with 5 μM IC87114 or vehicle control for 
1 h. Basal Rho GTPase activities were assessed under basal growing conditions (media 
containing 10% serum), serum-starvation conditions and serum-stimulated conditions.  For 
cell stimulations, cells that had been starved overnight were stimulated for 5 min with 10% 
FBS.  For each condition, equal volumes of cell lysates of pMX-neo control infected or 
5‟Myc-p110δ-overexpressing cells were subjected to a pull down assay with GST-RBD 
(RhoA-GTP)  or  GST-PBD  (Rac1-GTP  and  Cdc42-GTP),  followed  by  detection  of 
precipitated  Rho  GTPases  by  western  blot.    Equal  volumes  of  total  cell  lysates  were 
resolved on a separate SDS-PAGE gel to blot for total levels of RhoA, Rac1 or Cdc42. 
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Figure 7.15: Quantification of RhoA, Rac1 and Cdc42 activity under basal growing, 
serum-starvation or stimulated conditions in NIH 3T3 cells stably expressing pMX-
neo  or  5’Myc-p110δ.    Levels  of  GTP-bound  (a)  RhoA,  (b)  Rac1  or  (c)  Cdc42  were 
normalized against the total levels of each Rho GTPase and expressed as a fold-increase of 
pMX-neo control infected cells under serum-starvation conditions. 
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Figure 7.16: Effect of p110δ inhibition on Rho GTPase activity in the presence of 
serum or under serum-starvation conditions in pMX-neo control infected and 5’Myc-
p110δ-overexpressing cells.  (a) The RAW 264.7 macrophage cell line, pMX-neo control 
infected or 5‟Myc-p110δ-overexpressing cells seeded in media containing 10% serum were 
treated with 5 μM IC87114 or vehicle control for 1 h. Equal volumes of cell lysates were 
subjected to a pull down assay with GST-RBD followed by detection of precipitated RhoA 
by western blot.  Equal volumes of total cell lysates were resolved on a separate SDS-
PAGE gel to blot for total levels of RhoA. (b) Repeat of experiment described in part a) 
without  RAW  264.7  macrophage  cell  line  as  appositive  control  for  RhoA  activity.  (c) 
pMX-neo  control  infected  or  5‟Myc-p110δ-overexpressing  cells  were  seeded  either  in 
media containing 10% serum or media without serum and left overnight.  The following 
day cells were treated with5 μM IC87114 or vehicle control for 1 h. Equal volumes of cell 
lysates  were  subjected  to  a  pull  down  assay  with  GST-PBD  followed  by  detection  of 
precipitated Rac1 by western blot.  Equal volumes of total cell lysates were resolved on a 
separate SDS-PAGE gel to blot for total levels of Rac1. 
 
7.4.2 p110δ is not essential for acute serum-induced RhoA activation in NIH 3T3 cells 
Interestingly,  IC87114  treatment  of  both  pMX-neo-expressing  and  5‟Myc-p110δ-
overexpressing cells prior to serum-stimulation, did not enhance RhoA activity compared to 
DMSO-treated cells (Figure 7.15a).  Serum stimulation induced a significant increase in 
RhoA  activity  in  both  pMX-neo-expressing  and  5‟Myc-p110δ-overexpressing  cells 
compared to the level of GTP-bound RhoA under basal starvation conditions.  In fact, 
serum-stimulation of pMX-neo-expressing cells resulted in higher RhoA-GTP levels than 
5‟Myc-p110δ  overexpressing  cells.    These  data  demonstrate  that  RhoA  activity  can  be 
rapidly and transiently increased upon addition of serum and that this response does not 
appear to be dependent upon p110δ lipid kinase activity. 
RhoA-GTP
Total RhoA
Rac1-GTP
Total Rac1
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7.4.3  p110δ  appears  to  be  a  positive  regulator  of  Rac1  under  serum-starvation 
conditions in NIH 3T3 cells stably expressing pMX-neo or 5’Myc-p110δ 
It has been shown that in some cellular contexts, Rac1 negatively regulates RhoA activity, 
given that low levels of Rac1 activity correlate with high levels of RhoA activity (Sander, 
et al., 1999).   In contrast, it has been suggested that RhoA activity does not have an effect 
on  Rac1  activity,  suggesting  unidirectional  signalling  from  Rac  to  Rho  (Sander,  et  al., 
1999).    Taking  this  into  consideration,  one  would  speculate  that  in  5‟Myc-p110δ-
overexpressing  cells  under  starvation  conditions,  where  RhoA  activity  is  reduced  in 
comparison to serum conditions, Rac1 activity would be higher than that observed in the 
presence of serum.   Indeed, Rac1 activity was reduced in 5‟Myc-p110δ-overexpressing 
cells in the presence of serum conditions compared to pMX-neo-expressing cells and this 
increased  substantially  in  serum-starved  in  5‟Myc-p110δ-overexpressing  cells  (Figure 
7.15b). 
 
IC87114 treatment of 5‟Myc-p110δ-overexpressing cells appeared to have opposing effects 
on Rac1 activity depending on whether cells were treated in the presence or absence of 
serum.  In the presence of serum, IC87114 treatment induced a 2-fold increase in Rac1 
activity, suggesting p110δ is negatively regulating Rac1.  However, under serum-starvation 
conditions,  IC87114  treatment  reduced  Rac1  activity,  suggesting  p110δ  is  positively 
regulating  Rac1  under  these  conditions  (Figure  7.15b).      In  pMX-neo-expressing  cells, 
IC87114 treatment reduced Rac1 activity in both serum and starvation conditions, although 
the observed decrease in Rac1 activity was more apparent in the absence of serum. 
 
The reproducibility of p110δ-dependent activity of Rac1 in 5‟Myc-p110δ-overexpressing 
cells depending on the presence of serum is illustrated in a second independent experiment 
(Figure 7.16c).  Overall these data suggest that in NIH 3T3 cells stably overexpressing 
5‟Myc-p110δ, p110δ may be positively regulating Rac1 activity under serum-starvation 
conditions, which opposes high levels of RhoA activity.  In the presence of serum however, 
p110δ may be negatively regulating Rac1 activity, which allows for high RhoA activity 
induced by components of serum.   
 
7.4.4 Acute stimulation with serum does not induce Rac1 activity in NIH 3T3 cells 
stably expressing pMX-neo or 5’Myc-p110δ 
Unlike the induction of RhoA activity by serum, serum-stimulation of pMX-neo-expressing 
or  5‟Myc-p110δ-overexpressing  NIH  3T3  cells  did  not  increase  Rac1  activity.  This Chapter 7 
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suggests that the components of serum that stimulate RhoA activity do not activate Rac1 
and  are  unaffected  by  p110δ  overexpression  (Figure  7.15b).    Interestingly,  IC87114 
treatment prior to serum stimulation reduced Rac1 activity in 5‟Myc-p110δ-overexpressing 
cells, but had little effect on pMX-neo-expressing cells.  This corroborates the finding that 
in 5‟Myc-p110δ-overexpressing cells, p110δ is positively regulating Rac1 in the absence of 
serum (Figure 7.15b). 
 
7.4.5 p110δ may positively regulate Cdc42 under serum-starvation conditions in NIH 
3T3 cells stably overexpressing 5’Myc-p110δ 
Activation of Cdc42 has been implicated in the downregulation of RhoA activity (Sander, 
et al., 1999).  In general, Cdc42 activity under serum versus serum-starvation conditions 
followed a similar pattern to Rac1 activity.  In 5‟Myc-p110δ-overexpressing cells, Cdc42 
activity was higher under serum-starvation conditions compared to in the presence of serum 
and this was not further increased upon serum-stimulation.  IC87114 treatment increased 
Cdc42 activity in 5‟Myc-p110δ-overexpressing cells in the presence of serum but reduced it 
slightly under serum-starvation conditions.  The main difference between Cdc42 and Rac1 
activation in 5‟Myc-p110δ-overexpressing cells is that after quantification, overall Cdc42 
activity appears to be lower in 5‟Myc-p110δ-overexpressing cells compared to pMX-neo-
expressing cells.  This is largely due to the fact that the level of total Cdc42 is noticeably 
higher in 5‟Myc-p110δ-overexpressing cells compared to pMX-neo-expressing cells. 
 
7.4.6  Increased  RhoA  activity  in  NIH  3T3  cells  expressing  5’Myc-p110δ  does  not 
appear to be due to decreased p190RhoGAP activity 
NIH 3T3 cells-overexpressing 5‟Myc-p110δ have been shown to have high levels of GTP-
bound RhoA in normal growing conditions (in the presence of 10% serum).  The activity of 
RhoA can be regulated by a number of GEFs and GAPs, such as p190RhoGAP.  It was 
hypothesized that an increase in RhoA activity may result from a decrease in p190RhoGAP 
activity, which would inhibit RhoA inactivation by preventing hydrolysis of GTP to GDP.   
The activity of p190RhoGAP was examined by assessing the level of its phosphorylation 
on tyrosine residues, which has been shown to correlate with its activity (Zrihan-Licht, et 
al., 2000).  5‟Myc-p110δ-overexpressing cells growing in 10% serum were found to have a 
slight decrease in active p190RhoGAP (Figure 7.17).   
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Figure 7.17: Effect of p110δ  inhibition on p190RhoGAP activity in NIH  3T3  cells 
stably expressing pMX-neo or 5’Myc-p110δ.    pMX-neo  control infected and 5‟Myc-
p110δ-overexpressing cells were seeded in media containing 10% serum and left to adhere 
overnight.  The following day cells were treated with 5 μM IC87114 or vehicle control for 
1  h.  Cell  lysates  were  subjected  to  an  immunoprecipitation  with  an  anti  p190RhoGAP 
antibody.    Immunoprecipitates  were  separated  by  SDS-PAGE  and  immunoblotted  for 
phospho-tyrosine or p190RhoGAP.  Total cell lysates were resolved on a separate SDS-
PAGE gel and immunoblotted for P-Akt. 
 
Inhibition of p110δ with IC87114 further decreased p190RhoGAP activity, in both pMX-
neo-expressing and 5‟Myc-p110δ-overexpressing cells to the same extent (Figure 7.17).  
The  finding  that  IC87114  reduces  p190RhoGAP  activity  corroborates  the  finding  that 
macrophages  isolated  from  mice  with  homozygous  gene  inactivation  of  p110δ  have 
reduced  p190RhoGAP  activity  under  basal  and  CSF-1-stimulated  conditions 
(Papakonstanti, et al., 2007).  However, it is surprising that IC87114 treatment of pMX-
neo-expressing cells resulted in such a noticeable decrease in p190RhoGAP activity, since 
these cells express little endogenous p110δ.  In spite of this, these results suggest that the 
increase  in  RhoA  activity  observed  after  treatment  with  IC87114  for  both  control  and 
5‟Myc-p110δ-overexpressing cells in media containing serum is in part due to the decrease 
in p190RhoGAP activity.  These results also imply that in 5‟Myc-p110δ-overexpressing 
cells, p110δ does not regulate the basal activity of RhoA through p190RhoGAP alone.   
 
 
7.4.7 Inhibition of Rho or Rac activity alters cell morphology in NIH 3T3 cells stably 
expressing pMX-neo or 5’Myc-p110δ 
Cell  adhesion  and  spreading:  Increased  RhoA  activity  is  associated  with  a  contractile 
phenotype.  5‟Myc-p110δ-overexpressing cells were shown to have increased basal RhoA, 
particularly in the presence of serum, compared to pMX-neo-expressing cells and yet they 
also displayed an increased cell adherence area (Figure 7.9) and increased cell spreading in 
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adherence assays (Figures 7.10, 7.12).  The increased cell spreading in the adhesion assays 
is most likely a result of increased Rac1 activity, rather than increased RhoA activity, given 
that they were carried out under serum-starvation conditions, which correlated with high 
Rac1-GTP  levels  (Figure  7.15b).    To  assess  if  RhoA  activity  was  contributing  to  the 
increased cell spreading observed for 5‟Myc-p110δ-overexpressing cells, a cell adherence 
assay under serum-starvation conditions on glass coverslips was carried out with or without 
the ROCK inhibitor, Y-27632.   
 
Although increased cell spreading of 5‟Myc-p110δ-overexpressing cells on glass coverslips 
is  not  as  apparent  as  that  observed  on  fibronectin  or  gelatin  (Figure  7.12),  the  cells 
displayed increased membrane ruffling and less organized filopodia protrusions compared 
to control cells (Figure 7.18).  As observed previously (Figure 7.10), treatment of cells with 
IC87114,  reduced  cell  spreading  of  5‟Myc-p110δ-overexpressing  cells  and  membrane 
ruffling  at  both  30  min  and 1 h after seeding  the cells.    In pMX-neo-expressing cells, 
IC87114  treatment  had  little  effect  on  cell  spreading,  implying  that  in  5‟Myc-p110δ-
overexpressing  cells,  p110δ  is  playing  a  more  central  role  in  the  adhesion  process.    It 
appears that in 5‟Myc-p110δ-overexpressing cells p110δ is not acting through RhoA to 
mediate cell adhesion since inhibition of ROCK does not result in the same phenotype 
observed  after  IC87114  treatment.    Indeed,  inhibition  of  ROCK  results  in  a  similar 
phenotype in pMX-neo-expressing and 5‟Myc-p110δ-overexpressing cells, with both cell 
lines cells exhibiting numerous actin-rich cell processes typical of ROCK inhibition (Figure 
7.18).   
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Figure 7.18: Effect of IC87114 and Y-27632 on cell adhesion of NIH 3T3 cells stably 
expressing  pMX-neo  or  5’Myc-p110δ  on  glass  coverslips.  NIH  3T3  cells  stably 
expressing either pMX-neo control vector or 5‟Myc-p110δ were starved for 12 h, detached 
using trypsin and treated with either 5 μM IC87114 or vehicle control (DMSO) or 10 μM 
Y-27632.  Cells were left to adhere onto glass coverslips in the absence of serum for the 
indicated  times  before  fixation  with  4%  PFA.    Permeabilised  cells  were  stained  with 
phalloidin (F-actin) and DAPI (DNA). Scale bar = 10 μM.  
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Overall cell morphology on matrigel: To get an idea of the morphology of 5‟Myc-p110δ-
overexpressing  cells  on  a  three-dimensional  matrix,  images  were  taken  of  pMX-neo-
expressing cells and 5‟Myc-p110δ-overexpressing cells grown on matrigel 24 and 48 h 
after seeding.  
 
After 24 h, numerous pMX-neo-expressing cells displayed a rounded morphology, whereas 
5‟Myc-p110δ-overexpressing  cells  had  spread  over  the  matrigel  and  displayed  long 
membrane  protrusions,  indicating  that  5‟Myc-p110δ-overexpressing  cells  adhere  and 
spread more quickly than pMX-neo-expressing cells (Figure 7.19a).  Treatment of pMX-
neo-expressing cells with the small molecule Rac1 inhibitor, NSC23766, which binds the 
surface groove of Rac1 known to be critical for GEF specification (Desire, et al., 2005; 
Gao,  et  al.,  2004),  resulted  in  an  increase  in  the  number  of  cells  with  a    rounded 
morphology.    In  5‟Myc-p110δ-overexpressing  cells,  NSC23766  treatment  appeared  to 
prevent the formation of membrane protrusions and induced some cell rounding, although 
not to the same extent as pMX-neo-expressing cells (Figure 7.19a).  As observed in the 
adhesion  assay,  Y-27632  treatment  induced  the  formation  of  multiple  long  membrane 
protrusions in both pMX-neo-expressing cell and 5‟Myc-p110δ-overexpressing cells.   
 
After  48  h,  pMX-neo-expressing  cells  had  adhered  and  spread  more  over  the  matrigel 
compared to at 24 h.  5‟Myc-p110δ-overexpressing cells had a similar morphology to that 
observed at 24 h (Figure 7.19b).  Treatment of pMX-neo-expressing cells with NSC23766 
resulted in increased cell rounding, as observed 24 h after treatment, and also induced a 
degree of cell clustering.  Interestingly, 48 h after NSC23766 treatment of 5‟Myc-p110δ-
overexpressing cells, a striking change in cell morphology was observed.  Cells formed 
long  clusters,  with  an  appearance  not  dissimilar  from  that  observed  for  5‟Myc-p110δ-
overexpressing  cells  treated  with  IC87114  in  the  presence  of  serum  (Figure  7.6).    As 
observed  after  24  h  of  seeding  the  cells,  Y-27632  treatment  induced  the  formation  of 
multiple long membrane protrusions in both pMX-neo-expressing cells and 5‟Myc-p110δ-
overexpressing cells at 48 h after seeding.   
 
Collectively, these data indicate that 5‟Myc-p110δ-overexpressing cells are able to adhere 
and spread to and form their overall final cell morphology on matrigel more quickly than 
pMX-neo-expressing  cells.    5‟Myc-p110δ-overexpressing  cells  display  more  membrane 
protrusions,  possibly  a  tail  retraction  defect,  that  appears  to  mediated  by  Rac  activity, 
indicated by a reduction of membrane protrusions after 24 h of  Rac inhibition. However, Chapter 7 
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when  cells  are  more  confluent,  after  48  h  of  seeding  the  cells,  Rac  inhibition  induced 
„string-like‟  cell  clustering  in  5‟Myc-p110δ-overexpressing  cells,  which  may  be  due  to 
increased cell-cell contacts at this confluency.  Given that Rac inhibition induces a more 
striking phenotype in 5‟Myc-p110δ-overexpressing cells compared to pMX-neo-expressing 
cells, this suggests Rac activity has a more central role in this cell line. 
 
 
 
Figure 7.19: Morphology of NIH 3T3 cells stably expressing pMX-neo or 5’Myc-p110δ 
on  matrigel.  Cells  were  seeded  in  media  containing  10%  serum  on  matrigel.    20  μM 
NSC23766 or 10 μM of Y-27632 was added to the cell cuture media. Cell images were 
captured at (a) 24 h and (b) 48 h after seeding. 
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To assess the actin cytoskeleton of 5‟Myc-p110δ-overexpressing cells on matrigel, pMX-
neo-expressing cells and 5‟Myc-p110δ-overexpressing cells seeded on matrigel were fixed 
and  stained  with  Rhodamine-conjugated  phalloidin.    Compared  to  pMX-neo-expressing 
cells, 5‟Myc-p110δ-overexpressing cells displayed multiple lamellipodia protrusions and 
had an overall more irregular cell morphology (Figure 7.20).  This type of cell morphology 
is indicative of increased Rac activity, suggesting 5‟Myc-p110δ-overexpressing cells have 
increased Rac activity compared to pMX-neo-expressing cells. 
 
Figure  7.20:  Actin  cytoskeleton  of  NIH  3T3  cells  stably  expressing  pMX-neo  or 
5’Myc-p110δ on matrigel. The indicated cell lines were seeded on matrigel in 10% serum.  
48 h after seeding, cells were fixed and stained with Rhodamine-conjugated phalloidin. 
 
7.5 Discussion 
7.5.1  Overexpression  of  p110δ  in  NIH  3T3  cells  downregulates  p110ʱ  and  p110β 
expression 
A summary of the phenotypes observed in 5‟Myc-p110δ-overexpressing cells, which are 
discussion  in  the  following  sections,  can  be  found  in  Table  8.1  on  page  261.  Data 
presented in Chapter 6 indicated that overexpression of Gag-p110δ, Gag-p110δ-3‟CAAX 
and 5‟Myc-p110δ in NIH 3T3 cells resulted in reduction of p110ʱ expression to a level 
undetectable by immunoblotting.  Data presented in this chapter further corroborate the 
finding that in NIH 3T3 cells stably overexpressing p110δ, through transfection of 5‟Myc-
p110δ cDNA, endogenous p110ʱ expression is severely attenuated and in addition, p110β 
expression appeared to  be completely  abrogated.  These data indicate that the level  of 
p110δ expression regulates the protein expression of the other class IA PI3K isoforms.  
NIH  3T3  cells  have  extremely  low  endogenous  levels  of  p110γ  protein  expression, Chapter 7 
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therefore it is unlikely that downregulation of this isoform would have been detected in this 
cell  line,  although  it  was  not  investigated.    It  has  been  documented  previously  that 
overexpression one particular p110 isoform affects the expression levels of other isoforms 
that share the same regulatory subunit (Kang, et al., 2006).  In chicken embryo fibroblasts, 
the endogenous levels of p110ʱ are downregulated in cells overexpressing p110β or p110δ 
and  overexpression  of  p110δ  leads  to  reduced  endogenous  levels  of  p110ʱ  and  p110β 
expression (Kang, et al., 2006).   
 
There are also other examples in which high p110δ expression may be associated with low 
levels of p110ʱ, p110β and/or p110γ expression.  In four samples of primary human breast 
cancer tissue, which have high p110δ expression, three had low p110ʱ expression and one 
sample had low expression of both p110ʱ and p110β.  In normal breast tissue, which is also 
found  to  express  high  levels  of  p110δ,  p110ʱ  and  p110β  expression  remained  high 
(Sawyer, et al., 2003).   Analysis of p110 expression in leukaemic blast cells from patients 
with  acute myeloid leukaemia, has  revealed that p110δ is  detected at  consistently high 
levels  between  all  patients,  whereas  p110ʱ,  p110β  and  p110γ  expression  was  highly 
variable (Sujobert, et al., 2005).  Interestingly, in this study the leukaemic blast cell sample 
which had the highest detectable level of p110δ expression had undetectable p110ʱ and 
p110β  expression  and  extremely  low  p110γ  (Sujobert,  et  al.,  2005).    Similarly,  in  an 
independent investigation of PI3K isoform expression in leukaemic blast cells isolated from 
patients with acute myeloid leukaemia, p110δ expression was found to be consistently high 
in all samples in comparison to p110ʱ, p110β and p110γ expression, which was highly 
variable between patient samples (Billottet, et al., 2006).  These data suggest that in some 
transformed cells, which endogenously express high levels of p110δ, a downregulation in 
p110ʱ/p110β and/or p110γ expression can occur.  In these cells p110δ has become the 
principle  isoform  in  class  I  PI3K  signalling.    p110δ  has  been  shown  to  control  the 
directionality and, to a lesser extent, speed of migration in breast cancer cell lines (Sawyer, 
et al., 2003).  It would have been interesting to investigate the invasive and migratory 
capacity of samples of breast cancer cells and leukaemic blast cells which appear to only 
express p110δ in comparison to cells in which expression all class I PI3K isoforms remains.  
It is possible that p110δ mediates the downregulation of other class I PI3K isoform in these 
cells to gain an invasive/migratory advantage.  If this is the case, investigation into the 
mechanism by which downregulation of the other p110 isoforms occurs could offer novel 
therapeutic targets in breast cancer and acute myeloid leukaemia. 
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The  level  of  p85  expression  in  in  5‟Myc-p110δ-overexpressing  cells  appeared  largely 
unaltered.  There are strong indications that there is no excess monomeric p85 over p110 
subunits  (Geering,  et  al.,  2007b).    A  limiting  amount  of  p85  in  cells,  which  may 
preferentially  bind  the  exogenous  overexpressed  p110δ  subunits  in  5‟Myc-p110δ-
overexpressing  cells,  may  result  in  a  downregulation  of  the  other  endogenous  p110 
subunits.    Indeed,  in  other  studies  overexpression  of  p110  subunits  has  been  achieved 
without cotransfecting cDNAs for p85 and the exogenously expressed p110 subunits have 
been found to bind endogenous p85 (Auger, et al., 2000, Kang, et al., 2006, Link, et al., 
2005). 
 
The NIH 3T3 cell line I have created, which stably overexpresses 5‟Myc-p110δ, could be 
used to investigate the mechanism by which p110δ mediates downregulation of p110ʱ and 
p110β.    Downregulation  may  occur  at  the  level  of  transcription,  translation,  or  protein 
degradation.  Analysis of the mRNA expression of p110ʱ and p110β would help elucidate 
whether p110δ induces transcriptional repression of these isoforms, likewise treating cells 
with a proteasome inhibitor may determine whether p110δ mediates protein degradation of 
p110ʱ and p110β.  Acute inhibition of p110δ lipid kinase activity did not alter p110ʱ and 
p110β  protein  expression  in  5‟Myc-p110δ-overexpressing  NIH  3T3  cells  (Figure  7.2), 
however, it would be interesting to treat cells with the p110δ inhibitor for a longer time 
period to assess whether long-term p110δ inhibition restores p110ʱ and p110β expression.  
This  would  determine  whether  p110δ  lipid  kinase  activity  is  essential  for  the 
downregulation  of  p110ʱ  and  p110β.  Another  way  to  assess  whether  the  lipid  kinase 
activity of p110δ is required for the downregulation of p110ʱ and p110β expression is to 
stably express a kinase-dead p110δ in NIH 3T3 cells and determine the level of p110ʱ and 
p110β protein expression. 
 
Although the observation that p110δ overexpression leads to attenuated p110ʱ and p110β 
expression  is  interesting,  the  altered  PI3K  isoform  expression  in  NIH  3T3  stably 
overexpressing 5‟Myc-p110δ make it difficult to assign the phenotypes observed in these 
cells to p110δ overexpression or to p110ʱ and/or p110β downregulation.   
 
7.5.2 Serum-dependent activation of Rho GTPase signalling pathways 
We observed a clear difference in the actin-cytoskeleton and overall cell morphology of 
5‟Myc-p110δ-overexpressing  NIH  3T3  cells  depending  on  whether  cells  were  in  10% 
serum or whether cells had been starved of serum overnight.  Given that cell morphology is 
highly dependent on the relative activities of Rho GTPases, this difference is likely to be a Chapter 7 
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direct reflection of the differential activities of RhoA and Rac1, described below, which 
result from both p110δ overexpression and p110β downregulation.  The composition of 
serum is quite variable, containing numerous growth factors, such as IGF-1 and PDGF, and 
antibodies.  However, an important active constituent of serum is lysophosphatidic acid 
(LPA) (Eichholtz, et al., 1993). Given that p110β is activated downstream of LPA receptors 
(Guillermet-Guibert, et al., 2008, Yart, et al., 2002) the lack of p110β expression in 5‟Myc-
p110δ-overexpressing  NIH  3T3  cells  is  more  likely  to  affect  cell  morphology  in  the 
presence of serum.  In the absence of serum, we may be more likely to observe the effect of 
p110δ overexpression on cell morphology rather than the effect of p110β downregulation.  
It should not be forgotten, however, that p110ʱ was also downregulated in 5‟Myc-p110δ-
overexpressing NIH 3T3 cells, therefore it possible that the effect on cell morphology may 
be due to low levels of p110ʱ expression in addition to high levels of p110δ expression. 
 
Numerous  studies  have  documented  LPA-induced  Rho  GTPase  signalling  and  LPA-
induced p110β activation (Guillermet-Guibert, et al., 2008; Jalink, et al., 1994; Kranenburg, 
et al., 1999; Sugimoto, et al., 2006; Tigyi & Miledi, 1992; Van Leeuwen, et al., 2003; Yart, 
et al., 2002), and it is for these reasons that I have concentrated on possible differences 
downstream of LPA activation to explain the different phenotypes observed in pMX-neo-
expressing and 5‟Myc-p110δ-overexpressing in the presence or absence of serum.  It is, 
however, important to emphasize that the phenotypes observed could be mediated by other 
constituents of serum. 
 
LPA is a phospholipid that acts on its cognate GPCRs termed LPA1, LPA2, and LPA3.  
LPA1 is the most widely expressed and best characterised LPA receptor, whereas LPA2, 
and  LPA3  have  a  more  restricted  distribution  pattern  (Moolenaar,  et  al.,  2004).  LPA 
mediates a considerable array of cellular responses, all of which appear to be receptor-
mediated.  Not surprisingly for a platelet produced growth factor, LPA has all the hallmarks 
of a wound-healing agonist; stimulating the proliferation and migration of mesenchymal 
and  epithelial  cells,  having  vasoconstrictive  actions,  and  enhancing  the  production  of 
metalloproteases, which are all important events in tissue repair (Moolenaar, et al., 2004). 
 
7.5.2.1 GPCR signalling  
In common with other GPCRs, LPA receptors undergo rapid ligand-induced internalisation 
from the plasma membrane.  LPA receptors can couple to at least three distinct G-protein 
families,  namely  Gʱq/11,  Gi/0,  and  G12/13  (Figure  7.21).    G  proteins  are  heterotrimeric 
proteins  composed  of  ʱ,  β  and  γ  subunits.    They  effectively  function  as  dimers  since Chapter 7 
237 
 
receptor signalling is mediated either by the Gʱ subunit or the stable Gβγ complex. Gʱ-
GDP  associates  with  Gβγ  and  with  cytoplasmic  portions  of  the  typically  seven-pass 
membrane receptor. Upon ligand activation, the receptor acts as a GEF stimulating the 
exchange of GDP for GTP on the ʱ subunit.  Gʱ-GTP dissociates  from Gβγ and both 
entities  can  interact  with  effectors.  Hydrolysis  of  GTP  restores  Gʱ-GDP,  which  then 
reassociates  with  Gβγ  and  the  receptor  to  terminate  signalling.  Currently  there  are  20 
known Gʱ, 6 Gβ, and 11 Gγ subunits.  On the basis of sequence similarity, the Gʱ subunits 
have been divided into four families: Gs, Gi/o, Gq/11 and G12/13, which define both receptor 
and effector coupling (Neves, et al., 2002).   
 
 
Figure 7.21: LPA-induced GPCR signalling. LPA receptors can couple to at least three 
distinct G-protein families, namely Gq/11, Gi/0, and G12/13.  The major signalling pathways 
activated downstream of these G-proteins are as follows: 1) Gʱq activates phospholipase C 
(PLC) with subsequent PIP2 hydrolysis and Ca
2+ mobilisation from internal stores; 2) Gi 
mediates inhibition of adenylyl cyclase and activation of PI3K, which subsequently leads to 
activation of Rac; the corresponding βγ subunit to Gi is thought to couple to the Ras-MAPK 
signalling cascade; 3) G12/13 has been implicated in activation of RhoA (Fukuhara, et al., 
2000; Fukuhara, et al., 1999; Hart, et al., 1998; Kranenburg, et al., 1999). 
 
Gʱq  and  Gs  pathways:  Gʱq  activates  phospholipases  C  (PLC)  with  subsequent  PIP2 
hydrolysis and Ca
2+ mobilisation from internal stores (Figure 7.21) (Fukuhara, et al., 2000; 
Fukuhara,  et  al.,  1999;  Hart,  et  al.,  1998;  Kranenburg,  et  al.,  1999).  The  Gs  pathway 
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involves the activation of the second messenger cAMP, which connects to multiple cellular 
pathways regulating a variety of downstream effectors such as ion channels, transcription 
factors, and metabolic enzymes (Neves, et al., 2002).  
 
Gi Pathway: This pathway was originally identified by the ability of Gʱi to inhibit adenylyl 
cyclase and is inhibited by pertussis toxin (PTX), which catalyzes adenosine diphosphate 
ribosylation  of  the  Gʱ  subunit  preventing  it  from  interacting  with  the  receptor.  In  this 
pathway, both Gʱ and Gβγ subunits can communicate signals.  Gβγ directly couples to at 
least four effector molecules, and indirectly to the small GTPase Ras, to activate MAPKs 
(Kranenburg & Moolenaar, 2001; Moolenaar, et al., 2004). The effectors directly regulated 
by Gβγ include PLC-β, K1 channels, adenylyl cyclase, and PI3K (Neves, et al., 2002). 
 
G12 and G13 Pathways: Most of the experiments carried out to elucidate Gʱ12 and Gʱ13 
protein signalling have been in infected cells. It is unclear which receptors endogenously 
couple through Gʱ12 and Gʱ13 pathways.  Although Gʱ12 and Gʱ13 proteins share a high 
degree of sequence similarity, they have different signalling effectors. Gʱ12 is thought to 
stimulate phospholipase D, c-Src, and PKC by as yet unidentified mechanisms, which in 
most  cases  results  in  activation  of  the  MAPK  family.  Gʱ12  can  also  been  reported  to 
directly interact with Ras-GAP and Btk (Neves, et al., 2002).   
 
Two  receptors  that  couple  to  Gʱ13  in  the  native  setting  are  the  LPA  receptor  and  the 
thromboxane  A2  receptor.  Gʱ13  directly  interacts  with  and  activates  the  Rho-GEF, 
p115Rho-GEF, and thus activates Rho. Gʱ13 may also engage the PI3K pathway to activate 
the protein kinase Akt and regulate NFκB, through the activation of PYK2 (Shi & Kehrl, 
2001). 
 
7.5.3  Regulation  of  RhoA  activation  by  serum  in  5’Myc-p110δ-overexpressing        
NIH 3T3 cells 
LPA  is  well  known  for  inducing  a  striking  contractile  response,  mediated  by  RhoA 
activation, in non-muscle cells.  This was first observed in neuronal cells, in which LPA 
induces rapid neurite retraction and cell rounding (Jalink, et al., 1994; Tigyi & Miledi, 
1992).  The mechanism by which LPA activates RhoA is relatively well understood.  RhoA 
activation proceeds via Gʱ12/13 subunits, which bind directly to at least three Rho-specific 
GEFs promoting RhoA-GTP accumulation and activation of ROCK and serum response 
factor (SRF)-mediated  gene transcription  (Schmidt & Hall, 2002;  Van Leeuwen,  et  al., 
2003).  There is also evidence to suggest LPA-mediated RhoA activation involves protein-Chapter 7 
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tyrosine  kinase  activity  since  pretreatment  of  cells  with  the  tyrosine  kinase  inhibitors 
genistein or tyrphostin inhibits LPA-induced RhoA activation (Kranenburg, et al., 1999). 
 
Following  initial  LPA-induced  contractile  events  mediated  by  RhoA  activation,  the 
continuous presence of LPA promotes cell re-spreading, lamellipodia formation and cell 
migration, events mediated by Rac activation (Van Leeuwen, et al., 2003).  Activation of 
RhoA by LPA is rapid but transient, with maximal RhoA activity typically detected within 
a few minutes in different cell types (Kranenburg, et al., 1999; Van Leeuwen, et al., 2003).  
In  MEFs,  RhoA  activation  is  undetectable  after  10  minutes  of  LPA  stimulation  (Van 
Leeuwen, et al., 2003), which suggests that after an initial induction of RhoA-GTP by LPA, 
prolonged LPA stimulation results in an eventual downregulation of RhoA-GTP. 
 
As mentioned previously, RhoA activation leads to SRF-mediated gene transcription.  It 
has been shown that Gʱz, a member of the Gʱi subunit family, inhibits Gʱ12/13, Gʱq or Rho-
GEF-induced  SRE  reporter  activity,  although  it  appears  to  have  no  effect  on  RhoA 
activation itself (Dutt, et al., 2004). 
 
In the presence of serum, NIH 3T3 cells stably expressing 5‟Myc-p110δ had a substantially 
higher basal level of RhoA-GTP compared to pMX-neo-expressing cells (Figure 7.15a), 
although cells did not display the contractile phenotype associated with high RhoA activity 
(Figure 7.3).  As previously mentioned, prolonged LPA stimulation causes cell respreading, 
therefore  it  is  not  unexpected  that  cells  did  not  display  a  contractile  phenotype  under 
normal culturing conditions, however one might still expect 5‟Myc-p110δ-overexpresing 
cells to have a more rounded cell morphology compared pMX-neo-expressing cells, rather 
than the more spread morphology actually observed.  It would be interesting to investigate 
whether LPA is indeed the component of serum that mediates the high RhoA-GTP levels 
observed  in  cells  stably  expressing  5‟Myc-p110δ.    This  could  be  investigated  through 
incubating cells in serum-free media overnight, followed by prolonged stimulation with 
LPA. Alternatively, in principle, an LPA-neutralising antibody could be added to the serum 
to investigate the effect of blocking LPA signalling on RhoA-GTP levels in 5‟Myc-p110δ-
overexpresing cells.  This approach of using neutralizing antibodies could also be used to 
assess the contributions of the serum constituents IGF-1 and PDGF on the activities of the 
small Rho GTPases and cell morphology. 
 
In some cell types, LPA can activate the production of PI(3,4)P2 and PIP3 as strongly as 
growth factors.  Indeed, PI3K activation by LPA is now regarded as an important aspect of Chapter 7 
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LPA signalling in different cellular systems (Fang, et al., 2000; Roche, et al., 1998). An 
increasing body of evidence has implicated p110β downstream of GPCRs, such as LPA 
receptors, from the finding that G protein βγ subunits dramatically increase the activation 
by phosphotyrosine motifs of p110β but not other class I PI3Ks (Maier, et al., 1999), to the 
finding that p110β is predominantly activated downstream of GPCRs rather than proteins 
tyrosine kinases in a panel of agonists tested (Guillermet-Guibert, et al., 2008).  Upon LPA 
stimulation, Gab1 is phosphorylated by the transactivated EGF receptor, thereby possibly 
providing the phosphotyrosine motifs that are required for p110β activation (Laffargue, et 
al., 1999).   
 
Given that p110β expression in 5‟Myc-p110δ-overexpresing cells was undetectable, it is 
likely  that  signalling  pathways  mediated  by  LPA-induced  p110β  activation  are 
compromised in these cells.  It is possible that after prolonged LPA stimulation, RhoA 
activity is downregulated by a Gʱi-pathway involving p110β in pMX-neo-expressing NIH 
3T3 cells.  Indeed, as mentioned previously Gʱz, (a member of the Gʱi subunit family) 
inhibits Rho-GEF  induced SRE reporter activity  (Dutt, et  al.,  2004), therefore it is  not 
inconceivable that RhoA is downregulation is mediated downstream of Gʱi.  In 5‟Myc-
p110δ-overexpressing  NIH  3T3  cells,  this  ability  to  down-regulate  RhoA  may  be 
compromised by the lack of p110β expression, therefore high basal RhoA activity observed 
in these cells, in the presence of serum, is not as a direct result of p110δ overexpression but 
rather as a result of p110β downregulation (Figure 7.23).   
 
One way in which the hypothesis that p110β is involved in regulating RhoA activity could 
be investigated is through examining the RhoA-GTP levels in MEFs isolated from mice 
homozygous for p110β gene inactivation.  If the hypothesis is correct, one might expect to 
find increased basal RhoA activity in these cells compared to MEFs from WT mice.  Other 
approaches include using siRNA to knock-down p110β expression or treating cells with 
p110β  isoform-specific  inhibitors.    Given  that  in  certain  cellular  responses  the  adaptor 
function of p110β rather than its lipid kinase activity has been found to be critical (Jia, et 
al., 2008), a knock-down approach of p110β protein expression may be favourable. 
   Chapter 7 
241 
 
Figure 7.22: Representative confocal images of NIH 3T3 cells stably expressing pMX-
neo or 5’Myc-p110δ in the presence or absence of serum of to support the hypothetical 
models propsed in Figure 7.23. Cells were seeded in media containing 10% FBS on glass 
coverslips.  After 6 h, media was replaced with media without FBS for cells under serum-
starvation conditions or left in media containing 10% FBS.  Cells were fixed and stained 
after 24 h. a) and c) F-actin (green), DNA (DAPI) and P-paxillin (red); b) and d) F-actin 
(green), N-cadherin (red) and P-paxillin (yellow). 
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Figure 7.23: Hypothetical models for the activation of RhoA and Rac1 in the presence 
of serum and under serum-starvation conditions in NIH 3T3 cells stably expressing 
pMX-neo or 5’Myc-p110δ.  pMX-neo: (a) Serum stimulation results in RhoA activation 
via  G12/13  pathways,  however  prolonged  serum  stimulation,  specifically  prolonged  LPA 
stimulation, leads to RhoA downregulation, which is possibly mediated through p110β.  
Low  endogenous  levels  of  p110δ  exert  a  mild  negative  effect  of  RhoA  activity  and  a 
positive effect on Rac1 activity. (b) In the absence of serum neither G12/13 nor p110β are 
activated consequently leading to low levels of RhoA activity. 5’Myc-p110ʴ: (c) In the 
presence of serum RhoA activity is high through LPA-G12/13 signalling through Rho-GEFs, 
which  may  inhibit  Rac1  activity.    The  lack  of  p110β  expression  may  prevent 
downregulation of RhoA activity after prolonged LPA stimulation.  Growth factors and 
high p110δ expression lead to high levels of Akt phosphorylation. (d) In the absence of 
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serum and RhoA activity is attenuated through diminished G12/13 signalling, exogenously 
expressed p110δ has some constitutive lipid kinase activity which activates Akt, Rac1 and 
exerts a mild negative effect on RhoA activity.  Increased Rac1 activity is also likely to 
inhibit RhoA activity. 
 
Although p110β may play a role in downregulating RhoA activity after prolonged serum-
stimulation,  it  appears  as  though  p110β  is  not  involved  in  inhibiting  the  acute  serum-
induction of RhoA activity.  The addition of serum induced a significant increase in RhoA 
activity in both pMX-neo-expressing and 5‟Myc-p110δ-overexpresing cells (Figure 7.15a), 
which corroborates the  finding that inhibition  of p110β  has no  effect  on acute CSF-1-
induced RhoA activation in primary macrophages (Papakonstanti, et al., in preparation).  
Moreover, this result demonstrates that a high level of p110δ expression is not essential for 
the rapid induction of RhoA-GTP upon serum stimulation, given that serum-stimulation of 
pMX-neo-expressing cells resulted in a marginally higher level of RhoA-GTP compared to 
5‟Myc-p110δ-overexpressing cells and that IC87114 treatment did inhibit serum-induced 
RhoA-GTP in either cell line. 
 
In  both  pMX-neo  and  5‟Myc-p110δ-overexpressing  NIH  3T3  cells,  IC87114  treatment 
resulted in an increase in RhoA-GTP, corroborating the finding that p110δ is negatively 
regulating RhoA activity (Papakonstanti, et al., 2007).  These results demonstrate that a low 
endogenous level of p110δ is sufficient to mediate RhoA inhibition.  In light of this, one 
would expect cells that have high expression of p110δ to have low RhoA activity, however 
as explained,    5‟Myc-p110δ-overexpressing NIH 3T3 cells had higher levels of RhoA-
GTP.  These data indicates that expression of a solitary class I PI3K isoform, p110δ, is not 
sufficient to down-regulate RhoA activity and that other molecules, possibly p110β, are 
also required to attenuate RhoA-GTP levels. 
 
7.5.4 Regulation of Rac activation by serum in 5’Myc-p110δ-overexpressing NIH 3T3 
cells 
In contrast to RhoA, little is known about how LPA receptors may modulate the activity of 
Rac and/or Cdc42.  It has been shown that the LPA1 receptor, in addition to transiently 
activating  RhoA,  mediates  prolonged  activation  of  Rac  via  a  Gi-PI3K  pathway  that 
activates the Rac-GEF, Tiam1 (Figure 7.21) (Van Leeuwen, et al., 2003).   To corroborate 
this, in neuroblastoma cells, LPA-induced activation of Rac is more robust and prolonged 
than LPA-induced activation of RhoA (Van Leeuwen, et al., 2003). This activation of Rac 
is inhibited by PTX and wortmannin, which supports the idea that Rac is activated via Gi-Chapter 7 
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mediated stimulation of PI3K activity.  In chinese hamster ovary cells, LPA stimulates both 
Rac and Rho activity resulting in cell migration, indicating that both Rac and Rho can be 
activated at the same time (Sugimoto, et al., 2006), whereas in the absence of Gi function, 
LPA induces inhibition, rather than stimulation of cellular Rac activity (Sugimoto, et al., 
2006). 
 
Although activated via distinct G-protein pathways (RhoA by Gʱ12/13 and Rac by Gi), it is 
the  balance  between  RhoA  and  Rac  activation  which  determines  cell  morphology.  
Activated Rac has been shown to suppress RhoA activity and there is also evidence for the 
reverse being true (Sugimoto, et al., 2006; Yamaguchi, et al., 2001).   
 
In NIH 3T3 cells stably overexpressing 5‟Myc-p110δ, Rac1 activity was reduced in the 
presence of serum compared to pMX-neo-expressing cells, whereas under serum-starvation 
conditions 5‟Myc-p110δ-overexpressing cells had increased Rac1-GTP levels compared to 
pMX-neo-expressing cells (Figure 7.15b, Table 8.1).  Although it is a common conception 
that Rac1 inhibition on RhoA activity is unidirectional, as mentioned above there is also 
evidence that RhoA also inhibits Rac1 activation (Sugimoto, et al., 2006; Yamaguchi, et al., 
2001).  High RhoA activity in 5‟Myc-p110δ-overexpressing cells in the presence of serum 
may antagonize Rac1 activation.  However, under serum-starvation conditions where RhoA 
activity is reduced, p110δ-induced Rac1 activation may be uninhibited (Figure 7.23).   
 
7.5.5 p110δ may be a positive regulator of Rac1 activity and a negative regulator of 
RhoA activity in NIH 3T3 cells 
These hypotheses put forward to explain the differential levels of RhoA and Rac1 activity 
in NIH 3T3 cells stably expressing pMX-neo or 5‟Myc-p110δ, support the idea that p110δ 
positively regulates Rac1 activity and negatively regulates RhoA activity.  It is only due to 
the altered expression of the other class IA PI3K isoforms, namely reduction of p110β 
expression, that results in decreased Rac1 activity and increased RhoA activity in p110δ-
overexpressing cells in the presence of serum.  To support this idea, under conditions of 
serum-starvation, IC87114 treatment induced a significant reduction in Rac1 activity in 
5‟Myc-p110δ-overexpressing cells, indicating that overexpression of p110δ in the absence 
of  LPA  and serum  growth factors is  sufficient to  activate Rac1.   In contrast,  IC87114 
treatment induced the greatest increase in RhoA activity in p110δ-overexpressing cells in 
the  presence  of  serum,  indicating  that  p110δ  inhibition  in  addition  to  LPA  and  serum 
growth factors, is required for maximal RhoA activation. Chapter 7 
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7.5.6 Effect of p110δ overexpression in NIH 3T3 cells on the actin cytoskeleton and 
cell morphology 
In the presence of serum, 5‟Myc-p110δ-overexpressing cells had more actin stress fibres 
and sites of focal contact compared to pMX-neo-expressing cells, which correlated with the 
increased RhoA activity observed in these cells under these conditions (Table 8.1).  Given 
that RhoA activity is involved in the assembly of focal adhesions (Hotchin & Hall, 1995; 
Ridley & Hall, 1992), this was an expected finding.  In the absence of serum, 5‟Myc-
p110δ-overexpressing cells displayed a reduction in actin stress fibres compared to pMX-
neo-expressing cells, which reflects the shift observed from RhoA activity to Rac1 activity 
in these cells.  Interestingly, in the absence of serum 5‟Myc-p110δ-overexpressing cells 
appeared  to  have  more  sites  of  focal  contact  compared  to  pMX-neo-expressing  cells, 
indicating Rac1 activity may also be involved in focal adhesion formation.  Indeed, Rac1 
has been linked to the formation of actin stress fibres and focal adhesion assembly (Guo, et 
al., 2006), therefore it is possible that the increase in focal adhesions in 5‟Myc-p110δ-
overexpressing cells is mediated through p110δ-induced Rac1 activation.  It should also be 
considered  that  5‟Myc-p110δ-overexpressing  cells  have  an  increased  number  of  focal 
complexes rather than focal adhesions.  Focal complexes are the earliest forms of peripheral 
integrin-mediated contacts, which contain paxillin but do not contain the mature adhesion 
markers  found  in  focal  adhesions,  such  as  zyxin  (Zaidel-Bar,  et  al.,  2004).    Focal 
complexes are an important in the formation of lamellipodia protrusion, a process regulated 
by Rac, therefore it is possible that 5‟Myc-p110δ-overexpressing cells have an increased 
number of focal complexes mediated by p110δ-induced Rac1 activity. This could easily be 
investigated through immunofluorescence staining for the focal adhesion marker, zyxin. 
 
In the absence of serum, F-actin puncta staining, which colocalized with P-paxillin was 
observed  in  5‟Myc-p110δ-overexpressing  cells  (Figure  7.5a).    This  type  of  staining 
resembles that observed for podosomes (Linder, 2007).  Podosomes are dynamic adhesion 
sites  enriched  for  filamentous  actin,  which  were  initially  described  in  Src-transformed 
fibroblasts  (David-Pfeuty  &  Singer,  1980).    Podosomes  mediate  close  contact  with  the 
underlying substratum and contain several proteins namely, integrin, paxillin, vinculin and 
talin.  They are distinguishable from other adhesion foci by a dense actin core, organized as 
a  column  of  small  actin  filaments  surrounded  by  adhesion  proteins  (integrins)  and 
scaffolding proteins such as cortactin (Destaing, et al., 2003), PyK2 (Pfaff & Jurdic, 2001), 
WASP  (Calle,  et  al.,  2004a)  and  gelsolin  (Chellaiah,  et  al.,  2000).    Podosomes  are 
considered dynamic as they dissolve and reform in new locations, with a lifespan ranging Chapter 7 
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from 30 seconds to 12 min depending on cell type and the underlying substrate (Calle, et 
al., 2004a; Collin, et al., 2006; Evans, et al., 2003; Kanehisa, et al., 1990).  Although the 
precise role of podosomes remains to be elucidated, they are typically found in invasive 
cells and cells that cross tissue boundaries and they appear to be important for cell adhesion 
and substrate degradation (Burgstaller & Gimona, 2005; Lener, et al., 2006).  Given that 
podosomes  are  constantly  generated  in  moving  cells,  it  has  been  suggested  that  they 
possibly mediate effective progression of the leading edge during cell migration (Calle, et 
al., 2006).  Further investigations  need to  be carried out  to  assess whether the  F-actin 
structures identified in 5‟Myc-p110δ-overexpressing NIH 3T3 cells are indeed podosomes, 
such as staining for vinculin and cortactin.  It is possible that the actin structures observed 
are in fact invadopodia, rather than podosomes, which like podosomes contain cortactin but 
unlike  podosomes  do  not  contain  vinculin.    Invadopodia  are  mostly  formed  as  small 
clusters consisting of a few large actin-rich dots, rather than the more numerous evenly 
spaced podosomes, and form deeper root-like extensions into the matrix (Linder, 2007).  
Whereas podosomes are found in monocytic cells, endothelial cells and smooth muscle 
cells, invadopodia are frequently found in highly invasive carcinoma cells (Linder, 2007).  
However the distinction in fibroblasts is less clear cut, and podosome-type adhesions have 
been  categorized  both  as  podosomes  or  invadopodia.    In  either  case,  the  presence  of 
podosome-type  adhesions  in  5‟Myc-p110δ-overexpressing  NIH  3T3  cells  suggests  that 
these  cells  may  be  more  invasive  than  pMX-neo-expressing  cells,  which  would  be  an 
interesting avenue for further exploration. 
 
One particularly interesting observation was the effect of IC87114 treatment on 5‟Myc-
p110δ and pMX-neo-expressing NIH 3T3 cells in the presence of serum.  Under serum-
starvation conditions, IC87114 treatment partially reversed the morphological phenotype of 
5‟Myc-p110δ-overexpresssing cells to one that more closely resembled pMX-expressing 
cells (Figure 7.7, 7.9).  However, in the presence of serum, IC87114 treatment induced cell 
clustering, which was more apparent in 5‟Myc-p110δ-overexpresssing cells (Figure 7.6).  It 
is  possible  that  these  changes  in  cell  morphology  reflect  an  acute  response  to  p110δ 
inhibition mediated by a component of serum.  Indeed, many of the phenotypes observed 
for  5‟Myc-p110δ-overexpressing  cells  alter  between  serum  and  serum-starvation 
conditions,  an  effect  which  has  been  partly  attributed  to  the  downregulation  of  p110β.  
Analysis of the levels of phosphorylated Akt revealed that 5‟Myc-p110δ-overexpresssing 
cells had high levels of P-Akt in the presence of serum which is completely abrogated after 
1 h of IC87114 treatment, whereas under serum-starvation conditions although the level of 
P-Akt is higher in 5‟Myc-p110δ-overexpresssing cells compared to pMX-neo-expressing Chapter 7 
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cells, it is significantly lower than that observed in the presence of serum (Figure 7.8).  
These results indicate that the lipid kinase activity of p110δ is greater in the presence of 
serum, therefore it is possible that the difference in the effect of IC87114 treatment in the 
presence or absence of serum reflects the acute changes in PIP3 production and subsequent 
activation of downstream effectors.  It would be interesting to investigate the effect of 
p110δ inhibition over a longer time period to assess whether cells can adapt to low p110δ 
lipid  kinase  activity.    Finally,  the  substantial  increase  in  RhoA  activity  in  cells  after 
IC87114 treatment in the presence of serum (Figure 7.15) may induce a rapid lateral cell 
contraction, which results in the „stringy‟ cell clustering of 5‟Myc-p110δ-overexpressing 
cells. To further investigate this possibility, cells could be treated with a combination of 
IC87114  and  the  ROCK  inhibitor  Y-27632  to  assess  whether  inhibition  of  the  RhoA 
downstream effector prevents this type of cell clustering. 
 
7.5.7 Future work 
I  have  mentioned  a  number  of  possible  future  lines  of  investigation  throughout  this 
discussion, which are summarised below:  
  Investigation into the mode of downregulation of p110ʱ and p110β expression in 
5‟Myc-p110δ-overexpressing NIH 3T3 cells, such as analysis of p110ʱ and p110β 
mRNA  expression  and  proteasome  inhibition  to  induced  p110ʱ  and  p110β 
expression. 
  Determine whether  LPA, or indeed other components of serum, such as growth 
specific growth factors, are responsible for the induction of different phenotypes 
observed  for  5‟Myc-p110δ-overexpressing  cells  in  the  presence  or  absence  of 
serum. 
  Investigation into the possible role of p110β in attenuating RhoA activity, through 
the use of p110β-specific inhibitors, use of MEFs isolated from mice homozygous 
for p110β gene-inactivation or use of p110β-targeted siRNA. 
  Determine  whether  5‟Myc-p110δ-overexpressing  cells  express  increased  focal 
adhesions of focal complexes through staining for zyxin, to help elucidate whether 
these adhesions are a result of increase RhoA or Rac1 activity. 
  Investigate  the  possible  expression  of  podosomes/invadopodia  in  5‟Myc-p110δ-
overexpressing cells express and assess whether this correlates with the invasive-
potential of these cells. Chapter 7 
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  Examine  the  effect  of  p110δ  inhibition  on  pMX-neo  and  5‟Myc-p110δ-
overexpressing cells over a time period longer than 1 h and also the combination of 
p110δ and ROCK inhibition on cell morphology in the presence of serum. 
 
There are other potentially interesting areas of investigation, which are discussed in more 
detail below. 
 
7.5.7.1 Stable expression of untagged p110δ in NIH 3T3 cells  
Although N-terminal Myc tags are commonly included on exogenously expressed proteins, 
the possibility that such a tag interferes with the function, localization and stability of the 
tagged protein should not be overlooked.  Indeed, the addition of an N-terminal Myc tag on 
p110ʱ enhances p110ʱ protein stability (Yu, et al., 1998b).  Ideally, it would have been 
more advisable to stably express untagged p110δ in NIH 3T3 cells, but due to unforeseen 
complications with the p110δ-containing retroviral vector (discussed in section 6.4) this 
was not possible.  However, to gain a more reliable insight into the role of p110δ, future 
work should incorporate the characterisation of NIH 3T3 cells stably expressing untagged 
p110δ. 
 
7.5.7.2 Investigation into possible downstream effectors of p110δ that may play a role 
in the altered actin cytoskeleton and cell morphology associated with NIH 3T3 cells 
overexpressing 5’Myc-p110δ 
There are number of GEFs that specifically activate Rac, such as members of the Vav, Sos, 
Tiam, Swap-70 and P-Rex families (Hawkins, et al., 1995; Michiels, et al., 1995).  PIP3 
strongly activates the Rac-GEF activities of P-Rex1 and SWAP-70 in vitro (Shinohara, et 
al., 2002; Welch, et al., 2002) and weakly activates the Rac-GEF activities of Vav1, Sos1 
and Tiam1 (Han, et al., 1998; Innocenti, et al., 2003), implicating PI3K as a regulator of 
Rac-GEFs.    Indeed, in  epithelial  cells,  Tiam1-mediated Rac activation is  dependent  on 
PI3K activity (Sander, et al., 1998).  It would be of interest to explore the activity of some 
of these Rac-specific GEFs in NIH 3T3 cells overexpressing 5‟Myc-p110δ.  One particular 
Rac-GEF, β-Pix (p21-activated kinase [PAK]-interacting exchange factor), which has been 
shown  to  be  activated  downstream  of  PI3K  (Park,  et  al.,  2004),  makes  an  interesting 
candidate.  Rac1 binds directly to the SH3 domain of β-Pix through the proline stretch in its 
carboxy-terminus (ten Klooster, et al., 2006).  In addition to a Rac-GEF, β-Pix also acts as 
a signalling organizer by binding to the Arf-GAP paxillin kinase linker (PKL) as well as the 
Rac effector Pak1 (Bagrodia, et al., 1998; Manser, et al., 1998) (Figure 7.24).  It has been 
shown that the interaction of Rac1 with β-Pix mediates Rac1 targeting to membrane ruffles Chapter 7 
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and focal adhesions and Rac1-mediated cell spreading (ten Klooster, et al., 2006).  The 
interaction of Rac1 with β-Pix is controlled by Pak1, which competes for binding with β-
Pix.    It  would  be  interesting  to  assess  the  activity  of  β-Pix  in  NIH  3T3  cells  stably 
overexpressing 5‟Myc-p110δ, to determine whether p110δ-induced increased Rac1 activity 
is mediated through increased activation of β-Pix.  Given that β-Pix is involved in the 
formation of focal adhesion complexes, increased β-Pix activity in NIH 3T3 cells stably 
overexpressing 5‟Myc-p110δ would offer some explanation for the increased number of 
focal adhesion observed in these cells. 
 
 
Figure 7.24: Activation of the Rac-GEF, β-Pix downstream of PI3K. 
 
In addition to the apparent positive regulation p110δ appears to have on Rac1 in 5‟Myc-
p110δ-overexpressing cells, p110δ also seems to be negatively regulating RhoA activity.  
Downregulation  of  RhoA  activity  can  be  mediated  through  Rho-GAPs.    There  was  no 
significant  difference  in  the  Rho-GAP  activation  of  p190RhoGAP  in  5‟Myc-p110δ-
overexpressing  NIH  3T3  cells  compared  to  pMX-neo-expressing  cells  as  assessed  by 
tyrosine-phosphorylation, implicating that either this method of assessing  p190RhoGAP 
activation  is  not  sufficient  or  that  another  Rho-GAP  may  be  involved  in  RhoA-GTP 
hydrolysis. Inhibition of Rho-specific GEFs rather than activation of Rho-specific GAPs 
could also be involved in the inhibitory effect p110δ has on RhoA activity, which are areas 
that could be further explored. 
 
There are many PIP3 effectors which could be involved in the phenotype observed for 
5‟Myc-p110δ-overexpressing NIH 3T3 cells, one such effector is Pleckstrin-2 (PLEK2). 
The phenotypes observed in COS cells overexpressing PLEK2 (Hamaguchi, et al., 2007) 
closely resemble the phenotypes observed in NIH 3T3 cells stably overexpressing 5‟Myc-
p110δ.  PLEK2 is a 353 amino acid protein identified through its similarity to PLEK1.  
Both PLEK1 and 2 contain two PH domains in their amino- and carboxy-termini (Hu, et 
PI3K
β-Pix
Rac1
PAK1 PKLChapter 7 
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al., 1999).  Unlike PLEK1, PLEK2 is a poor substrate for PKC, but is a PIP3-binding 
protein, which is regulated by PI3K (Hamaguchi, et al., 2007).  Expression of PLEK2 in 
COS  cells  (which  have  low  endogenous  expression  of  PLEK2)  induces  increased  cell 
spreading on fibronectin or collagen-coated plates with cells (the average footprint size of 
cells  expressing  PLEK2  40%  greater  than  that  of  control  cells)  and  cells  also  display 
increased membrane ruffles (Hamaguchi, et al., 2007).  These phenotypes were abolished in 
cells expressing a PIP3-binding mutant, indicating that production of PIP3 is critical for 
PLEK2 activity.  Furthermore, coexpression of RFP-RhoA, RFP-Cdc42 or RFP-Rac1 with 
GFP-PLEK2 revealed that RFP-Rac1 tightly colocalized with GFP-PLEK2, whereas RFP-
RhoA or RFP-Cdc42 do not show colocalization with GFP-PLEK2  (Hamaguchi, et al., 
2007).    It  would  be  interesting  to  investigate  the  role  of  PLEK2  in  5‟Myc-p110δ-
overexpressing NIH 3T3 cells and the possibility that increased PIP3 production by p110δ 
mediates increased PLEK2 binding and induction of cell spreading. 
 
There are a number of downstream effectors of Rho GTPases that are implicated in actin 
reorganization, but the two main effector proteins are Wiskott Aldrich syndrome protein 
(WASP) and a WASP-like Verprolin-homologous protein (WAVE) (Bishop & Hall, 2000).  
It  is  possible that WASP and/or WAVE may play a role in  the increased lamellipodia 
formation  during  cell  spreading  and  possible  podosome  formation  in  5‟Myc-p110δ-
overexpressing  cells.    WASP  expression  is  restricted  to  haematopoietic  cells,  but  its 
homologue, N-WASP, is ubiquitously expresssed (Kolluri, et al., 1996; Rohatgi, et al., 
1999).  WASP directly  binds the cytoskeletal  organizer, actin-related protein  (Arp) 2/3 
complex (Machesky & Gould, 1999).  The Arp2/3 complex functions to create a branching 
network of filamentous actin and is localized at sites of active actin polymerization such as 
lamellipodia and the base of filopodia (Burns, et al., 2001; Mullins, et al., 1998).  WASP 
expression is also essential for podosome formation and is necessary for the recruitment of 
Arp2/3 complex to podosomes (Burns, et al., 2001; Calle, et al., 2004b).  In vitro, WASP 
binds specifically to the GTP-bound form of Cdc42 and to a lesser extent GTP-bound Rac 
(Aspenstrom, et al., 1996; Kolluri, et al., 1996).  Like WASP, WAVE also interacts with 
and activates the Arp2/3 complex (Machesky, et al., 1999).  WAVE precipitates with Rac 
and localizes to membrane ruffles, furthermore, an actin-binding domain mutant of WAVE 
inhibits Rac-induced ruffling, suggesting an in vivo link between WAVE and Rac (Miki, et 
al., 1998).  It would be interesting to investigate the expression and localization of WASP 
and WAVE in 5‟Myc-p110δ-overexpressing cells. 
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7.5.7.3  Investigation  into  the  motility  and  migratory  capacity  of  NIH  3T3  cells 
expressing pMX-neo or 5’Myc-p110δ 
Immunofluorescence  staining  of  pMX-neo  and  5‟Myc-p110δ-expresspressing  NIH  3T3 
cells have revealed clear difference in the cell cytoskeleton, however there has not been any 
investigation into how these cells move.  Given that organization of the cell cytoskeleton 
governs cell movement and that the different levels of Rho GTPase activity has a direct 
effect  on  cell  migration  (discussed  in  section  1.4.5),  one  might  expect  pMX-neo  and 
5‟Myc-p110δ-expresspressing  NIH  3T3  cells  to  have  different  motility  and  migratory 
capacities.  It is possible that the increased Rac1 activity in 5‟Myc-p110δ-expresspressing 
cells may results in an increased migratory capacity.  Indeed, in a mouse tumour model 
increased  Rac  activation  results  in  increased  aggressiveness  and  infiltration  of  PI3K-
induced lymphomas in both lymphoid and non-lymphoid organs (Strumane, et al., 2008).  
However,  since  it  is  a coordinated  activation  of  Rho  GTPase  that  induces  a  migratory 
response, it is possible that a disruption of the balance between RhoA and Rac1 activity (as 
seen in 5‟Myc-p110δ-expressing cells) may inhibit cell migration.   
 
Further evidence indicating that 5‟Myc-p110δ-expresspressing cells may have an increased 
migratory  capacity  over  pMX-neo-expressing  cells  is  that  p110δ  has  be  found  to  be 
important for the directionality and, to a lesser extent, speed of cell migration in breast 
cancer cell lines, whereas p110β was only required for speed of migration and p110ʱ did 
not appear to play a role in either parameter (Sawyer, et al., 2003).  Striking differences in 
cell migration of tumour cells has been found depending on whether the migration studies 
have been carried out on three-dimensional matrices or on two-dimensional tissue culture 
plates (Sahai & Marshall, 2003), therefore it will be important to carry out future migratory 
studies 5‟Myc-p110δ-expressing cells on three-dimensional matrices in addition to two-
dimensional studies.   
 
7.5.7.4  Investigating  the  localization  of  p110δ,  RhoA  and  Rac1  in  NIH  3T3  cells 
expressing pMX-neo or 5’Myc-p110δ 
Although the levels of active RhoA and Rac1 have been determined in NIH 3T3 cells 
expressing pMX-neo or 5‟Myc-p110δ their cellular localization has not been investigated.  
It  would  be  interesting  to  assess  whether  p110δ  and  RhoA  and/or  Rac1  colocalization 
occurs at the cell membrane, in the cytoplasm or possibly at podosomes. Furthermore, it 
would be interesting to assess whether the localization of RhoA and Rac1 differs in cells 
stably  expressing  5‟Myc-p110ʱ  or  5‟Myc-p110β  compared  to  cells  stably  expressing 
5‟Myc-p110δ.  These  investigations  rely  on  antibodies  that  can  be  used  for Chapter 7 
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immunofluorescence.  Since the exogenously expressed p110δ contains an N-terminal Myc 
tag, the commonly used anti-Myc antibody in immunofluorescence could be used for the 
detection  of  Myc-tagged  p110  subunits.    It  is  possible  to  detect  GTP-bound  RhoA  or 
Rac1/Cdc42  by  immunofluorescence  by  incubating  cells  with  a  GST-tagged  Rhotekin 
binding domain or GST-tagged Pak binding domain, respectively, followed by incubation 
with an anti-GST antibody that can subsequently be detected by a fluorescently-conjugated 
secondary antibody (Cascone, et al., 2003).  Therefore it would be feasible to carry out 
investigation into this area.  
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8 DISCUSSION 
In this study, we have focused on furthering our understanding of the isoform-specific role 
of p110δ using various cell-based models and have addressed the following questions: 
1)  Is coupling of class IA PI3Ks to tyrosine kinase receptors altered in untranformed 
versus transformed cellular states? 
2)  Is the leukocyte-restricted p110δ gene expression mediated by a leukocyte-specific 
promoter? 
3)  What  is  the  biological  impact  of  p110δ  overexpression  in  non-leukocyte 
mammalian cells?  
These areas of investigation have not always been straightforward and it is clear that further 
work is needed to further expand our understanding of the isoform-specific role of p110δ.  
However,  in  some  of  these  areas,  significant  advances  have  been  made.    The  results 
presented in Chapters 3 to 7 are summarised and discussed below. 
 
1) Is coupling of class IA PI3Ks to tyrosine kinase receptors altered in untransformed 
versus transformed cellular states? 
In primary, untransformed cells, a single PI3K isoform often appears to mediate most PI3K 
activity  downstream  of  a  given  receptor  and  inhibition  of  a  single  PI3K  isoform 
downstream of a given tyrosine kinase receptor often results in a severe impact on the 
biological responses controlled by this tyrosine kinase receptor. For example, in primary 
leukocytes, p110δ is often the 'dominant' class IA isoform with p110δ inhibition having a 
major impact on specific tyrosine kinase receptor signalling, such as c-kit and CSF-1 (Ali, 
et al., 2004; Papakonstanti, et al., 2007; Papakonstanti, et al., in preparation).  While my 
work was in progress, other scientists in the laboratory have documented that in primary 
macrophages, CSF-1 signalling is highly dependent on p110δ activity for the regulation of 
the  activities  of  Akt,  RhoA  and  PTEN,  as  well  as  proliferation  and  chemotaxis 
(Papakonstanti,  et  al.,  2007;  Papakonstanti,  et  al.,  in  preparation).    However  in 
immortalized macrophage cell lines, the p110ʱ isoform rather than p110δ takes up a more 
prominent role in CSF-1 receptor signalling, with more p110ʱ becoming recruited to the 
CSF-1 receptor (Papakonstanti, et al., in preparation).  It seems highly likely that coupling 
of class IA PI3Ks to tyrosine kinase receptors is altered in normal and transformed cellular 
states. I have investigated this question, focusing on the coupling of p110δ to the  c-kit 
tyrosine kinase receptor, which is almost entirely dependent upon p110δ activity for c-kit 
signalling in primary BMMCs (Ali, et al., 2004). 
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Three  approaches  were  taken  to  experimentally  immortalise  and  transform  primary 
BMMCs: 1) introduction of the HOX11 homeobox gene; 2) introduction of PMT; and 3) 
investigation into whether BMMCs with inactive p110δ [derived from our p110δ
D910A/D910A 
mice  (Okkenhaug,  et  al., 2002)] maintained in  culture for more than 6 weeks undergo 
„spontaneous transformation‟ in which another p110 isoform than p110δ might be able to 
signal  downstream  of  c-kit  to  substitute  for  the  kinase-dead  p110δ,  to  restore  c-kit 
signalling.    This  was  based  on  some  observations  that  p110δ
D910A/D910A  BMMCs 
maintained in culture for more than 6 weeks were often found to have increased p110ʱ 
protein  expression  associated  with  increased  p110ʱ  kinase  activity  compared  to  WT 
BMMCs,  suggesting  p110ʱ  may  compensate  for  the  kinase-dead  p110δ  (Ali  & 
Vanhaesebroeck, unpublished results). 
 
We found that introduction of HOX11 resulted in a less differentiated „early progenitor-
like‟ appearance of BMMCs, which had lost expression of c-kit and the other mast cell 
marker FcεRI.  Given that these cells no longer expressed c-kit they could not be used to 
assess the coupling of p110δ to this receptor and this line of investigation was not further 
pursued. 
 
We successfully introduced PMT in BMMCs by retroviral infection. PMT expression did 
not  appear  to  fully  transform  cells,  indicated  by  the  continued  dependency  of  PMT-
expressing  BMMCs  on  IL-3  for  cell  growth,  albeit  at  a  lower  concentration  than  WT 
BMMCs.  PMT-expressing BMMCs did not have increased levels of Akt phosphorylation, 
which is usually associated with PMT-induced cell transformation.  Also, expression of 
PMT  did  not  alter  c-kit  or  FcεRI  expression.  c-kit  appeared  to  remain  functionally 
dependent on p110δ for SCF-induced signalling in PMT-expressing BMMCs, at a similar 
level to WT BMMCs.  Most likely, this unaltered receptor coupling is related to the non 
„fully‟ transformed state of the PMT-expressing cells. 
 
SCF-induced  Akt  phosphorylation  is  almost  completely  abrogated  in  p110δ
D910A/D910A 
BMMCs,  emphasising  the  importance  of  p110δ  in  c-kit  signalling  (Ali,  et  al.,  2004).  
However, we found that in p110δ
D910A/D910A BMMCs maintained in culture for 12 weeks 
(long-term  culture),  SCF  stimulation  was  capable  of  inducing  substantial  Akt 
phosphorylation, raising the possibility that these cells had undergone some alterations that 
permit c-kit signalling.  After maintaining primary BMMCs in culture for longer than 6 
weeks, we observed an upregulation of p110ʱ expression in p110δ
D910A/D910A BMMCs with 
a concomitant decrease in p110β and p110δ expression, whereas p110 isoform expression Chapter 8 
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remained largely unaltered in WT BMMCs.  We found that in both long-term cultured WT 
and p110δ
D910A/D910A BMMCs, p110δ and p110ʱ were constitutively bound to c-kit with 
further recruitment of these isoforms to the receptor upon SCF stimulation.  Constitutive 
p110 binding to c-kit may be related to an incomplete starvation of SCF before the receptor 
binding assays were performed (since BMMCs are cultured in media containing SCF). No 
such recruitment to c-kit was observed for p110β or p110γ, either constitutively or upon 
SCF  stimulation.  Given  that  p110β  and  p110γ  are  not  recruited  to  c-kit  upon  SCF 
stimulation in either long-term cultured WT or p110δ
D910A/D910A BMMCs, this makes p110ʱ 
the  most  likely  candidate  to  signal  downstream  of  c-kit  in  long-term  cultured 
p110δ
D910A/D910A BMMCs. 
 
Despite the binding of p110ʱ to c-kit, WT BMMCs remained almost entirely dependent on 
p110δ for SCF-induced Akt phosphorylation.  Thus if p110ʱ is signalling downstream of c-
kit  in  long-term  cultured  p110δ
D910A/D910A  BMMCs,  the  switch  from  p110δ  to  p110ʱ 
signalling downstream of c-kit appears to have occured without altered p110 binding to c-
kit.  It is possible that in long-term cultured p110δ
D910A/D910A BMMCs, p110ʱ selectively 
recruits additional signalling proteins to the c-kit receptor complex, which does not occur in 
long-term  cultured  WT BMMCs,  however  this  area  would  require  further  investigation 
(discussed in section 3.5.3).  As mentioned in section 3.5.3, the time required and the cost 
of maintaining primary BMMCs in culture are factors that discourage further investigation 
into the „spontaneous transformation‟ events that appear to occur in long-term cultured 
p110δ
D910A/D910A BMMCs and this approach was no longer pursued. 
 
Since the approaches taken transform WT BMMCs did not appear to result in full BMMC 
transformation, it has not been possible to address the question of whether p110δ would 
remain the principle PI3K isoform downstream of c-kit in transformed BMMCs, which is 
possibly an area for further investigation.  Cell transformation can be achieved through 
overexpression of oncoproteins, such as SV40 large T antigen (Ali & DeCaprio, 2001), 
oncogenic p110ʱ (Samuels & Velculescu, 2004), oncogenic Ras (Spandidos, et al., 2002) 
or  oncogenic  c-kit  (Nagata,  et  al.,  1995).    The  human  mastocytoma  cell  line,  HMC-1, 
expresses  an  oncogenic  c-kit  receptor  (mediated  through  two  point  mutations),  which 
appears to be less dependent on p110δ (Billottet & Vanhaesebroeck, unpublished results).  
Since it is difficult to compare primary BMMC signalling with signalling in a mastocytoma 
cell line, it would be interesting to take primary BMMCs, transfect them with oncogenic c-
kit, and assess the resulting dependency of c-kit on p110δ.  This would allow a direct 
comparison between primary WT and oncogenic-c-kit-expressing BMMCs.  However, it is Chapter 8 
256 
 
not clear whether introduction of oncogenic c-kit, or any of the other oncogenes mentioned, 
alone would result in transformation of primary BMMCs.  Besides HMC-1, few other mast 
lines exist indicating that immortalization of primary BMMCs is not trivial.  In addition, I 
have  found  that  primary  BMMCs  are  difficult  to  transfect,  often  resulting  in  a  high 
proportion  of  cell  death  if  using  transfection  reagents,  or  resulting  in  low  transfection 
efficiency if retroviral infection has been employed, most likely due to the low proliferative 
rate of the cells. Therefore, future work in this area may prove to be relatively difficult.  
Future  plans  to  assess  the  dependency  of  CSF-1  signalling  in  transformed  primary 
macrophages, rather than immortalised cell lines, include using macrophages derived from 
Arf/p16-Ink4a  null  mice,  which  have  previously  been  show  to  grow  rapidly  and 
continuously in culture whilst remaining CSF-1-dependent (Randle, et al., 2001).  It could 
also be interesting to assess the dependency of c-kit on p110δ in BMMCs derived from 
these mice. 
 
2) Is the leukocyte-restricted p110δ gene expression mediated by a leukocyte-specific 
promoter? 
p110δ  is  produced  from  multiple  transcripts  with  distinct  upstream  untranslated  exons 
named, exon -1, -2a, -2b, -2c and -2d (exon 1 contains the ATG start codon).  All of these 
are  are  more  highly  expressed  in  leukocytes  compared  to  non-leukocytes.    The  most 
abundantly expressed p110δ transcript is p110δ-2a (containing exon -1 with exon -2a), 
followed  by  p110δ-2b  (containing  exon  -1  with  exon  -2b)  (Kok,  et  al.,  in  preparation; 
Verrall  &  Vanhaesebroeck,  unpublished  results).    Numerous  regions  of  genomic  DNA 
upstream  of  the  5‟  untranslated  exons  have  been  examined  for  promoter  activity  in 
leukocytes  and  non-leukocytes  with  little  indication  that  any  of  these  regions  mediate 
leukocyte-restricted  p110δ  gene  expression  (Verrall  &  Vanhaesebroeck,  unpublished 
results).    However,  bioinformatic  approaches  identified  a  50  bp  region  of  DNA  within 
mouse PIK3CD exon -2a (equivalent to a region immediately upstream of human PIK3CD 
exon -2a) which contains 7 different TF binding (TFB) sites. This TFB cluster contains 
binding sites for 4 TFs associated with regulation of  haematopoiesis  and expression of 
leukocyte  specific  genes,  namely  ETSF,  IRF,  NFAT  and  LEFF  (discussed  in  depth  in 
section 5.5.1) and is highly homologous across 8 species.  In luciferase reporter studies, in 
which mouse exon -2a was cloned into the promoter-less vector pGL3-Basic, exon -2a 
possessed a significantly higher increase in promoter activity in the leukocyte cell lines 
compared to the non-leukocyte cell lines.   
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A TATA box, which is commonly found in gene promoters, was not identified upstream of 
the  TFB  cluster.    TATA-less  promoters  commonly  contain  a  binding  site  for  the 
ubiquitously expressed TF, SP1 (Chen, et al., 1997).  This was also the case for PIK3CD 
with an SP1 binding site located 40 bp upstream of the start of the TFB cluster.  This SP1 
binding site might be responsible for the „basal‟ level of p110δ expression in most cell 
types.  Although the SP1 binding site was not incorporated in the region of DNA cloned 
into pGL3-Basic, it is possible that this site may enhance the promoter activity of the TFB 
cluster and increase PIK3CD gene expression.  Including the SP1 site with exon -2a in 
future luciferase reporter assays and subsequent mutational analysis of this site represents 
an  area  for  further  investigation.  In  addition,  the  relative  importance  of  individual  TF 
binding sites within the TFB cluster for PIK3CD gene expression was not investigated.  It 
would be extremely interesting to determine which TF binding sites are critical for PIK3CD 
gene expression through mutational analysis of these sites for separate gene assays.  IN 
addition, stable transfection of the reporter vectors containing the TFB cluster region, rather 
than the transient transfections that we carried out, could provide information regarding the 
epigenetic regulation of p110δ promoter activity. 
 
The  identification  of  a  leukocyte-specific  PIK3CD  gene  promoter  could  offer  a  new 
therapeutic target.  In addition to leukocytes, a high level of p110δ expression is observed 
in other cell types often associated with  cancer such as breast tumours, melanoma and 
glioma (Sawyer, et al., 2003).  In breast cancer cell lines, p110δ has a pivotal role in cell 
migration, suggesting that high p110δ expression may confer breast cancer cells with an 
increased  migratory  capacity  and  possibly  metastatic  potential  (Sawyer,  et  al.,  2003).  
Interestingly, all of the leukocyte-associated TFs that bind in the TFB cluster (ETSF, IRF, 
NFAT and LEFF) have also been implicated in breast cancer tumorigenesis (discussed in 
section 5.4.4).  It is possible that the high level of p110δ expression observed in breast 
cancer cells is mediated through increased activity of the newly identified PIK3CD gene 
promoter.    Targeting  TFs  that  bind  in  this  TFB  cluster,  subsequently  reducing  p110δ 
expression, could therefore be of therapeutic benefit and represents an interesting area for 
future investigation.  It would first be of interest to analyse the promoter activity of mouse 
exon -2a in breast cancer cell lines and other non-leukocyte cells which express high levels 
of p110δ, to examine whether these cells, unlike other non-leukocyte cells tested, are able 
to utilize this promoter.   
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3) What is the biological impact of p110δ overexpression in non-leukocyte mammalian 
cells?  
It was hypothesised that transfection of full length p110δ cDNA (including the -2a or -2b 
exons) could result in more effective p110δ expression in cells, compared to previous failed 
attempts to overexpress p110δ in which only the coding region of p110δ cDNA was used 
(Verrall & Vanhaesebroeck, unpublished results).  Upon stable transfection of such -2a or -
2b exon-containing p110 cDNAs in NIH 3T3 fibroblasts using plasmid-based transfection, 
we managed to increase p110δ mRNA expression in both instances (up to 10-fold compared 
to vector control-infected cells), but this did not result in a parallel overexpression of p110δ 
protein.  Pharmacological inhibition of the proteasome was found to lead to an increase in 
p110δ protein expression in p110δ-2a-transfectants, suggesting that exogenously expressed 
p110δ  may  be  subsequently  degraded  by  the  proteasome.    Coexpression  of  a  p110-
stabilising p85 subunit with p110δ-2a cDNA did not result in increased p110δ expression, 
however these data are difficult to interpret given that total p85 expression was also not 
increased in these cells.  
 
In transient transfections of p110δ-2a or p110δ-2b cDNAs in NIH 3T3 or HEK293T cells, 
a significant increase in the amount of p110δ mRNA expression (in the region of 100,000-
fold  compared  to  vector  control-infected  cells)  was  achieved  for  both  p110δ  cDNAs.  
However,  only  transfection  of  p110δ-2a  cDNA  and  not  p110δ-2b  cDNA  resulted  in 
transient p110δ protein overexpression in HEK293T or NIH 3T3 cells.  The importance of 
exon -2a in p110δ expression was further indicated by the finding that p110δ-2a makes up 
80% of the total p110δ transcripts found in the A20 leukocyte cell line.  Furthermore, 
promoter analysis of PIK3CD, discussed previously, identified a promoter region within 
exon  -2a  with  enhanced  leukocyte-specific  promoter  activity.    Together  these  findings 
indicate that exon -2a plays a positive role in regulating p110δ expression, which may 
explain  the  effective  transient  p110δ  overexpression  observed  through  transfection  of 
p110δ-2a and not p110δ-2b cDNA in NIH 3T3 and HEK293T cells.  
 
Overall, plasmid-based transfection of full-length p110δ cDNA in NIH 3T3 did not result 
in stable p110δ overexpression.  It is possible that the 10-fold increase in p110δ mRNA 
observed  after  stable  transfection  of  p110δ  cDNA  gave  rise  to  a  low  level  of  p110δ-
overexpression,  however  this  level  of  p110δ  expression  was  not  sufficient  for  efficient 
heterodimer  formation  and  subsequent  stabilization  of  p110δ,  therefore  exogenously 
expressed  p110δ  protein  was  degraded.    Indeed,  in  transient  transfections,  in  which Chapter 8 
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substantial p110δ overexpression was achieved, although not as high as p110δ expression 
observed in the A20 leukocyte cell line, p110δ mRNA was increased over 100,000-fold.   
 
Retroviral-mediated transfection has been employed in a number of studies investigating 
the effect of PI3K overexpression (Auger, et al., 2000; Kang, et al., 2006; Kinashi, et al., 
1999;  Kinashi,  et  al.,  2000;  Link,  et  al.,  2005).    This  method  of  gene  delivery  is 
advantageous over transfection of cDNAs in mammalian expression vectors as it results in 
superior gene transfer efficiency and a high degree of stable integration of exogenous DNA 
into  the  host‟s  genome.    Using  the  retroviral  vector,  pMX-neo  (Kinashi,  et  al.,  2000), 
human p110δ cDNA containing a 5‟Myc-tag and a 3‟ membrane-targeting CAAX motif 
was infected in NIH 3T3 cells, resulting in substantial stable overexpression of p110δ.  
Given that previous attempts to stably overexpression p110δ through transfection of p110δ-
2a or p110δ-2b cDNA in pCMV.Sport6 or pcDNA3.1(+), respectively, had failed, this was 
a momentous result. It would have been interesting to compare the levels of p110δ mRNA 
in retrovirally-infected and p110δ cDNA-transfected cells, in order to assess whether the 
success  of  retroviral  transduction  in  generating  p110  protein  expression  was  due  to 
enhanced mRNA production compared to plasmid-transfected cells.   
  
Although the retroviral system resulted in substantial stable p110 overexpression, it was not 
without its setbacks.  To determine whether stable p110δ overexpression was the result of 
the retroviral system used, the presence of a 5‟Myc tag and/or the 3‟ membrane targeting 
CAAX motif, we cloned cDNAs for untagged p110δ, 5‟Myc-p110δ or p110δ-3‟CAAX into 
the  pMX-neo  vector  and  introduced  these  constructs  into  NIH  3T3  cells  by  retroviral 
infection.  Unfortunately, transfection of pMX-neo containing untagged p110δ or p110δ-
3‟CAAX cDNA resulted, unexpectedly, in the production of Gag-p110δ fusion proteins.  
This was due to the presence of a translation start site of viral Gag, within the pMX-neo 
packaging signal, in frame with the translational start site of p110δ, which only occurred if 
a 5‟Myc-tag upstream of p110δ was not present.   
 
Overexpression  of  Gag  fusion  proteins  has  been  employed  to  investigate  a  protein‟s 
function (Aoki, et al., 2000; Vogt, et al., 2006), however the precise function mediated by 
the Gag protein is unknown.  Viral Gag translocates to the plasma membrane, therefore 
expression  of  Gag-p110δ  is  likely  to  result  in  localization  of  p110δ  at  the  plasma 
membrane.  From the results presented in Chapter 6, the expression of Gag-p110δ in NIH 
3T3  cells  is  seen  to  have  a  severe  impact  of  cell  morphology  but  only  under  serum-
starvation  conditions.    It  appears  that  this  effect  is  not  simply  the  result  of  plasma-Chapter 8 
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membrane  localization  and  constitutive  activation  of  p110δ,  given  that  expression  of 
5‟Myc-p110δ  with  a  membrane  targeting  3‟CAAX  motif  did  not  result  in  a  similar 
phenotype.  It is possible that this change in cell morphology, cell rounding, is in fact 
indicative of cell transformation as a result of the Gag sequence fused to p110δ (Vogt, P., 
Personal  communication),  although  cell  apoptosis  is  a  more  obvious  conclusion.  Gag 
proteins  could  also  be  made  in  NIH  3T3  cells  stably  expressing  the  control  pMX-neo 
vector, which were observed to have a similar morphology to WT NIH 3T3 cells indicating 
that it is the fusion of Gag to p110δ which induces the change in morphology observed in 
Gag-p110δ-expressing cells.  Further investigations into the oncogenicity of Gag-p110δ, 
such  as  performing  colony  formation  assays  on  pMX-neo-expressing  and  Gag-p110δ-
expressing  cells  could  shed  more  light  onto  the  impact  Gag-p110δ  expression  on  cell 
morphology, however the physiological relevance of these experiments is unclear. 
 
p110  subunits  are  stabilised  by  heterodimer  formation  with  PI3K  regulatory  subunits 
(Meier, et al., 2004; Ueki, et al., 2002a; Yu, et al., 1998b). The addition of an N-terminal 
tag to p110ʱ has been shown to supplant this requirement of p110ʱ for p85 (Yu, et al., 
1998b). It is therefore possible that the same is true for p110δ, given that we achieved 
stable overexpression of 5‟Myc-tagged p110δ in NIH 3T3 cells without coexpression of 
regulatory  subunits.  Similarly,  in  other  studies  in  which  p110  isoforms  have  been 
overexpressed, transfection of exogenous p85 was not required (Auger, et al., 2000; Kang, 
et  al.,  2006;  Link,  et  al.,  2005).    With  respect  to  heterodimer  formation  with  p85, 
overexpressed  5‟Myc-p110δ  may  not  act  in  the  same  way  as  overexpressed  untagged 
p110δ.  However, we found that 5‟Myc-p110δ was still capable of forming heterodimers 
with p85 regulatory subunits, although it was not determined whether the 5‟Myc-tag may 
affect the level of p85 binding.  Despite the clear limitations of using an N-terminal Myc-
tagged  p110δ  to  be  able  to  understand  the  impact  of  'natural'  untagged 
p110overexpression, our characterisation of 5‟Myc-p110δ-overexpressing NIH 3T3 cells 
has led to some interesting observations, summarised in Table 8.1.  
In  NIH  3T3  cells  stably  expressing  5‟Myc-p110δ,  we  found  that  endogenous  levels  of 
p110ʱ and p110β expression was severely attenuated or undetectable, indicating that the 
level  of  p110δ  expression  regulates  the  protein  expression  of  the  other  class  I  PI3K 
isoforms.    In  corroboration  with  this,  overexpression  of  Gag-p110δ  and  Gag-p110δ-
3‟CAAX  in  NIH  3T3  cells  also  resulted  in  reduction  of  p110ʱ  expression  to  a  level 
undetectable by immunoblotting.   
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Table 8.1: Summary of findings from NIH 3T3 cells stably overexpressing 5’Myc-
p110δ.  The relative level of expression of the indicated proteins or cytoskeletal entities 
between NIH 3T3 cells stably expressing pMX-neo or 5‟Myc-p110δ.  N/A indicates that 
this aspect has not been assessed.  
pMX-neo 5’Myc-p110δ
10% serum Starved 10% serum Starved
p110δ + N/A +++++ N/A
p110ʱ +++++ N/A + N/A
p110β ++++ N/A - N/A
p85  ++++ N/A +++++ N/A
p-Akt
Total Akt
+
+
-
+
++++++
+
+
+
RhoA-GTP + + ++++ ++
Rac1-GTP ++ ++ + ++++
Cdc42-GTP ++++ ++++ + ++
p190RhoGAP (P-Tyr)  + N/A + N/A
Stress fibres +++ ++ ++++ -
Focal contacts
(assessed by          
P-paxillin staining)
+ ++ +++ +++
Adherensjunctions
(assessed by N-
cadherin staining)
+ + + +
Cell surface area + + +++++ +++++
Cell spreading
Lamellipodia:
Fillopodia:
Area:
N/A
N/A
N/A
+
++++
+
N/A
N/A
N/A
++++
++
+++
Cell morphology on 
Matrigel
24h after seeding:
N/A N/AChapter 8 
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Furthermore, in a study using chicken embryo fibroblasts, the endogenous levels of p110ʱ 
are downregulated in cells overexpressing p110β or p110δ (Kang, et al., 2006).  There are 
also  indications  that  p110δ  may  regulate  expression  of  other  class  I  p110  isoform  in 
tumourigenesis.  High p110δ expression may be associated with low or undetectable p110ʱ, 
p110β  and/or  p110γ  expression  in  some  primary  human  breast  cancer  tissue  samples 
(Sawyer,  et  al.,  2003)  and  in  leukaemic  blast  cells  from  patients  with  acute  myeloid 
leukaemia  (Billottet,  et  al.,  2006;  Sujobert,  et  al.,  2005).    It  is  possible  that  in  some 
transformed cells, which endogenously express high levels of p110δ, a downregulation of 
other class I p110 isoform expression occurs, which consequently results in p110δ being 
the principle class I isoform participating in PI3K signalling.  The biological impact of 
these changes in p110 expression is unclear.  Given that p110δ has been shown to control 
the directionality and, to a lesser extent, the speed of in vitro migration in breast cancer cell 
lines (Sawyer, et al., 2003), it is possible that an invasive/migratory advantage is gained in 
cells in which p110δ is the principle PI3K isoform.   
 
Using the NIH 3T3 cells I have created, which stably overexpressing 5‟Myc-p110δ, the 
mechanism  by  which  p110δ  mediates  downregulation  of  p110ʱ  and  p110β  could  be 
investigated. Analysis of the mRNA expression of p110ʱ and p110β would help elucidate 
whether p110δ induces transcriptional repression of these isoforms, likewise treating cells 
with a proteasome inhibitor may determine whether p110δ mediates protein degradation of 
p110ʱ and p110β.  Acute inhibition of p110δ lipid kinase activity did not alter p110ʱ and 
p110β protein expression in 5‟Myc-p110δ-overexpressing NIH 3T3 cells, however it would 
be  interesting  to  investigate  whether  chronic  treatment  with  the  p110δ  inhibitor  could 
restore p110ʱ  and p110β  expression.  Alternatively, stable  expression of a kinase-dead 
p110δ would also help determine whether the lipid kinase activity of p110δ is required for 
downregulation of p110ʱ and p110β expression. 
 
The altered PI3K isoform expression in NIH 3T3 stably overexpressing 5‟Myc-p110δ make 
it  difficult  to  assign  the  phenotypes  observed  in  these  cells  (Table  8.1)  to  p110δ 
overexpression or to  p110ʱ/p110β  downregulation, or to  both.   A clear difference was 
observed  in  the  cell  morphology  between  pMX-neo-expressing  and  5‟Myc-p110δ-
overexpressing  NIH  3T3  cells.    Immunofluorescence  staining  of  the  actin  cytoskeleton 
revealed  obvious  differences  in  the  number  of  actin  stress  fibres,  the  number  of  focal 
contacts, the rate of cell spreading and adherence and emphasized the difference in the 
overall cell shape between the two cell lines (summarised in Table 8.1).  Moreover, these Chapter 8 
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differences were highly dependent on the presence of serum in the culture  media. The 
activities of the small RhoGTPases, RhoA, Rac1 and Cdc42, are tightly linked with the 
actin cytoskeleton, therefore the differences observed in the actin cytoskeleton of pMX-
neo-expressing  and  5‟Myc-p110δ-overexpressing  NIH  3T3  cells  are  likely  to  reflect 
differential RhoGTPase activation, which may result from p110δ overexpression and/or 
p110ʱ and p110β downregulation. 
 
PI3K  has  been  found  to  activate  Rac1  (Hawkins,  et  al.,  1995;  Innocenti,  et  al.,  2003; 
Kotani, et al., 1995) and more specifically p110δ has been found to negatively regulate 
RhoA activity (Papakonstanti, et al., 2007).  In general, the results presented in Chapter 7 
support the idea that p110δ is a positive regulator of Rac1 activity and a negative regulator 
of RhoA activity.  However, the idea that p110δ positively regulate Rac1 and negatively 
regulates RhoA became more complicated when the activities of these Rho GTPases were 
assessed in cells under normal growing conditions (i.e. in the presence of serum).   5‟Myc-
p110δ-overexpressing cells displayed a significantly higher level of RhoA-GTP compared 
to pMX-neo cells in the presence of serum, which appears to contradict the idea that p110δ 
is a negative regulator of RhoA activity. 
 
It is possible that p110β may be involved in the downregulation of RhoA activity after 
prolonged  serum-stimulation,  advocating  LPA  as  the  principal  constituent  of  serum 
mediating this effect.  LPA is one of the active constituents of serum that has been shown to 
stimulate both RhoA and p110β activation (Guillermet-Guibert, et al., 2008; Jalink, et al., 
1994;  Kranenburg,  et  al.,  1999;  Sugimoto,  et  al.,  2006;  Tigyi  &  Miledi,  1992;  Van 
Leeuwen, et al., 2003; Yart, et al., 2002).  Acute LPA stimulation induces cell contraction 
and rounding, mediated by RhoA activation (Kranenburg, et al., 1999; Van Leeuwen, et al., 
2003),  however  activated  RhoA  is  no  longer  detected  after  10  minutes  after  LPA 
stimulation and cells begin to re-spread (Van Leeuwen, et al., 2003), indicating that in the 
continuous presence of LPA RhoA activity is downregulated.  Given that 5‟Myc-p110δ-
overexpressing cells displayed high levels of RhoA-GTP despite the documented inhibitory 
effect of p110δ on RhoA activity (Papakonstanti, et al., 2007) and given that they expressed 
undetectable  levels  of  p110β,  we  hypothesize  that  p110β  may  play  a  role  in  the 
downregulation of RhoA-GTP in the continuous presence of serum, which is compromised 
in  5‟Myc-p110δ-overexpressing  cells.    Therefore,  high  RhoA  activity  in  5‟Myc-p110δ-
overexpressing cells in the presence serum may not be a result of p110δ overexpression per 
se,  but  a  result  of  p110β  downregulation.    Indeed,  p110δ  inhibition  in  5‟Myc-p110δ-Chapter 8 
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overexpressing cells in the presence of serum resulted in a significant increase in RhoA-
GTP levels, indicating that p110δ is in fact negatively regulating RhoA activity under these 
conditions. 
 
If the proposed model is correct, it is possible that the true effects of p110δ overexpression, 
as opposed to p110β downregulation, are observed in cells starved of serum.  Indeed, in 
5‟Myc-p110δ-overexpressing  cells  starved  of  serum  overnight,  basal  RhoA-GTP  levels 
were reduced and basal Rac1-GTP levels were increased compared to that detected in the 
presence  of  serum.    Moreover,  the  cell  morphology  observed  in  5‟Myc-p110δ-
overexpressing cells under serum-starvation conditions correlated with high Rac1 activity.  
Under  serum-starvation  conditions  5‟Myc-p110δ-overexpressing  cells  displayed  a 
reduction in actin stress fibres and associated focal adhesions, they were more spread on the 
substratum, and they displayed increased lamellipodia and membrane ruffling (during cell 
adhesion) compared to pMX-neo-expressing cells, all features associated with increased 
Rac1  activity  (summarsied  in  Table  8.1)  (Nobes  &  Hall,  1995;  Ridley,  et  al.,  1992).  
Furthermore, p110δ inhibition in 5‟Myc-p110δ-overexpressing cells substantially reversed 
some of these phenotypes, indicating that p110δ lipid kinase activity is needed for these 
responses.  
 
It  is  clear  that  the  effect  of  p110δ  overexpression  on  the  actin  cytoskeleton  and  the 
activation of the small RhoGTPases in NIH 3T3 cells is complex and is further complicated 
by the downregulation of p110ʱ and p110β expression.  Although a hypothetical model has 
been proposed for the effect of prolonged exposure to serum on the phenotypes observed in 
5‟Myc-p110δ-overexpressing  cells,  this  is  purely  speculative  and  the  impact  of  growth 
factors, such as IGF-1 and PDGF, in addition to other constituents of serum, rather than 
LPA, may well be the causative agents for the phenotypes observed.  Furthermore, the 
focus of this and the previous discussions in section 7.5, have been on p110β as a potential 
regulator of RhoA activity, however the impact of p110ʱ downregulation in 5‟Myc-p110δ-
overexpressing cells should not be overlooked.  Indeed, in endothelial cells, p110ʱ has been 
shown to positively regulate RhoA activity (Graupera, et al., 2008).  Further investigation is 
required to elucidate the regulatory roles of each PI3K isoform on RhoA/Rac1/ and Cdc42 
activity in NIH 3T3 cells.  One way in which this could be investigated, is through stable 
overexpression  of  5‟Myc-p110ʱ  or  5‟Myc-p110β  in  NIH  3T3  cells,  and  compare  the 
phenotypes  observed  with  5‟Myc-p110δ-overexpressing  NIH  3T3  cells.    Ideally, 
characterisation  of  NIH  3T3  cells  stably  overexpressing  untagged  p110ʱ/β/δ  would  be Chapter 8 
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carried out, to avoid any uncertainty regarding the biological function the 5‟Myc-tag may 
be exerting. 
 
There are numerous potentially interesting lines of investigation which could be carried out 
to further characterise NIH 3T3 cells overexpressing p110δ, which are discussed in more 
depth in section 7.5.7.  However, one area of particular interest is investigation into the 
migratory capacity of these cells.  There are indications that p110δ plays an important role 
in cell migration (Papakonstanti, et al., 2007; Sawyer, et al., 2003), therefore it would be 
interesting to investigate cell migration in cells in which p110δ has become the principle 
class  I  PI3K  isoform.    It  is  possible  that  p110δ-overexpressing  cells  have  a  migratory 
advantage  over  control  cells,  or  conversely  the  disruption  in  p110  expression  and  Rho 
GTPase  activation  may  have  a  negative  effect  on  cell  migration.    Analysing  tumour 
formation in nude mice after injection of 5‟Myc-p110δ-overexpressing cells would help 
assess  the  tumorigenicity  of  these  cells  and  may  provide  some  insight  the  metastatic 
potential of solid tumours which express high levels of p110δ. 
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